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Abstract 
Lung cancer is the leading cause of cancer related mortality worldwide and 
since the discovery of the important role that NRF2 plays in regulating the 
expression of phase II drug metabolism genes, NRF2 has been a highly studied 
therapeutic target. NRF2 signalling is often elevated in lung cancer due to 
mutations in NFE2L2, the gene that encodes NRF2; and KEAP1, the cytoplasmic 
regulator of NRF2. Since it became established that elevated NRF2 signalling 
provides a beneficial role to the tumour through enhancing proliferation, enabling 
survival in highly oxidative conditions and enhancing resistance to 
chemotherapeutic drugs; many groups have focussed on understanding KEAP1-
independent forms of NRF2 regulation.  
 It is now widely accepted that GSK-3 phosphorylation of the Neh6 domain 
of NRF2 is fundamental for SCFβ-TrCP-mediated degradation of the transcription 
factor. Previous work by other groups has indicated a potential role for a priming 
kinase to pre-phosphorylate the Neh6 domain and subsequently enhance GSK-
3 mediated phosphorylation and resulting 26S proteasomal degradation. In the 
first results chapter of this thesis it was demonstrated using the DYRK family of 
isoenzymes that the presence of a priming kinase enhances GSK-3 
phosphorylation and stimulates NRF2 degradation. Also, it has been shown that 
DYRK family members carry out priming of NRF2 through phosphorylating Ser-
347, which enhances subsequent phosphorylation of Ser-342 and Ser-338 by 
GSK-3; regulating both NRF2 activity and stability. Additionally, it was shown that 
altering the phosphorylation status of Ser-347 impacts cell proliferation and 
chemo-sensitivity to platinum-based compounds. The ability of other kinases to 
phosphorylate the Neh6 domain was also revealed.   
In the second results chapter of this thesis a bioinformatics style approach 
was utilized to analyse the impact of mutations in KEAP1, NFE2L2 and CUL3; in 
terms of their effect on NRF2 activity using the expression of NRF2-target genes 
as a read out. The following points were highlighted  from this analysis; (1) KEAP1 
mutations are more prevalent than NFE2L2 and CUL3 mutations in both lung 
cancer cell lines and tumours; (2) KEAP1 and NFE2L2 mutations vary in there 
associated zygosity’s, with KEAP1 mutations being predominantly homozygous 
and  NFE2L2 mutations being predominantly heterozygous; (3) mutations in 
xxx 
 
KEAP1 coexist with mutations in KRAS whereas, mutations in NFE2L2 co-exist 
with mutations in TP53 and (4) lung cancer cell lines and tumours harbouring 
mutations in KEAP1 have greater expression of NRF2-target genes than those 
harbouring either NFE2L2 or CUL3 mutations.  
In the third and final results chapter, both a panel of commercial cell lines 
and an in-house generated CRISPR/Cas9 panel of cell lines have been shown in 
multiple experiments to validate the bioinformatics findings of the previous 
chapter. Also, in this chapter it was identified that KEAP1 mutant cells are more 
reliant on the glutathione biosynthesis pathway for survival and therefore more 
sensitive to alterations in this pathway.  
The work demonstrated in this thesis has revealed new insights into the 
complex regulation of NRF2 and the importance of studying the mutations that 
lead to aberrant NRF2-signaling in lung cancer. Through showing the importance 
of a priming kinase in the regulation of KEAP1-independent degradation of NRF2, 
a completely novel alternative way of stimulating NRF2 degradation in the 
presence of a KEAP1 mutation is possible. The data displayed in the second and 
third results chapters highlights the importance of understanding the impact that 
mutations in KEAP1 and NFE2L2 have on NRF2 signalling; and suggests that 
theses mutations should not be grouped together in terms of the effect. 
Additionally, the data presented in the second and third results chapters 
highlights the importance of generating physiologically relevant NRF2 models. 
This greater understanding of the regulatory mechanisms in place to control the 
levels of NRF2 in the cell and the mutations that lead to aberrant NRF2-signalling 
in cancer will hopefully aid in the development of new therapeutic strategy to 
combat this disease.
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1.0 Introduction  
1.1 Oxidative stress  
All aerobic life needs to produce energy to survive. Aerobic metabolism is 
often utilized as it produces a greater energetic yield of 18 times more adenosine 
triphosphate (ATP) from a single molecule of glucose, than that of anaerobic 
metabolism. However, this larger energetic yield comes at a cost to the cell with 
the production of potentially damaging reactive oxygen species (ROS) such as: 
hydrogen peroxide (H2O2), hydroxyl radical (HO•), superoxide anion radical (O2•-
) and singlet oxygen (O2), as bi-products of the incomplete oxidation of oxygen 
(Halliwell, 2007). The O2•- anion is formed through the one electron reduction of 
O2 and is the precursor for the formation of other forms of ROS. Superoxide can 
also combine with nitric oxide, which is endogenously produced in the cell, to 
form extremely damaging peroxynitrite (Squadrito and Pryor, 1995). H2O2 is 
formed either spontaneously or through dismutation of superoxide, catalysed by 
the enzyme superoxide dismutase (SOD). Also, highly reactive singlet oxygen 
has been shown to react with ascorbate leading to the formation of H2O2 
(Kramarenko et al., 2006). H2O2 is considerably less reactive than other forms of 
ROS but therefore is more stable and has the potential to travel in to the cell 
nucleus and damage DNA (Halliwell, 2007;Turrens, 2003). Also, in the presence 
of carbon dioxide (CO2) H2O2 forms perocymonocarbonate (HCO4-), another 
potentially damaging radical (Bakhmutova-Albert et al., 2010). Incomplete 
reduction of H2O2 leads to the formation of highly reactive and unstable HO•. In 
an attempt to increase stability, HO• rapidly scavenges electrons from 
neighbouring molecules, resulting in a damaging chain reaction of electron 
scavenging.   
A homeostatic balance usually exists within the cell between the production 
of ROS and the antioxidant defences. Oxidative stress occurs when this balance 
is disrupted and the levels of endogenous ROS over powers the antioxidant 
defence capacity of cells, leading to damage of to several cellular components 
such as: DNA, protein and lipids, which can ultimately result in the development 
of disease.  
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1.1.1 Sources of reactive oxygen species  
The majority of endogenously generated ROS is thought to be produced 
as a by-product of other reactions in the cell and is largely produced by the 
electron transport chain. In addition, nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase (NOX) isoenzymes produce H2O2 intentionally for 
signal transduction (Meitzler et al., 2013).  
Mitochondria are known as the “power houses” of the cell, producing the 
majority (>80%) of total ATP formed from glucose through the process of 
oxidative phosphorylation (Figure 1.1). Oxidative phosphorylation is a multistep 
process that relies on the energy rich molecules nicotinamide adenine 
dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) that donate 
electrons in the reduction of molecular oxygen to water. This leads to several 
redox reactions that transport electrons across complexes I to IV. This electron 
transport is coupled to the transport of hydrogen ions across the mitochondrial 
membrane by the electron transport chain to generate a proton gradient and a 
transmembrane electrical potential that generates proton-motive force. The 
energy of the proton-motive force is used to power the ATP synthesis complex 
(also known as complex V) for the conversion of adenosine diphosphate (ADP) 
to yield ATP (Nickel et al., 2014). Under low levels of ADP, H+ ions accumulate 
causing the electron transport chain to become more reduced, which allows 
electrons to escape and react with molecular oxygen leading to an increased 
formation of O2•- (Berg  et al., 2002). 
Complex I and Complex III are the major sites of ROS production (primarily 
superoxide and some hydrogen peroxide) in the electron transport chain. 
Complex III is the main producer of superoxide in both heart and lung 
mitochondria. However, complex I is the main source of superoxide production in 
the brain and is linked with the enhanced ROS production associated with several 
diseases, which are discussed in greater detail later section 1.2 (Kudin et al., 
2005). The important roles that complex I and III play in the generation of ROS 
has been demonstrated with specific complex inhibitors. Administration of the 
complex I inhibitor rotenone and the complex III specific inhibitor antimomycin, 
have been shown in several models to lead to increased superoxide production 
and in the case of rotenone trigger apoptosis. Tumour necrosis factor alpha (TNF-
3 
 
a) has also been shown to inhibit complex I and trigger apoptotic cell death 
pathways (Li et al., 2003).   
Pharmacological compounds that induce members of the cytochrome 
P450 enzyme family have also been linked to the production of ROS. 
Phenobarbital administration has been shown to increase the expression of F2-
Isoprostanes (F2-isoPs), an established biomarker of in vivo oxidative stress. 
Cytochromes P450 catalyse the oxygenation of substrates coupled with the 
simultaneous reduction of O2, but this reaction has the potential to uncouple 
resulting in the production of ROS.  However, phenobarbital has also been shown 
to decrease the expression of the antioxidant defence enzyme, glutathione 
peroxidase, which may account for the increase in ROS levels (Dostalek et al., 
2008;Hrycay and Bandiera, 2015).  
Other intracellular sources of ROS include: peroxisomes, lipoxygenases 
and cyclooxygenases. Peroxisomes carry out several key processes in 
eukaryotic cells including fatty acid b-oxidation to produce acetyl CoA, NADH and 
FADH2, which results in the production of H2O2 as a bi-product (Poirier et al., 
2006;Foerster et al., 1981). The oxidative metabolism of arachnoid acid mediated 
by lipoxygenases and cyclooxygenases also leads to the production of ROS (Cho 
et al., 2011).  
Uncontrolled production of ROS leads to the modification of the structure 
and function of cellular proteins and lipids; and the modification of DNA. This can 
lead to cellular dysfunction: including impaired cell transport mechanisms, 
immune activation and inflammation, impaired energy metabolism, altered cell 
signalling and altered cell cycle; and ultimately result in the development of 
disease. 
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Figure 1.1: Overview of oxidative phosphorylation 
NADH and FADH2, provided from a variety of sources, and H+ ions produced by the hydrolysis 
of these two molecules is used to generate the proton gradient required to produce ATP. 
Sources of ROS are indicated in bold font. Adapted from (Bratic and Larsson, 2013). 
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1.2 Role of oxidative stress in disease  
It has been debated extensively whether the production of ROS is beneficial 
or deleterious for the cell and the impact that ROS has on cellular health maybe 
in part dictated by its levels. Cells are constantly producing reactive oxygen 
species; high levels of ROS are commonly linked with the development of 
disease. However, low levels of ROS have been shown to be pivotal to several 
physiological signalling pathways, such as MAPK signalling, through the 
modification of redox sensitive proteins which contain key cysteine residues that 
when modified change the protein into its active state. Tyrosine phosphatases 
are also cysteine rich proteins which under low levels of ROS (in particular 
hydrogen peroxide) are reversibly inactivated. This permits increased tyrosine 
phosphorylation of several proteins leading to their activation and the activation 
of several downstream signalling cascades that promote cell survival (Finkel, 
2001; Finkel, 2011). Low levels of hydrogen peroxide have been shown to 
reversibly convert cystine residues that exist as thiolate anions to the sulfenic 
form, this process is pivotal to several signal transduction pathways and is 
thought to not be damaging to the cell. However, in the presence of high levels 
of hydrogen peroxide thionate anions are irreversibly converted sulfinic /sulfonic 
ions, which are extremely damaging to the cell (Schieber and Chandel, 2014).  
 The immune system provides a means of defence for cells against potentially 
damaging pathogens and impaired immune signalling, through either inhibition or 
hyperactivation of the immune system, is associated with the development of 
several diseases. Phagocytic neutrophils and macrophages exploit the 
destructive power of ROS during the wound healing process to kill invading 
pathogens. High levels of oxygen are needed during wound healing to compete 
with the increase ATP demand for tissue repair. Phagocytic neutrophils and 
macrophage cells engulf invading bacteria into vacuole like structures called 
phagosomes which have high levels of the enzyme NOX. Upon intake of oxygen, 
NOX isoenzymes in the phagosome reduce oxygen to either O2•- or H2O2 which 
in high levels kills the engulfed invading bacteria, in a process called “respiratory 
burst”. Whilst the respiratory burst is being carried out, high levels of H2O2 are 
produced and released into the surrounding environment, halting the growth of 
neighbouring bacteria and ensuring complete eradication of all pathogenic tissue 
preventing the formation of chronic wounds. Chronic Granulomatous disease 
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(GCD) occurs in patients harbouring mutations in NOX, this means they cannot 
reduce oxygen to produce ROS and therefore are subject to numerous infections 
and chronic wound formations (Halliwell, 2006;Dunnill et al., 2017).  
The fact that the cell has a plethora of cell defences in place to combat 
ROS production indicates that these species may not be always beneficial to cell 
health but often pivotal to the development of disease. The balance between ROS 
production and elimination in the cell can be altered by either: deficiency in 
antioxidant defences, inhibition of complexes of the electron transport chain or 
exposure to xenobiotics. ROS production has been linked with a wide range 
pathological conditions such as neurological disorders (Parkinson’s disease and 
Amyotrophic Lateral Sclerosis (ALS)), ageing, diabetes and cancer.   
1.2.1 Neurological disorders and oxidative stress 
The development of Parkinson’s disease (PD) is thought to be linked to 
repetitive exposure to complex I inhibitors, which trigger O2•- production resulting 
in activation of the apoptotic cell death pathway. Mice that are administered 
rotenone have been shown to develop α-synuclein deposits in the brain, a 
classical hallmark of PD. These α-synuclein deposits have also been shown to 
induce ROS formation through inhibiting activating transcription factor 6 (ATF6), 
an important transcription factor involved in the unfolded protein response (UPR), 
leading to neurodegeneration (Turrens, 2003). Also, mutations in the 
mitochondrial targeting sequence (MTS), which is responsible for the 
translocation of  the antioxidant manganese SOD (MnSOD) to the matrix, have 
been identified in PD suffers suggesting a genetic link between dysregulation of 
ROS production and the development of PD (Zeeshan et al., 2016).  
ALS is an extremely debilitating muscular disorder of which the cause of 
90-95% of cases is unknown. The remaining 5-10 % of all cases have a familial 
link, and 10% of these familial cases have been shown to have mutations in the 
gene encoding copper-zinc superoxide dismutase (CuZnSOD). These mutations 
lead to blockage of the transport of the enzyme into the inter membrane space 
and results in increase superoxide production (Turrens, 2003). 
1.2.2 Ageing  
Ageing has been linked to the build-up of DNA damage, which can be 
measured through the presence of 8-oxo-deoxyguanosine (8-oxo-dG), through 
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continuous exposure to ROS. Studies have shown that increases in age are 
associated with an increase in mitochondrial superoxide and hydrogen peroxide 
formation leading to increased oxidation of proteins. Deficiency in the 
mitochondrial enzyme required for DNA repair are found in patients suffering from 
Cockyanes syndrome, a disease characterised by premature ageing. 
Conversely, drosphillia melanogaster models have shown that increased 
expression of the ROS defence enzymes, SOD and catalase, is associated with 
increased life span. However, administration of antioxidants has not been 
conclusively shown to have any effects on aging in human models (Pickering et 
al., 2012; Liochev, 2013; Barja, 1999).  
Human population studies have conclusively shown that women live 
longer than men. This increase in female life span maybe due to women having 
higher expression of the ROS defence enzyme, glutathione peroxidase. 
However, the exact mechanism behind this increase in glutathione peroxidase 
expression has not been determined but the female hormone oestrogen is 
thought to potential play a role (Viña et al., 2005).  
1.2.3 Diabetes mellitus   
High levels of oxidative stress have been shown to lead to the 
development of Diabetes mellitus (DM), a highly common metabolic and 
inflammatory disease. Diabetes can be divided into two subtypes that are called 
type 1 DM (T1DM) and type 2 DM (T2DM), which differ in their pathology but both 
exhibit impaired insulin signalling and high levels of ROS.  
T1DM is often diagnosed in early life and is associated with a genetic risk 
factor. In T1DM immune cells attack healthy β-cells in the pancreas, which are 
responsible for the production of insulin, through ROS induced respiratory burst 
(Huang et al., 2016). T2DM is often associated with excessive nutritional intake 
leading to high blood glucose levels (hyperglycaemia) that is coupled with a lack 
of physical exercise. High glucose levels promote the formation of ROS through 
increasing the levels of diacylglyerol (DAG), which subsequently activates protein 
kinase C (PKC) resulting in phosphorylation of NOX isoenzymes leading to 
increased formation of ROS (Giacco and Brownlee, 2010). The increased ROS 
production associated with diabetes arises predominantly through the electron 
transport chain, but may also be due to increases in the activity of nitric oxide 
synthase and peroxidases and also toll like receptor 4 signalling. In diabetes, the 
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high levels of ROS lead to activation of the apoptotic death pathways which lead 
to inflammation and insulin resistance through altering insulin receptor 
downstream signalling. The rate of apoptosis in the cell is normally tightly coupled 
with rate of autophagy. However, impairments in autophagy have been shown in 
DM leading to an accumulation of unfolded proteins resulting in dysfunction of the 
endoplasmic reticulum (ER) and ER stress.  
To further enforce the important role that oxidative stress plays in DM, 
alterations in the antioxidant defence system have been shown to be associated 
with this disease. For example, the levels of catalase and glutathione are 
decreased in T2DM patients (Newsholme et al., 2016;Volpe et al., 2018). Also, 
administration of antioxidants, such as mitoquionine, have been shown to inhibit 
β-cell death in cell models of DM (Zeeshan et al., 2016). Overall, these findings 
suggest that oxidative stress plays a fundamental role in DM development 
through increased ROS levels and impaired oxidative stress defences. 
1.2.4 Cancer 
Cancer is a multistep disease that has defined hallmarks associated with 
it.  The hallmarks of cancer include: increased angiogenesis, sustained cellular 
proliferation and metastatic potential, and resistance to cell death pathways 
(Hanahan and Weinberg, 2011;Hanahan and Weinberg, 2000). ROS can play a 
role in the establishment of each of these hallmarks. 
Cancer cells have enhanced oxygen and nutrient demand which requires 
additional blood flow. Angiogenesis is the formation of new blood vessels and is 
fundamental to cancer cell proliferation, and migration, and leads to life-
threatening metastatic disease (Nishida et al., 2006). Low levels of oxygen, 
known as hypoxia, leads to the activation of the transcription factor hypoxia 
inducible factor-1 (HIF-1). HIF-1 is composed of two isoforms, designated HIF-
1a and HIF-1b. The b isoform is constitutively active in all cells but the a isoform 
is regulated by ROS and activated upon exposure to H2O2 (Chandel et al., 
2000;Chang et al., 2008). HIF-1a functions to inhibit the major regulator of 
angiogenesis, vascular endothelia growth factor (VEGF) (Ramakrishnan et al., 
2014). VEGF has also been shown to activate NOX leading to ROS production, 
suggesting the presence of cycle of ROS stimulated angiogenesis in tumours. 
The requirement for ROS in the development of angiogenesis has been 
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demonstrated in both in vivo and in vitro models of the disease through the use 
of antioxidants and inhibitors of the mitochondrial electron transport chain. N-
acetylcysteine (NAC), a potent antioxidant, and rotenone (a complex I inhibitor) 
have been shown to inhibit angiogenesis through the suppression of VEGF (Xia 
et al., 2007;Kim and Byzova, 2014;Liou and Storz, 2010;Galanis et al., 2008).   
Metastasis occurs when cancer cells migrate through the blood circulation 
to proliferate in other locations in the body. The development of metastatic cancer 
dramatically decreases patient survival rate. For cells to migrate into the blood 
system they first must detach from the basal membrane. Metalloproteinases 
(MMPs), in particular MMP2 and MMP9, breakdown proteins of the extracellular 
matrix, freeing cells. High levels of ROS, caused by increased H2O2 production, 
activate MMPs and the expression of both MMP2 and MMP9 has been shown to 
be higher in several cancerous tissues in comparison to matched non-malignant 
control tissues (Roomi et al., 2009). Overexpression of the antioxidant defence 
enzyme MnSOD has been shown in rodent models to trigger cellular invasion 
(Connor et al., 2007). Also, high levels of mnSOD have been reported at the outer 
most edge of the tumour which is the location of the invading cells is and by 
contrast low levels of expression are found in the torpid centre of the tumour. This 
may be in part explained by the fact that mnSOD catalyses the conversion of 
superoxide to hydrogen peroxide which will stimulate the outer most edge of the 
tumour to invaded into the adjacent tissue (Zhang et al., 2002;Liou and Storz, 
2010).  
Errors in cell cycle are often implicated in the development of cancer. Cell 
cycle is an irreversible process controlled by cyclins and cyclin-dependant 
kinases (CDKs). Different combinations of cyclins and CDKs are activated and 
inhibited at different stages of the cell cycle. Once the cyclin has ensured the 
progression through to the next phase of the cycle they are degraded through 
ubiquitination, meaning that cell cycle is a unidirectional irreversible process. The 
activity of CDKs is controlled by the phosphatase, cdc25, and CDK-inhibitors 
(CKIs) (Barnum and O’Connell, 2014). Cdc25 stimulates cell cycle progression 
and is overexpressed in several cancer tissues. ROS decreases the activity of 
cdc25 through oxidising the highly reactive active site cysteine and through 
enhancing the degradation of the phosphatase (Rudolph J, 2005). ROS also 
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influences the ubiquitination of CKIs and can directly inhibit the proteasome 
(Verbon et al., 2012).   
The role that ROS plays in apoptosis has been studied since the discovery 
that H2O2 exposure induces apoptosis (Pierce et al., 1991). Apoptosis, also 
known as programmed cell death, is controlled through the inhibition of anti-
apoptotic proteins and the activation of pro- apoptotic proteins. There are two 
forms of apoptosis that take place in the cell, that  are called extrinsic receptor-
mediated apoptosis and intrinsic mitochondrial-associated apoptosis, and ROS 
plays a role in regulating both forms of apoptosis (Simon et al., 2000).  Extrinsic 
receptor-mediated apoptosis involves a variety of signalling cascades.  Nuclear 
factor–kappa beta (NF-κβ) is an anti-apoptotic protein that upon exposure to ROS 
is inhibited leading to apoptosis (Morgan and Liu, 2010). Also, apoptosis 
regulating kinase -1 (ASK-1) activity is controlled through ROS (Soga et al., 
2012). ASK-1 is inhibited under low levels of ROS through an association with 
thioredoxin 1 (Trx1). Upon exposure to ROS several key thiols of Trx1 are 
oxidized leading to its dissociation from ASK-1. Activated ASK-1, activates c-Jun 
N-terminal kinases (JNK) and active JNK signalling leads to increased release of 
pro-apoptotic protein cytochrome C and the phosphorylation mediated 
inactivation of anti-apoptotic protein, B-cell lymphoma 2 (BCL-2) (Yamamoto et 
al., 1999). Increased mitochondrial ROS leads to triggering of the intrinsic 
apoptosis pathway leading to the formation of pores in the outer mitochondrial 
membrane, this triggers the translocation of cytochrome C from the 
intermembrane space to the cytoplasm. In the cytoplasm, cytochrome C binds to  
Apoptotic protease activating factor 1 (Apaf-1)  and triggers the caspase cascade 
leading to cell death (El-Osta and Circu, 2016). Photodynamic therapy is often 
used for the treatment of breast and bladder cancer due to it being minimally 
invasive and with few associated side-effects. This therapy increases the levels 
of ROS, in particular highly cytotoxic singlet oxygen, through the interaction a 
specific wavelength of light, a photosensitiser and molecular oxygen (Jarvi et al., 
2012). 
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1.3 Cellular defences against ROS 
To combat the ever-present damage inflicted by ROS, the cell has 
developed an effective antioxidant defence system that comprises enzymatic 
(including; SOD, catalase (CAT) and glutathione peroxidase (GPX)) and non-
enzymatic components (including; vitamin E, vitamin A, thioredoxin and 
glutathione) that serve to remove them.  
1.3.1 Enzymatic antioxidants  
  Enzymatic antioxidants constitute the first line defence again ROS 
through suppressing or inhibiting ROS accumulation in cells (Ighodaro and 
Akinloye, 2017). SODs protect cells from the damaging and potent oxidizing 
effects of superoxide and limit the formation of hydroxyl radicals and nitric 
oxide. SODs function to covert two superoxide anions to molecular oxygen and 
H2O2, which can be later neutralised by catalases or glutathione peroxidases 
(Figure 1.2). SODs are a family of metalloenzymes that utilize metal ions as co-
factors, such as; zinc (Zn), copper (Cu) and manganese (Mn), for the 
dismutation of superoxide. Family members not only vary in the identity of their 
associated metal co-factor but also their localization. Due to the large 
associated superoxide production, mitochondria express SOD isoenzymes. 
SOD2, also known as manganese superoxide dismutase (MnSOD), is 
expressed in the matrix of mitochondria. By contrast, CuZnSOD, also known as 
SOD1, is associated with the inner membrane of the mitochondria. Cytochrome 
C, located in the inner membrane space can also interact with superoxide 
leading to the generation of oxygen and the reduction of cytochrome C. 
Reduced cytochrome C alters the pH of the inter membrane space and leads to 
the spontaneous dismutation of superoxide. Extracellular SOD (ECSOD), also 
known as SOD3, is associated with the extracellular space (Azadmanesh and 
Borgstahl, 2018; Turrens, 2003; Ighodaro and Akinloye, 2017). Accumulation of 
hydrogen peroxide through the dismutation of superoxide carried out by SOD 
isoenzymes, can be damaging to the cell. Also, H2O2 can be converted to 
hydroxyl radicles through the Fenton reaction in the presence of iron (Figure 
1.3). The Fenton reaction is commonly associated with cellular damage.  
  CAT is predominantly found in peroxisomes and functions to prevent the 
build-up of hydrogen peroxide by neutralizing it to molecular oxygen and water 
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by utilizing either iron or manganese as a co-factor (Shin et al., 2018). GPX 
isoenzymes are found in several cell compartments and function to neutralize 
H2O2 through the use of selenium as a co-factor coupled with the oxidation of 
glutathione. GPX is also involved in the conversion of lipid peroxidases to their 
corresponding alcohols and therefore limit lipid peroxidation. Since CAT is not 
expressed in mitochondria, GPX is responsible for the neutralization of all 
mitochondrial associated H2O2 (Ighodaro and Akinloye, 2017;Winterbourn, 
2013). GPXs show a higher affinity for H2O2 than CAT, and under normal 
homeostatic conditions the majority of H2O2 is degraded by GPXs. However, 
when H2O2 is expressed at very high concentrations both GPXs and CAT are 
activated (Shin et al., 2018). 
Mutations and deficiency in SOD, CAT and GPX isoenzymes have been 
implicated in a wide range of pathological disorders, highlighting the importance 
of enzymatic antioxidants in combating oxidative stress. 
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Figure 1.2:  Reactions catalysed by enzymatic antioxidants 
 
Figure 1.3: The Fenton reaction  
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1.3.2 Non-enzymatic antioxidants   
Non-enzymatic antioxidants function as the second line defence against 
ROS through scavenging radicals via donating an electron (Ighodaro and 
Akinloye, 2017).   
Vitamin C (also known as ascorbate) and vitamin E (also known as α-
tocopherol) are important water-soluble antioxidants provided from dietary 
sources. Vitamin C also functions as a co-factor for several other enzymes. Lipid 
peroxidation is a potentially damaging free radical chain reaction that contributes 
to the development of several diseases and vitamin C protects against lipid 
peroxidation through scavenging ROS. By contrast, vitamin E is a potent peroxyl 
radical (ROO•) scanger that limits lipid peroxidation. The hydroxyl group of 
vitamin E interacts with the peroxyl radical leading to the formation of lipid 
hydrogen peroxide and the vitamin E radical (Vit E-O•), which can then be 
reduced back to vitamin E through interaction with vitamin C, a process called 
vitamin E recycling (Traber and Stevens, 2011; McCay, 1985; Traber and 
Atkinson, 2007). Due to their potent antioxidant abilities, both vitamin C and 
vitamin E are attractive therapeutics. However, clinical trials involving theses 
vitamins have had very disappointing and conflicting results (Gaziano et al., 
2009).  
In mammalian cells thiol dependant antioxidant systems exist that are 
based around; glutathione (see chapter 5 for more detailed description) and Trx, 
both of which are thought to function in parallel within the cell but also engage in 
cross-talk. Trx has several important functions in the cell that include: the direct 
scavenging of ROS, reducing key cysteine residues in transcription factors 
leading to enhanced DNA binding, supplying reducing equivalents for the DNA 
synthesis enzyme ribonucleotide reductase and functioning as an electron 
donner for thioredoxin peroxidases (Mustacich and Powis, 2000;Lu and 
Holmgren, 2014). The biological activity of Trx arises from key cysteine residues 
located in the catalytic site, these cysteine residues are oxidized upon interaction 
with the substrate and then converted back to the reduced form by the NADPH-
dependant flavoenzyme, thioredoxin reductase (TrxR). There are distinct pools 
of Trx in the cell, the cytosolic pool utilizes Trx1 and TrxR1 isoforms  and the 
mitochondrial pool uses Trx2 and TrxR2 isoforms (Collet and Messens, 2010).  
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1.4 The NRF2 antioxidant defence system  
The ubiquitously expressed transcription factor, Nuclear factor erythroid 2-
related factor 2 (NRF2) is regarded as the master regulator of cellular oxidative 
stress defences through its ability to regulate the basal and inducible expression 
of wide range of target genes, some of which encode proteins with antioxidant 
activities. NRF2 is thought to be involved in the trans-activation of over 200 target 
genes, the majority of which are cytoprotective (Rojo de la Vega et al., 2018).  
1.4.1 Discovery of NRF2 
NRF2 was first identified in 1994 through a screen of a λgt 11 cDNA 
expression library isolated from K562 cells using a tandem repeat recognition 
probe with an extended activator protein -1 (AP-1) sequence (Moi et al., 1994). 
One of the clones that was isolated was identified as a ubiquitously expressed 66 
kDa protein with a cap’n’collar basic-region leucine zipper (CNC-bZIP) binding 
domain in its C-terminus and an acidic activator domain in the N-terminus. These 
researchers, gave this protein the name NRF2, the third member of the CNC-
bZIP family of proteins to be discovered.  
1.4.2 CNC-bZIP family members  
Members of the CNC-bZIP family include the following: caenorhabditis 
elegans (c.elegans) skinhead-1 (SKN-1) protein, drosophila melanogaster 
cap’n’collar protein (CncC), nuclear factor-erythroid 2 p45 subunit (NF-E2 p45), 
nuclear factor erythroid 2-related factor 1 (NRF1, gene name NFE2L1), NRF2 
(gene name NFE2L2), nuclear factor erythroid 2-related factor 3 (NRF3, gene 
name NFE2L3) and related proteins BTB and CNC homology 1(BACH1) and 
BACH2. Family members are characterized according to the presence of a 43-
amino acid homology region called the cap’n’collar (CNC) domain, located 
immediately at the N-terminus of the basic DNA binding domain.  
NF-E2 p45, expressed only in haematopoietic tissues, is the founding 
member of the CNC-bZIP family of proteins. The bZIP domain of NF-E2 p45 
shows extensive homology with both the drosophila CNC protein and the c.elgans 
protein SKN-1, and is thought to be involved in the activation of transcription 
(Kotkow and Orkin, 1995). In mice, knock out (KO) of NF-E2 p45 causes 
extensive haemorrhaging, as it regulates several critical genes involved in 
platelet production (Shivdasani et al., 1995).  
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Family members NRF1 and NRF2 are both ubiquitously expressed, 
control the expression of antioxidant response element (ARE) containing genes 
and both dimerize with small musculoaponeurotic fibrosarcoma (Maf) proteins 
(Bugno et al., 2015). However, there are several differences between the two 
CNC-bZIP family members. NRF1 KO in mice is embryonically lethal (Chan et 
al., 1998), whereas NRF2 KO mice are viable with no adverse phenotype (Chan 
et al., 1996). This highlights that these two transcription factors cannot 
compensate for each other. NRF1 is either associated with the ER membrane 
though its N-terminal domain (NTD), a domain which is absent from NRF2 (Figure 
1.4), or in the nucleus in its active form. For NRF1 to be activated it requires 
deglycosylation of several Asn residues, followed by proteolytic cleavage, this 
process is not required for NRF2 to be activated (Zhang et al., 2007b). Both NRF1 
and NRF2 are regulated at a transcriptional and a post-translational level. The 
levels of NRF2 are principally controlled through association with the cytoplasmic 
negative regulatory protein, Kelch-like ECH-associated protein 1 (KEAP1), 
resulting in 26S proteasomal degradation of the transcription factor (this will be 
discussed in detail later). NRF1 can also be bound by KEAP1, however this does 
not lead to the degradation of NRF1 (Zhang et al., 2006b). NRF1 has been shown 
to degraded through interactions with the F-Box and WD repeat domain-
containing 7 (FBW7) protein (Biswas et al., 2011), the beta-transducin repeat 
containing (β-TrCP) complex and the endoplasmic reticulum associated 
degradation (ERAD) ligase, Hrd1 (Tsuchiya et al., 2011). The transcriptional 
activity of NRF1 has also been shown to be influenced by both glycogen synthase 
kinase-3 (GSK-3) (Biswas and Chan, 2012)  and casein kinase 2 (CK2) (Tsuchiya 
et al., 2013).  
NRF3, unlike NRF1 and NRF2, is not ubiquitously expressed but is highly 
expressed in placenta and B-cells (Kobayashi et al., 1999). NRF3 KO mice are 
viable with no adverse phenotype (Derjuga et al., 2004). NRF3, like NRF1, due 
to its NTD is sequestered to the ER and must undergo deglycosylation of Asn 
residues and proteolytic cleavage for activation (Nouhi et al., 2007; Zhang et al., 
2009). Like both NRF1 and NRF2, NRF3 dimerises with small Maf proteins and 
binds to target genes containing ARE sequences. Also, NRF3 has been shown 
to be degraded by Hrd1 and β-TrCP (Chowdhury et al., 2017; Chevillard and 
Blank, 2011).  
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There is thought to be significant overlap in the ARE-containing genes that 
are trans-activated by NRF1 and NRF2. For example several genes involved in 
fatty acid metabolism have been shown to regulated by both NRF1 and NRF2 
(Tsujita et al., 2014). Due to their diverse subcellular localizations it is thought 
that NRF1, NRF2 and NRF3 may work in concert to mediate oxidative stress 
defences in the cell.  
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Figure 1.4: Domain structure of the three related CNC-bZIP transcription factors 
NRF1, NRF2 and NRF3. 
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1.4.3 Structure of NRF2  
Mouse NRF2 is composed of 597 and human NRF2 of 605 amino acids. 
NRF2 can be divided into seven highly conserved protein domains, called NRF2-
ECH homology (Neh) domains 1 – 7 (Figure 1.5). This nomenclature was chosen 
due to the extensive shared sequence identity of human NRF2 with the chick 
orthologue protein, erythroid cell-derived protein with CNC homology (ECH). 
Each of these seven Neh domains has a distinct function and confers a unique 
element to overall NRF2 signalling (Tebay et al., 2015; Itoh et al., 1995).  
The Neh1 domain of NRF2 contains the CNC-bZIP region, which was first 
characterised in drosophila melanogaster as a DNA-binding region, and is critical 
for the activity of the transcription factor and its ability to dimerize (Mohler et al., 
1991). The Neh2 domain has been demonstrated to be the site interaction with 
KEAP1 and is necessary for KEAP1-dependent degradation of NRF2 protein 
(Itoh et al., 1999). The most C-terminal domain of NRF2, Neh3, has been shown 
to function as a trans-activation domain and interacts with chromodomain 
helicase DNA binding protein 6 (CHD6) (Nioi et al., 2005). Both the Neh4 and 
Neh5 domains have been shown to function as transactivation domains that are 
required for the transcriptional activity of NRF2 (Zhang et al., 2007a). These 
domains also function to cooperatively bind the co-activator CREB binding 
protein (CBP) (Katoh et al., 2002). The Neh5 has also been demonstrated to be 
the interaction site with chromatin remodelling protein, BRG1 (gene name 
SMARCA4) (Zhang et al., 2006a) and the mediator subunit 16 (MED16) (which 
also binds to the Neh1 domain) (Sekine et al., 2016). The Neh6 domain is the 
site of KEAP1-indepedent regulation of the transcription factor through β-TrCP 
mediated degradation and the site of GSK-3 phosphorylation (McMahon et al., 
2004;Chowdhry et al., 2013;Rada et al., 2011). This form of NRF2 regulation will 
be discussed in detail later in Chapter 3. The Neh7 domain is the site of 
interaction with retinoid x receptor alpha (RxRα), which leads to inhibition of ARE-
driven target gene expression (Wang et al., 2013). 
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Figure 1.5: Detailed structure of human NRF2 
Each of the seven Neh domains within NRF2 are indicated on the figure in the grey boxes. 
The size of each domain is indicated below the figure between the stripped arrows. The 
function/ interaction of each domain is highlighted above the schematic.  
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1.4.4 Antioxidant response element (ARE) 
A common feature in all NRF2-target genes is the presence of a cis-acting 
DNA sequence that is responsive to oxidative stress in the promoter region, 
termed the ARE sequence. The ARE sequence was initially discovered in the 
early 1990’s through various mutational and deletion studies of the genes 
encoding the drug detoxification enzymes glutathione S-transferase alpha-2 
(GSTA2) and NAD(P)H dehydrogenase quinone 1(NQO1) (Rushmore and 
Pickett, 1990; Wang and Williamson, 1996; Favreau and Pickett, 1993; 
Rushmore et al., 1991). The significance of ARE sequences has been further 
highlighted through the use of various chemo-preventive agents such as 
butylated hydroxyanisole (BHA)  and ethoxyquin, which are thought to impart their 
anti-cancer effects through inducing the expression of drug detoxification genes 
(Hayes et al., 2000). ARE sequences have now been identified in over 200 genes, 
however it should be noted that ARE sequences show substantial variation (Nioi 
et al., 2003), genes can have multiple ARE sequences and not all ARE 
sequences are functional (Wasserman and Fahl, 1997). The core ARE sequence 
is often described as 5’-TGACNNNGC-3’, where N represents any amino acid 
(Nioi et al., 2003; Tebay et al., 2015). 
1.4.5 NRF2 mechanism of action and interaction with small MAF proteins  
NRF2 activity is dampened under normal homeostatic conditions due to 
the association with KEAP1 (this is discussed in detail in 1.5.2.2). Under 
conditions of oxidative stress or upon exposure to thiol-active electrophilic 
compounds, KEAP1 is altered in such a way that impairs its ability to ubiquitinate 
NRF2. This permits the stabilisation and translocation of NRF2 into the cell 
nucleus. Once in the cell nucleus NRF2 binds to ARE-sequences present in the 
promoter of NRF2-target genes (discussed in 1.4.3) in combination with small 
Maf (sMaf) proteins, resulting in active gene transcription. 
The sMaf family of transcription factors is composed of three members, called; 
MafG, MafF and MafK, which show no functional differences or differential 
expression patterns but can heterodimerize or homodimerize with themselves or 
members of the CNC bZIP family (Motohashi et al., 2004; Yoshida et al., 2005). 
The leucine zipper domain of sMaf proteins have been shown to hetrodimerize 
with the bZIP region in the Neh1 domain of NRF2. This interaction has been 
shown to influence the expression of several ARE-containing genes (Toki et al., 
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1997; Itoh et al., 1997). It is potentially not surprising that sMaf protein have been 
shown to interact with ARE sequence found in NRF2-target genes as this 
sequence closely resembles the Maf recognition element sequence, 
TGCTGAC(G)TCAGCA (Katsuoka et al., 2005; Yoshida et al., 2005). Small Maf 
protein expression is tightly regulated with high expression levels being 
associated with transcriptional repression. Oxidative stress (predominantly 
exposure to H2O2) and heat shock have both been shown to alter the expression 
pattern of small Maf proteins and therefore can regulate the expression of NRF2-
target genes (Blank, 2008).  
1.4.6 Genes regulated by NRF2  
To date there are over 200 validated NRF2-target genes that can be 
described broadly as cytoprotective. The control of such a large cohort of genes 
demonstrates the influence that NRF2 signalling plays in the cell. The 
development of NRF2 KO mice and potent NRF2 inducers has been key to the 
identification of several NRF2-target genes (Chorley et al., 2012; Thimmulappa 
et al., 2002; Hu et al., 2006). NRF2 was first implicated in regulation of the 
expression of target genes involved in drug detoxification, such those encoding 
glutathione s-transferase (GST) isoenzymes and NQO1. Now it its thought that 
NRF2 controls the expression of an array of  target genes that can be broadly 
divided into the following twelve subgroups: drug detoxification, glutathione-
based antioxidants, thioredoxin-based antioxidants, pentose phosphate pathway 
and NADPH regeneration, purine synthesis, iron sequestration, stress markers, 
proteasome subunits, serine/glycine biosynthesis, apoptotic proteins, autophagy-
related proteins and oxidative stress defences (a list of some NRF2-target genes 
that fall into theses twelve subgroups is given in Table 1.1.). Some differences 
exist between the magnitude of induction of certain NRF2-target genes between 
mice and humans. For example, in humans NRF2 robustly regulates the 
expression of certain aldo-keto reductase (AKR) family members but not GST 
isoenzymes, however the converse is seen in mice. By contrast NQO1 
expression is highly induced upon activation of NRF2 in both humans and mice 
(Tebay et al., 2015).   
Due to the extensive homology between NRF1 and NRF2, it was originally 
thought that both transcription factors could potentially control the same target 
genes. However, NRF1 KO mice are embryonically lethal, whereas NRF2 KO 
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mice are viable, suggesting that the two transcription factors have different 
functions. Generation of a hepatocyte specific NRF1 KO mice revealed that a 
loss of NRF1 does not affect the expression of prototypic NRF2 target genes but 
decreases the expression of ARE- containing target genes involved in stress 
reposes, glycolysis and transport of xenobiotics (Ohtsuji et al., 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24 
 
 
Biochemical 
function Short gene name Full description 
Drug 
detoxification 
ABCB6 ATP-binding cassette, subfamily B (MDR/Tap) member 6 
AKR1B10 Aldo-keto reductase family 1, B10 
AKR1C1 Aldo-keto reductase family 1, C1 
AKR1C3 Aldo-keto reductase family 1, C3 
NQO1 NAD(P)H: quinone oxidoreductase 1 
NFE2L2/ 
KEAP1 
expression 
NFE2L2 Nuclear factor (erythroid-derived 2)-like 2 
KEAP1 Kelch-like ECH-associated protein 1 
 
Antioxidants: 
GSH-based  
GCLC Glutamate-cysteine ligase catalytic subunit 
GCLM Glutamate-cysteine ligase modifier subunit 
GPX2 Glutathione peroxidase 2 
SLC7A11 Sodium-independent cysteine-glutamate antiporter 
Antioxidants: 
TXN-based 
PRDX1 Peroxiredoxin 1 
PRDX6 Peroxiredoxin 6 
SRXN1 Sulfiredoxin 1 
TXNRD1 Thioredoxin reductase 1 
TRDX Thioredoxin 
Pentose 
phosphate 
pathway (PPP) 
enzymes and 
NADPH 
generation 
G6PD Glucose-6-phosphate dehydrogenase 
IDH1 NADP-dependent isocitrate dehydrogenase 
ME1 Malic enzyme 1 
PGD 6-phosphogluconate dehydrogenase 
TALDO1 Transaldolase 
 
Purine 
synthesis  
MTHFD2 Methylenetetrahydrofolate dehydrogenase 
PPAT Phosphoribosyl pyrophosphate amidotransferase 
Iron signalling  
FTH1 Ferritin heavy polypeptide 
FTL Ferritin light polypeptide 
HMOX1 Heme oxygenase 1 
 
Proteasome 
subunits  
PSMA1 Proteasome subunit alpha type-1 
PSMA4 Proteasome subunit alpha type-4 
PSMB5 Proteasome subunit beta type-5 
PSMC1 Proteasome AAA-ATPase subunit Rpt2 
 
Serine/glycine 
biosynthesis 
PHGDH Phosphoglycerate dehydrogenase 
PSAT1 Phosphoserine aminotransferase 1 
SHMT2 Serine hydroxymethyltransferase 2 
Apoptotic 
proteins BCL2 B-cell lymphoma 2 
 
Autophagy  
SQSTM1 Sequestosome 1 (p62) 
ATG7 Autophagy protein 5 
ATG5 Autophagy protein 7 
CALCOCO2 Calcium binding and coiled – coil domain 2 
ULK1 UNC-51 autophagy activating kinase 1 
LC3B Microtubule-associated protein 1A/1B-light chain 3 B (LC3B) 
GABARAPL1 Gamma-aminobutyric acid receptor-associated protein 
Table 1.1: A list of genes regulated by NRF2 divided in different subgroups according 
to their function. 
25 
 
1.5 Molecular regulation of NRF2  
As NRF2 controls a plethora of ARE-containing target genes involved in a 
wide range of cellular processes and so several forms of molecular regulation 
exist to control the levels and the activity of the bZIP-CNC transcription factor in 
the cell. NRF2 is regulated at both a transcriptional and post-translational level 
and dysregulation of these molecular regulation events is often implicated in the 
development of disease. 
1.5.1 Transcriptional regulation of the NFE2L2 gene   
The ability to upregulate expression of drug-metabolizing enzymes is 
critical for cell survival upon exposure to stress. Several genes encoding drug-
metabolizing enzymes contain either ARE or xenobiotic response element (XRE) 
DNA sequences in their promoters. The transcription factor aryl-hydrocarbon 
receptor (AhR) binds to XRE sequences whereas NRF2 binds to ARE 
sequences. It was originally thought that these pathways were completely 
independent of each other but it has now been revealed that there is some degree 
of cross-talk between the two (Hayes et al., 2009). Multiple XRE sequences have 
been identified in NRF2 (Miao et al., 2005) which can be induced by AhR and the 
effect of compounds that induce ARE-driven gene expression has been shown 
to be reliant on the presence of AhR (Miao et al., 2004). Contrastingly, the 
induction of several AhR-target genes has been shown to be dependent on NRF2 
(Yeager et al., 2009; Ma et al., 2004). Also, though deletion and mutagenesis 
analysis it has been revealed that NFE2L2 contains two weak ARE-like 
sequences in its promoter region thereby enabling NRF2 to autoregulate its own 
expression (Kwak et al., 2002). 
Additionally, NFE2L2 contains a TPA-response element (TRE) within the 
ARE site which allows increased NFE2L2 transcription by the Kirsten rat sarcoma 
(KRAS) gene (Tao et al., 2014; Raghunath et al., 2018; DeNicola et al., 2011).  
1.5.2 Post-translational regulation of NRF2  
NRF2 is principally controlled at a protein stability level, with low and high 
levels of NRF2 being detrimental to cellular health.  In the cell, NRF2 is constantly 
being synthesized and degraded to allow a pool of rapidly available NRF2 to 
mediate the rapid cellular response upon detection of stress and attenuation of 
its turn-over. There are two main routes by which NRF2 is post-translationally 
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regulated, namely, KEAP1-dependent regulation and KEAP1-independent 
regulation, both of which result in 26S proteasomal degradation of the 
transcription factor.  
1.5.2.1 KEAP1-dependent degradation of NRF2 
Under homeostatic conditions ARE-containing gene expression is low due 
to KEAP1 impeding NRF2 transcriptional activity through controlling both the 
subcellular localization and rapid degradation of the transcription factor (Itoh et 
al., 2003). 
KEAP1 is a member of the BTB-Kelch family of proteins that functions as 
a substrate adaptor protein for the cullin 3 (CUL3) RING-box 1 (Rbx1) E3 
ubiquitination ligase complex (designated CRLKEAP1) to mediate 26S proteasomal 
degradation of target proteins (Pintard et al., 2004; Zhang et al., 2004). KEAP1 
is homodimer composed of five domains. As shown in Figure 1.6, the domains in 
KEAP1 are: the N-terminal region (NTR), a broad complex, tram-track, bric-a-
brac (BTB) domain which is responsible for the critical dimerization of KEAP1 
(Zipper and Mulcahy, 2002) and binding to CUL3, the cysteine rich intervening 
region (IVR), a Kelch-repeat domain which contains six Kelch-repeats that form 
a six-bladed b-propeller structure (Li et al., 2005; Canning et al., 2015). The Kelch 
repeat domain of KEAP1 binds to the amino-terminal Neh2 domain of NRF2  
which was originally thought to lead to impaired nuclear translocation of the 
transcription factor and thus decreased NRF2-target gene expression (Itoh et al., 
1999). However, it is now widely excepted that the binding of KEAP1 to the Neh2 
domain leads to the ubiquitination and proteasomal degradation of NRF2 (Itoh et 
al., 2003; McMahon et al., 2003). Several models have been proposed to explain 
the interaction between KEAP1 and NRF2, with the most widely excepted model 
being the two-site binding mechanism of the ‘hinge and latch’ model (also known 
as the ‘two-site tethering’ mechanism) (Tong Kit et al., 2006; McMahon et al., 
2006). This model is founded on that concept that two subunits of KEAP1 bind to 
one subunit of NRF2 through each KEAP1 subunit within the dimer binding to a 
different motif in the Neh2 domain (Figure 1.7). Importantly, it has also been 
proposed that the  KEAP1 dimer binds first to a high-affinity ETGE motif (hinge) 
and then subsequently to a 100-fold lower-affinity DLG motif (latch) (Tong et al., 
2006). Mutagenesis studies have revealed that the ETGE motif is essential for 
KEAP1 interaction with the Neh2 domain and the turnover of NRF2 (Kobayashi 
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et al., 2002;McMahon et al., 2003). Moreover, the bottom face of the b-propeller 
structure of KEAP1 is positively charged due to the presence of highly conserved 
Arg residues, which may form an electrostatic interaction with the acidic ETGE 
motif (Li et al., 2005). The Neh2 domain also contains a cluster of seven highly 
conserved Lys residues that have been shown to be critical for KEAP1-mediated 
ubiquitination of NRF2 (Tong et al., 2006;McMahon et al., 2006). Interaction of 
KEAP1 with cytoskeletal actin filaments has been shown to provided scaffolding 
that is essential for KEAP1 function (Kang et al., 2004). 
Under conditions of oxidative stress or upon exposure to electrophilic/thiol 
based compounds, several key cysteine residues in KEAP1 become modified 
and NRF2 can no longer be ubiquitinated (Itoh et al., 2003). NRF2 becomes 
locked in a conformation bound to KEAP1 in the cytoplasm. This leads to the 
accumulation and nuclear translocation of newly synthesized NRF2 as it can 
bypass the CRLKEAP1 complex. The fate of KEAP1 after cysteine modification is 
still under debate with some groups suggesting that KEAP1 becomes the target 
of CUL3 ubiquitination followed by degradation through a proteasome-
independent route (Zhang et al., 2005) and others suggesting it is degraded 
though autophagy (Taguchi et al., 2012).   
KEAP1 is regarded as a cysteine-rich protein with an average cysteine 
content of 4%, which is double that found in most proteins (Hansen et al., 2009; 
Tebay et al., 2015). There are 27 cysteine residues present in human KEAP1 and 
25 in the mouse protein. Interestingly, several of these cysteines are located next 
to positively charged amino acids which maintains them in a thiolate anion state. 
These cysteines residues have been extensively demonstrated to be the sensors 
of a variety of inducers leading to the hypothesis of the cysteine code, which 
hypothesises that different inducing compounds will modify different 
combinations of cysteine residues to modulate the NRF2 stress response 
pathway (Dinkova-Kostova et al., 2017). The best characterized and most studied 
cysteine is Cys-151 which is located in the BTB domain of KEAP1 (Figure 1.8) 
and has been shown to be the sensor for sulforaphane (SFN) (Zhang et al., 
2004;Zhang and Hannink, 2003), nitric oxide (McMahon et al., 2010), CDDO-
imidazolide (CDDO-Im) (Saito et al., 2016) and tert-butylhydroquinone (t-BHQ) 
(Takaya et al., 2012). Modification of Cys-151 by all three of these electrophiles 
or mutations of this site to a Ser residue leads to the activation of NRF2 through 
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inhibition of KEAP1 (Zhang et al., 2004). Cys-273 and Cys-288 are in the IVR 
domain and are essential for the ubiquitination of NRF2 (Zhang and Hannink, 
2003). Cys-273 can sense prostaglandins that are Michael reaction acceptors 
and Cys-288 can sense alkenals (McMahon et al., 2010; Kobayashi et al., 2009; 
Saito et al., 2016). Also, endogenous reactive metals, such as zinc (Zn2+), 
increase in the presence of chemical stressors and lead to activation of the NFR2-
signaling pathway through a non-covalent interaction with His-225,Cys-226 and 
Cys-613 (McMahon et al., 2010). ROS can also directly interact with cysteine 
residues of KEAP1 to stimulate NRF2 activity. Hydrogen sulphide (H2S) and H2O2 
have been shown to directly modify Cys-613 and Cys-226, inhibiting KEAP1 
activity (Hourihan et al., 2012; Fourquet et al., 2010). Also, several enzymes, 
such as PTEN, PARKIN, GAPDH contain highly reactive cysteine residues in 
there activate site, meaning that their activity can be strongly influenced by ROS 
levels (Go et al., 2015). 
Work by Ben Major and colleagues has revealed that KEAP1 not only 
binds NRF2 but can function as a substrate adaptor protein for several other 
proteins. These other KEAP1-binding proteins can function as indirect regulators 
of NRF2 activity through outcompeting NRF2 for KEAP1 binding, resulting in 
enhanced nuclear NRF2; this concept is discussed in more detail in Chapter 5 
(Hast et al., 2013).  
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Figure 1.6: Structure of human KEAP1 protein 
Different domains of KEAP1 are indicated in the light grey boxes. The size of each domain is 
highlighted below the figure between the striped arrows. The function/interaction of each 
domain is highlighted above the schematic.  
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Figure 1.7: Hinge and latch model of the interaction between KEAP1 and NRF2 binding.  
The DLG and ETGE motif sequences in the Neh2 domain to which KEAP1 binds are indicated 
above the schematic of human NRF2. KEAP1 is represented as a dimer; of which the Kelch 
domain binds NRF2 and the BTB domain interacts with CUL3/RBX1. 
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Figure 1.8: Location of four reactive Cys residues found within human KEAP The 
domains of human KEAP1 are shown in the grey boxes. The size of each domain is indicated 
below the figure between the striped arrows. The locations of four reactive Cys residues (C) 
are indicated above the schematic. 
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1.5.2.3 KEAP1–independent degradation of NRF2 
As discussed above, KEAP1 is responsible for the cytoplasmic regulation 
of NRF2 through stimulating ubiquitin-mediated degradation of the transcription 
factor. The nuclear regulation of NRF2 is considerably less well characterised 
and is mediated by a separate KEAP1-independent degradation route involving 
GSK-3 and the SCFβ-TrCP ubiquitin complex; this will be discussed in detail in 
Chapter 4.  
1.5.3 Metabolic regulation of NRF2 by AMPK and mTOR 
AMP-activated protein kinase (AMPK) functions to regulate several 
metabolic processes in the cell, such as proliferation, lipid metabolism, glucose 
metabolism and autophagy, which are also influenced by NRF2-signaling 
suggesting that there is a degree of cross-talk between theses pathways. AMPK 
is a serine/ threonine protein kinase that functions as an energy sensor and is 
activated under low levels of ATP to stimulate the production and decrease the 
consumption of ATP in the cell (Herzig and Shaw, 2018). Several groups have 
shown that AMPK directly interacts with NRF2 through phosphorylation of the 
CNC-bZIP protein at either Ser-40 or Ser-550, leading to enhanced nuclear 
accumulation of the transcription factor and increased expression of the NRF2-
target genes, NQO1 and HMOX1 (Mo et al., 2014;Joo et al., 2016).  
  NRF2 activity is also influenced by the mechanistic target of rapamycin 
(mTOR) pathway which dictates the activity of both NRF2-regulatory proteins 
KEAP1 and β-TrCP. The mTOR protein is a serine/threonine kinase that is exists 
in two structurally and functionally distinct protein complexes called; mTORC1 
and mTORC2, which function to regulate protein synthesis and autophagy. 
Hence alterations in the mTOR pathway are implicated in the development of 
several diseases, such as cancer which often have associated aberrant mTOR 
signalling (Laplante and Sabatini, 2012). The mTORC1 pathway regulates 
KEAP1 activity through phosphorylation of the autophagy adaptor protein, p62 at 
Ser-351 (Ichimura et al., 2013). Phosphorylation of p62 increases its affinity 
towards KEAP1 leading to KEAP1 degradation through autophagy and enhanced 
nuclear NRF2. The mTORC2 pathway influences NRF2 degradation through 
inactivating GSK-3 via phosphorylation of AKT at Ser-473, a site critical for AKT 
activity (Sarbassov et al., 2005). Inactivation of GSK-3 impairs the formation of 
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the phosphodegron motif to which the substrate adaptor protein β-TrCP binds, 
leading to enhanced NRF2 activity. 
1.5.4 Other proteins that regulate NRF2  
Regulation of NRF2 by KEAP1 and β-TrCP are by far the most well studied 
forms of regulation. However, there are additional mechanisms that alter NRF2 
activity but their overall contribution to NRF2 signalling is currently not well 
characterized.  
For example, the E3 ubiquitin ligase Hrd1, which is involved in the ERAD 
pathway, has been shown in the context of liver cirrhosis to ubiquitinate NRF2 
leading to the degradation of the CNC-bZIP protein (Wu and Rapoport, 2018; Wu 
et al., 2014). Acetylation is an important cellular process that involves the 
introduction of functional acetyl groups which can alter protein function. Multiple 
Lys residues in the DNA-binding Neh1 region have been shown to undergo 
acetylation by p300/CBP, under arsenite-induced oxidative stress (Sun et al., 
2009). These acetylation events are required for maximal binding of NRF2 to ARE 
sequences present in the promoters of NRF2-target genes and hence acetylation 
increases NRF2-target gene expression. Conversely the deacetylase sirutin 1 
(SIRT1) has been shown to decrease NRF2 acetylation, leading to impaired ARE 
binding and reduced NRF2-target gene expression (Kawai et al., 2010). 
Under conditions of hypoxia, NRF2 is regulated through a KEAP1-
independent route involving seven in absentia homolog 2 (SIAH2). SIAH2 is a 
key regulator of the hypoxic response that binds directly to NRF2 stimulating the 
proteasomal degradation of the transcription factor (Baba et al., 2013; Baba and 
Miyazaki, 2016).  
Also, NRF2 can undergo polysumoylation by small ubiquitin-related modifier 
1 (SUMO1) and SUMO2, which leads to the translocation of NRF2 to the nucleus.  
Polysumoylated NRF2 is then targeted by the E3 ubiquitin ligase, RING-finger 
protein 4 (RNF4) leading to its degradation (Malloy et al., 2013).  
1.6  The role of NRF2 in disease  
The levels of NRF2 are tightly regulated in the cell, with both low and high 
levels of the transcription factor contributing to the development of disease; high 
levels of NRF2 are associated with the promotion of cancer; and low levels of 
NRF2 are associated with Parkinson’s disease. Multiple mechanisms may lead 
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to abnormal NRF2 expression such as: mutations in KEAP1 and NFE2L2 (the 
gene that encodes NRF2 itself) (Huppke et al., 2017; Taguchi and Yamamoto, 
2017), hypermethylation of the KEAP1 promoter (Hanada et al., 2012) and 
alterations in KEAP1 activity through modification of cysteine residues. The role 
that NRF2 plays in the development of Parkinson’s disease, ageing, diabetes and 
cancer, will now be discussed briefly.  
1.6.1 Neurological disorders: Parkinson’s disease 
Since the emergence of strong evidence indicating the critical role of 
oxidative stress in the etiopathology of PD, research has focused on the 
involvement of NRF2 in this disease (Cuadrado et al., 2009). Nuclear 
accumulation of NRF2 is seen in PD affected neurones suggesting that NRF2 
activity is enhanced in the disease to increase antioxidant defences and combat 
oxidative stress (Ramsey et al., 2007). This interpretation is reinforced by the fact 
that NRF2 protects neurones from toxicity in PD mouse models using rotenone 
and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Todorovic et al., 
2016), as well as drosophila melanogaster models with genetic alterations in α-
synuclein (Barone et al., 2011). MPTP itself has also been shown to reduce the 
expression of NRF2 leading to the development of PD pathophysiology, which 
can be reversed by electroacupuncture which stimulates NRF2 expression (Lv et 
al., 2015). Also, the levels of glutathione, a major antioxidant whose synthesis is 
dependent on NRF2 activity, is lower in neurones from PD patients and NAC 
administration protects neurones against toxicity in transgenic mouse models 
with over expression of α-synuclein (Clark et al., 2010). Dimethyl fumarate (DMF), 
a potent NRF2 activator, has been shown in vivo to protect dopaminergic 
neurones against immune-related toxicity in a NRF2-dependant manner (Lastres-
Becker et al., 2016; Peng et al., 2016). Also, the NRF2 activator taurodeoxycholic 
acid (TUDCA) has shown promising results in vitro (Moreira et al., 2017).  
Accumulation of misfolded proteins leading to stress, is hallmark of PD. 
NRF2 plays a key role in modulating signalling involved in the UPR pathway and 
functions to stimulate α-synuclein degradation (Skibinski et al., 2017). 
1.6.2 Ageing  
The theory of ageing postulates that accumulative exposure the reactive 
oxidants over a lifetime leads to the damage of macro molecules resulting in 
ageing (Harman, 1956). It is now known that oxidative stress due to increase 
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ROS production and an impairment in antioxidant defences is a hallmark of 
ageing  and due to its function as the master regulator of the cell oxidative stress 
defences it is maybe not surprising that impaired NRF2 signalling is implicated in 
ageing (Zhang et al., 2015). However, a lot of contradicting data has been 
produced, with some groups demonstrating elevated NRF2 activity in ageing and 
others showing decreased expression of the transcription factor, but overall it is 
thought that NRF2 activity declines with age (Kuosmanen et al., 2018).  
Ageing studies using human bronchial epithelia cells from non-smoking 
young and elderly adults, show an increased basal expression of NRF2-target 
genes in the cells from the young adults but interestingly impaired induction of 
NRF2-target genes upon SFN treatment in the aged adults (Zhou et al., 2018).  
Also, higher ROS levels and decreased glutathione levels have been shown in 
the cortex of elderly patients and in NRF2 KO mice (Emir et al., 2011; Miller et 
al., 2012). The role that NRF2 plays in ageing has also been studied in the context 
of Hutchinson-Gifford progeria syndrome (HGPS), a rare premature ageing 
disorder found in children. HGPS is characterised by aberrant production of a 
mutant form of lamin protein called progerin, leading to oxidative stress. siRNA 
screens have shown impaired NRF2 signalling is a driver of the disease and the 
progerin protein itself has been shown to sequester NRF2, impairing the 
transcription of ARE-containing antioxidants genes, resulting in oxidative stress. 
Also, activation of NRF2 has been shown to reverse the phenotypic symptoms of 
progeria (Kubben et al., 2016). These data are further supported by work that has 
demonstrated that treatment with SFN enhances progerin clearance and viability 
in HGPS cell cultures (Gabriel et al., 2015).  
1.6.3 Diabetes mellitus  
Diabetes mellitus is a disease characterized by multiple pathophysiology’s 
and high levels of oxidative stress. Activation of NRF2 through genetic alterations 
in KEAP1 and pharmacologically through treatment with CDDO-Im has been 
shown in vivo to prevent the onset of diabetes (Uruno et al., 2013). Similar results 
have been seen with SFN treatment in a high fat fed hypoglycaemic mouse model 
of T2DM (Zhang et al., 2014). Diabetes patients often have impaired wound 
healing leading to development of chronic wound infections. Administration of 
RTA-408, a NRF2 -activator, has been shown to enhance wound healing in in 
vivo models of DM (Rabbani et al., 2018). Another feature of DM is impaired 
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vascular function which can lead to impaired cardiac function. The NRF2 activator 
DH404, a derivative of bardoxylone methyl, has been shown in both in vitro and 
in vivo models of DM to halt vascular injury.  
1.6.4 Cancer   
Unlike Parkinson’s disease, ageing and diabetes, were the antioxidant 
defences are comprised due to decreased NRF2 activity, NRF2 activity is 
increased in cancer cells and is thought to drive tumorigenesis. Cancer cell hijack 
NRF2 signalling and manipulate it to their advantage by promoting angiogenesis 
(Zhou et al., 2012), driving proliferation (Fan et al., 2017) and enhancing 
chemoresistance (Wang et al., 2008a). The complex role NRF2 plays in lung 
cancer will be discussed in detail in Chapter 4. However, it should be noted that 
aberrant NRF2 signalling is not only found in lung cancer, but is also found in 
pancreatic (Chio et al., 2016;Lister et al., 2011), colorectal (Sadeghi et al., 2017) 
and breast (Zhang et al., 2016;Lu et al., 2017) cancer. 
1.7 Project aims  
It is well known that NRF2 plays a role in several oxidative stress related 
diseases and that understanding the molecular mechanisms in place to control 
NRF2 activity is essential to understanding the transcription factor’s contribution 
to pathogenesis.  
The aims of this thesis are:  
• To establish a greater understanding of KEAP1-indepedent 
degradation of NRF2 through studying the involvement of a priming 
kinase. 
• To determine the differences (if any) between mutations in KEAP1 
and mutations in NFE2L2, in terms of their effect on NRF2 signalling.  
• To determine whether any specific vulnerabilities exist in KEAP1 
mutant cells that can be manipulated therapeutically.  
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2. Materials and methods  
2.1 Chemicals and reagents  
All chemicals were of the highest grade and were supplied by Sigma-
Aldrich Ltd (Poole, Dorset, UK), unless otherwise stated. All oligonucleotides 
were purchased from MWG-Eurofins UK LTD (Peartree Bridge, Milton Keynes, 
Buckinghamshire, UK) (sequences are shown in appendix 8.1). Horseradish 
peroxidase (HRP)- conjugated secondary antibodies were purchased from Bio-
Rad Laboratories (Perth, United Kingdom). PageRuler™ Plus Pre-stained protein 
Ladder, Dulbecco’s Modified Eagle Medium (DMEM), Opti-MEM™, Trypsin, 
Lipofectamine™ 2000 Reagent, Lipofectamine RNAiMAX Reagent, Foetal calf 
serum (FCS), Subcloning Efficiency™ DH5a™ Competent cells and TaqMan™ 
gene expression assays were purchased from ThermoFisher Scientific (Paisley, 
Scotland, UK). Competent Escherichia coli (E.Coli) cells BL21(DE3) and Stbl3 
were purchased from New England BioLabs Ltd. (Hitchin, England, UK). The 
following inhibitors: CT99021, MK2206, Harmine and ID-8, were all purchased 
from Selleckc hem (Munich, Germany). CDDO-Methyl ester (CDDO-ME) was 
purchased from Caymen Chemicals (Michigan, United states).  
2.2 DNA cloning and analysis  
2.2.1 Preparation of competent DH5a and BL21 cells 
Commercial stocks of DH5α and BL21 cells were expanded to make fresh 
stocks of competent cells for transformation of plasmids. A 5ml inoculum 
overnight culture was set up using a commercial stock of competent E.coli cells 
in Luria Broth (LB) (1% w/v bacto-tryptone, 0.5% w/v bacto-yeast extract, 171 
mM NaCl, H2O). No antibiotics were added for the preparation of DH5a cells but 
chloramphenicol (34 µg/ml) was used for the preparation of BL21 cells. The 
following day, 2 ml of the overnight culture was used to inoculate 200 ml fresh LB 
and cultured at 37°C in a shaking incubator until the optical density (OD) at 600 
nm reached 0.3-0.4. The culture was then subdivided equally into four 50 ml 
falcon tubes and incubated on ice for 30 min. Cells were then pelleted by 
centrifugation at 2,000 xg for 5 min at 4°C. The pellets were then resuspended in 
16 ml ice cold transformation buffer 1 (10 mM CaCl2.2H2O, 10% (v/v) glycerol, 30 
mM CH3COOK (pH7.5), 50 mM MnCl2.4H2O, 100 mM RbCl -final pH 5.8 obtained 
using 0.2 M acetic acid) and incubated on ice for 15 min. The cells were then 
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pelleted again as before, followed by resuspension of the pellet in 4 ml ice cold 
transformation buffer 2 (75mM CaCl2.2H2O, 0.15% (v/v) glycerol, 10 mM MOPS 
pH 6.8, 10 mM RbCl). The cells were then stored as 100 µl aliquots at -80°C.  
2.2.2 Transformation of plasmid DNA into competent cells  
Competent cells (50-100 µl) were mixed with 10-100 ng DNA and 
incubated on ice for 30 min. A heat shock treatment of 42°C for 45 sec was given, 
and the reaction mix was then incubated on ice for an additional 2 min. 500 µl LB 
was then added, and the reaction mix was incubated at 37°C for 45 min in a 
shaking heat block/water bath. Cells were pelleted by centrifugation at 16,000 xg 
for 1 min, resuspended in 30 µl fresh LB (without antibiotics) and spread evenly 
over an LB agar (1% w/v bacto-tryptone, 0.5% w/v bacto-yeast extract, 171 mM 
NaCl, 1.5% w/v bacto-agar, H2O) plate containing the appropriate antibiotic. 
Plates were then incubated overnight at 37°C to allow the formation of colonies 
which were picked the next day.  
2.2.3 Plasmid DNA Isolation – plasmid miniprep and maxiprep  
Bacterial colonies were inoculated in appropriate growth media (LB broth 
with selection antibiotics), expanded and prepped to extract plasmid DNA for 
sequencing and experimental use. On average three individual bacterial colonies 
were selected from one successfully transformed agar plate. They were screened 
for the plasmid of interested by inoculating a 5ml LB supplemented with antibiotic 
mini-culture and incubating overnight at 37°C in a shaking incubator, followed by 
isolation of the plasmid DNA using a QIAprep spin miniprep Kit (QIAgen, Hilden, 
Germany) according to manufactures guidelines, and sending to sequencing. 
After sequencing had confirmed the successful isolation of the desired plasmid, 
the construct was transformed and a 5 ml mini-culture set up as before but 
incubated only for 6 hr before using 4 ml of this mini-culture to inoculate an 400 
ml LB-antibiotic culture. This larger culture was incubated overnight at 37°C in a 
shaking incubator. The next day, plasmid DNA was isolated using the HiSpeed 
plasmid maxi kit (QIAgen) according to manufacturer’s guidelines.  
The concentration and purity of isolated plasmid DNA was determined by 
measuring its absorbance at 260 nm using a NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, Inc., Delaware, United States). 
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2.2.4 Production of glycerol stocks from bacterial cultures  
Glycerol stocks were prepared for every new plasmid (either generated or 
resourced) for long term storage. An 800 µl aliquot of the overnight large 
maxiprep culture was mixed with 200 µl 50% glycerol (diluted in H2O) in a 
cyrotube. Glycerol stocks were stored at -80°C. When required a small stab of 
the glycerol stock was removed and used to inoculate a 400 ml LB culture, 
supplemented with the required antibiotic.  
2.2.5 Restriction digestion and ligation  
To excise plasmid DNA from one vector to transfer it to another, restriction 
digests and ligations were carried out. All restriction digests were carried used 
FastDigest restriction enzymes and buffers (ThermoFisher Scientific). A 20 µl 
restriction digest reaction was set up containing: 5 µg DNA, 5 µl 10X FastDigest 
Green Buffer, 2.5 µl restriction enzyme (10,000 U/ml) and the remaining volume 
made up with ddH2O. The reaction mix was incubated 2 hr in a 37°C water bath. 
Successful digestion of the plasmid was confirmed by running the digested 
plasmid on agarose gel (1% agarose in TAE (tris base, glacial acetic acid, 0.5 M 
EDTA pH 8, H2O)) and comparing it with a non-digested control. After digestion, 
the insert DNA was excised from the agarose gel and purified. Purified insert DNA 
was then ligated with new backbone vector digested with the same restriction 
enzymes. Ligation was carried out overnight at room temperature using 1 µl of 1 
U/µl T4 DNA ligase enzyme (ThermoFisher Scientific) using vector and insert 
DNA in 1:3 molar proportion.  
2.2.6 Gel extraction  
To isolate a cut fragment of DNA after restriction enzyme digestion of a 
plasmid, gel extraction was carried out post-electrophoresis. The desired cut 
fragment of DNA was carefully excised from the gel using a scalpel. The fragment 
was purified using the QIAquick gel extraction kit (QIAgen) according to 
manufacturer’s guidelines.  
2.2.7 Site directed mutagenesis  
Primer pairs to insert a single amino acid substitution were designed to include 
the minimal number of base substitutions to encode the new desired amino acid. 
All primer sequences are listed in Appendix 8.1. The thermal cycling conditions 
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for the polymerase chain reaction (PCR) reaction are as described below, and 
the reaction set up was as described in Table 2.2.1. 
1. Initial denaturation at 95°C for 2 min  
2. Denaturation at 95°C for 20 sec  
3. Annealing at 60°C for 10 sec  
4. Extension at 68°C for 30 sec per Kb plasmid length  
5. Final extension at 68°C for 5 min  
Following PCR, DNA was further digested with 1.5 µl Dpn1 (per reaction) for 1 hr 
at 37°C to ensure full digestion of any potential methylated parental DNA 
template. The digested product was then transformed and plated onto specific 
antibiotic containing agar plates (see section 2.2.2 for details).  
Component and stock concentration Volume required for 1 reaction (30 µl) 
Template DNA 100 ng 
Forward primer (100 µM) 1.5 µl 
Reverse primer (100 µM) 1.5 µl 
10X PCR Buffer for KOD Hot Start DNA 
Polymerase 5 µl 
2 mM dNTPs 5 µl 
2.5 mM MgSO4 5 µl 
200 U KOD Hot start DNA Polymerase 1 µl 
dH2O X µl 
 
Table 2.2.1 : PCR reaction set up for site directed mutagenesis 
2.2.8 DNA sequencing  
Sequencing was carried out after site-directed mutagenesis and ligation 
reactions to confirm the correct nucleotide sequence using the sequencing 
primers listed in Table 2.2.2. The Genetic Core Services at Ninewells Hospital 
and Medical School, carried out all DNA sequencing. 
Vector/Insert Primer name Sequence (5-3’) 
pGEX pGEX Forward ATA GCA TGG CCT TTG CAG G 
pcDNA 3.1- V5/His T7 TAA TAC GAC TCA CTA TAG GG 
LentiCRISPRV2 SeqLentiCRISPRV2 HR GAG GGC CTA TTT CCC ATG ATT 
 
D17-32 mNrf2 pcDNA 3.1 
v5/His 
D17-32 mNrf2 Internal 
1 Forward 
GAA GGC CTT TTT TGC TCA GTT 
TCA AC 
D17-32 mNrf2 Internal 
2 Reverse 
AGA ATC CTC AAA ACC ATG AAG 
GAA ATG TG 
D17-32 mNrf2 Internal 
3 Forward 
CAC ATT TCC TTC ATG GTT TTG 
AGG ATT CTT TC 
20 cycles  
41 
 
D17-32 mNrf2 Internal 
4 Forward 
CGG AAA TGG AGG AGC TAG ATA 
GTG CCC CTG G 
GST-mNeh6+ pGEX / 
mNeh6- LacZ 
mNeh6+ Forward GCC TTC CTC CGC TGC CAT CAG TCA GTC ACT CTC TG 
mNeh6+ Reverse CAC ATT GGG ATT CAC GCA TAG GAG CAC TGT TC 
pGEX Forward ATA GCA TGG CCT TTG CAG G 
GST-hNeh6+ pGEX pGEX Forward ATA GCA TGG CCT TTG CAG G 
 
Table 2.2.2: Details of primers for DNA sequencing  
2.2.9 Generation of KEAP1KO CRISPR plasmids for stable cell line 
production  
To generate a panel of isogenic cell lines with multiple different genetic 
alterations, several DNA constructs were generated in the LentiCRISPRV2 
vector. The LentiCRISPRV2 plasmid and guide sequence for the generation of 
NRF2 knockout (KO) and NRF2 gain-of-function (GOF) cells were kindly gifted 
by Dr Laureano de la Vega (University of Dundee). This guide sequence was 
directed against the DLG and ETGE KEAP1 binding regions found in the Neh2 
domain of NRF2. Clones that do not repair in frame lead to generation of a NRF2 
KO and those that repair in frame through alteration in the KEAP1 binding site 
generate a NRF2 GOF mutant.  For the generation of KEAP1 KO cell lines paired 
oligonucleotide primers were designed against a region early on in exon 1, to 
ensure the majority of the KEAP1 protein is not transcribed. All guide sequences 
are provided in Appendix 8.2. 
Firstly, 5 µg LentiCRISPRV2 plasmid was digested and dephosphorylated 
with BsmBI for 30 min at 37°C. The composition of this reaction mix was as 
described in Table 2.2.3.  
 
Table 2.2.3 : Reaction composition for digestion and dephosphorylation of LentiCRISPRV2 
plasmids 
Component and stock concentration Volume/ amount required (total volume 60 
µl) 
LentiCRISPRV2 5 µg 
FastDigest BsmBI 3 µl 
FastAP (1U/µl) 3 µl 
10X FastDigest Buffer 6 µl 
100 mM DTT (freshly prepared) 0.6 µl 
ddH2O 34.7 µl 
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The DNA was then ran on a 1% agarose gel in TAE buffer. The larger (~15 
Kb) band of the digested vector plasmid was then gel purified using the QIAquick 
gel extraction kit. Each pair of oligonucleotides were then phosphorylated and 
annealed together as described in Table 2.2.4 under the following thermocycler 
conditions:  
1. 37°C for 30 min 
2. 95°C for 5 min then ramped down to 25°C at 5°C/ min 
Component and stock concentration Volume required (total volume 10 µl) 
Oligonucleotide 1 (100 µM) 1 µl 
Oligonucleotide 2 (100 µM) 1 µl 
10X T4 ligation buffer (New England 
BioLabs) 1 µl 
T4 polynucleotide kinase (New England 
BioLabs) 0.5 µl 
ddH2O 6.5 µl 
 
Table 2.2.4: Reaction set up for phosphorylation and annealing of oligonucleotides  
The annealed oligonucleotide pairs were then diluted 1:200 using ddH2O. 
A ligation reaction to inset the oligonucleotides into the LentiCRISPRV2 
backbone was set up as described below in Table 2.2.5.  
Component and stock concentration Volume/ amount required (total volume 11 µl) 
BsmBI digested plasmid 50 ng 
Diluted oligonucleotide pairs 1 µl 
2X Quick ligase buffer (New England 
BioLabs) 5 µl 
Quick ligase (New England BioLabs) 1 µl 
ddH2O 3 µl 
 
Table 2.2.5: Ligation reaction set up for generation of LentiCRISPRV2 plasmids 
The whole ligation reaction mix was then transformed into Stbl3 competent 
cells and spread evenly across LB agar plates supplemented with ampicillin (see 
section 2.2.2). Colonies were selected followed by DNA preparation using 
QIAprep spin miniprep kit (see section 2.2.3) and sent of sequencing (see section 
2.2.8). After correct insertion was confirmed through sequencing, larger 
quantities of DNA were prepared using HiSpeed plasmid maxi kit and stored at -
20°C until use. Also, glycerol stocks were generated for long term storage (see 
section 2.2.4).  
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2.2.10 Genomic DNA extraction and PCR reaction 
To determine the exact location of the genetic alteration and whether the 
mutations generated are homozygous or heterozygous, genomic DNA was 
extracted from the CRISPR cell lines and sent for sequencing. Cells were allowed 
to reach a confluency of 90% in a 6-well plate before harvesting genomic DNA. 
Cells were trypsinized, pelleted and then genomic DNA was extracted according 
to the manufactures protocol provided with the Nucleospin® Tissue kit 
(Macherey-Nagel, Duren, Germany).  
2.2.11 Sequencing of CRISPR cell lines  
Sequencing of the CRISPR cell lines was kindly carried out by Mr Thomas 
McCartney (MRC Protein Phosphorylation and Ubiquitination centre, University 
of Dundee). Shotgun cloning of the pooled PCR product (generated in 2.2.10) 
into TOPO vectors was carried out. Several clones per cell line were then 
selected, restriction digested with EcoRI to confirm the insert and then sequenced 
with a M13F primer (sequence 5-3’: GTA AAA CGA CGG CCA GT). 
2.3 Protein purification and analysis  
2.3.1 Recombinant protein expression in E.Coli  
To generate purified proteins for use in in vitro kinase assays, plasmid 
DNA was expressed in BL21 cells. All glutathione S-transferase (GST) fusion 
proteins were expressed and purified using E.Coli strain BL21 cells. 50 ng sample 
of the desired plasmid was transformed into BL21 cells and plated on LB-agar 
plates containing 100 µg/ml ampicillin and 34 µg/ml chloramphenicol. Plates were 
incubated at 37°C overnight in an incubator. The following day 2-4 single colonies 
were picked from the plates and grown overnight in a 10 ml culture of LB selection 
media, to prepare a starter culture. 
400 ml LB selection media was then inoculated with 4 ml above overnight starter 
culture and grown at 37° C in a shaking incubator. The OD of the bacterial culture 
was routinely monitored until an OD at 600 nm of 0.4-0.6 was reached. A 1 ml 
aliquot of the culture was collected at this point as a pre-induction sample. 0.5 
mM isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to the remaining 
culture and the cells were allowed to grow at 30°C under shaking conditions for 
4 hr. Another 1 ml aliquot was collected as a post-induction sample. The cells 
were pelted by centrifugation at 6,000 xg for 15 min at 4°C, the supernatant was 
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discarded and the pellet stored at -80°C. To confirm successful protein induction, 
both pre- and post-induction samples were pelleted by centrifugation at 13,000 
xg for 1 min and lysed in 30 µl of 2X NuPAGE™ LDS sample buffer 
(ThermoFisher Scientific), before running the samples on a 10% sodium dodecyl 
sulfate (SDS)-polyacrylamide gel (SDS-PAGE). The gel was stained with 5-10 ml 
SimplyBlue™ SafeStain coomassie (ThermoFisher Scientific) until the 
appearance of visibly clear distinguishable bands (approximately 1 hr). 
Coomasssie was then removed and the gel washed three times for 5 min intervals 
with water to reduce the background stain. Expression of the desired recombinant 
protein was confirmed by bands being present at the correct molecular weight in 
the post- induction sample and absent from the pre- induction sample.  
2.3.2 Protein purification  
All proteins expressed in BL21 cells were purified before experimental use. 
After confirming IPTG induced protein expression, the cell pellet was lysed in 10-
15 ml B-PER™ complete bacterial protein extraction reagent (ThermoFisher 
Scientific) depending on the size of the pellet. The pellet was vortexed and the 
15 ml lysate split equally into two 15 ml falcon tubes before placing on an orbital 
rotor at 4°C for 30 min. Following lysis, the lysate was centrifuged at 10,000 xg 
for 20 min at 4°C and the supernatant collected. The supernatant was then 
passed through 0.22 µm sterile filter and combined in one 15 ml falcon tube. GST-
fusion proteins were all affinity-purified using Glutathione SepharoseÒ 4B beads 
(Sigma-Aldrich), the beads were prepared by repeatedly washing the beads with 
10 volumes of phosphate buffer saline (PBS). 1 ml of GST beads was then 
incubated with 15 ml of lysate for 2 hr on an orbital rotator at 4°C. The beads 
were then pelleted by centrifugation at 13,000 xg for 1 min, and the supernatant 
retained, then washed three times for 5 min intervals with 10 ml wash buffer (50 
mM tris pH 7.5, 150 mM NaCl) on a rotor. The GST-fusion protein was then eluted 
from the beads using 500 µl of elution buffer (50 mM tris pH 8.8, 150 mM NaCl, 
10 mM reduced glutathione, final pH adjusted to pH 7.5) at room temperature for 
30 min. The elution step was repeated twice and 20 µl of each elution was lysed 
directly in 2X NuPAGE™ LDS sample buffer, before running on a 10% SDS-
polyacrylamide gel. Successful purification was confirmed by the presence of 
clear distinguishable bands at the correct molecular weight for the GST-fusion 
protein. Eluted proteins were then combined and injected into a Slide-A-Lyzer™ 
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dialysis cassette (10 K MWCO, ThermoFisher Scientific) then dialysed overnight 
at 4°C in dialysis buffer (50 mM tris pH 7.5, 150 mM NaCl, 10% glycerol), to 
remove the reduced glutathione. The concentration of the purified protein was 
then estimated by carrying out a detergent compatible (DC) assay, followed by 
SDS- PAGE and staining with SimplyBlue™ SafeStain coomassie using known 
bovine serum albumin (BSA) standards. Proteins were aliquoted and stored at -
80°C. 
2.4 Radioactive assays  
2.4.1 In vitro kinase MBP activity assays  
Before determining the ability of various kinases to phosphorylate NRF2 
mini-proteins, activity assays were carried out with each kinase against a well 
characterised substrate. All kinases, except for DYRK4 which was procured from 
ThermoFisher Scientific, were kindly provided by Dr James Hastie (Division of 
Signal Transduction Therapy, University of Dundee). Upon receiving, all kinases 
were assayed against Myelin Basic Protein (MBP). These activity assays ensured 
the same number of units of kinase were added to each reaction so the ability of 
the kinase to phosphorylate NRF2 could be compared with the ability of the 
kinase to phosphorylate MBP, a well-known substrate that is heavily 
phosphorylated. The details of the kinases the assay set up are provided in Table 
2.4.1. 
Component Volume required in a 50 µl assay 
0.1 µg Kinase 5 µl 
MBP (1 mg/µl) 15 µl 
Kinase Assay Buffer (50 mM Tris-Cl, 0.03% 
(v/v) Brij-35, 0.1% (v/v) β-mercaptoethanol) 25 µl 
10 mM MgCl2 and 0.1 mM [g-32P]-ATP 
(approx. 0.5x106 cpm/nmole) 5 µl 
 
Table 2.4.1: Reaction set up for kinase activity assays 
Kinases were diluted to 0.1 µg with kinase dilution buffer (50 mM Tris-Cl, 
0.03% (v/v) Brij-35), then mixed with MBP and kinase assay buffer. The reaction 
start times were staggered by 15 sec to ensure that each reaction was incubated 
for the same time period, by pipetting the 10 mM MgCl2 and 0.1 mM [g-32P]-ATP 
onto the side on the tube and then flicking it down into the reaction mixture and 
placing the tubes in a 30°C heat block while simultaneously starting the timer. 
The reactions were incubated at 30°C for various time points to ensure initial rate 
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conditions were met, before 40 µl of each reaction was spotted onto pencil 
numbered Whatman™Grade P81 ion exchange cellulose chromatography paper 
(Fisher Scientific, product has been discontinued) (1.5x1.5cm2). The papers were 
then dropped into 75 mM H3(PO4) to remove any unreacted ATP and then 
washed four times with 75 mM H3(PO4) for 5 min intervals, using a magnetic 
stirrer. For the final wash the papers were placed in acetone, and then air dried 
prior to scintillation counting in 2 ml Optifluid. As a control two “blanks” were set 
up in parallel that had no kinase present in the reaction mixture, the counts for 
these tubes were then subtracted from all experimental counts. For every new 
radioactive ATP stock pot used, a new ATP counter was made by diluting a 10 
mM ATP probe 1:100 with kinase dilution buffer and taking 10 µl of the dilution 
into a scintillation tube with 2 ml Optifluid. The ATP counter decays at the same 
rate as the ATP stock used in the experiment and therefore helped to determine 
the activity of the kinase.  
The kinase activity was calculated using the following formula:  
Kinase activity (pmol/min/µl) = (((scintillation counts – blank counts)/ (ATP 
activity) / (Assay))) time.  
2.4.2 In vitro kinase assays 
In vitro kinase assays were carried out to determine whether a kinase may 
target several different serine residues in the Neh6 domain of NRF2. Purified 
recombinant GST-tagged mNeh6+ protein, GST-tagged hNeh6+ or single amino 
acid mutants of GST-tagged m/hNeh6+ proteins, generated as described in 
section 2.2.7, were incubated with purified activated recombinant kinase in the 
presence of 10 mM MgCl2 and 0.1 mM [g-32P]-ATP in a 30°C heat block, 
composition of the reaction mix is given below in Table 2.4.2. The length of the 
assay varied between the four groups of kinases, dual specificity tyrosine-
phosphorylation regulated kinase (DYRK) and stress-activated protein kinase 
(SAPK) family members were subjected to a 10 min assay whereas JNKs and 
the “miscellaneous” kinases ((mixed-linage kinase-1 (MLK1), thr/tyr kinase (TTK), 
TANK-binding kinase 1 (TBK1) and cyclin-dependent kinase 9 (CDK9)) were 
tested in a longer 30 min assay. These time points were decided from the 
previous activity assays described above in section 2.4.1. All reactions were 
terminated by the addition of pre-warmed (heated at 75°C for 10 min) 4X LDS gel 
47 
 
loading buffer followed by boiling the sample for 10 min, the sample were then 
loaded on to a SDS-PAGE gel, and the excess [g-32P]-ATP was removed by 
electrophoresis. Gels were then stained with SimplyBlue™ SafeStain coomassie, 
dried onto filter paper and subjected to autoradiography. After which, the protein 
bands were excised and the incorporated radioactivity was determined by 
scintillation counting. “Blanks” containing only the purified protein but no kinase 
were included. Scintillation counts for blank reactions were subtracted from 
experimental readings to account for background radiation. The kinase activity 
towards the Neh6 + was then calculated using the formula given in section 2.4.1.  
 
Table 2.4.2:  Reaction set up for in vitro kinase assays 
2.4.3 In vitro two-step linked kinase assay  
To determine whether a kinase works in concert with GSK-3β to enhance 
GSK-3β mediated phosphorylation of NRF2, in vitro two-step linked kinase 
assays were carried out.  
In the first step, purified recombinant GST-mNeh6+ protein (0.1 µg/µl, 
substrate) or single base pair mutant GST-mNeh6+ proteins (0.1 µg/µl, substrate) 
generated from BL21 cells, were incubated with 2 mU/µl purified activated 
recombinant DYRK2, in the presence of 5 mM MgCl2 and 0.05 mM cold- [g-32P]-
ATP in a 30°C heat block for 2 hr. The reaction mix was then heated at 60°C for 
5 min to inactivate the kinase present, and then re-incubated at 30°C for 10 min 
to bring the reaction mix down to ambient temperature. Purified activated 
recombinant GSK-3β (6 mU/µl) along with of 5 mM MgCl2 and 0.05 mM [g-32P]-
ATP was then added and the reaction incubated at 30°C for a further 1 hr. All 
reactions were terminated by the addition of hot (heated at 75°C for 10 min) 4X 
LDS gel loading buffer followed by boiling the samples for 10 min, the samples 
were then loaded on to an SDS-PAGE gel, and the excess [g-32P]-ATP was 
removed by electrophoresis. Gels were then stained with SimplyBlue™ SafeStain 
Component Volume/ concentration required for 40 µl reaction 
Purified protein (GST-mNeh6+, GST-hNeh6+ 
or single amino acid mutants) 4 µg 
Kinase 2 mU/µl 
Kinase assay buffer (50 mM Tris-Cl, 0.03% 
(v/v) Brij-35, 0.1% (v/v) β-mercaptoethanol) 20 µl 
10 mM MgCl2 and 0.1 mM [g-32P]-ATP 
(approx. 0.5x106) 4 µl 
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coomassie, dried onto filter paper and then subjected to autoradiography. The 
protein bands were excised and the incorporated radioactivity was determined by 
scintillation counting. “Blanks” containing only the purified protein but no kinase 
were included. Scintillation counts for blank reactions were subtracted from 
experimental readings to account for background radiation. The kinase activity 
towards the Neh6 + was then calculated using the formula given in section 2.4.1. 
2.5 Isolation, quantification and analysis of cellular protein  
2.5.1 Protein extraction  
For the preparation of protein lysates for western blotting, protein was first 
extracted from cells using the following protocol. Cells were seeded and treated 
according to the requirements for the experiment. The media was aspirated off 
the cells and the cells were washed twice in PBS and then incubated in kinase 
lysis buffer (10%(w/v) sucrose, 50 mM tris-HCL pH 7.5, 1 mM EDTA pH 8.0, 1 
mM EGTA pH 8.0, 2 mM sodium vanadate (Na2VO3), 10 mM glycerophosphate, 
25 mM sodium fluoride (NaF), 5 mM sodium pyrophosphate (NaP2O5), 1% (v/v) 
NP-40) supplemented with cOmpleteÔ EDTA- free protease inhibitor cocktail 
tablets (Sigma-Aldrich) for 15 min on ice. Cells were then manually scraped into 
the buffer, transferred to an eppendorf and vortexed briefly before centrifugation 
at 12,000 xg for 10 min at 4°C.   
2.5.2 Protein quantification 
To ensure equal loading of protein samples for western blotting, protein 
quantification and normalisation was carried out on all new lysates. Total protein 
quantification was performed on the clarified lysates using a Bio-RadÔ DC 
protein assay kit (Bio-Rad) in a 96-well plate format. 5 µl of sample lysate was 
incubated with a 25 µl of a 50:1 (v/v) ratio of combined reagent A and reagent S, 
in triplicate in a 96-well plate. 200 µl of reagent B was then added to each well, 
before incubating the plate in the dark at room temperature for 15 min. The 
absorbance of each sample was then measured at 750 nm using a SpectraMax 
M2 (Molecular Devices, California, United States). 
The concentration of the protein in the cell lysate (mg/ml) was then 
quantified against BSA standards of known concentrations (4, 2, 1, 0.5, 0.25, 
0.125, 0.063 and 0 mg/ml). Samples were then diluted to a final concertation of 
1 µg/µl with a 1:10 mixture of kinase lysis buffer and 4X NuPAGE Ô LDS sample 
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buffer. Samples were then vortexed thoroughly, followed by heat denaturation of 
proteins by boiling at 100°C for 10 min, before loading onto a SDS-PAGE gel.  
2.5.3 SDS polyacrylamide gel electrophoresis using handmade gels 
Proteins in samples were separated according to their molecular weight 
through running down a SDS-PAGE gel. Denatured protein samples (typically 10-
20 µg) were loaded onto a SDS-PAGE of the desired density, along with 4 µl 
PageRulerä Plus Pre-stained protein ladder and separated according to the 
molecular weight of the protein. The gels were set in two layers; a bottom 
resolving gel and a top stacking gel, the composition of both gel layers is shown 
in Table 2.5.1. 
The gels were run using ThermoFisher Scientific mini gel tank at 100 V in running 
buffer (25 mM tris, 250 mM glycine, 0.1% (w/v) SDS) until the samples had 
successfully passed through the stacking gel. The voltage was then increase to 
190 V and ran until the dye front had almost reached the bottom of the gel. 
Component Resolving gel Stacking gel 
30% 37.5:1 Acrylamide:Bis solution (National 
diagnostics) 6-12% (v/v) 5% (v/v) 
1.25 M tris pH 6.8 - 126 mM 
1.25 M tris pH 8.8 375 mM - 
10% (w/v) SDS 0.1% (w/v) 0.1% (w/v) 
10% ammonium persulfate (APS) 0.1% (w/v) 0.1% (w/v) 
N,N,N’,N’-Tetramethylethylenediamine 
(TEMED) (Sigma-Aldrich) 0.04% (w/v) 0.01% (w/v) 
  
Table 2.5.1: Composition of stacking and resolving gels for SDS-PAGE 
 
2.5.4 SDS poly-acrylamide gel electrophoresis using pre-cast gels  
The electrophoresis of radioactive experiments was carried out using pre-
cast gels. Novex NuPAGEÔ 4-12% Bis-tris pre-cast protein gels were run using 
ThermoFisher Scientific mini gel tanks and 1x NuPageÔ MOPS SDS running 
buffer at 150V, until the dye front nearly reached the end of the gel. The gel was 
either transferred for western blotting or stained with SimplyBlue™ SafeStain 
coomassie for protein quantification. 
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2.5.5 Western blotting  
To allow the visualisation of proteins, gels were transferred to membranes, 
incubated with antibody and imaged, according to the following. After SDS-
PAGE, resolved proteins were then transferred onto either polyvinyl difluroride 
(PVDF) (ThermoFisher Scientific) or nitrocellulose membranes (ThermoFisher 
Scientific). All PVDF membranes were pre-soaked in 100% methanol 
immediately prior to use. The Bio-Rad Trans-Blot Ò cell system was used to 
transfer proteins to the membrane at 100V for 60 min using transfer buffer (25 
mM tris, 250 mM glycine, 20% (v/v) methanol) in the presence of an ice pack. 
The transferred membrane was then blocked in 5% (w/v) dried skimmed milk 
(Marvil) in TBS-T (50 mM Tris, 150 mM NaCl, 0.25% (v/v) Tween 20Ò) for 1 hr at 
room temperature with agitation. Post-blocking, the membrane was incubated for 
3-16 hr in the appropriate primary antibody diluted in 5% dried skimmed milk-
TBS-T (Appendix 8.3 antibodies and dilutions). The membranes were then 
washed 3 times with TBS-T for 5 min each time before incubation with the 
required HRP-conjugated secondary antibody diluted 1:2,000 or near-infrared 
fluorescent secondary antibody at a dilution of 1: 15,000 (LI-COR Biosciences, 
Nebraska, United states) in TBS-T containing 5% (w/v) dried skimmed milk for 1 
hr at room temperature. The membrane was the again washed a further 3 times 
with TBS-T for 5 min each. Membranes incubated with LI-COR secondary 
antibodies were shielded from light throughout the incubation and subsequent 
washing stages.  
For the imagining of membranes incubated with HRP-secondary 
antibodies, enhanced chemiluminesence (ECL) and autoradiography film were 
used to visualise the antibody-protein complexes. After the final wash the 
membranes were incubated with 1:1 mix of in-house ECL solution 1 (100 mM tris 
pH 8.5, 2.5 mM luminol, 0.4 mM r-coumaric acid) and ECL solution 2 (100 mM 
tris pH 8.5, 0.02% (v/v) hydrogen peroxide) before visualisation using 
autoradiography X-ray film. Membranes probed with near-infrared fluorescent 
secondary antibodies were imaged using a LI-COR Odyssey Ò CLx scanner. 
Quantification against a house keeping protein was carried out using the in-built 
LI-COR Image Studio software. 
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2.6 Cell culture and cell-based assays  
2.6.1 Cell culture conditions  
Cell lines described the table below, were all cultured in a humidified 
5%CO2  incubator at 37°C. All cell lines were maintained in DMEM supplemented 
with 10% (v/v) FCS. Table 2.6.1 lists all the cell lines used in this thesis along 
with their original source. 
Cell line Description Base medium Origin 
A549 
Human alveolar basal 
adenocarcinoma epithelial 
cells 
DMEM Hayes lab stocks 
NRF2 KO A549 
Genetically engineered 
CRISPR cells lines where the 
gene encoding NRF2 has 
been knocked out 
DMEM Dr Laureano de la Vega 
H460 Human lung pleural effusion cell line DMEM Hayes lab stocks 
H1299 Human non-small cell lung adenocarcinoma cell line DMEM 
Dr Laureano de la 
Vega 
NRF2 KO 
H1299 
Genetically engineered 
CRISPR cells lines were the 
gene encoding NRF2 has 
been knocked out 
DMEM Generated in lab 
NRF2 GOF 
H1299 
Genetically engineered 
CRISPR cell lines were the 
gene encoding NRF2 has 
been altered 
DMEM Generated in lab 
KEAP1 KO 
H1299 
Genetically engineered 
CRISPR cell lines were the 
gene encoding KEAP1 has 
been knocked out 
DMEM Generated in lab 
H2228 Human non-small cell lung adenocarcinoma cell line DMEM ATCC 
H1568 
Human lung adenocarcinoma 
cell line derived from a 
metastatic site; lymph node 
DMEM ATCC 
H1395 Human lung adenocarcinoma epithelial cells DMEM ATCC 
DLD1 
Human colorectal 
adenocarcinoma epithelial 
cells 
DMEM Dr Laureano de la Vega 
 
Table 2.6.1:Details of cell lines and culture conditions 
 
2.6.2 Sub-culturing cells   
Cell lines were sub-cultured every two to three days or when they reached 
a confluency of 80-90%. Cell growth media was removed and the cells were 
washed twice with pre-warmed sterile 1X PBS before the addition of 2-3 ml of 
0.025% trypsin (ThermoFisher Scientific) supplemented with 0.05% (v/v) EDTA 
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(0.05 mM). Upon addition of trypsin the flasks were re-incubated for 2-3 min at 
37°C, after which, any un-detached cells were cleared from the back wall through 
gentle agitation of the flask. Detached cells were re-suspended in fresh media, 
and the desired number of cells was transferred into a new flask containing fresh 
media and returned to the incubator.  
2.6.3 Cryopreservation of cells   
Any newly generated or newly obtained cell line in the lab was expanded 
and frozen down for long term storage in liquid nitrogen. Cells from a confluent 
flask were trypsinized and re-suspended in DMEM supplemented with 10% FCS 
to a final volume of 10 mls. Cells were then pelleted by centrifugation at 12,000 
xg for 3 min. The growth media was then removed and the cell pellet was re-
suspended in freezing media (90% FCS and 10% DMSO). Cells were frozen in 
1ml aliquots (approximately four 1 ml aliquots were obtained from a confluent 
T75-flask) in individual cryogenic vials (Corning, New York, United states). The 
cyrovials were stored at -80°C in a cryofreezing container overnight, before they 
were transferred to liquid nitrogen. When required, cells were revived from liquid 
nitrogen storage, by thawing the cells rapidly in a 37°C water bath. The thawed 
cells were then transferred in to a T-25 flask containing pre- media and incubated 
overnight. The next day, the cells were washed twice with sterile 1X PBS and the 
media was renewed. Cells were only used in experiments after they had 
undergone three passages after liquid nitrogen storage and had tested negative 
for mycoplasma contamination. 
2.6.4 Seeding cells 
Cells were counted using a haemocytometer and seeded at different 
densities depending on the experimental requirements. Cells were trypsinized 
and re-suspended thoroughly in a final volume of 10 ml of media. A volume of 20 
µl of the cell suspension was then mixed with 20 µl 0.4% trypan blue solution 
(Thermo Fisher Scientific) and 10 µl of the mix was counted with a Countess II 
FL automated cell counter (ThermoFisher Scientific). The cell suspension was 
then diluted with media to obtain the required cell count for the experiment.  
2.6.5 Transient transfection using Lipofectamine 2000Ô 
Transient transfections were carried out for the incorporation of plasmid 
DNA into mammalian cells. Cells were seeded in 6-well plates 24 hr prior to 
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transfection to achieve a confluency of approximately 80% the following day. DNA 
(1-2 µg) and Lipofectamine 2000Ô (µl) were transfected at a ratio of 1:3 into the 
desired cell line. Firstly, the plasmid DNA was combined with OptiMEMÔ and 
allowed to incubate for 20 min at room temperature. In a separate tube, 
Lipofectamine 2000Ô was combined with the same volume of OptiMEMÔ as the 
plasmid. Both transfection mixes were then combined and incubated for a further 
20 min, before gently adding drop wise to the wells containing 1.8 ml of fresh 
media. Cells were then either harvested 24 hr post-transfection or treated with 
drugs to be harvested at a later time point as per the experimental plan. 
2.6.6 Transient knock-down siRNA reverse transfections using 
Lipofectamineä RNAiMAX 
Short interfering RNA (siRNA) was transiently transfected into mammalian 
cells to knockdown genes of interest. A volume of 500 µl OptiMEM™ was 
combined with 20 nM siRNA (negative control or specific against the gene of 
interest) in a tube and mixed well. This was then transferred to one well of a 6-
well plate and the side of the plate agitated to ensure complete coverage of the 
well with the mixture. 5 µl of Lipofectamine ® RNAiMAX was then added to the 
well and incubated for 10 min at room temperature. Cells were trypsinzed and 
counted, according to sections 2.6.2 and 2.6.4 above, to plate 2x105 cells per 2 
ml/well in a 6-well plate. Cells were incubated for 48 hr before confirming the 
magnitude of the target gene knockdown at both a protein (through western 
blotting) and an mRNA level (through qPCR). Both the KRAS SMART pool of 
ON-TARGET plus siRNA and the negative control siRNA were purchased from 
Dharmacon (Dharmacon, Colorado, United States). 
2.6.7 Transfection for the generation of stable CRISPR/Cas9 cell lines 
For the generation of stable isogenic Clustered Regularly Interspaced 
Short Palindromic Repeats (CRISPR) cell lines with genetic alterations, plasmid 
DNA generated as described in section 2.2.8 was transfected into H1299 cells. 
H1299 cells were seeded in 6-well plates 24 hr prior to transfection to achieve a 
~80% confluency the following day. 2 µg of DNA for one of the following 
constructs was transfected into the cells as described in section 2.6.5: 
LentiCRISPRV2 empty plasmid, KEAP1KO-LentiCRISPRV2 or NRF2KO-
LentiCRISPRV2. One well was transfected with 2 µg of pMAX-GFP as a control 
to check transfection efficiency.  
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At 48 hr post-transfection the cells were treated with 2 µg/ml puromycin 
(Puromycin dihydrochloride; ThermoFisher Scientific) to kill any cells not 
possessing the resistance cassette from the LentiCRISPRV2 plasmid. A control 
well of H1299 cells that had not undergone any transfection was included, this 
well was treated with puromycin at the same time. Once all the cells in the control 
well had died, the cells in the remaining transfected wells were then trypsinized 
and transferred to a T-25 flask, this is the “pool” population. These flasks were 
then expanded, harvested for protein and RNA analysis, and then frozen liquid 
nitrogen cell stocks were produced.  
2.6.8 Colony selection for CRISPR cell lines  
To produce single cell clones the cells from the “pool” population were 
counted (as described in section 2.6.4) and seeded in 96-well plates. Three 
seeding densities were chosen: 0.5 cells per well, 1 cell per well, and 2 cells per 
well. Triplicate 96-well plates were seeded per density and each plate was 
screened regularly by eye to check for the presence of single colonies. Wells 
containing single colonies were then trypsinized and expanded into 24-well 
plates. Once the wells became confluent they were then further expanded into 
12-well plates and samples taken for western blotting and qPCR analysis to 
confirm genetic alteration. Positive clones where then expanded and liquid 
nitrogen stocks were produced.  
2.6.9 ARE luciferase reporter assay  
To determine the effect that phosphorylation of several serine resides in 
the Neh6 region of NRF2 has on NRF2-activity, luciferase reporter assays were 
carried out. NRF2 KO A549 cells were seeded in 6-well plates and co-transfected 
with an empty pcDNA3.1-V5/His expression vector or various D17-32 mNrf2 
pcDNA3.1-V5/His single amino acid site mutant expression plasmids (generated 
as described in section 2.2.7) along with the murine quinone reductase-based P-
1016/nqo1-Luc reporter construct and pRL-TK Renilla. A volume of 2 µg of each 
plasmid was transfected into the cells in each different experimental group. Cells 
were transfected as described in section 2.6.6. 24 hr post-transfection the cells 
were washed and the media replaced with 0.1% FCS DMEM to serum starve the 
cells. Cells were serum starved overnight for 16 hr before treatment with 
inhibitors; 5 µm MK2206, 5 µM CT99021,10 µM Harmine or a DMSO control for 
a further 18 hr in reduced serum 0.1% FBS DMEM. Plates were then washed 
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twice with PBS then harvested in 1X passive lysis buffer and transferred into 
white-walled clear bottom 96-well plates (Corning). The assay was carried out 
according to Promega guidelines for the Dual-LuciferaseÒ Reporter Assay 
System (Promega, Wisconsin, United states) using a GloMaxÒ-Multi+ Detection 
System with two injectors (Promega). All results were the normalised against the 
Renilla luciferase activity to account for transfection variability between 
experimental groups.  
2.6.10. b-galactosidase assay  
To determine what effect phosphorylation of several serine residues in the 
Neh6 region has on NRF2 protein stability, β-galactosidase assays were carried 
out. NRF2 KO A549 cells were seeded in 6-well plates and co-transfected with 
pcDNA3.1 expression vector for a V5-tagged fusion protein comprising mNeh6+ 
coupled C-terminally to LacZ, this plasmid is referred to as mNeh6+LacZ-V5, or 
with single amino acid site mutants of the same plasmid (generated as described 
in section 2.2.7).  An empty LacZ-V5 plasmid was included as a control. At 24 hr 
post-transfection the cells were serum starved by removing the media and 
replacing it with 0.1% FBS DMEM. After 16 hr of serum starvation, the cells were 
then drugged for a further 18 hr with inhibitors: 5 µm MK2206, 5 µM CT99021, 10 
µM Harmine or a DMSO control, also in reduced serum conditions. The plates 
were then washed twice in PBS and the cells harvested in 1x reporter lysis buffer 
and transferred into white-walled clear bottom 96-well plates. b-galactosidase 
activity was then measured according to the Promega Guidelines given in the β-
galactosidase Enzyme Assay System with Reporter Lysis Buffer kit (Promega) 
using a GloMax-Multi+ Detection System with two injectors. All results were 
normalised against total protein concentration, by harvesting the cells after the 
assay, according to the description given in sections 2.5.1 and 2.5.2. 
2.6.11 Fluorescent measurement of glutathione using mBC 
Monochloromobimane (mBC) is a non-fluorescent probe that when taken 
up into cells reacts with low molecular weight thiols, such as glutathione, and 
fluoresces. This resulting florescence can then be correlated to the amount of 
glutathione in the cell. Cells were seeded in 6-well plates so that after 24 hr they 
had reached ~80% confluency. The wells were washed twice with Dulbecco’s 
phosphate buffered saline (DPBS, ThermoFisher Scientific) with no calcium, 
magnesium or phenol red, and 1 ml mCB (ThermoFisher Scientific) diluted in 
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hanks balanced salt solution (HBSS, ThermoFisher Scientific) to a final 
concentration of 20 µM was added to the wells. HBSS alone was added to one 
well as a control and the value for this control well was taken away from all 
experimental readings to account for background cell florescence. Plates were 
then incubated in the dark for 30 min at room temperature. Fluorescence was 
measured using a SpectraMax M2 plate reader, with excitation at 390 nm and 
emission at 490 nm. All results were normalised against total protein 
concentration, by harvesting the cells after the assay, following the descriptions 
given in sections 2.5.1and 2.5.2. 
2.6.12 Determination of total, oxidized and reduced glutathione from cells 
using the enzymatic recycling method 
For a more robust measurement of glutathione and to obtain specific 
values for total, oxidized and reduced forms a protocol modified from Rahman et 
al. (2007) was used. Cells were seeded in 6-well plates so that on the day of the 
assay they had reached a confluency of ~80%. At 24 hr post-seeding cells were 
drugged with either 100 mM buthionine-sulfoximine (BSO) (Sigma-Aldrich) for 24 
hr or 5 µM NAC (Sigma-Aldrich) for 3 hr. Media was aspirated from plates and 
wells were washed twice with room temperature PBS. Cells were then manually 
scrapped from the back wall of the plate into 1 ml of PBS, followed by pelleting 
via centrifugation at 13,000 xg for 5 min at 4°C. Supernatant was carefully 
aspirated and pellets were flash frozen (either on dry ice or by submerging in 
liquid nitrogen). Pellets were re-suspended in 250 µl 0.25 M sucrose (sucrose 
dissolved in distilled water) and a 50 µl aliquot was taken for protein quantification 
according to section 2.5.2. A volume of 200 µl 2X extraction buffer (0.2% v/v 
Triton X-100, 0.2% v/v NP-40, 1.2% m/v 5-sulfosalicylic acid, 10% meta-
phosphoric acid, made up to 20 ml with 2x KPE (0.2 M potassium phosphate, 10 
mM EDTA)) was added to the remaining 200 µl of sample and mixed through 
briefly vortexing. Samples were centrifuged at 3,000 xg for 4 min at 4°C, 
supernatant was removed and kept on ice. 300 µl clarified lysate was taken for 
oxidized glutathione (GSSG) analysis. 6 µl of 1:10 2-vinylpyridine (diluted in 
1xKPE buffer) (Sigma-Aldrich) was added to each sample, and samples were 
incubated at room temperature for 1 hr. During this incubation time total 
glutathione analysis was carried out. After 1 hr, 18 µl triethanolamine (diluted 1:6 
with 1xKPE) (Sigma-Aldrich) was added and tubes were incubated for a further 
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10 min at room temperature to quench the excess 2-vinylpyridine. A sample of 
20 µl from each GSSG sample was pipetted in triplicate into a 96-well plate. 60 
µl 5,5’-dithio-bis-(2-nitrobenzoic acid (DNTB) (0.02 M dissolved in 1xKPE buffer) 
(Sigma-Aldrich) and 60 µl glutathione reductase (0.333 units per ml dissolved in 
1x KPE buffer) (Sigma-Aldrich) was then added to the 96-well plate. Plates were 
incubated at room temperature for 2 min before the addition of 60 µl β-NADPH 
solution (0.008 M dissolved in 1X KPE buffer) (Sigma-Aldrich). Absorbance at 
412 nm was then immediately read in a SpectraMax M2 plate reader with 
measurements taken every 30 sec for 2 min. For the determination of total 
glutathione, 50 µl of sample was diluted 1:6 with 1X KPE buffer. A volume of 20 
µl sample was then pipetted in triplicate into a 96-well plate and analysis carried 
out as before with GSSG samples. Seven-step serial dilutions from 26.4 µM to 
0.4125 µM of both GSH (reduced from) (Sigma-Aldrich) and GSSG (Sigma-
Aldrich) were used to generate standard curves. The concentration of total GSH 
and GSSG in the sample was calculated using linear regression to calculate the 
values obtained from the standard curve. Reduced glutathione was calculated by 
subtracting 2X GSSG reading from the total glutathione reading. All results were 
then normalised to total protein concentration in the sample. 
2.6.13 Colony formation assay with crystal violet staining  
To access the ability of cancer cell lines to propagate, colony formation 
assays were carried out. Cells were seeded at a density of 500 cells per 2 ml 
media/ well in 6-well plates. At 24 hr post-seeding the plates were drugged with 
inhibitors if required. Plates were then left for 2 weeks in a 37°C 5% CO2 
incubator. The media was then removed from the plates and the wells were 
washed twice with ice cold PBS. Cells were then fixed with ice cold methanol for 
30 min at room temperature with gentle agitation. Methanol was then removed 
from the plates and the colonies stained with 5%(w/v) crystal violet (Sigma-
Aldrich) for 1 hr at room temperature on a rocker. Plates were then washed 
repetitively in water to remove any unbound stain. Photographs of each well were 
taken.  
2.6.14 Proliferation studies using an IncuCyte ZoomÔ imagine system 
The basal proliferative kinetics across different live cell lines or in the 
presence of inhibitors was monitored using the IncuCyte ZoomÔ imaging system 
and software (percentage confluence) (Essen Biosciences, London, United 
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Kingdom). Initially, cells were seeded at a range of densities; 200, 500, 1000, and 
2000 cells per well in a 96-well plate. These plates were then scanned every day 
for 6 consecutive days at the same time of day and the cell density that showed 
clear exponential growth kinetics resulting in approximately 90-95% confluence 
within 6 days was chosen. From the prior experiment, 1000 cells per well were 
seeded in 96-well plates. 24 hr after, the plates were treated with respective 
inhibitors as per experimental design and scanned in the IncuCyte ZoomÔ. The 
plates were maintained in a 37°C 5% CO2 incubator in between scans and were 
scanned every day for 6 days. After 6 days, the percentage confluence of the 
wells was calculated using the IncuCyte ZoomÔ software.  
2.6.15 MTT  
3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide (MTT) 
assays were carried out in a 96-well plate format to access cell metabolic activity 
as a measurement of cell viability in the presence or absence of inhibitors 
combined with platinum-based chemotherapeutic agents. Cells were seeded at 
5,000 cells per 100 µl per well in triplicate in a 96-well plate. At 24 hr post-seeding 
the cells were treated with a six-stage cisplatin serial dilution from 25.33 µM, 
alone and in the presence of 5 µM MK2206, 5 µM CT99021,1 µM Harmine, 1 µM 
ID-8 or 100 mM BSO. After 72 hr, the media was removed and 100 µl of 1mM 
MTT (Sigma-Aldrich), diluted in PBS was added directly to the wells and the 
plates were incubated for 1 hr at 37°C at 5%CO2. The MTT solution was removed 
and 100 µl DMSO was added, and the plates were further incubated in the dark 
for 1 hr at room temperature on a shaking platform. Absorbance’s was then read 
using a SpectraMax M2 plate reader at a wavelength of 570 nm.  
2.6.16 Subcellular fractionation – nuclear and cytosolic separation  
To determine if a certain protein was located in either the nuclear or 
cytoplasmic compartment of the cell, subcellular fractionation was carried out. 
Cells were seed in 10 cm dishes to obtain a confluency of ~80-90% within 24 hr. 
If required cells were treated with 5 µM CT99021 for 24 hr. The media was then 
aspirated from the plates and the cells washed thoroughly twice in ice cold PBS, 
and then pelleted by centrifugation (13,000 xg) in 1 ml of PBS. Pelleted cells were 
then resuspended in 400 µl buffer A (10 mM hepes (pH 7.9), 10 mM KCL, 0.1 
mM EDTA, 0.1 mM EGTA, 1 mM b-mercaptoethanol) and left on ice for 10 min. 
10 µl of 10% (v/v) NP-40 was then added and the cells were lysed through 
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vortexting briefly. Samples were then centrifuged briefly at 13,000 xg for 
approximately 10 sec. The supernatant containing the cytoplasmic fraction and 
was transferred into a new eppendorf. The pellet was then washed four times by 
the addition of 400 µl buffer A, briefly vortexting and then centrifuging as before. 
After the forth wash, the pellet was resuspended in 100 µl buffer B (20 mM hepes 
(pH 7.9), 400 mM NaCL, 1 mM EDTA, 1 mM EGTA, 1 mM b-mercaptoethanol) 
and then sonicated for 10 sec. Lysates were then centrifuged at 13,000 xg for 15 
min at 4°C. The supernatant contains the nuclear fraction. 50 mM NaF and one 
cOmpleteÔ EDTA- free Protease Inhibitor Cocktail tablet was freshly added to 
10 ml aliquots of buffer A and buffer B immediately before use. A DC protein 
assay, and western blotting were carried out for the proteins of interest, as 
described above in sections 2.5.2, 2.5.3 and 2.5.5. 
2.6. 17 Cyclohexamide chase  
 Cyclohexamide (CHX) is an inhibitor of protein biosynthesis, which acts 
through halting translational elongation, that is often used to determine the half-
life of a protein. Cells were seeded in 6-well plates to obtain a confluency of ~80-
90% after 24 hr. A volume of 10 µl of a 100 mg/ml CHX solution (diluted in media) 
(Sigma-Aldrich) was then added to the wells at 15 min intervals from 0 min to until 
75 min. Media was then aspirated from the wells, before washing wells twice with 
PBS and then harvesting protein as described in section 2.5.1.  A DC assay and 
western blotting were then carried out for the proteins of interest. 
2.6.18 NQO1 activity assay 
The enzymatic activity of NQO1 in cells was determined using the 
“Prochaska” method adapted from Fahey et al. (2004). Cells were seeded at a 
density of 1x104 cells per 200 µl in a 96-well plate. At 24 hr post-seeding cells 
were drugged with a nine-step serial dilution starting at 50 nM CDDO-Me. Cells 
were incubated in drugs for 48 hr before analysis. Media was removed from wells 
by flicking contents in to the sink, plates were then washed with PBS using a 
BioTek microplate washer. A volume of 75 µl digitonin solution (6.5 mM digitonin, 
2 mM EDTA (pH 7.8)) was added to each well and plates were then placed on a 
shaking platform for 20 min. An aliquot of 20 µl from each well was then 
transferred to a 96-well plate for protein quantification. 200 µl assay buffer 
(composition of which is described in the Table 2.6.2 below) was added to each 
well and plates were incubated for 2 min at room temperature. 50 µl of dicoumarol 
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solution (0.3 mM dicoumarol, 5 mM KPO4 (pH 7.4), 0.5%DMSO) was then added 
before reading absorbance using a SpectraMax M2 plate reader at a wavelength 
of 570 nm. Readings were the normalised to total protein concentration of the 
sample.   
Reagent Volume (For 1x 96-well plate) 
0.5 M tris/HCL, pH 7.4 1 ml 
10% BSA (Sigma-Aldrich) 1 ml 
1.5% Tween20 133 µl 
7.5 mM flavin adenine dinucleotide (FAD) 
(Sigma-Aldrich) 13.3 µl 
150 mM glucose-6-phosphate sodium salt 
(G-6-P) (Sigma-Aldrich) 133 µl 
50 mM nicotinamide adenine dinucleotide 
phosphate (NADP) (Sigma-Aldrich) 12 µl 
G-6-P-D (1,000 u/ml) (Sigma-Aldrich) 40 µl 
MTT (Sigma-Aldrich) 6 mg 
25 mM menadione (Sigma-Aldrich) in 
acetonitrile (4.3 mg/ml in acetonitrile) 20 µl 
 
Table 2.6.2:  Chemical components of the assay buffer used in the NQO1 activity assay 
2.6.19 RNA extraction  
For the generation of cDNA for subsequent mRNA expression analysis, 
RNA was extracted from cells. Cells were seeded to produce a confluency of ~80-
90% on the day of harvest. Media was removed from the cells, followed by rinsing 
with PBS twice before adding 1-2 ml of trypsin (volume depending on the size of 
the plate) and incubating for 3 min at 37°C. The sides of the plates were then 
agitated to ensure the detachment of all cells. An equal volume of media was 
then added and the liquid resuspended several times before transferring to a pre-
chilled eppendorf. Cells were then pelleted through centrifugation at 13,000 xg 
for 10 min in a 4°C centrifuge before lysing the pellet in 200-350 µl RLT 
(supplemented with 2-mercaptoethanol (2ME) (Sigma-Aldrich). The lysed pellet 
was then passed through a QIAShedder (QIAgen) column. RNA was then 
extracted according to manufacturer’s guidelines using a RNAeasy Mini kit. An 
additional 15 min DNAse (QIAgen) digestion was carried out and the elution stage 
with RNA free water was repeated twice. RNA yield and purity was then 
measured using a using Nanodrop ND-1000 spectrophotometer. 
 2.6.20 Reverse transcription of RNA to cDNA 
   Extracted RNA was the reverse transcribed for 1 hr at 37°C to cDNA 
through PCR. A sample of 500 ng RNA was reverse transcribed to cDNA using 
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an Omniscript RT Kit (QIAgen) according to the manufacturers guidelines 
provided. The obtained cDNA was subsequently diluted to 50 ng/µl with 
RNAase free water. Samples were then stored at -20 until use.  
2.6.21 Measurement of mRNA expression using real time PCR - TaqManÒ  
To access the variations in gene expression across different cell lines and 
in the presence of inhibitors, real time (RT)-PCR was carried out. RT-PCR was 
preformed using a QuantStudioÒ 5 (ThermoFisher Scientific) system. All 
samples were analysed in triplicate and were normalised to the expression of a 
housekeepering gene. All reactions were performed using 250 ng of cDNA with 
0.6x TaqMan master mix (Universal Master Mix II, no UNG, (Applied 
Biosystems)) and in 96-well plate format (MicroAmp Optical 96-well Reaction 
plate with barcode, ThermoFisher Scientific) Plates were sealed using MicroAmp 
optical adhesive film (ThermoFisher Scientific) 
The probes used were either commercially bought optimised 20X mixes 
(Applied Biosystems) used at a final concentration of 1x or previously optimised 
individual primer (900 nM) and probes (200 nM) sets. Sources and sequences of 
all probes can be found in Appendix 8.4. 
The PCR conditions used are shown in Table 2.6.3. 
Temperature (°C) Time Cycles 
50 2 min 1 
95 10 min 1 
95 15 sec 40 60 1 min 
 
Table 2.6.3: PCR conditions for transcribing RNA into cDNA 
Probes used for RT-PCR contain a fluorescent 5’FAM reporter dye and a 
3’ TAMRA/MGB quencher. The ratio of change in Ct value (dCt) between the 
control and experimental samples relative to their respective loading controls, 
was determined using the Pfaffl method (Pfaffl, 2001). 
2.7 Bioinformatic analysis 
Bioinformatics analysis of cell lines was carried out using the TIBCO 
Spotfire® software. Three cell lines databases: Sanger, Cancer Cell Line 
Encyclopaedia (CCLE) and AstraZeneca were combined in TIBCO Spotifire® 
and filtered for lung cancer cell lines. This provided 239 cell lines that were then 
further filtered for the presence of mutations in genes of interest. Cell lines 
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possessing a mutation in a particular gene were then further filtered for the 
presence of mutations in additional genes.  
  NRF2-target genes expression analysis was carried out by first filtering the 
lung cancer cell lines (239 cell lines) for the presence of mutations in a gene of 
interest, then the mRNA expression of NRF2-target genes was compared 
between the population of cell lines harbouring mutations and those that are 
“wildtype” for the gene in question. Gene expression values were normalized 
using frozen robust multiarray analysis (fRMA) (McCall et al., 2010) and 
subsequently scaled between 1 and 100. The log2 of this value was reported for 
each gene in the TIBCO Spotfire® file. Hence, the expression data ranged 
between 0 and 6.64. For subsequent analysis of the alterations in classical NRF2-
target gene expression between; NFE2L2-mut, NFE2L2-wt (-KEAP1-mut), 
KEAP1-mut and KEAP1-wt (-NFE2L2-mut), only the Sanger data set was used. 
Average gene expression was calculated for the different groups of cell lines, and 
this value along with the standard error of the mean (SEM) was graphed. 
Bioinformatics analysis of tumour samples was preformed using cBioPortal 
software (Cerami et al., 2012;Gao et al., 2013). Lung cancer datasets were 
chosen and then filtered for the presence of mutations in certain genes. This 
provided the somatic frequency of mutation and the mutational mapping. The 
“enrichment” tab was then used to filtered for the presence of other somatic 
mutations. Log ratios and direction/tendency categorisation was provided by 
cBioPortal for the tumour data. Log ratios and direction/tendency categorization 
for the cell line bioinformatics data were calculated according to the cBioPortal 
method.  
2.8 Data Analysis  
Data analysis was carried out using GraphPad Prism ® 5 software. 
Statistical significance of the results was calculated using t-tests. Significant 
increases have been denoted throughout the text using the following symbols:  * 
p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Significant decreases are 
denoted with a $ symbol, with the same cut-offs applying. 
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3.0 KEAP1-independent regulation of NRF2 through the 
SCFβ-TrCP/ GSK3-β axis is dependent on the presence of 
a “priming kinase”. 
3.1 Introduction  
3.1.1 The Ubiquitin- proteasome system  
All eukaryotic proteins are degraded in the cell through either one of two 
routes; extracellular proteins that enter the cell under stressed conditions are 
degraded by lysosomes and intracellular proteins are degraded by the ATP-
dependant ubiquitin-proteasome system (UPS) under both stressed and 
unstressed conditions. Alterations in the UPS affect a wide range of biological 
processes such as cell cycle and apoptosis and are therefore implicated in a wide 
range of diseases, such as cancer, where impaired UPS function has been linked 
to poor prognosis (Shah et al., 2001).  
3.1.2 Ubiquitination process  
All proteins that are degraded by the proteasome first undergo labelling 
with the protein modifier ubiquitin in a process called ubiquitination which involves 
more than 1000 proteins. Ubiquitin is a small ubiquitously expressed 76-amino 
acid poly-peptide which is attached to the target protein though a multi-step 
cascade of reactions catalysed by three enzymes: ubiquitin-activating enzymes 
(E1s), ubiquitin-conjugating enzymes (E2s) and ubiquitin ligases (E3s) (Spataro 
et al., 1998).  First, E1s mediate the ATP-dependent activation of ubiquitin, 
followed by the conjugation of ubiquitin to an intermediate protein carried out by 
E2s and then finally E3s carry out the ligation of ubiquitin to a Lys residue on the 
target protein. Ubiquitination can involve the attachment of a single molecule of 
ubiquitin, which is called mono-ubiquitination or attachment of a chain of ubiquitin 
molecules through repetitive cycles of ubiquitination; this latter process is called 
poly-ubiquitination. The first ubiquitin molecule is bound to a specific Lys residue 
in the substrate and the chain is generated through the ubiquitination of the 
previous ubiquitin molecule at one of its seven lysine residues (Lys-6, Lys-1, Lys-
27, Lys-29, Lys-33, Lys-48 and Lys-63). Over 50% of all ubiquitin chains are 
formed through attachment at Lys-48 and attachment at this residue results in 
proteasomal degradation because poly-ubiquitin tags generated at this site can 
be recognized by the 26S proteasome to allow protein unfolding which is 
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essential for protein degradation (Robertson et al., 2018; Swatek and Komander, 
2016). 
The UPS is highly specific and the majority of this specificity is provided 
by the large family of E3 ubiquitin ligases, which can be subdivided into three 
main groups; Homologues to the E6AP carboxyl terminus (HECT) group, the 
really interesting new gene (RING) group and the RING-between RING (RBR) 
group. The rest of this chapter will focus on the function and regulation of the 
RING subgroup of E3 ligases (Robertson et al., 2018).  
3.1.3 SCF family of E3 ubiquitin ligase  
There are over 600 members of the RING family of E3 ubiquitin ligases 
that all catalyse the direct transfer of ubiquitin from the E2 enzyme to the 
substrate. Members of the RING subfamily can function as monomers, dimers or 
large multi-subunit complexes, such as the Skp, Cullin, F-box containing (SCF)-
complex of which there are 69 found in mammals (Gorelik et al., 2016). The SCF 
complex is composed of four components: an S-phase-kinase-associated 
protein-1 (SKP1), cullin-1 (CUL1), RBX1 and an interchangeable F-box protein. 
The F-box protein is the most variable component in the whole SCF complex and 
confers a high degree of specificity to the complex. Each of the four proteins are 
involved in different binding interactions to form the complex. RBX1 functions to 
bind to both CUL1 and the E2-conjugating enzyme, while CUL1 functions as a 
scaffold to join RBX1 to SKP1. SKP1 is composed of two domains, the N-terminal 
of which binds to CUL1 and the C-terminal domain that binds to the N-terminal of 
the F-box protein through an approximately 40-amino acid long F-box motif. The 
C-terminal region of the F-box protein binds substrates through protein: protein-
interaction domains such as WD40 repeats that adopt a β-propeller structure, 
which binds specifically to phosphorylated substrates and leucine-rich repeats 
(LRR) that have a α/β repeats and bind substrates independently of 
phosphorylation status (Robertson et al., 2018; Wu et al., 2003; Metzger et al., 
2012; Buetow and Huang, 2016; Pickart, 2001). 
3.1.4 SCFβTRCP complex  
Beta-Transducin repeat containing protein (β-TrCP) is a classical highly 
conserved example of an F-box protein, with seven C-terminal WD40 repeats 
that bind target substrates. There are two mammalian isoforms of β-TrCP, called 
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β-TrCP1 and β-TrCP2, which appear to be functionally redundant and therefore  
will be referred to in this thesis as only β-TrCP. 
 β-TrCP functions as an E3 ligase to a wide range of substrates which are 
involved in a variety of cell signalling pathways including; β-catenin, IKβ, SMAD3 
and Wee1, and hence dysregulation in β-TrCP is implicated in several diseases, 
such as cancer. However, one aspect that all β-TrCP substrates have in common 
is they all contain a destruction motif to which β-TrCP binds based around the 
sequence, DSGØXS, where both serine’s are phosphorylated, Ø represents a 
hydrophobic residue and X is any amino acid. When in its phosphorylated state, 
this motif is often referred to as the phosphodegron (Wu et al., 2003; Seo et al., 
2009). 
3.1.5 Interplay between GSK-3 and b-TrCP 
Due to the spacing between the two phosphorylated Ser residues in the 
DSGØXS β-TrCP destruction motif being similar to the GSK-3 substrate 
consensus sequence, Ser/Thr XXX(X) Phospho (Ser/Thr), it is to be expected 
that β-TrCP substrates are often first phosphorylated by GSK-3 (Figure 3.1.1). 
One such example is the classic β-TrCP substrate β-catenin. In this case, only 
when GSK-3 phosphorylates Ser-33, Ser-37 and Thr-41 of b-catenin is β-TrCP 
able to bind β-catenin resulting in its subsequent degradation. This suggests that 
GSK-3 phosphorylation regulates β-TrCP recognition and hence protein stability. 
Other examples of proteins phosphorylated by GSK-3 before subsequent β-TrCP 
mediated proteasomal degradation can occur include; Snail, MYC and many 
more (Liu et al., 2002; Gao et al., 2014 ;Robertson et al., 2018). 
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Figure 3.1.1:The destruction sequence for β-TrCP resembles the consensus priming 
sequence for GSK-3 
 (A)The degradation motif for β-TrCP in β-catenin reflects the prototypic consensuses 
degradation motif. The bold line under the sequence indicates where β-TrCP binds and the 
amino acid sequence displayed corresponds to human β-catenin. Phosphorylated residues 
are indicated with grey circles above them. The kinase phosphorylating at that site is indicated 
with the arrows above. (B) The priming sequence found in β-catenin conforms to the classical 
consensus priming sequence for GSK-3. Phosphorylated residues are indicated with grey 
circles above them. The kinase phosphorylating at that site is indicated with the arrows above.  
The sequence displayed corresponds to human β-catenin. (C) CK1 functions as a priming 
kinase phosphorylating β-catenin five amino acids C-terminal from the first GSK-3β 
phosphorylation site. This priming event enhances subsequent GSK-3β phosphorylation at 
three separate amino acids. Phosphorylation by GSK-3β forms the phosphodegron to which 
β-TrCP is recruited. The bold line under the sequence indicates where β-TrCP binds and the 
amino acid sequence displayed corresponds to human β-catenin. Phosphorylated residues 
are indicated with grey circles above them. The kinase phosphorylating at that site is indicated 
with the arrows above.  
 
 
 
A 
B 
C 
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3.1.6 GSK-3 signalling  
GSK-3 is a Ser/Thr kinase, so named after its ability to phosphorylate the 
substrate glycogen synthase, is ubiquitously expressed in human tissues, with 
some degree of tissue to tissue variability. Since the discovery of the involvement 
of GSK-3 in glycogen metabolism in 1980 (Cohen and Frame, 2001; Embi et al., 
1980) it has been found to be involved in a wide range of other cellular processes 
targeting over 100 proteins in the cell (including the transcription factors AP-1 and 
CREB), and due to this diverse range of substrates dysregulation of GSK-3 
signalling has been implicated in a wide range of diseases, such as, but not 
limited to: bi-polar mood disorder, Alzheimer’s disease, diabetes and cancer 
(Jope and Johnson, 2004).  There are two isoforms of GSK-3 present in humans, 
GSK-3α and GSK-3β, which appear to have very similar characteristics, apart 
from GSK-3α having a slightly heavier molecular mass of 51 kDa, in comparison 
to GSK-3β which runs at 47 kDa on a SDS-PAGE  (Sutherland, 2011).  
GSK-3 is unusual in comparison to other kinases in two aspects; firstly, 
that it is inhibited under growth factor stimulation and secondly that it requires its 
substrates to have already undergone a phosphorylation event by another protein 
kinase.  
3.1.7 Regulation by GSK-3 signalling  
Several different protein kinases have been shown to regulate GSK-3 
activity through phosphorylation of the N-terminal Ser-21 in GSK-3α and Ser-9 in 
GSK-3β.  GSK-3 is also found to be associated with multiprotein complexes, such 
as the axin-APC complex, that when altered regulates GSK-3 activity.  Also, GSK-
3 has been implicated to regulate its own activity through autophosphorylation of  
Tyr-279 and Tyr-216, in GSK-3α and GSK-3β respectively (Cole et al., 2004).   
One of the major breakthrough findings in terms of GSK-3 regulation was 
found by Cross and colleagues who demonstrated that AKT (also known as 
protein kinase B; PKB) directly phosphorylates GSK-3α at Ser-21 and GSK-3β at 
Ser-9, and that both these phosphorylation events results in inhibition of GSK-3 
activity (Cross et al., 1995). This inhibitory phosphorylation leads to a blocking of 
the substrate binding site. This is of particular interest as the AKT signalling 
pathway is extremely important for cell survival and is one of the most commonly 
deregulated pathways in cancer.  
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Amino acid stimulation that leads to activation of ribosomal protein S6 
kinase (S6K), growth factor stimulation leading to activation of the Ras/Raf 
pathway and active PKC signalling also lead to the inhibitory phosphorylation of 
GSK-3 through the same sites that are phosphorylated by AKT (Cohen and 
Frame, 2001). 
3.1.7.1 Autophosphorylation at Tyr279/Tyr216 in GSK3α/GSK-3β 
Tyr-279 in GSK-3α and Tyr-216 in GSK-3β are both located in the 
activation loop and have been shown to be phosphorylated under resting 
conditions. It is not unlikely that the phosphorylation at these sites impacts GSK-
3 activity as these residues are located in a very highly conserved region and 
phosphorylation at the equivalent position in mitogen-activated protein kinase 
(MAPK) has been shown to dramatically enhance MAPK activity (Hughes et al., 
1993). However, the function of this phosphorylation event and also the kinase 
that mediates it, is still under much debate. Work by Dajani and colleagues on 
the crystal structure of GSK-3β, suggested that Tyr-216 phosphorylation is not 
that influential in terms of regulating GSK-3β activity. However, they do show that 
when Try-216 is unphosphorylated it partially blocks the binding pocket to which 
the phosphate on the primed substrate (see below for explanation of priming) 
binds (Dajani et al., 2001). Therefore, having Tyr-216 phosphorylated may 
enhance binding but is not a requirement for binding and may have more of a 
pronounced effect in primed substrates. They do not elude to the protein kinase 
responsible. In contrast to this work, Cole and colleagues have reported that 
phosphorylation at both Tyr-279 in GSK-3α and Try-216 in GSK-3β is an 
autophosphorylation event mediated by GSK-3 itself, but they did not shown any 
data to indicate the function of this phosphorylation (Cole et al., 2004). 
3.1.7.2 Axin-APC complex  
WNT signalling is fundamental to cell growth and differentiation. In resting 
cells GSK-3β phosphorylates (in concert with Casein kinase 1; CK1) several 
serine residues in β-catenin which is fundamental for the recruitment of SCFβ-TrCP 
complex, which leads to the ubiquitination and destruction of β-catenin by the 
proteasome. Therefore, GSK-3β functions as a negative regulator of WNT 
signalling. When the ligand WNT is present GSK-3β is inhibited meaning β-
catenin can perturb proteasomal degradation. The phosphorylation of β-catenin 
by GSK-3β occurs in a multiprotein complex composed of: axin, adenomatous 
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polyposis coli (APC), β-catenin, CK1 and GSK-3β (Liu et al., 2002; Pronobis et 
al., 2015). The complex potentially functions to bring GSK-3β physically closer to 
β-catenin but, also interestingly when in this complex GSK-3 appears to be 
somewhat protected from other forms of GSK-3 regulation, such as inhibitory 
phosphorylation by the protein kinase AKT (Doble and Woodgett, 2003).  
3.1.8 GSK-3 specificity- the requirement for a priming kinase   
The phenomenon of pre-phosphorylation of a substrate by another kinase 
before GSK-3 can phosphorylate is called “priming” and is carried out by a 
“priming kinase”. The best characterised GSK-3 substrates have been shown to 
require priming by several different protein kinases. Some examples of primed 
GSK-3 substrates include; glycogen synthase which is primed by casein kinase 
2 (CK2) β-catenin which is primed by CK1 and eukaryotic initiation factor 2B 
(eIF2B) which is primed by DYRK2. It is important to identify and study these 
priming kinases as the presence of priming phosphorylation event enhances 
GSK-3 affinity towards the primed substrate by over 90% (Sutherland, 2011; 
Robertson et al., 2018). All priming phosphorylation events take place at an 
amino acid either 4 or 5 residues C-terminal from the proposed GSK-3 
phosphorylation site, conforming to the consensus sequence Ser/Thr 
XXX(PhosphoSer/Thr). Crystal structure studies have releveled that GSK-3 has 
a phosphate binding pocket that binds to the primed substrate positioning it closer 
to the GSK-3 catalytic site (Dajani et al., 2001).  It should be mentioned that there 
are some GSK-3 substrates that do not require priming but the mechanism by 
which GSK-3 targets these substrates is still poorly understood.  
3.1.9 The role of GSK-3 in disease  
GSK-3 is at the core of several important biological pathways and hence 
alterations in its signalling has been implicated in a wide range of diseases, of 
which three are discussed below.  
3.1.9.1 GSK-3 and Alzheimer’s disease  
Alzheimer’s disease (AD) is a chronic and progressive form of dementia 
with an exponentially increasing prevalence worldwide (Qiu et al., 2009). The 
symptoms of AD are extremely difficult to diagnose in the early stages of the 
disease and are subsequently often overlooked. The late stage of the disease 
presents with extremely debilitating cognitive defects. The two main forms of 
pathophysiology associated with the disease are the formation of cleaved b-
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amyloid peptides and aggregates of the microtubule associated protein, tau 
(Giese Karl, 2009). A small percentage of AD cases have a familial link, and in 
these instances, patients often possess mutations that lead to altered WNT 
signalling and a subsequent increase in GSK-3 activity. GSK-3 has also been 
linked to the development of sporadic AD, as GSK-3a is involved in the 
degradation of b-amyloid peptide but also the accumulation of this peptide has 
been shown to influence the activity of GSK-3b; this may in part enhance the 
GSK-3b mediated hyperphosphorylation of tau (Hernández et al., 2009). Over 30 
phosphorylation sites on tau have been identified to be potentially phosphorylated 
by GSK-3b. Hyperphosphorylated tau forms aggregates in axons and dendrites 
leading to diminished synaptic transmission and ultimately neurodegeneration.  
The generation of isoform specific and neuronal-specific GSK3 knock out 
mice has greatly aided the understanding of the role this kinase plays in the 
development of neurological disorders. Since post-mortem brains of AD patients 
show elevated activity of GSK-3b the majority of the mouse models of AD have 
focused on this isoform. Neuronal specific GSK-3b knock out mice show impaired 
function in memory tasks and also smaller dentate gyrus, which is the area of the 
brain responsible for memory (Gomez-Sintes et al., 2011; Kondratiuk et al., 
2013). Also knock down of both isoforms of GSK-3 leads to reduced tau 
phosphorylation resulting in less aggregate formation, in transgenic AD models 
(Hurtado et al., 2012).   
There is still much more to learn about the role GSK-3 plays AD but 
research is limited due to the lack of healthy and diseased human tissue (Kremer 
et al., 2011).  
3.9.2 GSK-3 and diabetes mellitus 
GSK-3 has often been linked with diabetes since the initial discovery of the 
ability of this kinase to regulate insulin signalling through phosphorylation of 
glycogen synthase, the key enzyme involved in glycogen metabolism. The 
inhibition of glycogen synthase in muscle tissue has been linked to the 
development of DM, with type 2 diabetic human patients showing a 2-fold 
induction of GSK-3 activity (Clodfelder-Miller et al., 2005). DM is a disease 
characterised by the impaired production and utilization of glucose, which is 
currently increasing in prevalence in the western world. Murine models of Type 2 
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DM have shown enhanced GSK-3b activity in the tissues of high-fat diet fed mice 
that are insulin insensitive. Also, GSK-3 has been implicated to be involved in the 
translocation of the principle glucose transporter, GLUT4, from the intracellular 
space to the plasma membrane (Chong et al., 2012). GSK-3 has been implicated 
to not only be hyperactivated in peripheral tissues leading to diabetes 
pathophysiology but also has been implicated to be associated with the cognitive 
impairment that is found in several diabetes patients. Studies have shown that 
insulin signalling in the brain leads to activation of the AKT pathways which 
results in the inhibition of GSK-3 activity and impaired glucose homeostasis (Jope 
et al., 2007). This supports the idea that there is several shared disease traits 
between diabetes and AD, with AD often being referred to as type 3 diabetes 
(Chong et al., 2012). 
3.1.9.3 GSK-3 and cancer  
Several proteins that play a role in key cancer pathways are required to be 
phosphorylated by GSK-3 for subsequent degradation through the SFCb-TrCP 
complex, but even though GSK-3 does play a role in cancer it is still under much 
debate whether that role is tumour promoting or tumour suppressive. GSK-3 
overexpression is seen in several cancer tumour types e.g. colon and ovarian 
and is thought to provide a tumour suppressor role by inhibiting the WNT 
signalling pathway through phosphorylation of b-catenin. Also, several cancer 
associated mutations have been shown to occur in GSK-3 substrates at the GSK-
3 phosphorylation or priming sites, this reduces GSK-3 mediated phosphorylation 
and hence the mutated protein evades SCFb-TrCP-mediated proteasomal 
degradation and accumulates in the cell.  For example, mutation in the GSK-3 
phosphorylation sites on b-catenin and c-Myc leads to an accumulation in these 
oncogenic proteins. GSK-3 is also a key negative regulator of the WNT, Notch 
and Hedgehog pathways, which are all heavily implicated in the development of 
cancer (McCubrey et al., 2014). The development and progression of GSK-3 
inhibitors for treatment of other diseases, such as AD and DM, is often halted due 
to concerns that their administration may lead to the development of cancer (Patel 
and Woodgett, 2008). Although this may be true, the data supporting this 
argument are extremely variable. However, recently published data highlights the 
potential for GSK-3 inhibitors to actually be beneficial in cancer treatment (Wang 
et al., 2008b; Ugolkov et al., 2016). 
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3.1.10 Development of reagents to study GSK-3: mouse models and 
inhibitors  
To gain a greater understanding of the complex role that GSK-3 plays in 
cell biology, isoform-specific mouse models and a range of targeted inhibitors 
have been developed. 
3.1.10.1 Mouse models  
A key breakthrough in understanding the differences between the two 
GSK-3 isoforms were the generation of isoform specific GSK-3a and GSK-3b 
knock out mice. Genetic knockout of the alpha isoform produced viable animals 
with no adverse phenotype. GSK-3a mice surprisingly showed increased glucose 
tolerance and insulin sensitivity, in comparison to wildtype matched control 
animals (MacAulay et al., 2007). MacAulay and colleagues attribute this to a 
reduction in plasma leptin levels. Interestingly the phosphorylation of glycogen 
synthase was unaltered in these animals, suggesting potentially different 
isoforms of GSK-3 mediate the phosphorylation of different target substrates. In 
contrast to the viable GSK-a specific knockout mice, GSK-3b knockout mice die 
in gestation due to severe liver damage (Hoeflich et al., 2000). Hoeflich and 
colleagues attribute this fatality to increased NFkB signalling leading to increased 
TNFα production. To understand more about the role that GSK-3b plays in a 
viable mouse model, tissue-specific GSK-3b knockout mice were generated 
(Patel et al., 2008). Genetic ablation of GSK-3b in the liver produced viable mice 
with no notable phenotype. However, skeletal muscle specific GSK-3b knockout 
mice were also viable but display enhanced glucose tolerance. This datum 
suggests that there may be tissue specific effects of GSK-3 isoforms. 
3.1.10.2 GSK-3 inhibitors  
GSK-3 is at the heart of several key pathways that are involved in several 
diseases, making it a useful therapeutic target. Lithium is a potent well 
characterised inhibitor of both GSK-3a and GSK-3b isoforms that has been used 
as the first line treatment of mood related disorders, such as bipolar disease, 
worldwide for decades (Freland and Beaulieu, 2012). Even though lithium is fairly 
specific it has been shown to inhibit other kinases (such as the CDK which  shares 
sequence identity with  GSK-), other non-kinase targets and also needs to be 
used at a very high concentration to completely inhibit GSK-3 activity (Bain et al., 
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2007). There are currently over 60 GSK-3 inhibitors available for the treatment of 
a wide range of diseases, from cancer to muscle wasting disorders (Robertson 
et al., 2018). The majority of compounds, like most protein kinase inhibitors, are 
ATP competitive meaning that they will inhibit all GSK-3 substrates at once and 
this could be detrimental to cell health. The fact that GSK-3 is involved in so many 
key biological processes raises the issue of selectivity, for example inhibition of 
GSK-3 may be beneficial in one disease e.g. treatment of Alzheimer’s disease 
setting but detrimental in another e.g. treatment of cancer. This in combination 
with the embryonic lethality of the GSK-3b knockout mice have halted the 
development of new more selective GSK-3 inhibitors. However, due to the unique 
requirement of GSK-3 for primed substrates there is the potential to develop 
inhibitors that target the binding site for the primed phosphate. So far, no drugs 
have been developed to successfully target this site, but phosphopeptides 
binding to this region show great potential (Cohen and Goedert, 2004).   
3.1.11 KEAP1-independent regulation of NRF2 protein stability and 
localization through the Neh6 domain  
Aberrant expression of NRF2 is found in several cancer types such as: 
liver, head and neck, ovary and lung, and its over-expression associated with 
poor prognosis (Shibata et al., 2008). In this case, it is thought that elevation of 
NRF2 signalling provides a chemo-resistant and highly proliferative ability to the 
cancer cell. There are several routes by which expression of the transcription 
factor can be increased; these include epigenetic silencing of KEAP1 through 
hypermethylation of the promotor region (Reviewed in (Guo et al., 2015)), 
accumulation of other ETGE-containing KEAP1-binding proteins indirectly 
influencing NRF2 through competing for KEAP1 (Hast et al., 2013), cysteine 
modification by oncometabolities (e.g. fumarate targeting Cys-151 and Cys-288 
of KEAP1) (Ooi et al., 2011) and somatic mutations in KEAP1 or NFE2L2 genes.  
Over 20% of lung cancer tumours have constitutive activation of the transcription 
factor due to mutations in either the negative regulatory protein, KEAP1 or 
NFE2L2 (Shibata et al., 2008). Somatic mutations throughout KEAP1, leading to 
a loss of function and “hot-spot” mutations in the DLG and ETGE motifs in 
NFE2L2, allow NRF2 to evade KEAP1-directed ubiquitination and degradation, 
leading to increased expression of cytoprotective genes. Tumours harbouring 
KEAP1 and NFE2L2 mutations are highly proliferative and intrinsically resistant 
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to chemotherapeutics. Therefore, understanding KEAP1-independent 
mechanisms by which NRF2 is degraded provides an alternative way to decrease 
NRF2 levels when KEAP1 is mutated.  
It has been suggested several times that there must be a separate form of 
NRF2 regulation other than the canonical KEAP1 degradation pathway. Work by 
McMahon et al (2004), found that when the Neh2 domain of NRF2 is removed 
the full-length mouse protein can still be degraded and only when both the Neh2 
and Neh6 domain are both removed does the protein significantly stabilise. They 
highlighted that this redox-independent Neh6 domain, corresponding to amino 
acids 329 to 339 in mouse NRF2, functions completely autonomously of KEAP1 
and may be critical to the regulation of NRF2 under extreme conditions of 
oxidative stress. Under these conditions KEAP1, which is predominantly 
cytoplasmic, would be rendered non-functional due to modification of its Cys 
residues, leading to a conformational change in the protein. Such modifications 
of KEAP1 results in the stabilization and translocation of NRF2 to the nucleus. 
McMahon et al., also postulate that potentially regulation through the Neh2 
domain and Neh6 domain can occur simultaneously but in different cellular 
compartments (McMahon et al., 2004).  
The link between NRF2 and GSK-3β was forged by Salazar and 
colleagues who through studying the subcellular localization of the transcription 
factor demonstrated that NRF2-acitivty is inhibited through phosphorylation by 
GSK-3β. GSK-3β was shown to negatively regulate NRF2-activity though 
stimulating its nuclear export (Salazar-Roa et al., 2006). This supports the 
previous finding that the NRF2 orthologue SKN-1 is inhibited by GSK-3β (An et 
al., 2005).  At this point the exact GSK-3β phosphorylation site(s) was unknown 
but the potential role of a priming kinase was suggested.  
 Subsequent papers reinforced this linked between NRF2 and GSK-3β 
through the study of neurological diseases. Short term oxidative stress, through 
exposure to H2O2, was documented to lead to nuclear accumulation of NRF2 but 
long term H2O2 induced oxidative stress was shown to enhance cytosolic NRF2 
levels through stimulation of its nuclear export (Rojo Ana et al., 2008; Rojo et al., 
2008).  
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A couple of years after McMahon and colleagues were making their 
observations a paper was published by Rada et al., supporting these findings and 
expanding on NRF2 regulation through the Neh6 domain. Rada et al., elegantly 
linked that fact that several transcription factors, such as Snail and β-Catenin are 
regulated by GSK-3 and the presence of an evolutionarily conserved cluster of 
Ser residues in the Neh6 domain to suggest that GSK-3 may phosphorylate the 
Neh6 domain. GSK-3 depletion through either chemical inhibition or siRNA gene 
knockdown was shown to enhance NRF2 protein levels, independently of 
KEAP1. Rada et al., went on to identify a putative β-TrCP binding motif, DSGIS, 
within the Neh6 region which GSK-3 phosphorylates. GSK-3 phosphorylation of 
Ser-335 and Ser-338 was highlighted to lead to the formation of a phosphodegron 
motif which is subsequently recognized by β-TrCP. They also supported the idea 
from the McMahon paper that the magnitude of oxidative stress may influence 
the mechanism by which NRF2 is degraded in the cell (Rada et al., 2011). A 
subsequent paper by the same group  (Rada et al., 2012) carried out several 
Nuclear Magnetic Resonance (NMR) and docking experiments to further validate 
that the Neh6 domain can be bound by β-TrCP specifically through Ser-335 and 
Ser-338. Then through the generation of several site mutants against the clusters 
of serine residues in the Neh6 domain, they determined the following; Ser-351 
and Ser-355 are not phosphorylated by GSK-3β, GSK-3 phosphorylates Ser-335 
and Ser-338 greater in the presence of intact Ser-342 and Ser-347 and 
phosphorylation of Ser-342 and Ser-347 still occurs in the absence of GSK-3 
suggesting other kinases may also phosphorylate the Neh6 domain. Rada and 
colleagues hypothesized that Ser-342 and Ser-347 could potentially function as 
a priming site(s) for GSK-3 activity. However, at this point they could not provide 
any data or suggest any kinases that may phosphorylate these sites (Rada et al., 
2011).  
The interaction between β-TrCP and the Neh6 domain was further 
substantiated by Chowdhry and colleagues who identified two non-identical 
regions within the Neh6 located at mouse amino acids 329-339 and 263-379, that 
are bound by β-TrCP (Chowdhry et al., 2013). Both these regions function to 
control the turnover of NRF2 completely independently of KEAP1. One motif has 
the sequence DSGIS and the other DSAPGS, with the former being regulated by 
GSK-3 and the latter not. This enforces the idea that GSK-3 is central to KEAP1-
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independent degradation of NRF2 by phosphorylating several key Ser residues 
in the Neh6 domain leading to the formation of the phosphodegron to which β-
TrCP binds.  
Whilst it is clear that GSK-3 and β-TrCP are capable of exerting KEAP1-
independent repression of NRF2, the notion that a priming kinase is necessary in 
order that GSK-3 can create a phosphodegron in the Neh6 domain of NRF2 to 
which β-TrCP binds has not been researched. The data in this chapter identifies 
the specific priming site(s) located in Neh6, gives examples of kinases that may 
prime NRF2 for phosphorylation by GSK-3, and demonstrates the impact of 
priming on NRF2 degradation in the cell.  
3.2 Results 
3.2.1 The Neh6 domain of NRF2 contains both β-TrCP binding sites and two 
potential priming sites and is highly conserved across several species 
NRF2 is principally controlled at a protein stability level through 26S 
proteasomal degradation. The Neh2 domain, spanning amino acids 1-87 in 
mouse Nrf2, contains both motifs to which KEAP1 binds. Under homeostatic 
conditions KEAP1 binds NRF2, recruits a CUL3 ligase, which ubiquitinates NRF2 
and labels the transcription factor for subsequent degradation by the 26S 
proteasome. The Neh6 domain of NRF2, spanning amino acids 328-380 of 
mNRF2, contains two motifs to which b-TrCP binds. These motifs are DSGIS and 
DSAPGS, which are highly conserved across several species (Chowdhry et al., 
2013 ;McMahon et al., 2004). The DSGIS motif has been shown to require 
phosphorylation at Ser-335 and Ser-338 (numbering referring to mouse NRF2 
(mNRF2)) to ensure maximal binding by b-TrCP (Rada et al., 2012; Rada et al., 
2011). By contrast, the binding of b-TrCP to the DSAPGS motif does not seem to 
be influenced by phosphorylation (Chowdhry et al., 2013) (Figure 3.2.1).  
The DSGIS motif is flanked on its C-terminal side by Ser-342 and Ser-347, 
both of which are located immediately adjacent to a Pro residue (i.e. Pro-343 and 
Pro-348) within a region that is highly conserved across species. The 
phosphorylation status of these two amino acids has been reported to influence 
the ability of GSK-3 to phosphorylate Ser-335 and Ser-338 (Rada et al., 2012; 
Rada et al., 2011), suggesting that phosphorylation of the DSGIS motif occurs in 
a progressive fashion. It is well known that GSK-3 has a specificity for substrates 
that have undergone a prior phosphorylation event mediated by another kinase 
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at an amino acid positioned either 4 or 5 amino acids C-terminal from the initial 
GSK-3 phosphorylation site. As shown in Figure 3.2.2, we propose that 
phosphorylation of NRF2 at Ser-342 and Ser-347 is mediated by a currently 
unknown kinase and functions as a priming event for subsequent phosphorylation 
by GSK-3b at Ser-335 and Ser-338. 
 
 
 
 
 
 
Figure 3.2.1: The Neh6 domain of NRF2 contains both β-TrCP binding sites and is highly 
conserved across several species. 
Schematic representation of the protein structure of mNRF2. Both KEAP1-dependent and 
KEAP-independent degradation regions are highlighted above in bold font, also the size of 
each Neh domain of mNRF2 is provided by the numbers between the dotted arrows. 
Underneath in the expanded Neh6 domain are the amino acid sequences corresponding to 
the Neh6 domain of NRF2 from mouse (m), human (h), rat (r), frog (f), and zebrafish (z), along 
with that of ECH (that is, chicken NRF2) that have been aligned using the T-Coffee tool 
(at http://www.ebi.ac.uk/Tools/msa/tcoffee/). White letters on a black background represent 
residues that are identical across at least half of the species studied, and black letters on a 
grey background are conserved residues. The two black outlined boxes contain the 
sequences enriched with Ser and Asp residues and are the regions to which β-TrCP binds. 
Within the black boxes, a solid horizontal bar is shown above sequences that represent 
putative β-TrCP-binding sites. The residues that are predicted to be phosphorylated by GSK-
3, based on the Scansite program (at http://scansite.mit.edu), are indicated at the bottom as 
vertical arrows. 
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Figure 3.2.2: Potentially there are two distinct phosphorylation sites, Ser-342 and Ser-
347, within the Neh6 domain which may function as priming sites for subsequent 
phosphorylation of Ser-338 and Ser-335 by GSK-3. 
Sequence alignment of the region within the Neh6 domain of mouse and human NRF2 that 
contains the site to which β-TrCP binds. It also shows the GSK-3 phosphorylation site(s) and 
the potential priming site(s). White letters on a black background represent residues that are 
identical between the two species. Black letters on a white background, highlight residues 
which are not conserved across the two species. The horizontal bar under the residues 
corresponds to the β-TrCP binding region. The residues that are predicated to be putative 
priming kinase sites, Ser-342 and Ser-347 (numbering corresponding to the mouse NRF2), 
based on the Scansite program (at http://scansite.mit.edu) are indicated. 
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3.2.2 GSK-3b activity towards the Neh6 domain of mNRF2 is enhanced in 
the presence of an additional kinase 
To determine whether GSK-3b mediated phosphorylation of the Neh6 
domain is enhanced by the presence of a prior phosphorylation event, we 
exploited the fact that mammalian cells express several protein kinases. 
Therefore, a Neh6-containing protein expressed in mammalian cells will have 
been exposed to several kinases, some of which might modify the protein. A 
construct corresponding to amino acids 290-410 of mNRF2 (a region that will now 
be referred to as the mNeh6+ region) with a C-terminal GST tag (referred to a 
GST-mNeh6+) was generated by Dr. Sudhir Chowdry. This construct was then 
expressed and purified from monkey kidney fibroblast-like COS1 cells. We then 
treated the purified GST-mNeh6+ with protein phosphatase 2A (PP2A, a Ser/Thr 
specific phosphatase), either with or without Okadaic acid (OA, which is an 
inhibitor of PP2A) before adding GSK-3b and [32P] ATP to the incubation mixture. 
As shown in Figure 3.2.3, the incorporation of [32P] phosphate into GST-mNeh6+ 
by GSK-3b was greatly accentuated in the presence of both PP2A and OA, 
relative to PP2A alone, suggesting that prior phosphorylation of the Neh6+ region 
by a kinase in COS1 cells enhances subsequent GSK-3b phosphorylation. 
Although, it should be noted that there are eight serine residues and five 
threonine residues within the GST tag sequence that could be potentially 
phosphorylated by GSK-3. Therefore, a purified GST tag should be included as 
a control. This experiment was carried out by Dr. Sudhir Chowdry.  
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Figure 3.2.3: GSK-3 activity towards mNeh6+ is diminished in the presence of a 
phosphatase suggesting that additional phosphorylation events effect GSK-3 
phosphorylation of mNRF2. 
 (A) To determine if the activity of GSK-3 towards the mNeh6+ region can be enhanced by 
other phosphorylation events, an in vitro kinase assay was set up with/without okadaic acid 
and in the presence or absence of PP2A. Two sets of reactions were setup. In the first set, the 
purified recombinant GST-tagged mNeh6+ protein (0.1 µg/µl, substrate), generated from 
mammalian (COS1) cells, was incubated with PP2A (2 mU) at 30°C for 30 minutes. Following 
the incubation period, OA (1 µM) was added and the reaction mix was incubated at 30°C for 
further 10 min, to inhibit PP2A. In the second set of reactions, the purified recombinant GST-
tagged mNeh6+ protein (0.1 µg/µl, substrate) was incubated with PP2A (2 mU) and OA (1 µM) 
together at 30°C for 30 minutes. Following this, purified activated recombinant GSK-3β (6m 
U/µl (kinase)) was added to both the reaction mixtures in the presence of 10 mM MgCl2 and 
0.1 mM [γ 32P]-ATP, and this was then further incubated for 120 min at 30°C. The reactions 
were terminated by addition of SDS gel loading buffer, the samples were loaded on a SDS-
PAGE gel, and the excess [Ɣ-32P]-ATP was removed by electrophoresis. Gels were then 
stained with coomassie stain, dried and subjected to autoradiography. After which, protein 
bands were excised and the incorporated radioactivity was determined by scintillation 
counting. This image is one representative of three independent biological replicates. (B) 
Scintillation counts from (A). Data displayed are mean value from three independent biological 
replicates and the associated standards error of the mean (SEM). Experiment carried out by 
Dr S. Chowdhry. 
B 
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3.2.3 Several members of the CMGC family protein kinases have the 
potential to phosphorylate the Neh6 domain of NRF2 
We identified protein kinases that may prime the Neh6 region of NRF2 by 
conducting an in vitro kinase screen, in collaboration with Dr James Hastie at 
DSTT, University of Dundee. In these experiments we examined the relative 
ability of kinases to phosphorylate a region of NRF2 that included the DSGIS 
motif, residues that GSK-3b can phosphorylate and where a potential priming 
kinase may target (mNRF2 amino acids 330-350 and hNRF2 amino acids 339-
359) from amongst a panel of 140 protein kinases; the enzyme panel examined 
had previously been used to identify small molecule inhibitors (Hastie et al., 2006; 
Bain et al., 2007). The capability of each kinase to phosphorylate the mouse and 
hNRF2-based 21-mer peptides was compared relative to its ability to 
phosphorylate a well-characterised standard peptide or protein (data not shown).  
From amongst this panel of kinases, Table 3.2.1 shows those that had the highest 
relative phosphorylation towards the NRF2-based peptides to background. 
Several kinases identified in the top 20 are members of the CMGC family of 
protein kinases. This is not to be unexpected as both Ser-342 and Ser-347 are 
flanked C-terminally by a proline residue, which is a requirement for CMGC 
kinases. Fifty-seven human CMGC kinases exist, which are highly evolutionarily 
conserved and have previously been shown to function as priming kinases for 
GSK-3 (e.g. CK2 primes b-catenin and DYRK primes eIF2B (Varjosalo et al., 
2013; Robertson et al., 2018)).  Interestingly, in our screen DYRK2 and DYRK3 
were ranked first and sixth respectively in terms of their ability to phosphorylate 
the two 21-mer peptides, showing a 5-fold higher phosphorylation of the mouse 
peptide in comparison to the human peptide. Besides DYRK2 and DYRK3, TTK, 
MLK, CDK9 and TBK1 also extensively phosphorylated the two 21-mer peptides.  
Because two of the DYRK family members exhibited high activity towards the 21-
mer peptides, along with the known ability of DYRK isoenzymes to prime 
substrates for GSK-3b, we decided to investigate further whether these enzymes 
can prime the Neh6 region of NRF2 for GSK-3b.  
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Table 3.2.1: Kinase screen against mouse and human peptides indicates that several 
members of the CMGC family of kinases phosphorylate the Neh6 region 
 (A) A kinase screen was carried out using a mouse 21-mer peptide corresponding to a region 
in the Neh6 domain with the sequence FNDSDSGISLNTSPSRASPEH and a human 21-mer 
peptide with the sequence FNDSDSGISLNTSPSVASPEH; in both instances a KK dipeptide 
was attached to the N-terminal end to assist with immobilization of the peptides. The table 
depicts the top 20 kinases with the highest relative activity towards the mouse and human 
peptides compared to their standard peptides (positive controls). All of the top 20 kinases are 
members of the CMCG family of kinases. The kinases listed have been ranked in the second 
column according to their rate of phosphorylation of the 21-mer peptides.  DYRK2, TTK and 
MLK1 were all ranked equal top. 
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3.2.4 All four DYRK family members phosphorylate the Neh6+ region of 
mNRF2 to varying abilities, with DYRK2 and DYRK4 showing the greatest 
activity 
To determine the ability of the four DYRK family members to 
phosphorylate the Neh6 domain of mNRF2, we exploited the fact that bacterially 
expressed recombinant proteins are exposed to very little kinase activity and 
therefore will be unphosphorylated. Thus, GST-mNeh6+ was expressed and 
purified from E.coli (BL21(DE3)pLysS) cells and incubated with one of the four 
DYRK family members; DYRK1A, DYRK2, DYRK3 or DYRK4, in the presence 
of  [Ɣ-32P]-ATP. It should be noted that there is an additional splice variant of 
DYRK1 called DYRK1B. However, DYRK1B has a very cell specific expression 
pattern and therefore was not included in our experiments.  
DYRKs are a group of evolutionally conserved kinases that as their name 
suggests can phosphorylate both Tyr and Ser/Thr residues flanked by a C-
terminal Pro residue. DYRKs are activated by autophosphorylation of a tyrosine 
residue located in their activation loop. DYRK family members have been 
reported to have roles in cell cycle, proliferation, mRNA splicing and synaptic 
signalling (Soppa and Becker, 2015). Before carrying out any experiments all 
kinases were assayed against a known substrate to determine their activity and 
ensure each kinase was used at the same activity (data not shown). The largest 
incorporation of phosphate into GST-mNeh6+ occurred in the presence of DYRK2 
and DYRK4 suggesting they show greater activity towards the Neh6 domain than 
DYRK1A and DYRK3 (Figure 3.2.4). Phosphorylation of GST-mNeh6+ was 
greater when the kinases were at a concentration of 2 mU/µl than at 1 mU/µl, 
suggesting initial rate kinetics was reached.  
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3.2.5 DYRK family members phosphorylate the Neh6 domain of mNRF2 
predominantly at Ser-347 
To identify which residue(s) is phosphorylated by the DYRK family of 
kinases, a series of point mutants (S338A, S342A and S347A) were generated 
in GST-mNeh6+ by mutating these Ser residues to an Ala, they can no longer be 
phosphorylated. GST-mNeh6+, or the single base pair mutants generated were 
expressed and purified from E.coli (BL21(DE3)pLysS) cells, then incubated with; 
DYRK1A, DYRK2, DYRK3 or DYRK4. As shown in Figure 3.2.5, only when Ser-
347 is mutated to Ala is there a loss of phosphorylation by all four DYRK kinases. 
This suggests that DYRK primes the Neh6 domain by phosphorylating Ser-347, 
independently of the phosphorylation status of neighbouring Ser residues. 
Interestingly, the DYRK isoenzmyes were all still able to phosphorylate the S342A 
mutant protein, suggesting this site is not a priming site but potentially a GSK-3b 
phosphorylation site. 
 
 
 
Figure 3.2.4: DYRK2 and DYRK4 phosphorylate the Neh6+ region of mNRF2 better than 
other DYRK family members 
(A) To determine if all members of the DYRK family can phosphorylate the Neh6 domain of 
mNRF2, purified recombinant GST-tagged mNeh6+ protein (0.1 µg/µl, substrate) generated in 
E. coli (BL21(DE3)pLysS) cells was incubated (in a reaction mixture of 40 µl) with purified 
activated recombinant DYRK1A, DYRK2, DYRK3, or DYRK4, at a concentration of 2 mU/µl or  
1mU/µl for 10 min in the presence of 10 mM MgCl2 and 0.1 mM [Ɣ-
32P]-ATP at 30°C. The 
reactions were terminated by addition of SDS gel loading buffer ,20 µl of each sample was 
loaded on a SDS-PAGE gel, and the excess [Ɣ-32P]-ATP removed by electrophoresis. Gels 
were then stained with coomassie dye, dried and subjected to autoradiography. After 
autoradiography, protein bands were excised from the gel and the incorporated radioactivity 
determined by scintillation counting. This image is one representative image of three 
independent biological replicates. (B) Scintillation counts from figure (A). DYRK1A is 
represented by the white bars, DYRK2 is shown by the black bars, DYRK3 is shown by the 
light grey bars and DYRK4 by the stripped bars. Kinase concentrations are given below the 
figure. The data shown is the average from three independent replicates and the associated 
SEM. 
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3.2.6 DYRK2 phosphorylates Ser-347 enhancing subsequent 
phosphorylation of the Neh6 domain by GSK-3b 
We next carried out a two-step linked assay with DYRK2 and GSK-3b to 
determine whether pre-incubating GST-mNeh6+ with DYRK2 leads to enhanced 
phosphorylation by GSK-3b. In the first step, bacterially purified GST-mNeh6+ or 
a single base-pair mutant protein, was incubated with DYRK2 in the presence of 
non-radioactively labelled ATP for 120 min; this first stage allows DYRK2 to 
phosphorylate GST-mNeh6+ priming it for GSK-3b. After 120 min, the reaction 
mix was heated at 60ºC for 5 min to inactivate the DYRK2 present. The reaction 
was then cooled before the addition of GSK-3b and [g-32P] ATP for 30 min. This 
means that the read out of this assay represents the ability of GSK-3b to 
phosphorylate GST-mNeh6+ protein. As shown in Figure 3.2.6, in the presence 
of DYRK2 and GSK-3b, GST-mNeh6+ is heavily phosphorylated. Mutation of Ser-
342 to Ala does not affect GSK-3b phosphorylation, suggesting that DYRK2 
phosphorylation is also unaltered. However, when Ser-347 is mutated to Ala there 
is a loss in GSK-3b phosphorylation, suggesting that priming by DYRK2 has been 
decreased. 
Figure 3.2.5: DYRK family members phosphorylate the Neh6 domain in mNRF2 
predominantly at Ser-347 
(A) To determine which Ser residue(s) in the Neh6 domain are targeted by members of the 
DYRK family of kinases, purified recombinant GST-tagged mNeh6+ protein or single base-pair 
mutants of mNeh6+ protein (0.1µg/µl, substrate) generated in E.coli (BL21(DE3)pLysS) cells 
were incubated in a reaction mixture of 40 µl with 2 mU/µl purified activated recombinant 
DYRK1A, DYRK2, DYRK3 or DYRK4, for 10 min in the presence of 10 mM MgCl2 and 0.1 mM 
[Ɣ-32P]-ATP at 30°C. The reactions were terminated by addition of SDS gel loading buffer, then 
20 µl of each sample was loaded on a SDS-PAGE gel, and the excess [Ɣ-32P]-ATP was 
removed by electrophoresis. Gels were then stained with coomassie dye, dried and subjected 
to autoradiography, after which, protein bands were excised and the incorporated radioactivity 
determined by scintillation counting. This image is representative of three independent 
biological replicates. (B) Scintillation counts from figure (A). GST-mNeh6+ is represented in the 
white bars, GST-mNeh6+(S338A) is shown in the black bars, GST-mNeh6+(S342A) is shown 
in the light grey bars and GST-mNeh6+(S347A) in the striped grey bars. The identity of the 
kinases is given below the figure. The data displayed is the average from three independent 
replicates and the associated SEM. 
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3.2.7 The identity of the amino acid residue at position 345 influences the 
ability of DYRK2 to phosphorylate the Neh6 domain in mNRF2 
The in vitro kinase screen (Table 3.2.1) revealed that both DYRK2 and 
DYRK3 can phosphorylate the 21-mer peptide designed from mNRF2 
considerably better than the equivalent human 21-mer peptide. Interestingly, only 
one amino acid difference exists between the mouse and the human peptide 
sequences; in mNRF2, the amino acid at position 345 is an Arg (R) residue, 
whereas the corresponding amino acid in hNRF2 is a Val (V) residue. To 
determine whether the identity of the amino acid at this position influences 
phosphorylation by DYRK2, we generated a fusion protein compromising GST 
linked at its C-terminal end to amino acids 299-419 of hNRF2, which we refer to 
as GST-hNeh6+, and single base-pair V345R mutant. We then incubated 
bacterially purified GST-mNeh6+, GST-hNeh6+ and GST-hNeh6+(V345R) with 
DYRK2 in the presence of [g-32P] ATP (Figure 3.2.7). Phosphorylation of GST-
Figure 3.2.6: DYRK2 enhances phosphorylation of mNeh6+ by GSK-3b through 
phosphorylating S347A 
(A) A two-step in vitro kinase linking assay was setup to establish if DYRK2 can function as a 
priming kinase for GSK-3β by phosphorylating Ser-347. In the first step, purified recombinant 
GST-tagged mNeh6+ protein (0.1 µg/µl, substrate), or single base-pair mutant GST-
mNeh6+(S347A) protein (0.1 µg/µl, substrate), generated in E.coli (BL21(DE3)pLysS) cells 
were incubated (in a reaction mixture of 4 0µl) with 2 mU/µl purified activated recombinant 
DYRK2, in the presence of 5 mM MgCl2 and 0.05 mM cold-ATP at 30°C for 120 min. The 
reaction mixture was heated at 60°C for 5 min to inactivate the kinase and re-incubated at 30°C 
for 10 min before initiating the second step of the two-step of the assay. Purified activated 
recombinant GSK-3β (6 mU/µl (kinase)) was then added to the reaction mixtures in the 
presence of 5 mM MgCl2 and 0.05 mM [Ɣ-
32P]-ATP and incubated at 30°C for 60 min. 
Thereafter, the reactions were terminated by addition of SDS gel loading buffer, 20 µl of each 
sample was loaded onto a SDS-PAGE gel, and the excess [Ɣ-32P]-ATP was removed by 
electrophoresis. Gels were then stained with coomassie dye, dried and subjected to 
autoradiography, after which protein bands were excised and the incorporated radioactivity 
determine by scintillation counting. The image is from one experiment and is representative of 
three independent biological replicates. (B) Scintillation counts for (A). GST-mNeh6+ is 
represented in the white bar, GST-mNeh6+(S342A) is shown in the black bar and GST-mNeh6+ 
is shown in the light grey bar. The data displayed is the average from three independent 
replicates and the associated SEM. 
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hNeh6+ by DYRK2 was considerably weaker than phosphorylation of GST-
mNeh6+, matching up with the data we saw in the kinase screen. Remarkably, 
when Val-354 in GST-hNeh6+ was replaced with a Arg residue, phosphorylation 
by DYRK2 was increased, though not to the extent observed with GST-mNeh6+ 
as substrate. These findings suggest that the identity of the amino acid positioned 
two residues N-terminal to the DYRK2 phosphorylation site can affect its activity 
towards the substrate. 
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Figure 3.2.7: The identity of the amino acid at position 345 influences phosphorylation 
of the Neh6 domain by DYRK2 
(A) Sequence alignment of the region surrounding the GSK-3 phosphorylation sites in mouse 
and hNRF2 reveals only one amino acid difference between the two species; this is Arg-345 
in mNRF2, which is equivalent to Val-354 in hNRF2. (B) To determine if the identity of amino 
acid 345 (mouse numbering) influences DYRK2 phosphorylation of the Neh6 domain, purified 
recombinant GST-tagged mNeh6+ protein (0.1 µg/µl, substrate) or purified recombinant GST-
hNeh6+ protein (0.1 µg/µl, substrate) or a single site mutant of GST-hNeh6+(V345R) protein 
(0.1 µg/µl, substrate) generated in E.coli (BL21(DE3)pLysS) cells were incubated in a reaction 
mixture of 40 µl with purified activated recombinant DYRK2 (2 mU/µl) for 10 min in the 
presence of 10 mM MgCl2 and 0.1 mM [Ɣ-
32P]-ATP at 30°C. The reactions were terminated 
by addition of SDS gel loading buffer, the samples (20 µl) were loaded onto a SDS-PAGE gel, 
and the excess [Ɣ-32P]-ATP was removed by electrophoresis. Gels were then stained with 
Coomasssie Brilliant Blue dye, dried and subjected to autoradiography, after which protein 
bands were excised and the incorporated radioactivity determined by scintillation counting. 
This image is from one experiment and is representative of three independent biological 
replicates. (C) Scintillation counts obtained from (B). GST-mNeh6+ is represented in the white 
bar, GST-hNeh6+ is shown in the black bar and GST-hNeh6+(V345R) in the light grey bar. 
The data displayed is the average from three independent replicates with the associated SEM.  
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3.2.8 The ability of all DYRK family members to phosphorylate the Neh6 
domain is influenced by the identify of amino acid 345 
To establish whether the identify of amino acid 345 influences the ability 
of all four DYRK family members to phosphorylate the Neh6 domain, we carried 
out an in vitro kinase assay with all four isoenzymes in the presence of bacterially 
purified GST-mNeh6+, GST-hNeh6+ and GST-hNeh6+(V345R). All four DYRK 
family members were able to phosphorylate GST-mNeh6+ to a greater extent 
than GST-hNeh6+ (Figure 3.2.8). As seen in the previous figure, mutating Val-
345 in GST-hNeh6+ to an Arg, partially rescued phosphorylation. This reinforces 
the idea that the identity of neighbouring residues around the phosphorylation site 
influences the ability of DYRK family members to phosphorylate mNRF2.  
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3.2.9 Kinases identified in the 21-mer peptide screen phosphorylate the 
GST-mNeh6+ fusion protein through different sites 
To further validate the kinase screen data (Table 3.2.1), we carried out 
several in vitro kinase assays against purified bacterially-synthesised GST-
mNeh6+. As shown in Figure 3.2.9A and B, all four SAPK family members are 
able to phosphorylate GST-mNeh6+, to varying extents, with SAPK3 and SAPK4 
exhibiting the highest phosphorylation. To determine whether this 
phosphorylation of the mNeh6+ domain by SAPK isoenzymes occurs through at 
Ser-347, the same site as utilized by DYRK isoenzymes, or thorough the other 
potential Ser-342 priming site, we incubated bacterially purified GST-mNeh6+, or 
single amino acid site mutant constructs with SAPK2A, SAPK2B, SAPK3 or 
SAPK4. By contrast with data obtained with DYRK isoenzymes (Figure 3.2.5), 
mutation of Ser-347 to Ala had little effect on the ability of SAPK isoenzymes to 
phosphorylate GST-mNeh6+ (Figure 3.2.9C and D). However, replacement of 
Ser-342 with an Ala residue decreased the ability of all four SAPK isoenzymes to 
phosphorylate the mutant GST-mNeh6+ protein, suggesting that this family of 
Figure 3.2.8: The identity of the amino acid at position 345 influences the ability of 
all DYRK isoenzymes to phosphorylate the Neh6 domain. 
 (A)To determine if amino acid 345 (mouse numbering) influences the ability of all four 
DYRK family members to phosphorylate the Neh6 domain, purified recombinant GST-
mNeh6+ protein (0.1 µg/µl) or purified recombinant GST-hNeh6+ protein (0.1 µg/µl) or a 
single site mutant of GST-hNeh6+(V345R) protein (0.1 µg/µl) generated from E.coli 
(BL21(DE3)pLysS) cells were incubated in a total reaction mix of 40 µl with purified 
activated recombinant DYRK1A, DYRK2, DYRK3 or DYRK4 (each at 2 mU/µl) for 10 min 
in the presence of 10 mM MgCl2 and 0.1 mM [Ɣ-
32P]-ATP at 30°C. The reactions were 
terminated by addition of SDS gel loading buffer, 20 µl of each sample was then loaded 
on a SDS-PAGE gel, and the excess [Ɣ-32P]-ATP was removed by electrophoresis. Gels 
were then stained with coomasssie dye, dried and subjected to autoradiography, after 
which protein bands were excised and the incorporated radioactivity determined by 
scintillation counting. The data shown are from one experiment and is representative of 
three independent biological replicates. (B) Scintillation counts from (A). 
GST-mNeh6+ is represented in the white bars, GST-hNeh6+ is shown in the light grey bars 
and GST-hNeh6+(V345R) in the light grey bars. The identity of the kinases is given below 
the figure. The data shown is the average of three independent replicates with the 
associated SEM. 
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protein kinases may prime mNRF2 for modification by GSK-3b through 
phosphorylation of Ser-342. 
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Figure 3.2.9: Members of the SAPK family phosphorylate the Neh6 domain of 
mNRF2 predominantly through Ser-342. 
(A) To determine if SAPK family members can phosphorylate the Neh6 domain of mNRF2, 
purified recombinant GST-tagged mNeh6+protein (0.1 µg/µl, substrate) generated in E.coli 
(BL21(DE3)pLysS) cells was isolated on glutathione-agarose beads and incubated with 
purified activated recombinant SAPK2A, SAPK2B, SAPK3, or SAPK4, at either at 
concentration of 2 mU/µl or 1 mU/µl in a reaction mixture of 40 µl for 10 min in the presence 
of 10 mM MgCl2 and 0.1 mM [Ɣ-
32P]-ATP at 30°C. The reactions were terminated by 
addition of SDS gel loading buffer, 20 µl of each sample was then loaded on a SDS-PAGE 
gel, and excess [Ɣ-32P]-ATP was removed by electrophoresis. Gels were then stained with 
Coomassie Brilliant Blue dye, dried, and subjected to autoradiography, after which protein 
bands were excised and the incorporated radioactivity determined by scintillation 
counting. This image is one representative image of three independent biological 
replicates. (B) Scintillation counts from (A) SAPK2A is represented by the white bars, 
SAPK2B is shown in the black bars, SAPK3 is shown in the light grey bars and SAPK4 is 
shown in the stripped bars.  Kinase concentrations are given below the figure. This data 
shown is the mean value from three replicates and the associated SEM.(C) To determine 
which Ser residue in the Neh6 domain is targeted by members of the SAPK family, purified 
recombinant GST-mNeh6+ protein or single base-pair mutants for mNeh6+ protein (0.1 
µg/µl, substrate) generated in E.coli (BL21(DE3)pLysS) cells were incubated in a reaction 
mixture of 40 µl with 2 mU/µl purified activated recombinant SAPK2A, SAPK2B, SAPK3 
or SAPK4, for 10 min in the presence of 10 mM MgCl2 and 0.1 mM [Ɣ-
32P]-ATP at 30°C. 
The reactions were terminated by addition of SDS gel loading buffer, 20 µl of each sample 
was then loaded on a SDS-PAGE gel, and the excess [Ɣ-32P]-ATP was removed by 
electrophoresis. Gels were then stained with coomassie dye, dried, and subjected to 
autoradiography, after which, protein bands were excised and the incorporated 
radioactivity determined by scintillation counting. This image is representative of three 
independent biological replicates. (D) Scintillation counts from (C). GST-mNeh6+ is 
represented in the white bars, GST-mNeh6+(S342A) is shown in the black bars and GST-
mNeh6+(S347A) is shown in the light grey bars. The identity of the kinase is given below 
the figure. The data displayed is the mean value from three independent replicates and 
the associated SEM. 
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Of the kinases examined, all three JNK family members: JNK1, JNK2 and JNK3, 
were amongst the most active in phosphorylating the 21-mer peptides in the in 
vitro screen (Table 3.2.1). To determine whether all three JNK isoenzymes 
phosphorylate the Neh6 domain to a similar extent, we incubated bacterially 
synthesised GST-mNeh6+ with either JNK1, JNK2 or JNK3. As seen in Figure 
3.2.10A and B, JNK3 seems better at phosphorylating GST-mNeh6+ than the two 
other JNK family members. This was surprising as the screen results suggest 
that JNK1 should have been better than JNK2 and JNK3 at phosphorylating 
Neh6. Potentially there is altered folding in the larger fusion protein than the 21-
mer peptide used in the screen, which may alter the ability of some kinases to 
bind. To investigate whether phosphorylation of the Neh6 domain by JNK 
isoenzymes occurs through either Ser-342 or Ser-347, bacterially purified GST-
mNeh6+, single amino acid site mutants of GST-mNeh6+ or a double mutant of 
GST-mNeh6+, in which both potential priming sites are mutated, were incubated 
with the three JNK proteins. The data displayed in Figure 3.2.10C and D show 
that phosphorylation by all three JNK family members is reduced in the fusion 
protein containing S342A or in the S342A/S347A double mutant protein. 
Phosphorylation by JNK3 appears to be enhanced when Ser-347 is mutated to 
Ala. Taking all the data in Figure 3.2.10 together, it is apparent that JNK 
isoenzymes can phosphorylate mNeh6+ but it is currently unclear which site they 
target.  
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Figure 3.2.10: Members of the JNK family can also phosphorylate the Neh6 
region, but it is unclear through which site 
 (A) To determine if different members of the JNK family can phosphorylate the 
Neh6 region to different abilities, purified recombinant GST-tagged mNeh6+ protein 
(0.1 µg/µl, substrate) generated from E.coli (BL21(DE3)pLysS) cells was incubated 
with purified activated recombinant: JNK1, JNK2, or JNK3, at either at concentration 
of 2 mU/µl or 1 mU/µl for 30 min in the presence of 10 mM MgCl2 and 0.1 mM [Ɣ-
32P]-ATP at 30°C. The reactions were terminated by addition of SDS gel loading 
buffer, the samples were loaded on a SDS-PAGE gel, and the excess [Ɣ-32P]-ATP 
was removed by electrophoresis. Gels were then stained with coomasssie, dried 
and subjected to autoradiography. After which, protein bands were excised and the 
incorporated radioactivity was determined by scintillation counting. This image is 
one representative image of three independent biological replicates. (B) Scintillation 
counts from figure (A). JNK1 is represented in the white bars, JNK2 is shown in the 
black bars and JNK3 is shown in the light grey bars. Kinase concentrations are 
displayed under the figure. The data displayed on the graph is the mean value from 
three independent biological replicates and the associated SEM. (C) To determine 
which serine residue in the Neh6 region is targeted by members of the JNK family 
of kinases, purified recombinant GST-tagged mNeh6+ protein or single/double base-
pair mutants for mNeh6+ protein (0.1 µg/µl, substrate) generated from E.coli 
(BL21(DE3)pLysS) cells were incubated with 2 mU/µl purified activated 
recombinant, JNK1, JNK2 or JNK3, for 30 minutes in the presence of 10 mM MgCl2 
and 0.1 mM [Ɣ-32P]-ATP at 30°C. The reactions were terminated by addition of SDS 
gel loading buffer, the samples were loaded on a SDS-PAGE gel, and the excess 
[Ɣ-32P]-ATP was removed by electrophoresis. Gels were then stained with 
coomasssie, dried and subjected to autoradiography. After which, protein bands 
were excised and the incorporated radioactivity was determined by scintillation 
counting. This image is representative of three independent biological replicates. 
(D) Scintillation counts from figure (C). GST-mNeh6+ is represented by the white 
bars, GST-mNeh6+(S342A) is shown in the black bars, GST-mNeh6+ (S347A) is 
shown in the light grey bars and GST-mNeh6+(S342/347A) is shown in the stripped 
bars. The identity of the kinase is shown below the figure. The data displayed on 
the graph is the mean value from three independent biological replicates and the 
associated SEM. 
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Using the 21-mer peptide-based screen, TTK and MLK1 came out ranked 
equal first with DYRK2, and CDK9 and TBK1 were ranked equal fourth. However, 
when we compared the ability of TTK, MLK1, CDK9 and TBK1 to phosphorylate 
bacterially synthesised GST-mNeh6+ purified on glutathione-agarose beads to 
that of DYRK2, we found that all four kinases showed significantly less 
phosphorylation of the fusion protein relative to DYRK2, as shown is Figure 
3.2.11A and B. To determine which specific site these four kinases phosphorylate 
in the Neh6 domain, we incubated bacterially purified GST-mNeh6+, or a single 
amino acid site mutant or a double mutant protein with either MLK1, TTK, TBK1 
or CDK9.  As seen is Figure 3.2.11C and D, mutation of Ser-342 and Ser-347 
lead to a reduction in phosphorylation by TTK. Whilst mutation of Ser-347 to Ala 
did not influence phosphorylation by CDK9 and mutation of Ser-342 to Ala lead 
to a slight reduction. Phosphorylation of any of the fusion proteins by either MLK1 
and TBK1 was too low to draw any conclusions.  
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Figure 3.2.11: MLK1, TTK, TBK1 and CDK9 phosphorylate the Neh6 domain to 
varying degrees 
 (A) To determine if MLK1, TTK, TBK1 and CDK9, can phosphorylate the Neh6 region, 
purified recombinant GST-tagged mNeh6+ protein (0.1 µg/µl) generated in E.coli 
(BL21(DE3)pLysS) cells was incubated in a reaction mixture of 40 µl with purified activated 
recombinant MLK1, TTK, TBK1 or CDK9, at either at concentration of  2 mU/µl or 1 mU/µl 
for 3 hr in the presence of 10 mM MgCl2 and 0.1 mM [Ɣ-
32P]-ATP at 30°C; purified 
recombinant DYRK2 (2 mU/µl) was used as a positive control. The reactions were 
terminated by addition of SDS gel loading buffer, 20 µl of each sample was loaded on a 
SDS-PAGE gel, and the excess [Ɣ-32P]-ATP removed by electrophoresis. Gels were then 
stained with Coomassie dye, dried and subjected to autoradiography, after which protein 
bands were excised and the incorporated radioactivity determined by scintillation counting. 
The image is representative of three independent biological replicates. (B) Scintillation 
counts from (A). DYRK2 is represented by the white bars, MLK1 is shown in the black bars, 
TTK is shown in the light grey bars, TBK1 is shown in the stripped bar and CDK9 is shown 
in the stripped grey bar. Kinases concentrations are indicated below the figure. The data 
displayed is the average from three independent replicates and the associated SEM. (C) To 
determine which Ser residue in the Neh6 domain is targeted by MLK1, TTK, TBK1 and 
CDK9, purified recombinant GST-tagged mNeh6+ protein or single/double base-pair 
mutants of the mNeh6+ protein (0.1 µg/µl) generated from E.coli (BL21(DE3)pLysS) cells 
were incubated in a reaction mixture of 40 µl with 2 mU/µl purified activated recombinant 
MLK1, TTK,TBK1 or CDK9, for 3 hr in the presence of 10 mM MgCl2 and 0.1 mM [Ɣ-
32P]-
ATP at 30°C. The reactions were terminated by addition of SDS gel loading buffer, 20 µl of 
each sample was then loaded on a SDS-PAGE gel, and the excess [Ɣ-32P]-ATP removed 
by electrophoresis. Gels were then stained with coomassie dye, dried and subjected to 
autoradiography, after which, protein bands were excised and the incorporated radioactivity 
determined by scintillation counting. This image is representative of three independent 
biological replicates. (D) Scintillation counts from (C). GST-mNeh6+ is represented in the 
white bars, GST-mNeh6+(S342A) is shown in the black bars, GST-mNeh6+(S347A) is shown 
in the light grey bar and GST-mNeh6+(S342/347A) is shown in the stripped bar. The identity 
of kinase is given below the figure.  The data displayed is the average from three 
independent replicates and the associated SEM. 
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3.2.10 Immunochemical validation that DYRK2 and SAPK3 phosphorylate 
the mNeh6 domain at Ser-342 and Ser-347, respectively 
To provide further evidence that DYRK2 and SAPK3 phosphorylate the 
Neh6 domain of mNRF2 through Ser-342 and Ser-347 respectively, an 
immunochemical-based assay was carried out using our in-house phospho-
specific antibodies raised against peptides that contained a phosphorylated Ser 
residue at positions equivalent to either Ser-342 or Ser-347. In these 
experiments, bacterially synthesised GST-mNeh6+, a single amino acid site 
mutant or a double amino acid mutant protein was incubated with either DYRK2 
or SAPK3 for 1 hr in the presence of non-radioactively labelled ATP. Samples 
were then loaded on to a SDS-PAGE gel, transferred to PVDF membrane and 
blocked in 5% (w/v) milk for 1 hr before probing overnight with the appropriate 
phospho-specific antibody; all phospho-specific antibodies underwent dot blotting 
to determine their specificity and dilution before use, as shown in Appendix 8.6. 
No phosphorylation was detected by the P-338 (which detects phosphorylation 
at Ser-338) NRF2 antibody in any of the experimental conditions suggesting that 
is site is only phosphorylated in the presence of GSK-3b (Figure 3.2.12). 
Phosphorylation of Ser-342 appears to be still slightly detected by the P-342 
(which detects phosphorylation at Ser-342) NRF2 antibody when the site is 
mutated to Ala indicating the antibody may not by phospho-specific for this site. 
Detected phosphorylation of Ser-342 is enhanced in the presence of SAPK3 but 
not DYRK2, and the opposite is seen in terms of phosphorylation of Ser-347. Only 
in the presence of DYRK2 is phosphorylation at Ser-347 detected, and in the 
presence of GST-mNeh6+(S347A) or GST-mNeh6+(S342/347A) proteins the 
phosphorylation at this site is completely lost suggesting the antibody is highly 
phospho-specific. 
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Figure 3.2.12: DYRK2 and SAPK3 phosphorylate Ser-342 and Ser-347, respectively 
An immunochemical assay was carried out to determine whether DYRK2 and SAPK3 
phosphorylate the same Ser residues in the Neh6 domain of mNRF2. Purified recombinant 
GST-tagged mNeh6+ protein (0.1 µg/µl), or mNeh6+ protein bearing a single or double point 
mutations (0.1 µg/µl) were generated in E.coli (BL21(DE3)pLysS) cells was incubated in a 
reaction mixture of 40 µl with purified activated recombinant DYRK2 or SAPK3 (each at a 
concentration of 2 mU/µl) for 1 hr in the presence of 10 mM MgCl2 and 0.1 mM cold ATP at 
30°C. The reactions were terminated by addition of SDS gel loading buffer, the samples (20 
µl) were loaded on a SDS-PAGE gel, and excess ATP removed by electrophoresis. Gels were 
transferred onto PVDF membrane, blocked in 5% (w/v) milk- TBST and then incubated 
overnight with either phospho-Ser-338 (P-338), phospho-Ser-342 (P-342) or phospho-Ser-347 
(P-347) NRF2 antibodies.  
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3.2.11 Phosphorylation of mNRF2 at Ser-338 and Ser-342 by GSK-3, and at 
Ser-347 by DYRK isoenzymes leads to a reduction in its transcriptional 
activity 
To study the impact that GSK-3 and DYRK enzymes have on the 
transcriptional activity of mNRF2 an ARE-luciferase reporter assay was 
performed using pharmacological agents to inhibit kinases of interest; 5 µM 
MK2206 was employed to inhibit AKT, 5 µM CT99021 was employed to inhibit 
GSK-3, and 10 µM Harmine was employed to inhibit DYRK isoenzymes. The 
effects of these inhibitors on the activity of ectopic mNRF2D17-32-V5 and mutants 
derived from it (i.e. S335A, S338A, S342A and S347A) was examined in human 
lung NRF2 KO A549 cells, which harbour mutant KEAP1 and have had hNRF2 
knocked out by CRISPR/Cas9 gene editing. As shown in Figure 3.2.13, treatment 
with either CT99021 or Harmine led to an increase in ARE-driven transcription by 
both ectopic mNRF2D17-32-V5 and mNRF2D17-32(S335A)-V5. These results were 
anticipated because it was envisaged that inhibition of either GSK-3 or a priming 
kinase would result in a reduction in SCFb-TrCP-mediated degradation of mNRF2, 
leading to an increase in mNRF2 protein and thus enhanced transactivation 
activity. The fact that ARE-driven luciferase activity increased in NRF2 KO A549 
cells transfected with mNRF2D17-32(S335A)-V5 when treated with CT99021 or 
Harmine suggests that this site may not be phosphorylated by GSK-3, even 
though it is part of the motif to which b-TrCP binds. In the presence of MK2206, 
transcriptional activity of both mNRF2D17-32-V5 and mNRF2D17-32(S335A)-V5 in 
NRF2 KO A549 cells was found to be decreased. This is because when AKT is 
inhibited, GSK-3 remains in its active non-phosphorylated state, and therefore is 
able to phosphorylate NRF2, leading to SCFb-TrCP-directed degradation of the 
transcription factor. The transcriptional activities of mNRF2D17-32(S338A)-V5, 
mNRF2D17-32(S342A)-V5 and mNRF2D17-32(S347A)-V5 were not altered by 
CT99021, Harmine or MK2206. These findings are consistent with the notion that 
Ser-388, Ser-342 and Ser-347 are phosphorylated by GSK-3 and DYRK 
isoenzymes.  
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Figure 3.2.13: Phosphorylation of mNRF2 at Ser-338 and Ser-342 by GSK3 and at Ser-
347 by DYRK isoenzymes diminishes transcriptional activity 
NRF2 KO A549 were co-transfected with an empty pcDNA3.1-V5/His expression plasmid or 
various Δ17-32 mNRF2 pcDNA3.1-V5/His mutant expression plasmids (as indicated at the 
bottom of the figure) along with the murine quinone reductase 1-based P-1016/nqo1-Luc ARE-
containing reporter construct and the pRL-TK Renilla control plasmid. Equal amounts of DNA 
(2 µg) were transfected into NRF2 KO A549 cells in the different experimental groups. After 
overnight transfection, the cells were serum-depleted for 16 hr, followed by treatment with 
kinase inhibitors, or vehicle control, for a further 18 hr before the ARE-driven luciferase activity 
was measured. All results were normalized to renilla luciferase activity. The data are presented 
as follows: cells treated with DMSO in open bars; cells treated with MK2206 in black bars; 
cells treated with CT99021 in grey bars and cells treated with Harmine in striped bars. The 
data displayed are the mean values from three biological replicates and the associated SEM. 
T-tests were calculated using GraphPad Prism software. All significant increases are denoted 
with the * symbol; * represents P< 0.05, ** P<0.01 and ** P< 0.001. P values > 0.05 were 
deemed not significant and are denoted by “ns”. Significant decreases are denoted with a $ 
symbol, and the same cut offs applied.  
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3.2.12 Phosphorylation of mNRF2 at Ser-338 and Ser-342 by GSK-3b, and at 
Ser-347 by DYRK leads to a reduction in its protein stability 
To determine the impact that GSK-3 and DYRK enzymes have on the 
stability of mNRF2 protein, a b-galactosidase assay was carried out using the 
mNeh6+-LacZ fusion protein and its associated S335A, S338A, S342A and 
S347A mutants.  Expression constructs for these proteins were transfected into 
NRF2 KO A549 cells, which were then treated with a same panel of kinase 
inhibitors used in Figure 3.2.13 before b-galactosidase activity was measured. As 
displayed in Figure 3.2.14, similar b-gal activity results were observed for the 
mNeh6+-LacZ proteins as were obtained for the previous ARE-luciferase activity 
experiments. Specifically, treatment with CT99021 and Harmine increased the 
abundance of both mNeh6+-LacZ and mNeh6+(S335A)-LacZ. Whereas, 
treatment with MK2206 resulted in a decrease in abundance of mNeh6+-LacZ 
and mNeh6+(S335A)-LacZ, as evidenced from b-gal activity. By contrast, 
treatment with CT99021, Harmine or MK2206 did not affect the protein stability 
of either mNeh6+(S338A)-LacZ, mNeh6+(S342A)-LacZ or mNeh6+(S347A)-LacZ. 
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Figure 3.2.14: Phosphorylation of mNRF2 at Ser-338 and Ser-342 by GSK3 and at Ser-
347 by DYRK2 leads to reduction in protein stability 
NRF2 KO A549 cells were transfected with a pcDNA3.1 expression vector for a V5-tagged 
fusion protein comprising mNeh6+ coupled at its C-terminus to LacZ (i.e. mNeh6+LacZ -V5), 
or expression vectors for mNeh6+LacZ-V5 bearing individual amino acid mutations as 
indicated in the figure above. As a control NRF2 KO A549 cells were transfected with the 
empty LacZ-V5 expression vector. After overnight transfection, the cells were serum-starved 
for 16 hr followed by treatment with kinase inhibitors for a further 18 hr before the β-gal activity 
was measured, which was later normalized against protein concentration. The data are 
presented as follows: cells treated with DMSO in open bars; cells treated with MK2206 in black 
bars; cells treated with CT99021 in gray bars and cells treated with Harmine in striped bars. 
The data displayed are the mean value from three biological replicates and the associated 
SEM. T-tests were calculated using GraphPad Prism software. All significant increases are 
denoted with the * symbol; * represents P< 0.05, ** P<0.01 and ** P< 0.001. P values > 0.05 
were deemed not significant and are denoted by “ns”. Significant decreases are denoted with 
a $ symbol, and the same cut offs applied.  
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3.2.13 Altering GSK-3 and DYRK phosphorylation with small molecule 
inhibitors influences the chemosensitivity of lung cancer cells lines 
towards cisplatin. 
To determine if regulation of NRF2 by GSK-3 or DYRK could impact cell 
viability, sensitivity to the platinum-based chemotherapeutic agent cisplatin was 
accessed using the MTT assay. Human A549 cells, which express high levels of 
hNRF2 due to a mutation in KEAP1 and a hypermethylation of the KEAP1 
promoter, were treated with serial dilutions of cisplatin in the absence or presence 
of 5 µM MK2206, 5 µM CT99021, 1 µM Harmine or 1 µM ID-8; the latter 
compound is a pan DYRK family inhibitor that was included to support any effects 
observed with Harmine. A shown in Figure 3.2.15 and Table 3.2.2, treatment with 
MK2206 re-sensitizes cells to cisplatin, this is as expected because AKT inhibition 
will stimulate SCF-b-TrCP mediated degradation of hNRF2. Conversely, treatment 
with CT99021, Harmine or ID-8 enhances the resistance of A549 cells to cisplatin. 
However, since treatment with CT99021, Harmine and ID-8 increases the IC50 
towards cisplatin making the cell more resistant, this means that the curve 
generated does not reach 50% percentage cell viability, even at the highest 
concentration of cisplatin. This means that the IC50 values given for treatments 
with these three inhibitors is an estimated value extrapolated from the data 
displayed. It should also be noted that all of the inhibitors used will have NRF2-
independent affects also.  
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Treatment
Average IC50 (µM)
Cisplatin 
Cisplatin, 5µM 
MK2206 
Cisplatin, 5µM 
CT99021 
Cisplatin, 1µM 
Harmine
Cisplatin, 1µM 
ID-8
26.1 8.1 40.8 45.4 63.5
Stdev 3.0 2.7 7.4 5.4 6.3
Statistical significance 
(compared to cisplatin alone)
- * ns * **
Figure 3.2.15: Sensitivity of the human lung cancer cell line A549 toward cisplatin is 
alerted in the presence of inhibitors that either alter GSK-3 signalling. 
To determine whether sensitivity towards cisplatin might be influenced by hNRF2 through 
manipulation of its DSGIS-containing phosphodegron, AKT, GSK-3 and DYRK activities in 
A549 cells were inhibited using MK2206, CT99021 and Harmine (or ID-8), respectively, in the 
presence of various concentrations of cisplatin, before a MTT assay was performed. The 
mean percentage cell viability (from three separate wells) and the associated percentage error 
are displayed. These data shown are from one experiment that is representative of three 
independent biological replicates.  
 
 
Table 3.2.2: Manipulation of GSK-3 priming kinases ability to phosphorylate hNRF2 
affects chemosensitivity. 
 Table showing that combining cisplatin treatment with either AKT inhibition, GSK-3 inhibition or 
DYRK inhibition influences sensitivity. Data displayed is the mean value from three independent 
biological replicates and the associated StDev.  All IC50 values andT-tests were calculated using 
GraphPad Prism software. All significant increases (relative to the cisplatin alone data) are 
denoted with the * symbol; * represents P< 0.05, ** P<0.01 and ** P< 0.001. P values > 0.05 
were deemed not significant and are denoted by “ns”. Significant decreases are denoted with a 
$ symbol, and the same cut offs applied.  
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3.2.14 Alterations in GSK-3 and DYRK phosphorylation of hNRF2 affects 
cell proliferation 
The proliferative ability of A549 cells in the presence of 5 µM MK2206, 5 
µM CT99021, 1 µM Harmine or 1 µM ID-8 was accessed using the IncuCyte 
ZoomÔ imaging system and through colony formation assays, to determine 
whether priming phosphorylation by DYRK or phosphodegron formation by GSK-
3 altered cell proliferation. The data displayed in Figure 3.2.16, show that 
inhibition of AKT leads to a reduction in cell growth. Whereas, inhibition of GSK-
3, or DYRK leads to an enhancement of cell proliferation. This suggests that 
altering the ability of GSK-3 to phosphorylate of hNRF2 through either targeting 
the kinase itself or targeting its associated priming kinase can affect cancer cell 
proliferation.  
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3.3 Discussion 
In this chapter the role for a priming kinase in the degradation of NRF2 
through the SCFβ-TrCP complex has been characterised.  Phosphorylation by a 
priming kinase will enhanced subsequent GSK-3β mediated phosphorylation of 
the Neh6 domain resulting in the proteaosomal degradation of NRF2.  
3.3.1 The proposed mechanism by which NRF2 undergoes a priming event 
before GSK-3 phosphorylation is similar to that seen with the classic β-
TrCP substrate β-catenin 
The degradation of β-catenin is a classic example of the required amino 
acid spacing between a priming kinase site and subsequent GSK-3 
phosphorylation sites. As shown in Appendix 8.7, phosphorylation of Ser-45 of β-
catenin by CK1  primes the substrate for successive phosphorylation by GSK-3 
at  residues 41,37 and 33 (Marin et al., 2003). These phosphorylation events lead 
to the recruitment and binding of SCFβ-TrCP resulting in the ubiquitination of β-
catenin and its degradation. We have demonstrated in this chapter the priming of 
NRF2 for phosphorylation by GSK-3 using the DYRK isoenzymes as examples. 
DYRK enzymes phosphorylate NRF2 at Ser-347, priming for subsequent 
Figure 3.2.16: Phosphorylation of hNRF2 at Ser-338 and Ser-342 by GSK3 and at Ser-
347 by DYRK2 leads to enhanced proliferation. 
 (A) Proliferative ability was accessed using IncuCyte ZOOMÔ, which measures free space in 
a cell culture dish that can then be correlated with cell proliferation. Approximately 24 hr after 
seeding, A549 cells were drugged with either: DMSO, 5 µM MK2206, 5 µM CT99021, 1 µM 
Harmine or 1 uM ID-8. Plates were then scanned every 24 hr for 6 consecutive days and 
maintained in a 37oC 5% CO2 incubator. Graphs were then generated using IncuCyte ZOOM™ 
software analysis package. The graph displayed is the mean value from 6 wells in one 
experiment and the associated SEM. This is representative of three independent biological 
replicates. (B) Representative images taken using the Incucyte Zoom taken from one well with 
each of the drug treatments on the 6th day. (C) The ability of A549 cells to form colonies was 
accessed through crystal violet staining. Cells were seeded at a low density, then drugged 
with the respective inhibitors for two weeks. After which the colonies were fixed and the plates 
stained. Images shown are from one experiment and are representative of three independent 
biological replicates. 
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phosphorylation at Ser-342 and Ser-338 by GSK-3. Leading to degradation of 
NRF2 in the same manner as that of β-catenin.  
3.3.2 Impact that commonly occurring cancer mutations will have on this 
pathway 
Even though mutations in the genes that encode β-TrCP and GSK-3 are 
very rare in cancer (and appear to be redundant in their effect), KEAP1-
independent degradation of hNRF2 will be altered in several tumours due to 
mutations in genes that influence GSK-3 activity. Mutations in PI3KCA and PTEN 
both lead to hyper-activation of AKT and are very commonly found in lung cancer 
tumours (Campbell et al., 2016).  Aberrant AKT signalling will lead to increased 
phosphorylation of GSK-3 at Ser-9 and Ser-21, meaning that it will be inactive. 
Under such conditions manipulating the priming of hNRF2 will not be able to 
stimulate degradation. Suggesting that the mutational landscape of a tumour 
would have to be characterized before treatment with compounds that alter the 
priming of hNRF2.   
3.3.3 Inhibition of DYRK will affect the priming of other substrates not just 
NRF2 
Although targeting the priming kinase is a more selective way of reducing 
GSK-3 signalling than inhibiting GSK-3 itself, increasing DYRK activity will not 
only affect NRF2. Woods and colleagues have demonstrated the DYRK family 
members prime both eIF2B and tau by phosphorylating Ser-539 and Thr-212, 
respectively (Woods et al., 2001). eIF2B is fundamental to translation initiation in 
all mammalian organisms that is often elevated in cancer, providing a pro-survival 
advantage to the cancer cell (de la Parra et al., 2018). Tau the microtubule 
associated protein is often hyperphosphorylated by GSK-3 in Alzheimer’s 
disease. This suggests that treatment with DYRK activators would be beneficial 
in cancer to reduce the levels of NRF2 and inactivate eIF2B and could potentially 
decrease tau phosphorylation also.  
3.3.4 Conflicting results: DYRK1A has been shown previously to enhance 
the expression of the NRF2-target gene NQO1 
The model we proposed in this chapter implies that an increase in DYRK 
activity will stimulate mNRF2 degradation and thus lead to a reduction mNRF2-
target gene expression. NQO1 is a prototypical NRF2-target gene that has been 
shown to be decreased upon NRF2 silencing. Work by Noll et al suggests that 
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DYRK1A increases nuclear mNRF2, independently of KEAP1, through either 
directly phosphorylating mNRF2 itself or through an indirect mechanism involving 
ERK1/2 (Noll et al., 2012). They make these conclusions from a series of 
experiments using the inhibitor Harmine, which they refer to as a DYRK1A 
inhibitor, however work by Bain et al. (2007) would suggest that Harmine can 
inhibit all DYRK isoenzymes. Also, there appears to be some variability in the 
expression of mNRF2 target genes which are induced upon the nuclear 
localization of mNRF2, with HMOX1 decreasing and NQO1 remaining 
unchanged in the liver of their overexpression DYRK1A mouse. Noll and 
colleagues attribute this to the fact the NQO1 is not only controlled by NRF2 but 
also by arylhydrocarbon receptor but they overlook the fact NQO1 can also be 
transcriptionally activated by c-Jun and NRF1 (Jaiswal, 2000). The decrease in 
HMOX-1 expression they account for by an increase in NF-κB signalling. Due to 
the variability in the data and that they haven’t fully characterized the 
phosphorylation site for DYRK1A at either Ser-400 or Ser-569, at this time it is 
difficult to compare this data to the findings in this chapter. 
3.3.5 Phosphorylation of Ser-335 is mediated by an unknown kinase 
Rada and co-workers were the first group to identify the two sites to which 
β-TrCP binds NRF2, Ser-335 and 338 (Rada et al., 2012). They demonstrated 
through the use of NMR and docking experiments that GSK-3 mediates the 
phosphorylation of both of these sites in the Neh6 domain of mNRF2 leading to 
the formation of the phosphodegron to which β-TrCP binds. The data in this 
chapter supports the notion that GSK-3 phosphorylates Ser-338 but indicates the 
phosphorylation at Ser-335 is not carried out by GSK-3.  Data displayed in Figure 
3.2.13 and 3.2.14 show that when Ser-335 is mutated to Ala, treatment with the 
GSK-3 inhibitor, CT99021, still induces mNRF2 transcriptional activity and protein 
stability. Also, treatment the AKT inhibitor, MK2206, which will lead to an increase 
in GSK-3 activity, decreases both mNRF2 transcriptional activity and protein 
stability. This suggests that Ser-355 is not phosphorylated by GSK-3. This is also 
supported by the idea that the spacing between subsequent GSK-3 
phosphorylation sites in a substrate is normally three amino acids, this suggests 
that GSK-3 would not be able to phosphorylate both Ser-335 and Ser-338 
because of their only being a two amino acid gap between both sites (Dajani et 
al., 2001). A potential reason for the variation between our findings and the Rada 
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et al., paper, is that we have used single site mutant constructs and purified 
proteins. Whereas, they have used a double mutant construct, were both Ser-
335 and 338 have been mutated to Ala. We believe that with this double mutant 
construct the majority of its effect is due to the mutation of the 338 site and not 
the 335 site. At this point we don’t have any data to indicate what kinase may 
phosphorylate Ser-335 but the amino acid sequence around the site conforms to 
a classical CK1 consensus sequence, D/EXXS/T, where X is any amino acid 
(Marin et al., 2003).  
3.3.6 Development of DYRK activators to reduce NRF2 signalling in lung 
cancer   
The data shown here with the two pan-DYRK inhibitors, Harmine and ID-
8, demonstrates that DYRK can phosphorylate the Neh6 region at Ser-347 
priming for subsequent GSK-3β phosphorylation. However, inhibition of DYRK 
would not be advantageous for the treatment of lung cancer patients with high 
levels of hNRF2. As inhibition of DYRK would reduce GSK-3β phosphorylation 
and halt SCFβ-TrCP mediated degradation of the transcription factor. Unfortunately, 
there is currently no activators of DYRK available which has in part impeded to 
progress of this research. A potential route moving forward would be to carry out 
DYRK isoform specific gene knock downs using siRNA but one caveat would be 
that when one DYRK isoform is depleted it is likely that another isoform will step 
into its role. Another approach would be to carry out over expression experiments, 
to show that over expression of DYRK enhances GSK-3β phosphorylation and 
leads to a reduction in hNRF2 signalling. Though care would have to be taken to 
ensure that overexpression did not generate an artificial scenario where DYRK 
levels were considerably higher than that found in cells.  
3.3.7 Regulating the substrate specify of DYRK isoforms  
3.3.7.1 DYRKs show isoform specific preferences for the position of an 
arginine residue in the substrate protein. 
Work by Campbell and Proud revealed that the identity of the amino acids 
neighbouring a DYRK phosphorylation site dictates which member of the DYRK 
family that will target that substrate (Campbell and Proud, 2002). They show that 
both DYRK2 and DYRK3 have a preference for an Arg residue at either -2 or -3 
from the DYRK phosphorylation site. However, DYRK1A will only phosphorylate 
when there is an Arg at position -3. The specificity for DYRK4 was not analysed 
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in this publication. Interestingly, when the sequence surrounding the Ser-347 
phosphorylation site in the Neh6 is compared between human and mNRF2 the 
only difference between the two sequences is the presence of a Arg residue at -
2 in mNRF2 and a Val residue at the same position hNRF2. This potentially 
accounts for the five-fold higher phosphorylation of the mouse peptide in 
comparison to the human peptide by both DYRK2 and DYRK3 in the in vitro 
kinase screen (Table 3.2.1). This highlights the importance of looking at the 
neighbouring amino acid sequence that surrounds a phosphorylation site to aid 
in the determination of the kinase which targets that site.  
3.3.7.2 Localisation of DYRK isoforms  
Another way by which substrate specificity is determined for DYRK 
isoenzymes is by subcellular localization. The localization of endogenous 
DYRK1A shows tissue specific variances of either cytoplasmic or nuclear. 
Whereas, DYRK3 is almost completely nuclear. Little is known about DYRK4 but 
it is thought to be both cytoplasmic and nuclear. Interestingly the subcellular 
localization of DYRK2 appears to be in part influenced by stress. Under genotoxic 
stress conditions DYRK2 translocates from the cytosol to the nucleus (Sergi et 
al., 2011). Since KEAP1 is predominantly cytoplasmic, it has been suggested that 
regulation through the Neh6 domain via β-TrCP is a nuclear event  (Chowdhry et 
al., 2013). This is further supported by the fact that several components of the 
SCF degradation machinery are found in the nucleus (Lassot et al., 2001). If we 
assume that β-TrCP mediated degradation of NRF2 occurs in the nucleus, then 
we look to see which DYRK family members are nuclear. It suggests that 
phosphorylation of Ser-347 could be mediated by either DYRK3 or DYRK4, or 
potentially DYRK2 under stressed conditions. However, it is not currently known 
whether phosphorylation of the Neh6 region by either a priming kinase or GSK-3 
occurs before translocation into the nucleus or within that subcellular 
compartment.  
3.3.8 Concluding remarks  
This work in this chapter has demonstrated that several kinases are able 
to phosphorylate the Neh6 region of NRF2, functioning as a priming event for 
subsequent GSK-3 mediated phosphorylation. DYRK has been shown to prime 
for GSK-3 phosphorylation of various substrates, and here we have used this 
family of kinases to demonstrate priming of NRF2. This provides a completely 
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novel way of stimulating NRF2 degradation, deceasing cell proliferation and re-
sensitizing cancer cells to chemotherapeutics agents, which could be applied to 
the treatment of tumours with mutations in KEAP1 or NFE2L2. However, the work 
done here does add to the ongoing argument that GSK-3 inhibition has the 
potential to be oncogenic. Therefore, it would be advantageous to produce either 
small molecules that target DYRK isoforms increasing their expression or the 
primed phosphate to which GSK-3 binds, mimicking a constitutively primed GSK-
3.  
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4. Bioinformatics analysis of the prevalence, co-
occurrence and impact of mutations in KEAP1 and 
NFE2L2 in lung cancer cell lines and tumours. 
 
4.1 Introduction  
Cancer does not develop as a consequence of a single mutation but rather 
involves several gain-of-function mutations in oncogenic genes and loss-of-
function mutations in tumour suppressor genes occurring in the one cell 
(Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011).  
Historically, lung cancer was an extremely rare disease pre-twentieth 
century but has increased dramatically in prevalence in recent decades and is 
now the leading cause of cancer associated mortality worldwide with an 
estimated 1 million deaths per year (Evans, 2013; Torre et al., 2015; The Cancer 
Genome Atlas Research, 2014). Cancer research UK (CRUK) has named lung 
cancer as one of the four cancers of substantial unmet need due to its associated 
poor 5-year survival rate and modest advancements in diagnosis and treatment 
in the past decade. 
4.1.1 Treatment of lung cancer is dependent on stage of diagnosis  
The effectiveness and treatment type available to combat lung cancer is 
crucially dependant on the stage of the cancer at time of diagnosis (Shiono et al., 
2015). Early stage cancer can be diagnosed through either computed 
tomography (CT) or bronchoscopy and treatment of the disease is often very 
effective (Nanavaty et al., 2014). There are four main stages of lung cancer 
numbered I-IV. Stage I lung cancer has the highest overall survival rate as 
patients may be treated by surgical resection which offers the lowest rate of 
recurrence. Stage II cancer can also be surgically removed in appropriate 
patients but  adjuvant chemotherapy is given post-operatively to ensure complete 
removal of the disease (Dasari and Tchounwou, 2014; Hensing, 2014). Adjuvant 
chemotherapy for lung cancer often takes the form of a platinum-doublet regime 
in which the platinum-based compound is often cisplatin, in combination with a 
third-generation chemotherapeutic agent, such as docetaxel, gemcitabine or 
paclitaxel (Baggstrom et al., 2007; Horita et al., 2017). Cisplatin is a cytotoxic 
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anti-neoplastic compound that interacts with DNA, causing DNA cross-links and  
the formation of adducts, which halt DNA replication and leads to the activation 
of several signalling cascades that induce apoptotic cell death (Dasari and 
Tchounwou, 2014; Siddik, 2002). Chemotherapy targets highly replicative cells, 
such as cancer cells which have increased metabolic demand, but will also affect 
non-cancerous cells. This off-target effect may account for some of the side 
effects associated with chemotherapy in patients, such as vomiting and hair loss, 
as gastrointestinal and hair follicle cells replicate extensively (Evans, 2013).  
However, the majority of lung cancer diagnosed is at a late stage (stage 
IV). Presentation is delayed for a number of reasons; the disease is largely 
asymptomatic in the early stages, symptoms when present are poorly defined 
and often attributed to other diseases, and a significant proportion of patients fear 
a cancer diagnosis and may mask initial symptoms (Evans, 2013). An estimated 
80% of patients present with advanced stage disease that is no longer curative 
(Tod et al., 2008). At this later stage, surgical intervention is not possible and 
often palliative chemotherapy is the only option.  
4.1.2 Histological subtypes of lung cancer   
Lung cancer can be broadly divided into two main histological groups: 
small cell lung cancer (SCLC) which accounts for 15% of all lung cancer cases 
and non-small cell lung cancer (NSCLC) which accounts for the remaining 85% 
(Evans, 2013). SCLC has a stronger disease focal point of origin arising in the 
larger airways and presents as a very aggressive rapidly proliferative tumour with 
extensive metastasis to distal sites (Nanavaty et al., 2014). NSCLC is often found 
in the peripheral tissue and can be histologically further subdivided, according to 
the tissue of origin, into adenocarcinoma (which is the most prevalent), squamous 
carcinoma and large cell carcinoma (Pikor et al., 2013).  
4.1.3 The role that environmental factors play in the development of lung 
cancer 
Cigarette smoke has been linked to the development of lung cancer and 
poor disease outcome for decades (Shiono et al., 2015), with smokers being 10-
20 times more likely to develop the disease than non-smokers (Hensing, 2014). 
The popularity associated  with smoking is a relatively new cultural phenomenon 
and maybe in part explains why this disease was very rare before the twentieth 
century (Torre et al., 2015). The carcinogenic effects of smoking accumulate over 
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time and hence lung cancer is more prevalent in the elderly population. Smoking 
is not the sole risk factor associated with lung cancer, as exposure to other 
environmental factors also contributes to the development of the disease, 
including: asbestos, radon gas, arsenic and silica (Hensing, 2014; Evans, 2013). 
These additional environmental factors, along with exposure to second-hand 
cigarette smoke, may play a role in the development of lung cancer in non-
smokers. Lung cancer, predominantly of the NSCLC histological type, has been 
diagnosed in “never-smokers” and in these cases, is thought to be driven by 
genetic alterations and the types of environmental factors listed above. Never-
smoker is a term given to an individual who has consumed under 100 cigarettes 
in their lifetime (Torre et al., 2015).  
4.1.4 The role that genetic factors play in the development of lung cancer   
Research into the role played by genetic alterations in development of 
NSCLC has rapidly progressed due to the high frequency (approximately 10-15 
% of cases) of this lung cancer subtype occurring in never-smokers (Samet et al., 
2009). However, the identification of novel driver genes in NSCLC has been 
extremely challenging due to its associated high somatic mutation rate that leads 
to the accumulation of passenger mutations. Lung adenocarcinoma (ADC) and 
lung squamous cell carcinoma (SQCC), respectively the first and second most 
common forms of NSCLC, have both shared and unique genetic landscapes 
(Campbell et al., 2016). Comprehensive molecular profiling of both ADC and 
SQCC revealed thirty-eight significantly mutated genes in ADC and twenty 
significantly mutated genes in SQCC, with six commonly mutated genes in both 
lung cancer subtypes, these include TP53, RB1, ARID1A, CDKN2A, PIK3CA and 
NF1 (Campbell et al., 2016). Due to the few overlapping mutations, it is thought 
that somatic mutations in driver genes are different between ADC and SQCC. 
These divergences become clearer when the patterns of mutations in two lung 
cancer subtypes are analysed independently.  
Molecular profiling by ‘The Cancer Genome Atlas’ (TCGA) consortium of 
230 ADC samples from untreated patients revealed eighteen significantly 
mutated genes (The Cancer Genome Atlas Research, 2014), as shown in Table 
4.1.1. These included, but were not limited to, TP53 (mutated in 46%), EGFR 
(mutated in 14%), KRAS (mutated in 33%), PIK3CA (mutated in 7%), STK11 
(mutated in 17%) an KEAP1 (mutated in 19%). Interestingly, when pathway 
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analysis was carried out to determine which cell signalling pathways are 
commonly dysregulated in ADC due to mutations, it was highlighted that 
alterations in oxidative stress pathways occur in 22% of tumours due to mutations 
in KEAP1 (mutated in 19%), CUL3 (mutated in less an 1%) and NFE2L2 (mutated 
in 3%) (The Cancer Genome Atlas Research, 2014).  
 
 
 
 
Gene name Mutational frequency (%) 
TP53 46 
KRAS 33 
KEAP1 17 
STK11 17 
EGFR 14 
NF1 11 
BRAF 10 
SETD2 9 
RMB10 8 
MGA 8 
MET 7 
ARID1A 7 
PIK3CA 7 
SMARCA4 6 
RB1 4 
CDKN2A 4 
U2AF1 3 
RIT1 2 
 Table 4.1.1: Identification of commonly mutated genes in lung adenocarcinoma  
Summary of the 18 significantly mutated genes identified by the TCGA (The Cancer 
Genome Atlas Research, 2014). The left-hand column of the table displays the gene 
name and the right-hand column is the percentage mutational frequency for each gene 
out of the 230 ADC samples analysed.  
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Analysis of the mutational landscape of 178 SQCC samples (Table 4.1.2) 
from untreated patients revealed ten significantly mutated genes, including TP53 
(mutated in 81%), CDKN2A (mutated in 15%), PTEN (mutated in 15%), PIK3CA 
(mutated in 16%), KEAP1 and NFE2L2 (The Cancer Genome Atlas Research, 
2012). These data demonstrated that SQCC have much fewer mutations in 
EGFR and KRAS, which are very commonly mutated in ADC, but higher 
frequencies of mutation in PTEN and PIK3CA. However, they revealed that 
dysregulation in oxidative stress pathways, as seen in the ADC cases, was 
similarly observed in 34% of SQCC tumours, due to mutations (or copy number 
alterations) in KEAP1 (mutated in 12%), CUL3 (mutated in 7%) and NFE2L2 
(mutated in 19%). The study also highlighted that mutations in KEAP1 and CUL3 
are often loss-of-function mutations that occur mutually exclusive to mutations in 
NFE2L2 (The Cancer Genome Atlas Research, 2012).  
Even though there is a large genetic divergence between ADC and SQCC, 
both subtypes of NSCLC show dysregulation of oxidative stress pathways due to 
mutations in KEAP1, NFE2L2 and CUL3, three genes that are fundamental to 
homeostatic redox signalling.  
 
 
 
 
 
 
 
 
 
Gene name Mutational frequency (%) 
TP53 81 
CDKN2A 20 
PTEN 16 
PIK3CA 15 
KEAP1 15 
MLL2 12 
HLA-A 8 
NFE2L2 8 
NOTCH1 7 
RB1 3 
Table 4.1.2: Identification of commonly mutated genes in lung squamous cell 
carcinoma  
Summary of the ten significantly mutated genes identified by the TCGA (TCGA,2012). 
The left-hand column of the table displays the gene name and the right-hand column is 
the percentage mutational frequency for each gene out of the 178 SQCC samples 
analysed. 
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4.1.5 Impact of mutations that dysregulate the KEAP1-NRF2 axis  
Due to their increased metabolic demand and the switch from oxidative 
phosphorylation to glycolytic metabolism, cancer cells themselves produce a 
large amount of ROS (Vander Heiden et al., 2009; Nogueira and Hay, 2013). To 
withstand this highly oxidative environment, cancer cells often activate the NRF2 
signalling pathway to neutralized ROS and thus inhibit apoptosis and 
senescence. One way by which cancer cells enhance NRF2 activity is through 
somatic mutations in NFE2L2 and KEAP1, which lead to increased NRF2 activity 
through impairing KEAP1-mediated proteasomal degradation of the transcription 
factor. Also the expression of oncogenic mutations in primary murine cells has 
been shown to directly enhance NRF2 activation and decrease levels of 
intracellular ROS (DeNicola et al., 2011).The exact stage during tumourigenesis 
at which KEAP1 or NFE2L2 become mutated is still unknown, but it has been 
suggested that it is unlikely to occur during cancer initiation, but rather during 
cancer progression (Hayes and McMahon, 2009).  
4.1.5.1 Mutations in NFE2L2  
Somatic mutations in NFE2L2 have been documented in both lung cancer 
cell lines and in tissues. They have been shown to correlate with poor prognosis 
and are more predominantly found in SQCC than ADC (Sasaki et al., 2010; 
Sasaki et al., 2013a). Mutations in NFE2L2 are thought to be gain-of-function 
mutations resulting increased copy number expression of the transcription factor 
(Sasaki et al., 2012). Somatic mutations in NFE2L2 are clustered, with a clear 
focal enrichment point. This type of ‘hot spot’ mutational pattern is characteristic 
of mutations in oncogenes, which typically occur within a small region of the gene 
(Baeissa et al., 2016). Mutations in these regions will have a pronounced effect 
on NRF2 signalling as NRF2 does not have to undergo posttranslational 
modification for KEAP1 to bind to it, and so the structural integrity of these sites 
is fundamental for homeostatic NRF2 regulation Therefore, mutation of the DLG 
and ETGE motifs will lead to constitutive activation of NRF2 independently of 
oxidative stress (Shibata et al., 2008).  
Work by TCGA revealed that mutations in KEAP1, NFE2L2 and PTEN 
never co-occur in the same tumour (The Cancer Genome Atlas Research, 2012). 
Mutations in NFE2L2 have been demonstrated to co-occur with PIK3CA 
mutations (Scheffler et al., 2014) but an extensive analysis  of the co-occurrence/ 
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mutual exclusivity of NFE2L2 mutations with mutations in other lung cancer 
related genes is lacking.   
4.1.5.2 Mutations in KEAP1  
Unlike mutations in NFE2L2, somatic mutations in KEAP1 are found 
spread throughout the protein, which represents the mutational patterned 
associated with tumour suppressor genes, and are often associated with low 
KEAP1 expression (Hast et al., 2014; Ohta et al., 2008). Due to their wide 
distribution, it is difficult to attribute a function to all the mutations in KEAP1. 
Another point of divergence between KEAP1 and NFE2L2 mutations, is that 
those in KEAP1 are commonly associated with ADC (Sasaki et al., 2013b). 
Research has also highlighted that several mutations in KEAP1 are G>T 
transversions, which are characteristic mutations associated with exposure to 
tobacco smoke. This may in part explain why KEAP1 mutations often co-occur 
with KRAS mutations in ADC, which are also correlated with high smoking 
incidence (Singh et al., 2006; Ahrendt et al., 2001; Romero et al., 2017). 
Work by Ben Major and colleagues, demonstrated that the majority of 
mutations in KEAP1 do not affect the binding and ubiquitination of NRF2 but 
somehow halt proteasomal degradation of the transcription factor (Hast et al., 
2014). Passenger mutations were also identified in KEAP1 that do not appear to 
influence NRF2 degradation. Also, a small population of KEAP1 mutations were 
actually shown to decrease NRF2 activity through increased binding of KEAP1 to 
NRF2, these mutations where given the name “super binders” or additionally 
NRF2-complexed hypomorph (ANCHOR) mutations. It is thought that the 
presence of theses mutations leads to a stabilisation of KEAP1 and a specific 
increase in NRF2 expression but the function of such mutations is still not fully 
understood (Hast et al., 2014; Cloer et al., 2018). One of the biological functions 
of KEAP1 is to serve as a redox sensor due to the presence of reactive cysteine 
residues such as, Cys-151, Cys-273 and Cys-288, which surprisingly are not 
found to be mutated in lung cancer (Hayes and McMahon, 2009). Overall KEAP1 
mutations have been shown to lead to loss of function of KEAP1 or disruption of 
the molecular interaction between KEAP1 and NRF2, both of which result in 
enhanced nuclear accumulation of NRF2 and increased expression of NRF2-
target genes (Ohta et al., 2008; Padmanabhan et al., 2006).  
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4.1.5.3 Mutations in CUL3  
In comparison to mutations in KEAP1 and NFE2L2 that have been 
extensively studied for their role in lung cancer, CUL3 mutations do not seem to 
have attracted much attention and are poorly understood. Results of a detailed 
genetic screen to identify lung cancer drivers in mice revealed that CUL3 may 
function as a tumour suppressor in cooperation with mutant PTEN (Dorr et al., 
2015). This is supported by the fact that reduced expression of CUL3 protein and 
mRNA has been documented in several lung cancer cell lines and tumours 
harbouring mutations in CUL3. Gene siRNA knockdown studies have indicated 
that a CUL3 mutation may enhance tumour proliferation through stimulating the 
NRF2–signalling pathway and therefore inducing expression of antioxidant genes 
(Loignon et al., 2009).  
Breast cancer cell lines and tumours often show decreased NRF2 
expression and higher ROS levels, which can be mimicked in cells through over-
expression of CUL3 (Loignon et al., 2009), suggesting that CUL3 negatively 
regulates NRF2 expression. Studies into papillary renal cell carcinoma (PRCC) 
show that mutations in CUL3 lead to a loss of function of the gene, which elevates 
NRF2-signaling in PRCC tumours (Ooi et al., 2013).  
4.1.6 The role that mutations in the NRF2 pathway play in enhancing cell 
proliferation and the development of chemo-resistance 
The development of drug resistance is a huge therapeutic hurdle in the 
treatment of NSCLC and is one of the major reasons for the poor outcome 
associated with the disease, with the response rate for first line chemotherapy in 
patients only being 30% (Homma et al., 2009). Many mechanisms are implicated 
in the development of drug resistance such as: increased expression of ATP-
dependant drug transporters leading to increased drug efflux out of the cell, 
insensitivity to apoptosis and increased expression of drug detoxification genes 
(Gottesman, 2002). All pathways implicated in the development of drug 
resistance involve genes that are transcriptionally regulated through NRF2. 
Indeed, siRNA-mediated knockdown of NRF2 has been shown to increase 
sensitivity to anti-cancer drugs and enhance cell proliferation (Homma et al., 
2009).  
Platinum-based chemotherapeutics function to damage DNA and 
stimulate ROS production leading to cancer cell death. However, resistance to 
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platinum chemotherapeutics can arise through several NRF2-dependent routes 
(Choi and Kwak, 2016). Upregulation of NRF2 has been shown to decrease 
levels of intracellular ROS, leading to reduced apoptosis and increased cancer 
cell survival. Also, GCLC, GCLM, GPX2 and several GSTs, key genes involved 
in the biosynthesis and utilization of glutathione, are all transcriptionally regulated 
by NRF2. Increased levels of NRF2 lead to increased intracellular glutathione 
levels and increased glutathione-conjugation to drugs, including anti-cancer 
agents (Lan et al., 2018). The conjugation of glutathione with drugs is catalysed 
by GST isoenzymes, and functions to reduce toxicity and intracellular 
concentrations of the drug through efflux of the conjugated drugs via pumps, such 
as multidrug resistance-associated protein 1(MRP1) (Gamcsik et al., 2012) (The 
importance of glutathione-conjugation is discussed in greater detail in Chapter 5). 
Several ATP-dependent drug-efflux pumps, including MRP1, are regulated by 
NRF2 (Ji et al., 2013). The presence of mutations in NFE2L2 and KEAP1 leading 
to high levels of NRF2 protein and increased expression of MRP transporters 
(Mahaffey et al., 2012). Expression of the NRF2-target gene AKR1C1 has also 
been linked with enhanced drug resistance. With siRNA mediated knockdown of 
AKR1C1 in the KEAP1 mutant NSCLC cell line, A549, leading to a marked 
reduction in resistance to cisplatin (Chen et al., 2017). Also HMOX-1, a NRF2-
target gene associated with stress responses has been shown to be increased in 
pancreatic tumours, and depletion of HMOX-1 gene expression leads to  re-
sensitization of these cells (Berberat et al., 2005). 
Rapid cellular proliferation is one of the major hallmarks of cancer and is 
often due to dysregulation of normal cell cycle events (Feitelson et al., 2015). 
High levels of NRF2, due to mutations/hypermethylation of KEAP1, has been 
linked to enhanced cell proliferation. This is thought to be due to induction of  a 
G1 phase arrest in the cell cycle (Homma et al., 2009). Additionally, several NRF2 
effector genes are involved in the regulation of metabolic pathways, which in the 
presence of aberrant NRF2 may lead to enhanced proliferation (Mitsuishi et al., 
2012). 
The role that mutations in KEAP1 and NFE2L2, and to a later extent CUL3, 
play in the development of lung cancer has been extensively investigated. Also, 
the impact that NRF2 plays in the development of drug resistance through its 
diverse range of downstream target genes has been very well characterized. 
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However, an extensive analysis into the co-occurrence of KEAP1/NFE2L2/ CUL3 
mutations with other mutations, the zygosity of these mutations and the effect 
that these mutations have on the expression of NRF2-target genes associated 
with the development of resistance is lacking. In this chapter, we have employed 
a bioinformatics approach to address these points and demonstrate dramatic 
differences in the context and consequences of mutations in KEAP1, NFE2L2 
and CUL3.  
4.2 Results  
4.2.1 KEAP1 and KRAS are the two most commonly mutated genes in lung 
cancer cell lines, whereas tumours harbour a high number of PIK3CA and 
KRAS mutations 
Initially we investigated the occurrence of mutations in genes involved the 
NRF2-signalling pathway in both lung cancer cell lines and tumours. Using the 
software TICBO Spotfire®, we combined and filtered the Sanger, Cancer cell line 
encyclopaedia (CCLE) and AstraZeneca datasets for lung cancer cell lines. At 
this point we did not further subdivide the datasets to analyse specific histological 
subtypes of lung cancer but looked at the disease as a whole. This gave us 239 
lung cancer cell lines in total, which we then filtered for those harbouring 
mutations in KEAP1, NFE2L2, CUL3, KRAS, EGFR, PTEN, PIK3CA and STK11, 
and then calculated the percentage of cell lines containing each mutation. We 
chose to study the impact of these mutations because the literature suggests that 
they have the potential to alter NRF2 degradation.  
Interrogation of these datasets revealed that amongst the eight genes 
examined, mutations in KRAS (20%) and KEAP1 (12%) were the top most 
common events amongst the 239 human cell lines (Table 4.2.1A). Moreover, 
interrogation of the human pan-lung cancer tumour dataset, which included 1144 
tumours of mixed histology (Campbell et al., 2016), showed mutations in PIK3CA 
(24%) and KRAS (23%) were the two most common events (Table 4.2.1B). The 
increased frequency of PIK3CA mutations in the tumour data set in comparison 
to the cell line database may be due to the tumour dataset containing a larger 
proportion of SQCC samples, which often have mutations in this gene.  
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Together, these data suggest that in lung cancer, mutations in KEAP1 
arise more commonly than mutations in either NFE2L2 or CUL3, and that 
mutations in NFE2L2 are more common than mutations in CUL3.  
 
 
 
 
 
 
 
 
 
A 
B 
Table 4.2.1: Frequency of mutations in genes associated with the NRF2-signalling 
pathway in lung cancer 
(A) Incidence of mutations in KEAP1, NFE2L2, CUL3, KRAS, EGFR, PTEN, PIK3CA and 
STK11 in the human lung cancer cell line dataset comprising of 239 cell lines; percentages are 
shown in parentheses. Mutations are ranked according to their prevalence in the right-hand 
column of the table. (B) Incidence of mutations in KEAP1, NFE2L2, CUL3, KRAS, EGFR, 
PTEN, PIK3CA and STK11 in the human pan-lung cancer tumour dataset of 1144 tumours; 
percentages are shown in parentheses. Mutations are ranked according to prevalence in the 
right-hand column of the table. 
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4.2.2 Adenocarcinoma tumours have a higher frequency of mutations in 
KRAS and KEAP1 than do squamous tumour samples 
 
To determine if the frequency of mutations in genes that cause 
dysregulation of NRF2-signalling vary between different histological subtypes of 
NSCLC, we carried out the same analysis for the eight selected genes, as in 
section 4.2.1, but in separate ADC (The Cancer Genome Atlas Research, 2014) 
and SQCC (The Cancer Genome Atlas Research, 2012) datasets. This revealed 
a high frequency of mutation in KRAS (82%), KEAP1 (19%) and STK11 (19%) 
amongst 230 ADC specimens in the dataset (Table 4.2.2A). The high frequency 
of mutations in both KEAP1 and KRAS genes is possibly not surprising because 
they have been reported to frequently occur in ADC (The Cancer Genome Atlas 
Research, 2014; Sasaki et al., 2013b); however, what is surprising is the low 
frequency of EGFR mutations, which have been shown to be extremely prevalent 
in ADC (The Cancer Genome Atlas Research, 2014). By contrast with ADC, 
amongst the 178 SQCC specimens, mutations in PIK3CA (48%), NFE2L2 (19%) 
and KEAP1 (14%) were commonly observed (Table 4.2.2B). This correlates with 
the data produced by TCGA showing the PIK3CA mutations are more prevalent 
in SQCC than ADC and often occur alongside NFE2L2 mutations (The Cancer 
Genome Atlas Research, 2012). Also, it supports the notion that mutations in 
KEAP1 are more common in ADC than mutations in NFE2L2 but in SQCC the 
opposite is observed, with NFE2L2 mutations being more common than those in 
KEAP1. CUL3 mutations rarely occur in either of the histological subtypes of 
NSCLC. It was also noted that the frequency of PTEN mutations was low in both 
tumour data sets, and CUL3 mutations are thought to occur alongside PTEN 
mutations.  
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Table 4.2.2: Frequency of mutations in genes associated with the NRF2-signalling 
pathway in ADC and SQCC tumors 
(A) Incidence of mutations in KEAP1, NFE2L2, CUL3, KRAS, EGFR, PTEN, PIK3CA and 
STK11 in human lung ADC tumour dataset comprising of 230 specimens; percentages are 
shown in parentheses. Mutations are ranked according to prevalence in the right-hand column. 
(B) Incidence of in KEAP1, NFE2L2, CUL3, KRAS, EGFR, PTEN, PIK3CA and STK11 in 
human lung SQCC tumour dataset comprising of 178 specimens; percentages are shown in 
parentheses. Mutations are ranked according to prevalence in the right-hand column.  
A 
B 
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4.2.3 Mutations in KEAP1 co-occur with mutations in KRAS and STK11 in 
both lung cancer cell lines and tumours 
Identifying which mutations tend to co-occur or are mutually exclusive with 
mutations in KEAP1 may give a greater understanding of the role that KEAP1 
mutations play in carcinogenesis.  
To determine whether somatic mutations in KEAP1 co-occur with 
mutations in KRAS, STK11, PTEN, PIK3CA, NFE2L2, CUL3 and EGFR, the 
same lung cancer dataset of 239 cell lines mentioned previously was used. 
Filtering the 239 cell lines for those harbouring mutations in KEAP1 yielded 28 
cell lines, and these were then screened for additional mutations in the seven 
other genes of interest. This revealed KEAP1 mutations have a strong co-
occurrence with KRAS, STK11 and PIK3CA mutations, with positive log ratio 
values (Table 4.2.3A). The existence of KEAP1 and oncogenic driver mutations 
in KRAS has been documented before (Romero et al., 2017). The fact that 
mutations in KEAP1 and KRAS occur alongside mutations in STK11 is to be 
expected as STK11 mutations have been shown to co-exist with KRAS mutations 
in ADC (The Cancer Genome Atlas Research, 2014). KEAP1 mutations were 
shown to not occur alongside mutations in PTEN, NFE2L2, CUL3 and EGFR, as 
revealed by negative log ratio values. The notion that KEAP1 and NFE2L2 
mutations do not occur together has been documented in the literature before. 
However, the idea that CUL3 mutations do not occur with KEAP1 mutations has 
not been documented before, but these data are not very robust due to the low 
frequency of CUL3 mutations in cell lines.  
To determine whether the same patterns of co-existence of KEAP1 
mutations with other mutations are seen in both cell lines and tumours, the same 
analysis was carried out using a human pan-lung cancer dataset (Campbell et 
al., 2016). This dataset contains 170 tumours with mutations in KEAP1. Amongst 
these 170 tumour samples, KEAP1 mutations were found to co-occur with 
mutations in KRAS, STK11 and CUL3, and are mutually exclusive with mutations 
in PTEN, PIK3CA, NFE2L2 and EGFR (Table 4.2.3B). These data slightly deviate 
from the findings for the cell line dataset, but the tumour dataset contains more 
data points, making it more robust. 
Interestingly mutations in KEAP1 were found to not occur alongside mutations in 
EGFR in either dataset, which is commonly mutationally activated in ADC. 
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Table 4.2.3: Co-occurrence of mutations in KEAP1 with mutations in other genes that 
are associated with the NRF2-signalling pathway 
(A) The 28 KEAP1 mutant lung cancer cell lines were filtered for the presence of mutations in 
KRAS, STK11, PTEN, PIK3CA, NFE2L2, CUL3 and EGFR. Mutations with a positive log ratio 
are designated as tending to co-occur with KEAP1 mutations, whereas those with a negative 
log ratio are designated as having a tendency of mutual exclusivity with mutations in KEAP1. 
(B) 1144 pan-lung tumour samples were filtered for the expression of KEAP1 mutations, 
yielding 170 KEAP1 mutant tumours. Then further sub-filtered for the presence of mutations 
in KRAS, STK11, PTEN, PIK3CA, NFE2L2, CUL3 and EGFR. Log ratios and tendency of 
mutations to occur with KEAP1 mutations were assigned as indicated above.  
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4.2.4 Mutations in NFE2L2 co-occur with mutations in PIK3CA and CUL3 in 
both lung cancer cell lines and tumours 
To determine whether somatic mutations in NFE2L2 co-occur alongside 
other mutations that influence the degradation of NRF2, both the lung cancer cell 
line and tumour datasets were filtered for those that harbour mutations in 
NFE2L2. The eight cell lines with mutant NFE2L2 and the 105 tumours with 
mutant NFE2L2 (described in Campbell et al. (2016)) were then screened for the 
presence of additional mutations in KRAS, STK11, PTEN, PIK3CA, KEAP1, 
CUL3 and EGFR. This revealed that in both the cancer cell lines and in tumours 
mutations in NFE2L2 co-occurred alongside mutations in PIK3CA and CUL3, with 
positive log ratio values in both lung cancer cell lines and tumours (Table 4.2.4A 
and B). The idea that CUL3 mutations occur alongside NFE2L2 mutations is 
surprising as they seem likely to result in similar effects, inhibition of NRF2 
degradation through the 26S proteasome.  
Interestingly, mutations in NFE2L2 were found to be mutually exclusive 
from mutations in KRAS and STK11 in both the cell line and tumour datasets. As 
noted previously, KRAS and STK11 mutations co-exist with mutations in KEAP1. 
Since mutations in NFE2L2 and KEAP1 do not occur together, they co-occur with 
different oncogenic driver genes.   
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4.2.5 Mutations in CUL3 co-occur alongside mutations in PTEN, PIK3CA 
and NFE2L2 in both lung cancer cell lines and tumours 
The co-occurrence of somatic mutations in CUL3 with other mutations that 
could influence NRF2 degradation was analysed in both the lung cell line and 
tumour datasets. First the lung cancer cell lines and tumours were filtered for the 
presence of mutations in CUL3, which identified eight CUL3 mutant cell lines and 
51 CUL3 mutant tumours. CUL3 mutant cell lines and tumour samples were then 
filtered for the presence of additional mutations in KRAS, STK11, PTEN, PIK3CA, 
KEAP1, NFE2L2 and EGFR.  
In the lung cancer cell lines, CUL3 mutations appear to co-exist with 
mutations in KRAS, PTEN, PIK3CA, KEAP1, NFE2L2 and EGFR, and are 
B 
Table 4.2.4: Co-occurrence of mutations in NFE2L2 with mutations in other genes that 
are associated with the NRF2-signalling pathway 
 (A) Eight NFE2L2 mutant lung cancer cell lines were filtered for the presence of mutations in 
KRAS, STK11, PTEN, PIK3CA, KEAP1, CUL3 and EGFR. Mutations with a positive log ratio 
are designated as having a tendency of co-occurrence with NFE2L2 mutations, whereas those 
with a negative log ratio are designated as having a tendency of mutual exclusivity with 
mutations in NFE2L2. (B) 1144 pan-lung tumour samples were filtered for mutations in 
NFE2L2, yielding 150 NFE2L2 tumours then further sub-filtered for the presence of mutations 
in KRAS, STK11, PTEN, PIK3CA, KEAP1, CUL3 and EGFR. Log ratios and tendency of 
mutations to occur with NFE2L2 mutations were assigned as indicated above.  
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mutually exclusive with mutations in STK11 (Table 4.2.5A). These findings either 
suggest that CUL3 mutations occur alongside many other mutations that will 
influence the degradation of NRF2, so CUL3 mutations themselves may not play 
a huge role in halting NRF2 degradation, or that the number of CUL3 mutants 
analysed is not sufficient to produce robust data. In lung tumours, mutations in 
CUL3 co-occur with mutations in PTEN, PIK3CA, and NFE2L2, and are mutually 
exclusive with mutations in KRAS, STK11, KEAP1 and EGFR, which is in 
agreement with previously published data indicating the CUL3 and PTEN 
mutations complement each other (Dorr et al., 2015). The tumour dataset has a 
considerably larger number of CUL3 mutant samples, indicating that these data 
may be more reliable. Interestingly, CUL3 mutations occur alongside PTEN 
mutations in both the lung cell line and tumour datasets, whereas KEAP1 and 
NFE2L2 mutations have been shown to be mutually exclusive to mutations in 
PTEN in every analysis.  
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4.2.6 KEAP1 mutations co-occur with MET and MYC mutations in both lung 
cancer cell lines and tumours 
Several driver mutations, such as mutations in EGFR, KRAS, PTEN and 
MET have been identified in lung cancer (Luo and Lam, 2013; Zhu et al., 2017). 
Since somatic mutations in KEAP1 tend to co-occur with oncogenic driver 
mutations in KRAS and STK11, we wondered if KEAP1 mutations co-exist with 
mutations in other driver genes. We therefore filtered both the lung cancer cell 
line dataset and the tumour dataset for samples h8arbouring mutations in KEAP1, 
and then screened this KEAP1 mutant sub-population for the presence of 
additional mutations in the lung cancer driver genes: BRAF, CDKN2A, ERBB2, 
Table 4.2.5: Co-occurrence of mutations in CUL3 with mutations in other genes that are 
associated with the NRF2-signalling pathway 
 (A) Eight CUL3 mutant lung cancer cell lines were further sub-filtered for the presence of 
mutations in KRAS, STK11, PTEN, PIK3CA, KEAP1, NFE2L2 and EGFR. Mutations with a 
positive log ratio are designated as having a tendency to co-occur with CUL3 mutations, 
whereas those with a negative log ratio are designated as having a tendency of mutual 
exclusivity with mutations in CUL3. (B) 1144 pan-lung tumour samples were filtered for the 
expression of CUL3 mutation, yielding 51 CUL3 mutant tumours. Then further sub-filtered for 
the presence of mutations in KRAS, STK11, PTEN, PIK3CA, KEAP1, NFE2L2 and EGFR. Log 
ratios and tendency of mutations to occur with CUL3 mutations were assigned as indicated 
above.  
B 
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HRAS, MET, MYC, NOTCH and TP53. This revealed that in both the lung cancer 
cell lines and the lung tumours, KEAP1 mutations co-exist with mutations in 
HRAS, MET, and MYC (Table 4.2.6). Interestingly, in the cell line data set, KEAP1 
mutations co-exist with mutations in TP53, a commonly mutated gene in NSCLC. 
By contrast, in the tumour data set, KEAP1 mutations appear to be mutually 
exclusive with mutations in TP53. One potential reason for this discrepancy 
between the cell line and tumour data sets is that in the process of cancer cell 
immortalization they often undergo a procedure that alters the status of TP53 
(Metz et al., 1995). Also TP53 mutation status in human cancer cell lines is quite 
controversial and often incorrect (Leroy et al., 2014).  
 
 
 
A 
B 
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4.2.7 Mutations in NFE2L2 co-occur with mutations in MET, MYC, NOTCH 
and TP53 
In view of the fact that somatic mutations in NFE2L2 do not occur with 
mutations in the oncogenic driver gene KRAS (Table 4.2.4), we examined 
whether NFE2L2 mutations might co-occur with other common oncogenic 
mutations. We therefore first filtered both the lung cancer cell line dataset and the 
tumour dataset for the presence of a NFE2L2 mutation, and then screened the 
two NFE2L2 mutant sub-populations for additional mutations in BRAF, CDKN2A, 
ERBB2, HRAS, MET, MYC, NOTCH and TP53. Surprisingly, NFE2L2 mutations 
were found to co-occur with mutations in TP53 in both the cancer cell line and 
tumour datasets (Table 4.2.7). We surmise that because mutations resulting in 
NRF2 upregulation seem to be involved in cancer progression rather than cancer 
initiation, mutations in NFE2L2 and KEAP1 will co-exist with mutations in 
oncogenic driver genes. Thus collectively, our analyses indicate that KEAP1 
mutations co-exist with mutations in KRAS, whereas NFE2L2 mutations co-exist 
with mutations in TP53.  
 
 
 
 
 
Table 4.2.6: Co-occurrence of mutations in KEAP1 with mutations in other genes that 
are commonly associated with lung cancer. 
(A) 28 KEAP1 mutant lung cancer cell lines were filtered for the presence of mutations in 
BRAF, CDKN2A, ERBB2, HRAS, MET, MYC, NOTCH and TP53. Mutations with a negative 
log ratio are designated as having a tendency of mutual exclusivity with mutations in KEAP1, 
whereas those with a positive log ratio are designated as having a tendency of co-occurrence 
with KEAP1 mutations. (B)1144 pan-lung cancer tumours were filtered for the presence of 
mutations in KEAP1, yielding 170 KEAP1 mutant tumours. Then further sub-filtered for the 
presence of mutations in: BRAF, CDKN2A, ERBB2, HRAS, MET, MYC, NOTCH and TP53. 
Log ratios and tendency of mutations to occur with KEAP1 mutations were assigned as 
described above. 
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Table 4.2.7: Co-occurrence of mutations in NFE2L2 with mutations in other genes that 
are commonly associated with lung cancer.  
(A) Eight NFE2L2 mutant lung cancer cell lines were sub-filtered for the presence of mutations 
in BRAF, CDKN2A, ERBB2, HRAS, MET, MYC, NOTCH and TP53. Mutations with a negative 
log ratio are designated as having a tendency of mutual exclusivity with mutations in NFE2L2, 
whereas those with a positive log ratio are designated as having a tendency of co-occurrence 
with NFE2L2 mutations. (B)1144 pan-lung cancer tumours were filtered for the presence of 
mutations in NFE2L2, yielding 150 NFE2L2 mutant tumours. Which were then further sub-
filtered for the presence of mutations in BRAF, CDKN2A, ERBB2, HRAS, MET, MYC, NOTCH 
and TP53. Log ratios and tendency of mutations to occur with NFE2L2 mutations were 
assigned as indicated above.  
B 
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4.2.8 CUL3 mutations co-occur with mutations in MYC, NOTCH and TP53, 
in both lung cancer cell lines and tumours 
Since somatic mutations in CUL3 show mutual exclusivity with KRAS 
mutations, we wondered whether they co-exist with mutations in TP53, as is the 
case for somatic mutations in NFE2L2, or with other oncogenic driver genes. Both 
the cancer cell line dataset and the tumour dataset were filtered for the presence 
of mutations in CUL3 and this CUL3 mutant sub-population was then screened 
for additional mutations in: BRAF, CDKN2A, ERBB2, HRAS, MET, MYC, NOTCH 
and TP53. Interestingly, like NFE2L2 mutants, the cancer cell lines and the 
tumour samples with mutant CUL3 both co-existed with mutations in TP53 (Table 
4.2.8). This is possibly expected because our previous analysis revealed that 
mutations in NFE2L2 and CUL3 can co-occur. 
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4.2.9 Most KEAP1-mutant cancer cell lines harbour homozygous missense 
mutations that translate into single amino acid changes distributed across 
the protein 
To gain greater understanding of the impact that somatic mutations in 
KEAP1 have in terms of impairing NRF2-degradation we analysed the zygosity 
and the location of the mutations in the lung cancer cell lines. This revealed that 
amongst the 28 KEAP1-mutant cell lines in the cancer cell dataset (see, Table 
4.2.1), 89% of them processes homozygous mutations. The majority of the 
mutations identified were single missense mutations, which often lead to the 
introduction of a Cys amino acid in the protein (Table 4.2.9). Consistent with 
previously published data, we also saw that none of the key redox sensitive Cys 
residues were mutated (Hayes and McMahon, 2009). Also, the majority of KEAP1 
Table 4.2.8: Co-occurrence of mutations in CUL3 with mutations in other genes that are 
commonly associated with lung cancer 
(A) Eight CUL3 mutant lung cancer cell lines were sub-filtered for the presence of mutations 
in BRAF, CDKN2A, ERBB2, HRAS, MET, MYC, NOTCH and TP53. Mutations with a negative 
log ratio are designated as having a tendency of mutual exclusivity with mutations in CUL3, 
whereas those with a positive log ratio are designated as having a tendency of co-occurrence 
with CUL3 mutations.  (B) 1144 pan-lung cancer tumours 51 were filtered for the presence of 
mutations in CUL3, then further sub-filtered for the presence of mutations in BRAF, CDKN2A, 
ERBB2, HRAS, MET, MYC, NOTCH and TP53. Log ratios and tendency of mutations to occur 
with CUL3 mutations were assigned as described above. 
B 
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mutations were found in ADC cell lines, which supports data generated by the 
TCGA consortium showing that KEAP1 mutations are more prevalent in ADC 
than SQCC (The Cancer Genome Atlas Research, 2014).  
In an attempt to understand the significance of the somatic mutations in 
KEAP1, we mapped them onto a schematic of the protein. Like others (Hast et 
al., 2014), we found that mutations in KEAP1 translate into changes throughout 
the entire protein, showing no clear focal point (Figure 4.2.1A). This mutational 
pattern is not only seen in lung cancer, KEAP1 is frequently mutated in head and 
neck cancer also showing no clear focal point of mutation (The Cancer Genome 
Atlas et al., 2015). Quantification of the localization of the mutations suggests that 
a disproportionate number of mutations occur in regions of KEAP1 encoding the 
Kelch-repeat domain (Figure 4.2.1B). This is to be expected as the Kelch-repeat 
domain is the region of KEAP1 that binds NRF2, and mutations in this site could 
potentially lead to increased NRF2 activation through inhibition of binding and 
subsequent degradation of NRF2. Furthermore, mutations in both the IVR and 
BTB domains of KEAP1 were also identified, which will potentially effect KEAP1 
dimerization and CUL3 binding. 
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Table 4.2.9:  Most KEAP1 mutant cell lines harbor homozygous missense mutations 
and are of the adenocarcinoma histological subtype 
Table showing the name of the 28 cell lines harboring mutations in KEAP1 and the disease 
subtype, location that the mutation occurs in the protein, whether it is 
heterozygous/homozygous and the variant classification. An asterisk (*) symbol indicates the 
insertion of a stop codon. The p. symbol indicates a molecular change in the primary structure 
of the protein.  
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Figure 4.2.1: Most KEAP1 mutant cell lines harbor mutations that are distributed 
throughout the protein structure 
(A) Mapping of the KEAP1 mutations found in the 28 cell lines onto a schematic of the KEAP1 
protein structure. The locations of each mutations are indicated above the schematic. The 
amino acid numbering conferring to each specific functional domain of the protein is given 
below separated by dotted arrows. (B) Graphical quantification of (A). 
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4.2.10 Most NFE2L2 mutant cell lines harbour heterozygous missense 
mutations, located in the Neh2 domain 
To gain an understanding of the impact that somatic mutations in NFE2L2 
have in terms of NRF2 function we analysed the zygosity and location of the 
mutations in the lung cancer cell lines. Out of the eight NFE2L2 mutant cell lines 
(from Table 4.2.1), all but one  cell line, LK-2, possess heterozygous mutations 
(Table 4.2.10). The majority of these cell lines have missense mutations in 
NFE2L2 and were from a range of diverse histological backgrounds. When we 
mapped these mutations onto a schematic of the NRF2 protein, the majority 
(75%) localized to the Neh2 domain (Figure 4.2.2). However, we did identify one 
cell line that harboured a mutation in the Neh5 domain and one in the Neh1 
domain. Mutations in the Neh2 domain have been documented to lead to 
increased NRF2 activation through halting KEAP1-dependent degradation of the 
transcription factor. In the case of the Neh5 and Neh1 domains, they are involved 
in transactivation and DNA-binding, respectively, and could therefore also 
influence NRF2 activity in tumours. Interestingly, MED16 has been shown to bind 
directly to the Neh5  and Neh1 domains in NRF2 and positions the transcription 
factor close to the transcriptional machinery (Sekine et al., 2015). MED16 
interaction the NRF2 has been demonstrated to be essential for the inducible 
transcription of several NRF2-target genes. Thus, mutations in both the Neh1 and 
Neh5 could potentially alter NRF2 activity, possibly via MED16, but it is difficult 
to determine what effect a mutation in the Neh5 or Neh1 domain would have on 
NRF2 degradation. 
NFE2L2 is often also mutated in head and neck cancer with a tendency 
for mutations to occur in the Neh2 domain but also a few mutations in Neh5, Neh7 
and Neh1 domains (The Cancer Genome Atlas et al., 2015). Interestingly 
NFE2L2 mutations in both lung cancer and head and neck cancer do not occur 
in the Neh6 domain, which is the site of GSK-3 phosphorylation and β-TrCP 
binding.  
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Table 4.2.10: Most NFE2L2 mutant cell lines harbor heterozygous missense mutations 
and are from various histological backgrounds 
Table showing the name of the eight cell lines harboring mutations in NFE2L2 and the 
disease subtype, location of the mutation, whether it is heterozygous / homozygous and the 
variant classification. 
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Figure 4.2.2: Most NFE2L2 mutant cell lines harbor mutations in the gene that encode 
the Neh2 domain of NRF2 
(A) Mapping of the NFE2L2 mutations found in the eight cell lines onto a schematic of NRF2 
protein structure. The location of each mutation are indicated above the schematic. The amino 
acid numbering conferring to each specific functional domain of the protein is given below 
separated by dotted arrows. (B) Graphical quantification of (A). 
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4.2.11 Most CUL3 mutant cell lines harbour heterozygous missense 
mutations, located in the first half of the CUL3 protein 
To gain greater understanding of the impact that somatic mutations in 
CUL3 have in terms of impairing NRF2-degradation we analysed the zygosity 
and location of the mutations in the lung cancer cell lines. Table 4.2.11 shows 
that the majority, (88.9%), of CUL3 mutant cell lines possess heterozygous 
missense mutations and were from a range of diverse histological backgrounds. 
In an attempt to ascribe a function to the CUL3 mutations, we mapped them onto 
a schematic of the CUL3 protein. This revealed that 77.8% of mutations were 
located between amino acids 1- 413, a region that we have referred to as region 
1 (Figure 4.2.3); the N-terminal  region 1 is thought to be the site that binds the 
BTB subunit of KEAP1 (Canning et al., 2015). We also identified two mutations 
in the cullin site. It is difficult determine what effect theses mutations will have on 
NRF2 degradation. 
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Table 4.2.11: Most CUL3 mutant cell lines harbor heterozygous missense mutations 
Table showing the name of the eight cell lines harboring mutations in CUL3 and the disease 
subtype, location of the mutation, whether it is heterozygous / homozygous and the variant 
classification  
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Figure 4.2.3: Most CUL3 mutant cell lines harbor mutations that map to region 1 of the 
protein  
(A) Mapping of the CUL3 mutations found in the eight cell lines onto the surface of a schematic 
of the CUL3 protein. The location of each mutation is indicated above the schematic. The 
amino acid numbering conferring to each specific functional domain of the protein is given 
below separated by dotted arrows. (B) Graphical quantification of (A).  
A 
B 
Region1 Region 2 Region 3 
152 
 
4.2.12 KEAP1 mutant cell lines with the highest mRNA expression of NQO1 
tend to have mutations in the Kelch-repeat domain 
To further understand what effect KEAP1 mutations have on NRF2 
degradation, we analysed expression of the NRF2-target gene NQO1 in the cell 
lines harbouring KEAP1 mutations. Table 4.2.12 shows that out of the 28 KEAP1-
mut cell lines, those with the highest NQO1 mRNA levels all harbour homozygous 
missense mutations. Suggesting that a homozygous mutation in KEAP1 leads to 
a greater increase in NRF2 activity than a heterozygous mutation. Figure 4.2.4 
shows that when the locations of the KEAP1 mutations in these cell lines were 
mapped onto the structure of KEAP1 protein, the majority of mutations (80%) are 
located in regions of the gene that encode the Kelch-repeat domain. The same 
analysis was carried out looking at NRF2 mRNA levels (data not shown). This in 
combination with the data shown in section 4.2.9, indicates that the majority of 
KEAP1 mutations found in lung cancer cell lines occur in the Kelch-repeat domain 
and mutations in this region will inhibit NRF2 degradation and subsequently 
enhance NRF2-target gene expression. Collectively, these results suggest that 
the presence of a KEAP1 mutation in lung cancer is an indicator of enhanced 
NRF2 activity. 
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Table 4.2.12: Characteristics of the KEAP1 mutant cell lines with the highest expression 
of NQO1 mRNA 
Table highlighting the top ten KEAP1 mutant cell lines with the highest expression of NQO1 
mRNA, in no particular order. The name of the cell lines are given in the far left-hand side 
column, then the disease subtype, location of the mutation, the zygosity of the mutation and 
the variant classification; as indicated in the second top line of the table. 
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Figure 4.2.4: The KEAP1 mutant cell lines with the highest expression of NQO1 
predominantly possess mutations in the Kelch-repeat domain 
(A) The locations of the mutations associated with high levels of NQO1 are highlighted in bold 
font and are elevated above the schematic representing the KEAP1 protein. (B) Graphical 
quantification of (A) showing that the top ten NQO1 expressing KEAP1 mutant cell lines. The 
first number displayed above the bars highlights the number of mutations found in that specific 
KEAP1 region that are found in the top ten NQO1 expressing cell lines. The number after 
represents the total number of mutations found in that region of KEAP1 out of the 28 cell lines 
analysed. 
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4.2.13 The NFE2L2 mutant cell lines that express highest levels of NQO1 
only have mutations in the Neh2 domain of NRF2 
To further understand what effect NFE2L2 mutations have on NRF2 
activity, we analysed the expression of the NRF2-target gene NQO1 in cell lines 
harbouring NFE2L2 mutations. Table 4.2.13 and Figure 4.2.5 show that out of the 
eight NFE2L2-mut cell lines, those with the highest NQO1 expression 
predominantly harbour heterozygous missense mutations in the Neh2 domain of 
NRF2, more specifically localized to the KEAP1 binding regions, DLG and ETGE. 
MED16 interaction with NRF2 has been shown to be critical for the transcription 
of the NRF2-target gene, NQO1 (Sekine et al., 2015). This could be impaired in 
NCIH748 and NCIH1436 cells which harbour mutations in the Neh5 and Neh1 
domains respectively, accounting for their low NQO1 expression. Taken together 
with the data in section 4.2.10, these findings indicate that NFE2L2 mutations 
predominantly occur in the Neh2 domain of the protein and will lead to enhanced 
NRF2-target gene expression through inhibiting the binding of KEAP1 to NRF2 
and subsequent proteasomal degradation of the transcription factor. 
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Table 4.2.13: The top five NFE2L2 mutant cell lines with the highest expression of NQO1 
mRNA 
Table highlighting the top five NFE2L2 mutant cell lines with the highest expression of NQO1 
mRNA, in no particular order. The name of the cell lines are given in the far left-hand side 
column, then the disease subtype, location of the mutation, the zygosity of the mutation and 
the variant classification, as indicated in the second top line of the table. 
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Figure 4.2.5: The NFE2L2 mutant cell lines with highest expression of NQO1 mRNA 
possess mutations in the Neh2 region of NRF2 
(A) The locations of the mutations associated with high levels of NQO1 are highlighted in 
bold font above the schematic representing the NRF2 protein. (B) Graphical quantification 
of (A) showing that the top five NQO1 expressing NFE2L2 mutant cell lines. The first 
number displayed above the bars highlights the number of mutations found in that specific 
NRF2 region that are found in the top five NQO1 expressing cell lines. The number after 
represents the total number of mutations found in that region of NFE2L2 out of the eight 
cell lines analysed. 
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4.2.14 CUL3 mutant cell lines with the highest expression of NQO1 mRNA 
poses mutations in region 1 of the protein 
To further understand what effect CUL3 mutations have on NRF2 
degradation, we analysed the expression of the NRF2-target NQO1 in cell lines 
harbouring CUL3 mutations. Table 4.2.14 shows that out of the eight CUL3-mut 
cell lines the top five mutants with the highest expression of NQO1 process 
homozygous missense mutations. Figure 4.2.6 shows that the mutations in these 
CUL3 mutant cell lines are predominately located in region 1 and few have 
mutations in the cullin domain. These data, in combination with the data in section 
4.2.11, suggest that the majority of mutations in CUL3 will lead to impaired NRF2 
degradation as they occur in region 1 of CUL3 and lead to enhanced NQO1 
expression. This supports the idea that CUL3 mutations tend to result in a loss of 
function of the protein (Ooi et al., 2013).  
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Table 4.2.14: The top five CUL3 mutant cell lines with the highest expression of NQO1 
mRNA 
Table highlighting the top five CUL3 mutant cell lines with the highest expression of NQO1 
mRNA, in no particular order. The name of the cell lines is given in the far left-hand side 
column, then the disease subtype, location of the mutation, the zygosity of the mutation and 
the variant classification, as indicated in the second top line of the table. 
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Figure 4.2.6: The top five CUL3 mutant cell lines with the highest expression of NQO1 
mRNA tend to have mutations in region 1 of the protein.   
(A) The location of the mutations associated with high levels of NQO1 are highlighted in 
bold font above the schematic representing the CUL3 protein. (B) Graphical quantification 
of (A) showing that the top five NQO1 expressing CUL3 mutant cell lines. One of the cell 
lines indicated has a mutation the Cullin region of CUL3 also harbours a mutation in Region 
2. The first number displayed above the bars highlights the number of mutations found in 
that specific CUL3 region that are found in the top five NQO1 expressing cell lines. The 
number after represents the total number of mutations found in that region of CUL3 out of 
the eight cell lines analysed. 
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4.2.15 KEAP1 mutant cell lines show greater expression of ABCB6, 
AKR1B10, AKR1C1, AKR1C2, AKR1C3 and NQO1 
To determine what effect the presence of a KEAP1, NFE2L2 or CUL3 
mutation has on the expression of NRF2-target genes associated with drug 
detoxification, we analysed the expression of ABCB6, AKR1B10, AKR1C1, 
AKR1C2, AKR1C3 and NQO1, in the presence of each mutation. Using the cell 
line data set (239 cell lines in total), which has been previously described, we 
filtered for the presence of either a KEAP1, NFE2L2 or CUL3 mutation.  We then 
analysed the expression of six NRF2–target genes associated with drug 
detoxification in the mutant subgroups for that particular gene against their 
wildtype counterparts. 
As shown in Figure 4.2.7A, KEAP1-mut cell lines (28 cell lines) have 
significantly higher expression of all of the six target genes analysed in 
comparison to the KEAP1-wt cell lines (211 cell lines). With the most pronounced 
increase being seen in the expression of AKR1B10, which is 67-fold higher in the 
KEAP1-mut cell lines in comparison to the KEAP1-wt cell lines. 
The expression of the same six target genes was analysed in cell lines 
harbouring NFE2L2 mutations and is displayed in Figure 4.2.7B. NFE2L2-mut 
cell lines (8 cell lines) have significantly higher expression of AKR1C1, AKR1C2, 
AKR1C3 and NQO1, in comparison to NFE2L2-wt cell lines (231 cell lines). 
However, ABCB6 and AKR1B10 expression is not significantly altered between 
the two cell line populations. In comparison to the KEAP1-mut cell lines the 
magnitude of elevation in NRF2-target gene expression in the NFE2L2-mut cell 
lines are considerably less. 
A similar pattern of NRF2-target gene expression as seen in the NFE2L2-
mut cell lines was seen in the CUL3-mut cell lines (8 cell lines) (Figure 4.2.7C), 
showing significantly increased expression of AKR1C1, AKR1C2, AKR1C3 and 
NQO1 but not significantly altered ABCB6 or AKR1B10 expression, in 
comparison to CUL3-wt cell lines (231 cell lines). 
These data suggest that the presence of a KEAP1 mutation has a greater 
effect on the expression of NRF2-target genes that are involved in drug 
detoxification, than the presence of a NFE2L2 or CUL3 mutation. 
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4.2.16 KEAP1 mutant cell lines have significantly higher expression of 
NRF2-target genes associated with glutathione production and utilization, 
than cell lines harbouring mutations in NFE2L2 or CUL3 
To determine if other subgroups of NRF2-target genes show higher 
expression in KEAP1 mutant cell lines than NFE2L2 or CUL3 mutant cell lines, 
we analysed the expression of NRF2-target genes associated with glutathione 
biosynthesis and utilization. As shown in Figure 4.2.8, KEAP1-mut cell lines (28 
cell lines) show significantly higher expression of GCLC, GCLM, GPX2 and 
SLC7A11 in comparison to KEAP1-wt cell lines (211 cell lines), with the highest 
fold change between KEAP1-mut and KEAP1-wt cells being in GPX2 expression, 
where a 3-fold change was observed. When we analysed the expression of the 
same four NRF2-target genes in the NFE2L2-mut cell lines (8 cell lines) no 
significant alterations in the expression of GCLC, GCLM or SLC7A11 were 
Figure 4.2.7: KEAP1-mut cells show higher expression of all six NRF2-target target 
genes associated with drug detoxification in comparison to cell lines harboring 
mutations in NFE2L2 or CUL3 
The white bars on each of the graphs represents the cell line population that is wildtype (wt) 
for the gene in question and the black bars represents the cell line population that is mutant 
(mut) for the gene in question. Fold change values for each gene relative to the wt cell line 
group is displayed under each graph. (A) Analysis of the expression six NRF2-target genes 
associated with drug detoxification in cell lines that are either KEAP1-mut (28 cell lines) or 
KEAP1-wt (211 cell lines). The KEAP1-wt cell line population includes cell lines that harbor 
mutations in NFE2L2 and CUL3. No KEAP1-mut cell line also has a NFE2L2 mutation but one 
KEAP1-mut cell line has an additional CUL3 mutation. (B) Analysis of the expression of NRF2-
target genes associated with drug detoxification in cell lines that are either NFE2L2-mut (8 cell 
lines) or NFE2L2-wt (231 cell lines). The NFE2L2-wt cell line population includes cell lines that 
harbor mutations in KEAP1 and CUL3. One NFE2L2-mut cell line also harbors a mutation in 
CUL3. (C) Analysis of the expression of NRF2-target genes associated with drug detoxification 
in cell lines that are either CUL3-mut (8 cell lines) or CUL3-wt (231 cell lines). The CUL3-wt 
cell line population includes cell lines that harbour mutations in KEAP1 and NFE2L2. One 
CUL3-mut cell line also harbours a mutation in KEAP1 and a separate CUL3 mutant cell line 
has an additional mutation in NFE2L2. Bars on all three graphs represent the mean value 
obtained, and the error plotted is the associated SEM. All statistical analysis was carried out 
using GraphPad Prism 5 software. All significant increases are denoted with the * symbol; * 
represented a P< 0.05, ** P<0.01 and ** P< 0.001. P values > 0.05 were deemed not significant 
and are denoted by “ns”.  
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observed, between the NFE2L2-mut and NFE2L2-wt (230 cell lines) cell line 
populations. However, a significant increase in the expression of GPX2 was 
noted, with a 4-fold change between the mut and wt cell populations. CUL3-mut 
cell lines (8 cell lines) have significantly elevated expression of GCLM and GPX2 
in comparison to CUL3-wt cell lines (230 cell lines). Also showing the largest fold 
change in expression in the gene GPX2, with a fold change value of 3. The 
expression of GCLC and SLC7A11 was not significantly altered by the presence 
of a CUL3 mutation. 
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4.2.17 KEAP1 mutant cell lines show significantly higher expression of 
NRF2-target genes associated with cell metabolism than cell lines 
harbouring mutations in NFE2L2 or CUL3 
It has been reported that NRF2 influences cell metabolism through 
positively controlling the expression of genes involved in the pentose phosphate 
pathway (PPP) and in NADPH generation. To determine whether the presence 
of mutations in KEAP1, NFE2L2 or CUL3 affects expression of metabolism-
related genes we analysed the expression of G6PD, IDH1, ME1, PGD and 
TALDO1. As shown in Figure 4.2.9A, KEAP1-mut cell lines have significantly 
higher expression of all six metabolism genes analysed in comparison to KEAP1-
wt cell lines, with the largest fold change being seen in the expression of G6PD. 
However, NFE2L2-mut cell lines do not have significant alterations in the 
expression of any of metabolism related genes analysed when compared to 
NFE2L2-wt cell lines (Figure 4.2.9B). CUL3-mut cell lines show significantly 
higher expression of ME1 and TALDO1 but no significant alterations in the 
Figure 4.2.8: GSH-based antioxidant NRF2-target genes are more elevated in KEAP1-mut 
cell lines than cell lines harbouring mutations in NFE2L2 or CUL3  
The white bars on each of the graphs represents the cell line population that is wildtype (wt) for 
the gene in question and the black bars represents the cell line population that is mutant (mut) for 
the gene in question. Fold change values for each gene relative to the wt cell line group is displayed 
under each graph. (A) Analysis of the expression of four GSH-based antioxidant NRF2-target in 
cell lines that are either KEAP1-mut (28 cell lines) or KEAP1-wt (211 cell lines). The KEAP1-wt 
cell line population includes cell lines that harbor mutations in NFE2L2 and CUL3. No KEAP1-mut 
cell line also has a NFE2L2 mutation but one KEAP1-mut cell line has an additional CUL3 
mutation. (B) Analysis of the expression of GSH-based antioxidant NRF2–target genes in cell lines 
that are either NFE2L2-mut (8 cell lines) or NFE2L2-wt (231 cell lines). The NFE2L2-wt cell line 
population includes cell lines that harbor mutations in KEAP1 and CUL3. One NFE2L2-mut cell 
line also harbors a mutation in CUL3. (C) Analysis of the expression of GSH-based antioxidant 
NRF2 –target genes in cell lines that are either CUL3-mut (8 cell lines) or CUL3-wt (231 cell lines). 
One CUL3-mut cell line also harbours a mutation in KEAP1 and a separate CUL3 mutant cell line 
has an additional mutation in NFE2L2. Bars on all three graphs represent the mean value obtained, 
and the error plotted is the associated SEM. All statistical analysis was carried out using GraphPad 
Prism 5 software. All significant increases are denoted with the * symbol; * represented a P< 0.05, 
** P<0.01 and ** P< 0.001. P values > 0.05 were deemed not significant and are denoted by “ns”.  
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expression of G6PD, IDH1 or PGD, in comparison to CUL3-wt cell lines (Figure 
4.2.9C).  
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4.2.18 KEAP1 mutant cell lines have significantly higher expression of the 
stress related NRF2-target gene HMOX1, in comparison to cell lines 
harbouring mutations in NFE2L2 or CUL3 
 HMOX1 is a classical NRF2-target gene that is involved in stress 
pathways and iron metabolism, and has been implicated in the development of 
drug resistance. We analysed the expression of HMOX1 in lung cancer cell lines 
harbouring mutations in either KEAP1, NFE2L2 or CUL3.  As shown in Figure 
4.2.10, KEAP1-mut cell lines have significantly greater expression of HMOX1 in 
comparison to KEAP1-wt cell lines, with a fold-change in expression of 2. 
Surprisingly, when we analysed the expression of HMOX1 in cell lines with 
mutations in NFE2L2 or CUL3, we found that neither of these mutations showed 
significantly higher expression of HMOX1 in comparison to their corresponding 
wildtype cell line group. 
Figure 4.2.9: Genes associated with the PPP and NADPH generation are significantly 
elevated in cell lines with KEAP1 mutations in comparison to those with mutations in 
NFE2L2 or CUL3  
The white bars on each of the graphs represents the cell line population that is wildtype (wt) 
for the gene in question and the black bars represents the cell line population that is mutant 
(mut) for the gene in question. Fold change values for each gene relative to the wt cell line 
group is displayed under each graph. (A) Analysis of the expression of NRF2-target genes 
associated with the PPP and NADPH generation in cell lines that are either KEAP1-mut (28 
cell lines) or KEAP1- wt (211 cell lines). The KEAP1-wt cell line population includes cell lines 
that harbor mutations in NFE2L2 and CUL3. No KEAP1-mut cell line also has a NFE2L2 
mutation but one KEAP1-mut cell line has an additional CUL3 mutation. (B) Analysis of the 
expression of NRF2-target genes associated with the PPP and NADPH generation in cell lines 
that are either NFE2L2-mut (8 cell lines) or NFE2L2-wt (231 cell lines). The NFE2L2-wt cell 
line population includes cell lines that harbor mutations in KEAP1 and CUL3. One NFE2L2-
mut cell line also harbors a mutation in CUL3. (C) Analysis of the expression of NRF2-target 
genes associated with the PPP and NADPH generation in cell lines that are either CUL3-mut 
(8 cell lines) or CUL3-wt (231 cell lines). One CUL3-mut cell line also harbours a mutation in 
KEAP1 and a separate CUL3 mutant cell line has an additional mutation in NFE2L2. Bars on 
all three graphs represent the mean value obtained, and the error plotted is the associated 
SEM. All statistical analysis was carried out using GraphPad Prism 5 software. All significant 
increases are denoted with the * symbol; * represented a P< 0.05, ** P<0.01 and ** P< 0.001. 
P values > 0.05 were deemed not significant and are denoted by “ns”. 
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4.3 Discussion  
Mutations in KEAP1 and NFE2L2 are often grouped together in terms of 
their effect on NRF2 signalling, and mutations in CUL3 are often not studied. In 
this chapter we have carried out a comprehensive bioinformatics analysis and 
have made the following key findings: (1) KEAP1 mutations are more prevalent 
than mutations in NFE2L2 and CUL3; (2) KEAP1 mutations co-occur with 
mutations KRAS and are mutually exclusive with mutations in NFE2L2 and TP53; 
(3) mutations in NFE2L2 co-occur with mutations in TP53 and are mutually 
exclusive with mutations in KEAP1 and KRAS; (4) mutations in KEAP1 are 
predominantly homozygous missense mutations spread throughout the KEAP1 
protein; (5) mutations in NFE2L2 are predominantly heterozygous missense 
mutations that cluster to the DLG and ETGE motifs located in the Neh2 domain 
and (6) cell lines harbouring mutations in KEAP1 have increased expression of 
NRF2-target genes in comparison to cell lines with NFE2L2 or CUL3  mutations. 
Figure 4.2.10: Cell lines harbouring mutations in KEAP1 have significantly higher 
expression of the stress related NRF2-target gene, HMOX1, in comparison to cell lines 
harbouring mutations in NFE2L2 or CUL3 
The white bars on each of the graphs represents the cell line population that is wildtype (wt) 
for the gene in question and the black bars represents the cell line population that is mutant 
(mut) for the gene in question. Fold change values for each gene relative to the wt cell line 
group is displayed under each graph. (A) Analysis of the expression of HMOX1 in cell lines 
that are either KEAP1-mut (28 cell lines) or KEAP1-wt (211 cell lines). The KEAP1-wt cell line 
population includes cell lines that harbor mutations in NFE2L2 and CUL3. No KEAP1-mut cell 
line also has a NFE2L2 mutation but one KEAP1-mut cell line has an additional CUL3 
mutation. (B) Analysis of the expression of HMOX1 in cell lines that are either NFE2L2-mut (8 
cell lines) or NFE2L2-wt (231 cell lines). The NFE2L2-wt cell line population includes cell lines 
that harbor mutations in KEAP1 and CUL3. One NFE2L2-mut cell line also harbors a mutation 
in CUL3. (C) Analysis of the expression of HMOX1 in cell lines that are either CUL3-mut (8 
cell lines) or CUL3-wt (231 cell lines). Bars on all three graphs represent the mean value 
obtained, and the error plotted is the associated SEM. All statistical analysis was carried out 
using GraphPad Prism 5 software. All significant increases are denoted with the * symbol; * 
represented a P< 0.05, ** P<0.01 and ** P< 0.001. P values > 0.05 were deemed not significant 
and are denoted by “ns”.  
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4.3.1 Why mutations in NFE2L2 and KEAP1 do not occur together but you 
get CUL3 mutations with NFE2L2 mutations 
We, like others, have found that mutations in KEAP1 and NFE2L2 are 
mutually exclusive to each other and never occur within the same cell line or 
tumour (The Cancer Genome Atlas Research, 2012; Shibata et al., 2008). It 
would be logical to presume that these mutations do not occur together because 
there is a level of redundancy with both mutations resulting in the same 
phenotype, namely, impaired degradation of NRF2 by KEAP1. Consistent with 
the previous findings of Fukutomi et al., (2014), we found mutations in NFE2L2 
predominately occur in the DLG and ETGE KEAP1-binding motifs that are located 
in the Neh2 domain of NRF2. There is strong evidence supporting the idea that 
mutations at these sites in NRF2 increase its activity through inhibiting KEAP1-
mediated degradation of the transcription factor (Fukutomi et al., 2014). 
Interestingly, we found that mutations in NFE2L2 and CUL3 do sometimes 
occur together in the same tumour, suggesting that the mutation in CUL3 might 
potentially influence other cellular functions besides NRF2 signalling. CUL3 is 
one member of the cullin family of scaffold proteins that function recruit protein 
substrates for ubiquitination (Wimuttisuk et al., 2014). CUL3 binds to the BTB 
region of KEAP1 and KEAP1 binds NRF2. However, there are over 200 BTB 
domain containing proteins in human cells that all have the potential to be bound 
by CUL3 (Pintard et al., 2004). Therefore, some of the mutations in CUL3 that we 
have analysed may not affect NRF2 degradation but the degradation of other 
oncogenic genes, meaning that mutations in CUL3 may enhance oncogenesis 
independently of NRF2 and can occur alongside NFE2L2 mutations. 
4.3.2 KRAS mutations coexist with KEAP1 mutations and NFE2L2 
mutations occur with TP53 mutations  
From the analysis described in this chapter we have discovered that 
mutations in KEAP1 co-exist with mutations and KRAS, whereas mutations in 
NFE2L2 tend to co-occur with mutations in TP53. Since mutations in KEAP1 and 
NFE2L2 mutations do not co-exist, there appears to be a segregation of each 
NRF2 influencing mutation with a different oncogenic driver mutation. In view of 
the fact that upregulation of NRF2 activity is not associated with cancer initiation 
but with tumour progression, it would be reasonable to suggest that the mutation 
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in KRAS or TP53 arises as an early event that precedes mutation in KEAP1 or 
mutation in NFE2L2, respectively.  
KRAS is a member of the RAS family of evolutionally conserved GTPases. 
Mutations in RAS genes have been implicated in a wide range of cancers, with 
KRAS being the most commonly mutated family member. KRAS mutations are 
regularly associated with ADCs and are thought to arise through exposure to 
tobacco smoke (Ahrendt et al., 2001). Somatic mutations in KRAS commonly 
occur at either codon 12, 13 or 61 and result in the aberrant activation of KRAS 
signalling. Once activated KRAS signals to a wide range of downstream effector 
proteins that are involved in several signalling pathways that are implicated in 
cancer progression, such as the PI3K-AKT pathway that drives cell survival and 
the RAF-MEK-ERK pathway that is involved in cell proliferation (Westcott and To, 
2012). Research has shown that oncogenic activating mutations in KRAS lead to 
the generation of high levels of mitochondrial  ROS (Storz, 2016) through a 
variety of pathways such as activation of HIF-1α and HIF-2α signalling (Chun et 
al., 2010), suppression of respiratory chain complex I and III leading to a 
reduction in the mitochondrial transmembrane potential resulting in mitochondrial 
dysfunction (Hu et al., 2011b), and alterations in NADPH oxidase activity (Kong 
et al., 2013). However, when ROS increases to uncontrollable levels it triggers 
senescence or cell death pathways, so to ensure its survival the KRAS mutant 
cancer cell must suppress the heightened production of ROS so that it can benefit 
from the oncogenic influence of ROS without becoming subject to senescence or 
apoptosis. It has been suggested that the KRAS mutant cancer cells do this 
through upregulating NRF2 expression, by either directly increasing expression 
of the NFE2L2 gene (DeNicola et al., 2011) or by acquiring somatic mutations in 
KEAP1, NFE2L2 or CUL3. We like others, have shown that mutations in KRAS 
and KEAP1 commonly occur together. Potentially this is because only a mutation 
in KEAP1, and not in NFE2L2 or CUL3, is able to effectively combat the enhanced 
ROS produced when KRAS is mutated, but we currently have no data to support 
this.  
P53 is a transcription factor that is activated upon DNA damage, which 
regulates the expression of a wide range of downstream target genes, of which 
many have contrasting functions. Several p53 target genes lead to cell cycle 
arrest allowing the cell time repair DNA damage but also expression of some p53 
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target genes has been shown to induce apoptosis of damaged cells in a ROS 
dependant manner. To permit the increase in ROS levels required for p53-
induced apoptosis, p53 has been shown to suppress NRF2-dependant 
transcription of several ARE containing NRF2-target genes (Faraonio et al., 
2007). Contrary to this idea, several p53-target genes, such as SESN1 (also 
known as sestrin 1), SESN2 (also known as sestrin 2), SOD2 and GPX1, have 
been shown to decrease ROS levels. Interestingly, p53 has also been shown to 
regulate the expression of GLS2 (also known as Glutaminase 2), which is the key 
enzyme involved in the conversion glutamine to glutamate, required for 
glutathione synthesis (Rotblat et al., 2012). It has also been shown that p53 may 
indirectly regulate NRF2 through stimulation of the NF-κB pathway (Tung et al., 
2015) or directly through promoting the nuclear localization of the transcription 
factor (Lisek et al., 2018). By contrast, NRF2 has also been shown to regulate 
p53 expression. Murine double minute 2 (MDM2), the E3 ubiquitin ligase, that 
ubiquitinates  p53 at several Lys residues leading to proteasomal degradation of 
the transcription factor, is responsible for maintaining low levels of p53 in resting 
cells (Gibbons et al., 2014). P53 itself can regulate the expression of MDM2 
through a negative feedback loop but also NRF2 can control the expression of 
MDM2 through an ARE sequence (You et al., 2011), suggesting that active NRF2 
will lead to increased levels of MDM2 activity and decreased expression of p53 
protein. P53 is a tumour suppressor that becomes mutated in lung cancer, 
especially upon exposure to tobacco smoke (Gibbons et al., 2014),  leading to 
oncogenesis typically characterized by uncontrolled cell division. This will lead to 
an accumulation of ROS, so to inhibit ROS induced apoptosis TP53 mutant 
cancer cells increase NRF2 activity. We believe we are the first group to report 
that mutations in TP53 show strong co-occurrence with mutations in NFE2L2. 
However, due to the complex feedback regulatory loop between NRF2 and p53 
it is difficult to understand why a NFE2L2 mutation would be selected instead of 
a mutation in KEAP1.  
4.3.3 Why are somatic mutations in KEAP1 homozygous and those in 
NFE2L2 heterozygous?  
One of the most interesting and exciting discoveries that has emerged 
from the research described in this chapter is that mutations in KEAP1 are 
predominately homozygous whereas mutations in NFE2L2 are predominantly 
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heterozygous. We will discuss this theme more in Chapter 5, but currently we 
have no data to explain why mutations in KEAP1 and NFE2L2 have different 
zygosities associated with them, but we believe this does in part account for their 
associated different levels of NRF2 activity. We speculate several potential 
reasons for this: (1)  a homozygous mutation in NFE2L2 have been evolutionally 
selected against; (2) mutations in KEAP1 tend to be homozygous because 
KEAP1 functions as a dimer; (3) that to combat the high levels of ROS produced 
by KRAS mutations KEAP1 mutations have to be homozygous whereas TP53 
mutations do not cause to such an elevation of ROS and only lead to homozygous 
mutations in NFE2L2 and (4) mutations in tumour suppressors tend to be 
heterozygous indicating that KEAP1 may be a tumour suppressor (this idea is 
discussed in more detail in the final discussion section, Chapter 6). 
4.3.4 The idea that the frequency of CUL3 and NFE2L2 mutations is low so 
we cannot make robust conclusions  
In this chapter we have used a combination of three datasets in our cell 
line analysis, which has significantly strengthened our findings and enhanced the 
number of cell lines harbouring each mutation. However, this only gave us eight 
NFE2L2 and eight CUL3 mutant cell lines. These small numbers, means that we 
cannot be fully confident in the robustness of the data generated. To enhance our 
confidence, we have carried out the same analyses in tumour datasets. Using the 
tumour datasets not only increase the robustness of the data, because they have 
large n numbers, but also ensures our data are more clinically relevant. All tumour 
databases used in this chapter were generated by the TCGA consortium.  
4.3.5 KEAP1 mutant cell lines have very high drug detoxification gene 
expression 
In Figure 4.2.7, we analysed the expression of the NRF2-target genes 
associated with drug detoxification, namely, ABCB6, AKR1B10, AKR1C1, 
AKR1C2, AKR1C3 and NQO1, in cell lines with the presence of KEAP1, NFE2L2 
or CUL3 mutations. Expression of all four AKRs (AKR1B10, AKR1C1, AKR1C2 
and AKR1C3) show significant elevation in expression between the KEAP1-mut 
and KEAP1-wt cell populations with large associated fold change values of 67, 5, 
48 and 5 respectively. These were highest fold change values in expression for 
any gene analysed in the presence of any mutation. This suggests that KEAP1 
mutant cell lines selectively increased the expression of this subgroup of NRF2-
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target genes, potentially this is due to them being highly resistant to platinum 
based drugs as the presence of KEAP1 mutation has been demonstrated to 
dramatically influence platinum sensitivity (Tian et al., 2016). Also, 
overexpression of several members of the AKR family of genes has been 
documented in tumours from smokers. This is thought to be due to the AKRs 
being involved in the metabolism of the two major chemical carcinogens found in 
cigarette smoke (Penning, 2017). Since KEAP1 mutations have been linked to 
smoking and occur alongside mutations in KRAS which are also linked with 
smoking, its maybe not surprising that we see increased expression of AKRs in 
KEAP1 mutant cell lines. However, it should be highlighted that the expression 
data analysis was only done in lung cancer cell lines; which will have various 
smoking statuses, mixed histology and may or may not have been exposed to 
chemotherapy. 
4.3.6 The limitations of this bioinformatics analysis  
Bioinformatics is a useful biological tool to look for patterns in large data 
sets and identify potential new areas of research. However, there are several 
limitations to bioinformatics analysis, such as discussed previously the size of 
your dataset will influence the robustness of the data generated. Also, it is critical 
that all bioinformatics findings are validated experimentally. 
We have analysed the expression of several NRF2-target genes in which 
we look at mRNA expression levels from several datasets that have been 
combined together, however these values do vary between the individual data 
sets. This could be due to the technique used to obtain and analyse the mRNA 
expression in each cell line and also by the cell culture conditions.  
One limitation of our dataset, which will discuss again in Chapter 5, is that 
when we compare the expression of NRF2-target genes in the presence of a 
certain mutation we have not accounted for the presence of other mutations that 
will influence the expression of that gene. For example, in Figure 4.2.7 in the top 
image we compared the expression of six drug detoxification genes in the 
presence of a KEAP1 mutation. In this analysis there are 28 cell lines that harbour 
a KEAP1 mutation these cell lines do not harbour mutations in NFE2L2 so all the 
NFE2L2 mutant cell lines will be represented in the KEAP1-wt sub-group. The 
presence of a NFE2L2 mutation would lead to the elevation in expression of all 
six genes analysed and hence the KEAP1-wt population will have enhanced 
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expression of these genes. So, we are in fact comparing the expression of NRF2 
target genes between cell lines harbouring a mutation in KEAP1 and cell lines 
that are wildtype for KEAP1 mutation but harbour mutations in NFE2L2.  
To correct for this, we could omit the NFE2L2 mutant and the CUL3 mutant 
cell lines from the KEAP1 wildtype cell population and repeat the analysis and do 
the converse for the NFE2L2 mutant analysis. Sadly, we would have had to do 
this filtering at the very beginning of our analysis while we still had access to the 
bioinformatics software. However, we have managed to reanalyse data looking 
at the expression of a subset of prototypic NRF2-target genes using the Sanger 
dataset this data will be presented in Chapter 5. 
4.3.7 Additional data that was not included  
Due to space constraints we have had to omit several pieces of 
bioinformatics data form this chapter. Including analysis of the expression of 
NRF2-target genes associated with: TXN-based antioxidants (PRDX1, PRDX6, 
SRXN1 and TXNRD1), purine biosynthesis (MTHFD2 and PPAT), iron 
metabolism (FTH1 and FLT), proteasome subunits (PSMA1, PSMA4, PSMB5 
and PSMC1), serine/glycine biosynthesis (PHGDH, PSAT1 and SHMT2), 
apoptosis (BCL2, also the non NRF2-target genes BAD, BAX, BID and MCL1) 
and autophagy (ATG5, ATG7, CALCOCO2, SQSTM1 and ULK1). The 
expression these genes and the genes shown in this chapter, were also analysed 
in the presence of a PTEN or PIK3CA mutation. 
4.3.8 Conclusions  
Molecular profiling of the mutations implicated in lung carcinoma led to the 
discovery of the high frequency of EGFR mutations in ADC patients. Patients are 
now screened from the presence of an EGFR mutation and if deemed EGFR 
positive are treated with tyrosine kinase inhibitors (TKIs) with very promising 
results, highlighting the impact that genetic analysis can have on patient outcome. 
Since the discovery that aberrant expression of NRF2 leads to aggressive and 
chemo-resistant lung cancer, the field has predominantly focused on how to 
therapeutically decrease NRF2 levels and not on the genetic events that have led 
to the increased expression of the transcription factor. In this chapter through the 
use of bioinformatics dataset for lung cancer cell lines and tumours we have 
demonstrated the following: i) KEAP1, NFE2L2 and CUL3 mutations co-exist with 
different oncogenic mutations, mutations in these three genes map to regions of 
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each protein that will influence KEAP1 mediated degradation of NRF2; ii) KEAP1, 
NFE2L2 and CUL3 mutations are different in terms of their effect on the 
expression of NRF2-target genes; iii) KEAP1 mutations are predominately 
homozygous whereas NFE2L2 mutations are predominantly heterozygous. 
There is still a lot of work that needs to be carried out to validate these findings 
and to get a more comprehensive understanding of the impact that mutations in 
KEAP1, NFE2L2 and CUL3 play in lung carcinogenesis.   
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5. The identification of glutathione biosynthesis as a 
new selective therapeutic target in KEAP1 mutant lung 
cancer cell lines.  
 
5.1 Introduction 
Glutathione is an abundant thiol-containing tripeptide found in almost all 
mammalian tissues that is composed of glutamic acid, cysteine and glycine 
(Meister and Anderson, 1983). Due to its potent antioxidant ability, glutathione 
has been implicated in the development and progression of several diseases, 
including cancer. The antioxidant activity of glutathione is due to the sulfhydryl 
group (SH) of the cysteinyl moiety functioning as a proton donor, giving 
glutathione its ability to control: the thiol status of other proteins, to detoxify 
electrophiles, drive cellular proliferation, and augment antioxidant defences 
(Gamcsik et al., 2012; Lu, 2009).  
5.1.1 The role of glutathione in cancer  
Glutathione levels have been documented to be altered in several cancer 
cell lines and tumours of various tissues of origins such as: liver, head and neck, 
ovary, colon, brain, breast, stomach, oesophagus and lung (Gamcsik et al., 
2012). It is thought that the elevation in glutathione levels provides a pro-survival 
advantage to the cancer cell through inhibiting apoptosis, preventing senescence 
and conferring resistance to anticancer therapies.  
5.1.1.1 Glutathione regulation of JNK and ASK-1 to control apoptosis 
Anticancer therapies often exploit the toxic potential of oxidative stress. 
However, it should be noted that cancer cells  produce a large amount of ROS 
due to their increased metabolic demand and the switch from oxidative 
phosphorylation to glycolytic metabolism (Vander Heiden et al., 2009; Nogueira 
and Hay, 2013). Both radiotherapy and chemotherapy lead to an increase in ROS 
production that is sufficient to cause cell death through apoptosis (Traverso et al., 
2013). GST isoenzymes constitute a family of cytoprotective phase II drug-
metabolizing enzymes that catalyse the addition of glutathione to either an anti-
cancer drug or an endogenous protein through the formation of a thiol-ester bond 
(Tew, 1994). The GST family can be sub-divided into two families. These have 
been categorised as follows: the membrane-associated microsomal GST 
proteins (which are involved in leukotriene and prostaglandin metabolism, 
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sometimes called MAPEGs); the mitochondrial GST (sometimes called Kappa); 
and the cytosolic GST isoenzymes of which there are seven classes designated: 
Alpha, Mu, Pi, Sigma, Theta, Zeta and Omega (Hayes et al., 2005).  
Amongst the cytosolic GST proteins, both class Mu and Pi enzymes have 
been implicated in the development of drug resistance through inhibiting MAPK 
signalling by non-enzymatic protein-protein interactions (Townsend and Tew, 
2003). JNK and ASK-1 are both inhibited under homeostatic conditions and once 
activated lead to the stimulation of signalling cascades resulting in apoptosis. 
GST P1-1 is the most abundant of all the transferases and has been reported to 
be overexpressed in several cell lines that have acquired resistance in vitro 
through repetitive exposure to antineoplastic drugs. JNK activity is low under non-
stressed conditions through a C-terminal association with GST P1-1. The 
converse of this has also been demonstrated with exposure to ultraviolet (UV) 
light leading to activation of JNK through inhibition of GST P1-1 (Adler et al., 
1999; Wang et al., 2001). ASK-1 has been shown to be activated under 
conditions of heat shock through the dissociation of ASK-1 from GST M1-1 
(Dorion et al., 2002). Thioredoxin has also been shown to regulate ASK-1 
expression, similar to GST M1. However, thioredoxin mediated regulation of ASK-
1 is redox-dependent (Saitoh et al., 1998).   
Rapid cellular proliferation is one of the classical hallmarks of cancer. 
Studies carried out in both cell culture models and patients have revealed that 
treatment with the glutathione biosynthesis inhibitor BSO reduces cell 
proliferation through stimulation of apoptotic pathways, such as the JNK pathway 
(Schnelldorfer et al., 2000). This has been confirmed through the use of GST 
P1/P2 KO mice which show a reduced proliferative response, due to aberrant 
JNK signaling (Ruscoe et al., 2001). Also glutathione has been shown to regulate 
cell proliferation through apoptosis-independent pathways, potentially through 
alterations in NF-κB signaling via IKKβ (Reddy et al., 2007). 
5.1.1.2 The role of glutathione in drug resistance  
Over-expression of several GST isoenzymes in mammalian cells leads to 
the development of drug resistance (Puchalski and Fahl, 1990). SCLC cell lines 
and tumours have low innate resistance to antineoplastic drugs but often develop 
multi-drug resistance. Examination of such cells led to the discovery of the ATP-
dependant ABC transporter, MRP, which was shown to be overexpressed in a 
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SCLC cell line that had acquired resistance to doxorubicin (Cole et al., 1992). 
MRP has now been shown to be responsible for the transport of several 
electrophilic anti-cancer drugs (especially alkylating agents) conjugated to 
glutathione, such as cisplatin (Lan et al., 2018). This conjugation of glutathione 
with electrophilic drugs serves two important functions: firstly, it inactivates the 
toxic properties of the drug, secondly, it makes the drug a substrate for the pump 
(Gamcsik et al., 2012).  MRP1, the most well studied and characterised of the 
MRP family of transporters, is often overexpressed in oncogenic tissues and is 
thought to lead to resistance through enhancing export of anti-cancer drugs out 
of the tumour cell (Cole, 2014; Cole and Deeley, 2006).  
MRP has also been shown to be involved in the transport of both reduced 
and oxidized glutathione, and hence is involved in cellular health through the 
maintenance of the reduced to oxidized glutathione ratio and ensuring high 
intracellular concentrations of reduced glutathione (Rappa et al., 1998).   
5.1.2 The glutathione biosynthetic pathway  
The levels of total glutathione in the cell are tightly regulated by balancing 
its production and utilization. The de novo biosynthesis of glutathione is a two-
step ATP-dependant process (Figure 5.1.1). The first rate-limiting step involves 
the formation of γ-glutamylcysteine from glutamic acid (which is produced by the 
enzymatic conversion of glutamine by the enzyme glutaminase (GLS)) and 
cysteine. This is catalysed by glutamate-cysteine ligase (GCL) which is a 
heterodimeric enzyme composed of a catalytic subunit, the glutamate-cysteine 
ligase catalytic (GCLC) subunit and a modifier subunit, the glutamate-cysteine 
ligase modifier (GCLM) subunit. The second stage involves production of 
glutathione from γ-glutamylcysteine and glycine, catalysed by glutathione 
synthase (GS). The production of glutathione in the cell under homeostatic 
conditions is dependent on the availability of dietary cysteine and GCL activity 
(Traverso et al., 2013;Daseul Kim et al., 2015). Once transported into the cell 
through the transporter xCT, cystine rapidly auto-oxidizes to cysteine, leading to 
the production of ROS. Therefore, the majority of the cysteine in the cell 
originates from the γ-glutamyl cycle, in which γ-glutamyltranspeptidase (GGT) 
breaks down the peptide bond in releasing cysteine (Lu, 2009; Meister, 1983). 
Cysteine can also be produced from methionine in a process called the 
cystathionine pathway (Meister and Anderson, 1983). However, this pathway is 
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only found to be active in hepatic cells and is redundant in all other cell types 
(Tarver and Schmtdt, 1939). 
Glutathione is found in either one of two states in the cell: reduced 
glutathione (GSH) or oxidized glutathione (GSSG) (Kaplowitz et al., 1985) (Figure 
5.1.2). The majority of glutathione in the cell is in the reduced GSH form which 
reaches intracellular concentrations in the milli-molar range. By contrast, the 
levels of GSSG in the cell represent approx. only 1% of the total glutathione and 
only reach the micro-molar range (Akerboom et al., 1982).  
Figure 5.1.1: Schematic diagram showing the influence that NRF2 plays on the 
production of glutathione in the cell 
Glutamine is transported into the cell through the transporter SLC1A5 and rapidly converted 
to glutamate, catalysed by GLS. Glutamate can then be either; converted to α-ketoglutarate, 
be exported out of the cell in exchange for the import of cystine through the transporter xC- or 
used to produce glutathione. To produce glutathione, glutamate is converted to γ-
glutamylcysteinine by GCL. γ-glutamylcysteine and glycine are then converted to glutathione 
in a reaction catalysed by GS. GPX2 uses GSH as a co-factor for the neutralisation of H2O2. 
The pool of cysteine in the cell can be replenished through GGT breakdown of GSH. The three 
building blocks of glutathione are highlighted in yellow boxes. Highlighted in the green 
coloured boxes are NRF2-target genes; GCLC, GCLM, SLC7A11, GPX2 and GGT, which all 
play fundamental roles in the production and utilization of the glutathione in the cell. 
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Figure 5.1.2: The chemical conversion of reduced glutathione to oxidized glutathione 
GSH shown in the top grey box can be converted to oxidized glutathione shown in the bottom 
grey box. GSSG is composed of two molecules of GSH linked by a disulphide bond. Once 
oxidized, the reaction can occur in the reverse catalysed by glutathione reductase (GR) using 
NADPH as a co-factor, producing GSH. The ratio of GSH to GSSG is often used as an indicator 
of oxidative stress.  
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5.1.3 The role of NRF2 in regulating glutathione levels  
The transcription factor NRF2 functions as a master regulator of the 
oxidative stress defences of the cell through its ability to  transcriptionally activate 
of over 200 cytoprotective genes, including those involved in both the production 
and utilization of glutathione (Tebay et al., 2015). All NRF2-target genes possess 
at least one ARE-sequence in their promoter regions (Rushmore and Pickett, 
1990; Rushmore et al., 1991). Pioneering work by Masi Yamamoto and 
colleagues demonstrated the influence that NRF2 plays on the expression of 
ARE-containing genes through the generation of a knockout mouse (Itoh et al., 
1997). They provided evidence that GST gene induction by butylated BHA was 
diminished in the absence of NRF2, suggesting that the transcription factor 
regulates expression of multiple drug detoxification genes. In subsequent years, 
ARE sequences have been discovered in multiple important detoxification genes 
such as GSTA1, GSTM1, GCLC, GCLM and NQO1, which have also been shown 
to be transcriptionally regulated by NRF2.  
5.1.3.1 NRF2 in glutathione production  
The initial rate limiting step in de novo biosynthesis of glutathione is 
catalysed by the enzyme GCL, which is composed of two subunits encoded by 
two separate genes GCLC and GCLM.  GCLC, is a 73 kDa subunit that is 
responsible for the catalytic activity of GCL and is also involved in the feedback 
inhibitory loop controlling the levels of glutathione produced (Lu, 2013). GCLM is 
a 28 kDa subunit that lacks catalytic activity but regulates the kinetic properties 
of GCLC. Both the GCLC and GCLM genes contain ARE sequences in their 
promoter regions and not surprisingly are therefore upregulated in the presence 
of oxidative stress (Erickson et al., 2002). Kenny MacLeod and colleagues carried 
out a siRNA knock down of KEAP1 in human keratinocyte HaCaT cells followed 
by a microarray to identify candidate NRF2-target genes. In total they identified 
23 genes that were increased over 2-fold in comparison to the control, which 
included both GCLC and GCLM. Under cell culture conditions, the intracellular 
level of glutathione was found to be increased in HaCat cells when KEAP1 was 
silenced and decreased when NRF2 was knocked out, suggesting that NRF2 
regulates glutathione levels  ex vivo through controlling expression of GCLC and 
GCLM (MacLeod et al., 2009). Using knockout mice, others have reported that 
Nrf2 controls the expression of both GCLC and GCLM subunits of GCL 
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(Thimmulappa et al., 2002) and loss of Nrf2 has also been shown to result in low 
intracellular levels of glutathione (Morales-Pantoja et al., 2016; Blake et al., 2010; 
Chan et al., 2001). 
The availability of cysteine is a limiting factor in glutathione biosynthesis. 
xC- is a cell surface antiporter, that transports extracellular cystine into the cell 
coupled to the anti-port of intracellular glutamate at a ratio of 1:1(Koppula et al., 
2018). The xC- transport system is a heterodimer composed of two proteins; 
solute carrier family 7 member 11 (xCT, encoded by the gene SLC7A11) and 
solute carrier family 3 member 2 (encoded by the gene SLC3A2). SLC7A11 is 
responsible for the transporter ability of the xC- complex, whereas SLC3A2 is 
responsible for the recruitment of SLC7A11 to the plasma membrane (Koppula 
et al., 2017). Work by Shiro Bannai and colleagues, identified several ARE-
sequences in the promoter region of SLC7A11 and demonstrated that NRF2 can 
regulate the expression of this gene (Sasaki et al., 2002). This has been further 
validated in breast cancer cell lines, demonstrating that under conditions in 
intracellular oxidative stress xC- is upregulated due to the nuclear translocation 
of NRF2 leading to the active transcription of SLC7A11 (Verschoor and Singh, 
2013; Habib et al., 2015).   
5.1.3.2 NRF2 in glutathione utilization 
The total levels of cellular glutathione are not only being dictated by its 
production but also by its consumption. GPX isoenzymes are selenium–
dependant enzymes that protect membranes from ROS through catalysing the 
reduction of H2O2, or organic hydroperoxides, to water and alcohols by utilizing 
GSH as a co-factor. There are currently eight human GPX isoenzymes, known 
as GPX1-8, which all show different localizations and substrate specificity (Margis 
et al., 2008). GPX2, also known as gastrointestinal GPX, has been shown to 
contain a functional ARE-sequence and its expression is reduced in Nrf2 KO mice 
(Banning et al., 2005). Also GPX2 has been revealed to be induced in response 
to carcinogenic cigarette smoke, through cigarette smoke inhibiting the 
interaction between KEAP1 and NRF2 leading nuclear accumulation of NRF2 
and the active transcription of GPX2 (Singh et al., 2007) . 
5.1.4 Alterations in NRF2 signalling in lung cancer  
NRF2 is often elevated in several types of cancer and this is associated 
with poor prognosis (Shibata et al., 2008). Lung cancer is a classic example of a 
184 
 
cancer where increased NRF2 signalling confers an advantage to the cancer cell 
through increasing cellular proliferation, metabolism and the ability to withstand 
oxidative stress. This upregulation of the transcription factor is commonly due to 
somatic mutations in the gene encoding the negative regulatory protein KEAP1 
or mutations in NFE2L2 (mutations that lead to increased NRF2 activity are 
discussed in detail in Chapter 4). Mutations in both of these genes are often 
grouped together in their ability to halt KEAP1-dependent proteasomal 
degradation of NRF2, and thus stimulate NRF2-dictated gene expression (Hast 
et al., 2014). Expression of genes associated with glutathione biosynthesis and 
utilization, namely GCLC, GCLM, SLC7A11 and GPX2, have been shown to be 
elevated in lung cancer in the presence of the aforementioned mutations in 
KEAP1 and NFE2L2.  
To date, work in the field has clearly linked an increase in NRF2 activity 
found in lung cancer, due to mutations in KEAP1 and NFE2L2, to an increase in 
intracellular glutathione levels through increased expression of the NRF2-target 
genes such as GCLC, GCLM and SLC7A11. However, to date, no one has looked 
at the consequences of KEAP1 and NFE2L2 mutations separately to determine 
whether they exert similar effects in terms of their effect on glutathione. The data 
in this chapter characterises several differences between KEAP1 mutant and 
NFE2L2 mutant cell lines and highlights the selective therapeutic opportunity of 
targeting the glutathione pathway in KEAP1 mutant cell lines when compared 
with NFE2L2 mutant cell lines.  
5.2 Results  
 
5.2.1 Several of the most commonly mutated genes in lung cancer encode 
proteins that have the potential to activate NRF2 
Cancer does not originate from one mutation in a single gene but through 
the combination of several mutations in range of different genes for proteins with 
critical functions. High levels of NRF2 activity are found in both lung cancer cell 
lines and  tumours, and is associated with poor prognosis (Shibata et al., 2008). 
This upregulation in NRF2 activity can arise through several different routes but 
one of the most common is mutations in the genes encoding KEAP1 and NRF2 
(Tebay et al., 2015). Although, these are not the only mutations that will result in 
an elevation in NRF2 signalling. As shown in Figure 5.2.1, mutations in genes 
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encoding the proteins EGFR, STK11 (gene name LKB1), PIK3CA, and PTEN are 
also likely to lead to an elevation in the abundance and activity of the transcription 
factor through inhibiting SCFb-TrCP-mediated degradation. Also, mutations in 
CUL3, which are often not included in the literature, will lead to an increase in 
NRF2 levels through impairing KEAP1-dependent degradation.  
 
 
Figure 5.2.1: Several proteins whose genes are commonly mutated in lung cancer 
activate the NRF2-signaling pathway 
Pathway diagram showing the interplay between proteins whose genes are commonly 
mutated in lung cancer and how they link to NRF2-signalling. All proteins donated with a * are 
encoded by genes that are commonly mutated in lung cancer. The light blue cascade on the 
far right-hand side highlights how mutations in; EGFR, KRAS, PIK3CA, PTEN and STK11 (the 
gene that encodes the protein LKB1) influence the degradation of NRF2 through altering GSK-
3 phosphorylation and inhibiting the SCFβ-TrCP axis. The green boxes on the left-hand side of 
the diagram represents how mutations in CUL3 and KEAP1 halt 26S proteasomal degradation 
of NRF2. Mutations can also occur in NFE2L2 which leads to changes in the DLG and ETGE 
motifs, and flanking amino acids, that interact with KEAP1.  
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5.2.2 In lung cancer, somatic mutations in KEAP1 are more prevalent than 
those in NFE2L2 and have a greater effect on NRF2-target gene expression.  
To determine whether the presence of a KEAP1 mutation has the same 
effect as a NFE2L2 mutation, in terms of NRF2 signalling, we carried out a 
bioinformatics analysis of lung cancer cell lines using NRF2-target gene 
expression as a read out of NRF2-signalling. Using the software TIBCO Spotfire® 
we combined Sanger, AstraZeneca, and CCLE datasets. Focusing on pan lung 
cancer (i.e., no specific histological subtype) we filtered the cell lines for the 
presence of mutations in KEAP1 and NFE2L2. We found that none of the cell 
lines in the datasets harboured both a mutation in KEAP1 and NFE2L2. Out of 
239 cell lines in the datasets, 28 harbour mutations in KEAP1 whereas only 8 
harbour mutations in NFE2L2, making KEAP1 mutations over three times more 
prevalent than NFE2L2 mutations (Table 5.2.1).  
We then compared the expression of seven prototypic NRF2-target genes, 
namely, AKR1B10, AKR1C1, AKR1C3, NQO1, GCLC, GCLM and HMOX1, 
between cell lines that were grouped together as follows: those harbouring 
mutations in KEAP1 (i.e., KEAP1-mut), wildtype (wt) for KEAP1 (i.e., KEAP1-wt), 
harbouring mutations in NFE2L2 (i.e., NFE2L2-mut) or wt for NFE2L2 (i.e., 
NFE2L2-wt). As shown in Figure 5.2.2A and 5.2.2B, the KEAP1-mut cell lines 
show a greater elevation in expression of all the seven NRF2-target genes 
analysed when compared with the NFE2L2-mut cell lines. One of the most 
pronounced changes between the KEAP1-mut and NFE2L2-mut cell lines is that 
of the expression of AKR1B10. Neither KEAP1-mut nor NFE2L2-mut cell lines 
show an elevation in mRNA for NFE2L2 in comparison to their wildtype 
counterparts. This is to be expected as changes in NRF2 signalling will only be 
affected at a translational level and not a transcriptional level.  
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Table 5.2.1: Frequency of mutation in either KEAP1 or NFE2L2 amongst the lung cancer 
cell line dataset 
Bold font indicates the total number of KEAP1(28) and NFE2L2 (8) mutant cell lines out of the 
239 analysed. The rest of the table indicates the number of instances that KEAP1 and NFE2L2 
mutations with mutations co-occur with mutations in other genes that may alter NRF2 
degradation. 
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Figure 5.2.2: Somatic mutations in KEAP1 are more prevalent and have a greater effect 
on NRF2-target gene expression than those in NFE2L2.  
The black bars on each graph represent the mutant cell line population and the white bars 
represent the wildtype population. The names of all seven genes analysed is given on the x-
axis. The fold-change in expression of particular ARE-driven genes within the cell lines 
harbouring mutant KEAP1 or NFE2L2 relative to the expression in the remaining cell lines 
harbouring wildtype KEAP1 or NFE2L2 is displayed underneath the graph A horizontal dash 
represents no significant fold-change in gene expression. Significant changes in gene 
expression in the mut cell lines relative to the wt cell lines are displayed on each graph. (A) 
Analysis of the expression of seven prototypic NRF2-target genes in lung cancer cell lines that 
are either KEAP1-mut (28 cell lines) or KEAP1-wt (211 cell lines) (B) Analysis of the 
expression of seven prototypic NRF2-target genes in lung cancer cell lines that are either 
NFE2L2-mut (8 cell lines) or NFE2L2-wt (231 cell lines). Data presented on both graphs 
represent the mean value obtained, and the error plotted is the associated SEM. Statistical 
analysis was carried out using GraphPad Prism 5 software. All significant increases are 
denoted as follows:  *, P< 0.05; **, P<0.01; *** P< 0.001. P values > 0.05 were deemed not 
significant and are denoted by “ns”. Significant decreases are denoted with a $ sign.  
B 
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5.2.3 Lung cancer cell lines in the Sanger data set that harbour mutations 
in KEAP1 display higher levels of expression of NRF2-target genes than 
those harbouring NFE2L2 mutations. 
As no one cell line poses both a mutation in KEAP1 and NFE2L2, this 
means that in the previous analysis, shown in Table 5.2.1, KEAP1-mut cell lines 
will be compared against cell lines that are wt for KEAP1 mutation but also some 
cell lines will harbour NFE2L2 mutations. This may not have a pronounced effect 
on the data generated for the KEAP1 analysis because there are only eight cell 
lines that harbour a NFE2L2 mutation, meaning that out of the 211 KEAP1-wt cell 
lines, 203 will be wildtype for both NFE2L2 and KEAP1 mutation. However, this 
could have a large impact on the analysis of NFE2L2 mutations, because when 
we compare the expression of ARE-driven genes in eight NFE2L2-mut cell lines 
with expression in the 231 NFE2L2-wt cell lines, 28 of NFE2L2-wt cell lines will 
possess a mutation in KEAP1 and only 203 will be wildtype for both KEAP1 and 
NFE2L2 mutation. This means the changes in gene expression may not look as 
pronounced because the NFE2L2-wt population will have elevated expression 
because it includes cell lines with mutant KEAP1.  
To try to account for this ‘contamination’ of the wild-type dataset we 
reanalysed expression of our chosen seven prototypic NRF2-target genes using 
only the Sanger dataset. Table 5.2.2 highlights the major caveat of this analysis, 
as due to analysing only one dataset we were not able to get all the data points 
we had in the first analysis because the number of cell lines is limited. We 
identified 14 cell lines in the Sanger dataset that harbour mutations in KEAP1 and 
four that harbour mutations in NFE2L2 out of the 122 cell lines in total. As shown 
in Figure 5.2.3A and B, the overall the magnitude of NRF2-target gene expression 
across the two mutant populations appears to be less than observed in Figure 
5.2.2A and B. It was found that KEAP1 mutant cell lines still had significantly 
higher expression of six out of the seven NRF2-target genes in comparison to the 
KEAP1/NFE2L2-wt cell lines (i.e. KEAP1-wt lines from which those with mutant 
NFE2L2 had been removed). The only gene to be changed by this analysis, when 
compared with Figure 5.2.2A, is HMOX1 which is not significantly altered 
between KEAP1-mut and KEAP1/NFE2L2-wt cell groups. However, the elevation 
in NRF2-target gene expression in the NFE2L2-mut cell lines does appear to be 
dramatically reduced when the KEAP1-mut cell lines were removed from the 
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analysis. Nevertheless, the overall pattern still holds with KEAP1-mut cell lines 
showing enhanced NRF2-target gene expression relative to the NFE2L2-mut cell 
lines.  
 
              
 
 
 
 
 
 
 
 
Number of cell lines harbouring mutations 
KEAP1-mut KEAP1-wt (-NFE2L2-mut) NFE2L2-mut NFE2L2-wt (-KEAP1-mut) 
14 108 4 94 
Table 5.2.2: Indicating the number of cells lines that harbor a mutation in KEAP1 and 
NFE2L2 out of the 122 cell lines analyzed using the Sanger dataset 
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Figure 5.2.3: Lung cancer cell lines in the Sanger dataset that harbour mutant KEAP1 
show higher expression of NRF2-target genes than those with mutations in NFE2L2 
 The black bars on both graphs represent the mutant cell line population and the white bars 
the wildtype population. The names of all seven genes analysed is given on the x-axis. The 
fold-change in expression of particular ARE-driven genes within the cell lines harbouring 
mutant KEAP1 or NFE2L2 relative to the expression in the remaining cell lines harbouring 
wildtype KEAP1 or NFE2L2 is displayed underneath the graph. A horizontal dash indicates no 
significant fold-change in gene expression. Significant changes in gene expression in the mut 
cell lines relative to the wt cell lines are displayed on each graph. (A) Analysis of the expression 
of seven prototypic NRF2-target genes in lung cancer cell lines that are either KEAP1-mut (14 
cell lines) or KEAP1-wt (-NFE2L2-mut) (108 cell lines). (B) Analysis of the expression of seven 
prototypic NRF2-target genes in lung cancer cell lines that are either NFE2L2-mut (4 cell lines) 
or NFE2L2-wt (- KEAP1-mut) (94 cell lines). Data presented on both graphs represent the 
mean value obtained, and the error plotted is the associated SEM. Statistical analysis was 
carried out using GraphPad Prism 5 software. Significant increases are denoted as follows:  *, 
P< 0.05; **, P<0.01; *** P< 0.001. P values > 0.05 were deemed not significant and are 
denoted by “ns”. Significant decreases are denoted with a $ sign.  
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5.2.4 The diverse genetic composition of the six commercially-available cell 
lines used to validate the bioinformatics analyses.  
To validate the findings made in the bioinformatics analysis, six 
commercial cells lines were analysed in terms of their NRF2- signalling. As shown 
in Table 5.2.3, the six cell lines included two KEAP1-mut cell lines, two NFE2L2-
mut cell lines and two “wildtype” cell lines with mutations in neither KEAP1 nor 
NFE2L2.  These were as follows: representing KEAP1-mut cell lines, A549 and 
H460 cell lines both harbour homozygous mutations in KEAP1 and homozygous 
mutations in KRAS (also H460 cells also have a heterozygous mutation in CUL3 
and a heterozygous mutation in PIK3CA); representing NFE2L2-mut cell lines, 
H2228 and H1568 cell lines possess heterozygous mutations in NFE2L2 and 
homozygous mutations in TP53; representing “wildtype” cell lines, H1299 and 
H1395 are wildtype for genes that are known to effect NRF2-signalling (notably, 
H1299 cell lines cells have a partial deletion in the gene for p53). It should be 
noted at this time that the function of some of these mutations is unknown, but all 
are thought to be oncogenic.  
Table 5.2.4, demonstrates the histological diversity of the six cell lines 
chosen. The majority of the cell lines are derived from adenocarcinomas (A549, 
H2228, H1568, H1395), though H460 is a large cell carcinoma cell line, and 
H1299 is from a lymphoid metastasis.  
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Table 5.2.3: Diverse genetic composition of the six commercial cell lines used to 
validate the bioinformatics analyses.  
Somatic mutations in genes associated with lung cancer amongst the six commercial cell lines 
purchased from ATCC for validation of the bioinformatics analyses are indicated. The first 
column on the left-hand side shows the name of the cell line. Subsequent columns give details 
of the mutant gene (as shown at the top of the table), location of the mutation and whether the 
mutation is heterozygous or homozygous.  
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5.2.5 Lung cancer cell lines that harbour mutant KEAP1 contain greater 
protein expression of NRF2-target genes than NFE2L2 mutant cell lines. 
To examine whether lung cell lines with mutant KEAP1 overexpress 
NRF2-target genes to a greater extent than those with mutant NFE2L2, western 
blotting of proteins encoded by NRF2-target genes was carried out. Protein was 
extracted from the chosen representative KEAP1-mut (A549 and H460), 
NFE2L2-mut (H2228 and H1568) and “wildtype” (H1299 and H1395) cell lines.  
Aliquots (20 µg protein) of cell lysates were resolved according to molecular mass 
by SDS-PAGE, followed by western blotting for the protein expression of several 
NRF2-target genes. As shown in Figure 5.2.4, the two KEAP1-mut cell lines, 
show higher protein expression of varying degrees of the majority of the NRF2-
target genes, when compared to the two NFE2L2-mut cell lines.  
 
 
 
 
Table 5.2.4: Histological composition of the six commercial cell lines used to validate 
the bioinformatics analyses. 
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Figure 5.2.4: KEAP1 mutant lung cancer cell lines have greater protein expression of 
several NRF2-target genes in comparison to NFE2L2 mutant cell lines.  
Protein expression analysis was carried out by western blotting. The name of each cell line is 
given at the top of the image, the name of the proteins being analysed is given down the left-
hand side and their corresponding molecular weights down the right-hand side. The 
immunoblots data displayed are one representative image of three independent biological 
replicates. 
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5.2.6 KEAP1-mutant lung cancer cell lines express greater NRF2-target 
gene mRNA than do NFE2L2-mutant cell lines 
To establish whether the increases in expression of proteins encoded by 
NRF2-target genes in KEAP1-mut and NFE2L2-mut cell lines, seen in Figure 
5.2.5, are mirrored at a mRNA level. RNA was harvested from all six cell lines, 
then reverse transcribed into cDNA, before TaqMan qRT-PCR was carried out to 
access mRNA levels of several NRF2-target genes. 
 Figure 5.2.5 panels A-K reveal relatively higher levels of mRNA of NRF2-
target genes in the two KEAP1-mut cell lines (A549 and H460) when compared 
with levels in the two NFE2L2-mut cell lines (H2228 and H1568). Surprisingly, 
NRF2 mRNA expression (shown in panel L) across the six cell lines does not 
correlate with the mRNA expression of the downstream NRF2-target genes. This, 
taken with the data shown in Figure 5.2.4, suggests that NRF2 mRNA itself it not 
a good marker of NRF2-target gene expression in lung cancer cell lines, 
presumably because it is principally controlled at the level of protein stability.  
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 Figure 5.2.5: KEAP1 mutant cell lines express higher mRNA levels of NRF2-target 
genes than NFE2L2 mutant cell lines 
 
Analysis of mRNA expression across a panel of six cell lines. In every graph, the KEAP1-mut 
cell lines (A549 and H460) are represented in the solid white and adjacent black-striped bar, 
NFE2L2-mut cell lines (H2228 and H1568) are shown in the solid black and black-striped bars 
and KEAP1/NFE2L2 “wildtype” cell lines (H1299 and H1395) are shown in the grey and grey-
striped bar. (A-K) mRNA expression of NRF2-target genes (L) NFE2L2 mRNA expression. All 
mRNA expression data presented was normalized to expression of the housekeeper 18S for 
each cell line. The mean of three independent experiments is plotted with the associated SEM 
value. T-tests were carried out to calculate significant changes in comparison to H1299 cells. 
All statistical analysis was carried out using GraphPad Prism 5 software. Significant increases 
are denoted with the * symbol; * represents P< 0.05, ** P<0.01 and ** P< 0.001. P values > 
0.05 were deemed not significant and are denoted by “ns”. Significant decreases are denoted 
with a $ symbol, and the same cut offs applied.  
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5.2.7 KEAP1 mutant cell lines show a greater proliferative ability than 
NFE2L2 mutant cell lines.  
The proliferative capacity of cell lines harbouring mutations in KEAP1 or 
NFE2L2 was accessed using the IncuCyte® Zoom imaging system and crystal 
violet clonogenicity assays. As shown in Figure 5.2.6A, A549 and H460 cell lines 
which both harbour mutations in KEAP1 show a greater proliferation rate across 
six consecutive days than the H2228 and H1568 NFE2L2-mut cell lines. To 
access the colony formation ability of the six cell lines, each was seeded at the 
same low density and left to grow for two weeks, after which the colonies were 
fixed with ice-cold methanol before being stained with crystal violet. The A549 
and H460 KEAP1-mut cell lines yield more stained colonies than either of the 
H2228 and H1568 NFE2L2-mut cell lines, Figure 5.2.6B. It is potentially not 
surprising that the two KEAP1-mut cell lines show enhanced proliferation as both 
of these cell lines also harbour additional mutations in KRAS which have been 
studied extensively for their ability to enhance cellular proliferation (Sunaga et 
al.,2011). Therefore, it is difficult at this time to attribute the highly proliferative 
capacity of the A549 and H460 cells solely due to their KEAP1 mutation.  
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5.2.8 To eliminate the issue of the genetic diversity seen in the panel of six 
cell lines, a panel of isogenic CRISPR/Cas9 cell lines was generated 
The six commercial cell lines used in the previous figures have a wide 
genetic diversity (as shown in Table 5.2.3) and this means it is not possible to 
attribute the changes in NRF2-signaling to just the presence of a KEAP1 mutation 
or a NFE2L2 mutation. Also, the data generated in the previous chapter 
highlighted that KEAP1 and NFE2L2 mutations tend to differ in their zygosity. 
Both A549 and H460 cells contain homozygous mutations in KEAP1 and both 
H2228 and H1568 cells harbour heterozygous mutations in NFE2L2, meaning 
that we cannot directly compare these four cell lines. In an attempt to overcome 
this obstacle an isogenic panel of CRISPR/Cas9 cell lines was generated using 
the H1299 cell line background in order to mimic a KEAP1 mutation or a NFE2L2 
B 
Figure 5.2.6: KEAP1-mut cell lines show higher proliferative capacity than NFE2L2-mut 
cell lines.  
 
(A) Proliferation was assessed over six consecutive days using the IncuCyte® Zoom imaging 
system and percentage confluence was calculated using the associated software. Cells were 
seeded at a low density and plates were scanned every 24 hr for six consecutive days. In 
between scanning plates were maintained in a 37oC 5% CO2 incubator. Data shown are one 
representative of three independent biological replicates, with the mean value (from 6 
identically treated wells) and the associated SEM displayed on the graph. (B) To access colony 
formation a crystal violet colony stain was carried out. Cells were seeded at a low density and 
left to grow for two weeks. After which, plates were fixed with methanol and stained with crystal 
violet. The images shown are one representative of three independent biological replicates.  
KEAP1-mut  NFE2L2-mut  
H2228 H1568 H460  
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mutation, and so allow a direct comparison of their effects. The steps involved in 
the generation of the four cell CRISPR/Cas9 cell lines is shown in Figure 5.2.7. 
Guide RNA sequences were designed to target early in exon 1 of KEAP1 and 
cloned into the LentiCRISPR-V2 backbone. The plasmid used to generate both 
the NRF2 knockout and NRF2 gain-of-function cell lines was kindly provided by 
Dr Laureano de la Vega (University of Dundee). Plasmids were then transfected 
into H1299 cells, 48 hr after which puromycin was added, to remove any non-
transfected cells. After cells had recovered from puromycin selection to a 
confluency of approx. 80-90% in the well, the cells were trypsinized and seeded 
at a density of one cell per well in 96-well plates. The residual cell population was 
cultured in flasks and frozen down; this is the “pooled” population. The 96-well 
plates were then routinely screened by eye to ensure the growth of only one 
colony per well. Once the colony had reached approx. 80-90% confluency in the 
well, it was trypsinised and expanded to a 24-well plate. After the cells in the 24-
well plate grew to a confluency of 80-90%, they were trypsinised and 90% of the 
total cells were taken for mRNA and protein analyses. The remaining 10% of cells 
were transferred to a 12-well plate and left to grow until the protein/mRNA data 
was obtained for that clone. Positive clones, showing the desired alterations in 
both mRNA and protein expression, were expanded and frozen down for long 
term storage at -80oC. The details of the four cell lines generated is given in Table 
5.2.5. An empty vector cell line (EV H1299) was made through the transfection 
of an empty LentiCRISPR-V2 plasmid containing no guide RNA sequence. A 
KEAP1 knock out cell line, referred to as KKO H1299, was generated to mimic a 
cell line processing a mutation in KEAP1. A NFE2L2 gain-of-function cell line, 
referred to as GOF H1299 was generated to mimic a cell line with a mutation in 
the Neh2 domain of NRF2. Also, a NFE2L2 knock out cell line, referred to as 
NKO H1299, was generated to ensure that all of the parameters of NRF2-
signaling that will be accessed across the panel are dependent on NRF2. 
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Figure 5.2.7: Diagram of the step-wise generation of the CRISPR/Cas9 cell lines 
 
The four stages taken to generate the panel of four CRISPR/Cas9 cell lines are 
highlighted down the left-hand side of the image 
Table 5.2.5: Details for the four CRISPR/Cas9 generated cell lines 
Table explaining the cell line name, details of the four CRISPR/Cas9 cell lines that were 
generated using the parental H1299 cell line and the corresponding predicted level of NRF2. 
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5.2.9 Identification of H1299-derived CRISPR/Cas9-manipulated cell lines 
with altered NRF2 activity. 
To be sure that the CRISPR/Cas9 protocol was successful and that we 
had generated the desired cell lines, expression of several NRF2-target genes 
was assessed at both an mRNA and a protein level, across several clones. 
Figure 5.2.8A show the changes in protein expression and the 
densitometry, across just two clones per cell line. On average, between 30 and 
40 clones were analysed per cell line. As assessed by western blotting, clone 2 
KKO and clone 8 KKO both contained KEAP1 knockout cells due to their 
increased abundance of NRF2 and NQO1 proteins when compared with the 
empty vector H1299 cell line (EV). Also, as assessed by western blotting, clone 
20 and clone 40 NKO had reduced levels of NQO1 protein when compared with 
the EV cell line indicating they contain NRF2 knockout cells; however, NRF2 
protein levels were not clearly altered in these cells when compared to the control.  
Both clone 31 GOF and clone 38 GOF were found to have higher NQO1 protein 
levels when compared with the EV control cell lines suggesting the cells have 
enhanced NRF2 activity. 
TaqMan mRNA analysis was carried out to determine whether the 
expression of NFE2L2, KEAP1 and NQO1 was appropriately changed in the cell 
lines, as shown in Figure 5.2.8B. When compared to the EV H1299 cell line, both 
clone 2 and clone 8 KKO have enhanced expression of NQO1, consistent with 
them representing KEAP1 knockout cells. Clone 20 and clone 40 NKO cell lines 
show reduced expression of NQO1 in comparison to the EV control cell line, 
consistent with them representing NRF2 knock out cells. By contrast, clone 31 
and clone 38 GOF have elevated NQO1 mRNA levels when compared to the EV 
H1299 cells, consistent with them containing NRF2 gain-of-function cells.  
From the above analyses, clone 8 KKO, clone 40 NKO and clone 31 GOF 
were selected for further study, and the rest of the experiments described in this 
chapter used these cell lines, referring to them as KKO, NKO and GOF, 
respectively.  
At the time that these analyses were carried out we did not have an 
antibody that could detect KEAP1. However, we did repeat the KEAP1 protein 
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analysis across the three chosen clonal cell lines at a later date; the data that are 
subsequently obtained is shown in Appendix 8.8. 
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Figure 5.2.8: Confirmation via protein and mRNA analyses of the generation of four 
H1299-derived CRISPR/Cas9 cell lines 
 
(A) The levels of NRF2 (the band corresponding to NRF2 is indicated with a * symbol), NQO1 
and GAPDH proteins were analysed across the EV, two positive KEAP1-knockout clones 
(clone 2 KKO and clone 8 KKO), two positive NRF2-knockout clones (clone 20 NKO and 
clone 40 NKO) and two positive NRF2 gain-of-function (GOF) clones (clone 31 GOF and 
clone 38 GOF). This image is representative of three independent biological replicates. (B) 
Densitometry of (A) normalized to GAPDH (house keeper) protein expression was carried 
out using the In-built LI-COR odyssey software. The mean protein expression value from 
three independent biological replicates is plotted with the associated SEM. Statistically 
significant changes relative to the EV cell line are displayed on each graph. A T-test was 
carried out using GraphPad Prism software to calculate significant alterations in expression, 
significant increases are marked with a * and significant decreases with a dollar sign. (C) 
The mRNA levels of NFE2L2, KEAP1 and NQO1 were analysed across the same cell lines 
as in (A). The data displayed are gene expression normalized to the expression of the house 
keeper protein, actin. The mean value from three independent biological replicates in plotted 
with the associated SEM. All significant increases are denoted with the * symbol; * 
represents P< 0.05, ** P<0.01 and ** P< 0.001. P values > 0.05 were deemed not significant 
and are denoted by “ns”. Significant decreases are denoted with a $ symbol, and the same 
cut offs applied.  
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5.2.10 KEAP1-knockout H1299 cells show higher levels of nuclear NRF2 
than do NRF2-gain-of-function H1299 cells 
NRF2 translocates into the nucleus to bind ARE sequences in the 
regulatory regions of its target genes and so increase their transcription. To 
determine whether KKO cells have higher levels of active nuclear NRF2, in 
comparison to GOF cells, western blotting of subcellular fractions was carried 
out. 
All four EV, KKO, NKO and GOF H1299 CRISPR/Cas9 cell lines were 
seeded in large dishes. Once the cells reached a confluency of approx. 80-90% 
they were collected and fractionated through a series of centrifugation steps with 
two buffers. Aliquots (30 µg of protein) from both the cytoplasmic (C) and nuclear 
(N) fractions for each cell line were then loaded onto a SDS-PAGE gel and 
western blotting was carried out. As shown in Figure 5.2.9A, KKO cells have 
higher levels of nuclear NRF2 in comparison to both the EV and GOF cell lines. 
This may in part account for the considerably higher NQO1 expression in the 
KKO cells when compared to the GOF cells as more nuclear NRF2 suggests 
more active transcription of its target genes. To determine whether the nuclear 
accumulation of NRF2 in the KKO cell line could be further enhanced through 
inhibition of SCFb-TrCP-mediated degradation of NRF2, cells were treated with the 
GSK-3 inhibitor CT99021 for 24 hr prior to fractionation. The nuclear levels of 
NRF2 do not appear to be altered by CT99021 treatment in any of the four 
CRISPR cell lines (Figure 5.2.9B). To confirm that this was not due to incomplete 
inhibition of GSK-3, before fractionation 20% of the treated whole-cell lysate was 
retained and immunoblotted for GSK-3 and pGSK-3 Ser9/21. In both Figure 
5.2.10A and B Lamin A/C has been included as a positive control for nuclear 
fractionation and alpha-tubulin is used as a positive control for the cytoplasmic 
fraction. 
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LAMIN  A/C
NRF2
C N C N C N C N
EV KKO GOF NKO
5µM CT99021         - - +        +        - - +         +               - - +         +        - - +        + 
EV KKO NKO 
GOF
C         N        C       N       C        N        C        N                C          N        C        N       C       N         C        N  
NRF2 
LAMIN B2 
100 kDa
100 kDa
63/74 kDa
68 kDa
α-TUBULIN 52 kDa
α-TUBULIN 52 kDa
A 
Figure 5.2.9: KEAP1-knockout H1299 cells show higher nuclear NRF2 protein levels 
than NRF2-gain-of-function H1299 cells.  
 
(A) Subcellular fractionation of the four CRISPR/Cas9 cell lines empty vector (EV), KEAP1 
knock out (KKO), NRF2 knock out (NKO) and NRF2 gain of function (GOF). This image is 
representative of images obtained from three independent biological replicates. (B) Cells were 
treated with either DMSO or 5 µM CT99021 for 24 hr before fractionation. This image one 
representative image of three independent biological replicates. (C) To confirm that treatment 
with CT99021 leads to an inhibition of GSK-3, all four CRISPR/Cas9 cell lines were treated 
with either DMSO of 5 µM CT99021 for 24 hr before checking protein expression via western 
blot. This image is from one experiment and is representative of three independent biological 
replicates. 
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5.2.11 The half-life of endogenous NRF2 protein is greater in KKO H1299 
cells than in GOF H1299 cells. 
Endogenous NRF2 protein is relatively unstable with a half-life of 
approximately 30 min in resting cells (McMahon et al., 2003). A longer NRF2 half-
life would suggest that degradation of the transcription factor was less efficient 
and would indicate higher NRF2 activity. To determine whether the half-life of 
NRF2 protein differs in the KKO and GOF cell lines, a CHX chase experiment 
was carried out; CHX is a potent inhibitor of protein synthesis, which can be used 
to assess protein stability. Cells were treated with CHX for either: 0, 15, 30, 45, 
60 or 75 min before cells were collected and protein extracted. Portions (30 µg of 
protein) of cell lysate were loaded on SDS-PAGE and western blotting was 
carried out to detect NRF2 protein levels. As shown in Figure 5.2.10A and B, the 
half-life of endogenous NRF2 protein in KKO H1299 cells is considerably longer 
than in GOF H1299 cells, with calculated half-lives of 63 min and 35 min 
respectively.  
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5.2.12 The activity of NQO1 is higher in KKO H1299 cells than in GOF H1299 
cells.  
To determine if NQO1 activity is higher in the KKO cells than in the GOF 
cells, an adapted version of the Prochaska NQO1 enzyme assay was carried out 
(Fahey et al., 2004). The data displayed in Figure 5.2.11, reveal that KKO cells 
(shown in the black bar) have enhanced NQO1 activity in comparison to the GOF 
cells (shown in the dark grey bars) at every concentration of CDDO-ME. Not 
surprisingly, treatment with CDDO-ME does not appear to increase NQO1 activity 
in the KKO cells. Possibly more surprisingly, CDDO-ME also failed to increase 
NQO1 activity in GOF cells. This is likely to be because CDDO-ME functions to 
inhibit KEAP1-mediated ubiquitination of NRF2. Reassuringly, it was found that 
NQO1 activity was increased by CDDO-ME in EV H1299 cells in a dose-
dependent manner, and as expected the NQO1 activity in the NKO cell line was 
found to be unaffected by CDDO-ME treatment.  
  
 
 
 
Cell line 
EV H1299 KKO H1299 NKO H1299 GOF H1299 
Half-life of endogenous NRF2 (min) 24.8 63.5 - 34.7
Fold change relative to EV H1299 
cells 
- 2.6 - 1.4
Figure 5.2.10: The half-life of endogenous NRF2 protein is greater in KEAP1-knockout 
H1299 cells than in NRF2-gain-of-function H1299 cells  
(A) CHX chase was used to determine the half-life of endogenous NRF2 protein in the four 
CRISPR/Cas9 cell lines. This image is representative of three independent biological 
replicates. (B) Table showing the calculated half-life of endogenous NRF2 across the four 
CRISPR cell lines. The half-life of endogenous NRF2 in the NKO H1299 cells could not be 
calculated due to the low protein expression.  
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Figure 5.2.11: KEAP1-knockout H1299 cells have significantly greater NQO1 activity in 
than NRF2-gain-of-function H1299 cells 
The enzymatic activity of NQO1 across the four CRISPR/Cas9 cell lines was determined 
following treatment with increasing doses of an inducing agent. Bars on the graph represent 
the mean value normalized to total protein concentration and associated SEM. T-tests were 
carried out to calculate significant changes in comparison to H1299 cells at each concentration 
of CDDO-ME. All statistical analysis was carried out using GraphPad Prism 5 software. All 
significant increases are denoted with the * symbol; * represents P< 0.05, ** P<0.01 and ** P< 
0.001. P values > 0.05 were deemed not significant and are denoted by “ns”. Significant 
decreases are denoted with a $ symbol, and the same cut offs applied.  The *** indicates that 
the KKO cells had statistically higher NQO1 activity in comparison to the EV cells in the 
presence of every concentration of CDDO-ME. The $$$ indicates that the NKO cells have 
statistically lower NQO1 activity in comparison to the EV at each concentration of NRF2-
activator. 
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5.2.13 Optimization for the use of an NRF2 activator.  
To gain a greater understanding about the alterations in NRF2-target gene 
expression across the CRISPR panel, an NRF2 activator was selected. Firstly, 
as a control, “wild-type” EV H1299 cells were treated for either 3 hr (shown in 
Figure 5.2.12A) or 24 hr (shown in Figure 5.2.12B) with either SFN, CDDO-ME, 
or tBHQ; DMSO was used as a vehicle control. At the 3-hr time point, an increase 
in NRF2 protein levels, relative to the DMSO vehicle control, was observed 
following treatment with SFN, both concentrations of CDDO-ME and both 
concentrations of tBHQ. The greatest increase in NRF2 protein levels at this time 
point was seen with 100 nM CDDO-ME. The 3-hr time point was too early to see 
changes in levels of NQO1 protein level.  
At the 24-hr time point all inducers at all concentrations increased NRF2 
protein levels relative to the control. All NRF2-activators increased NQO1 protein 
expression after treatment for 24 hr, with the most pronounced increase seen 
with 50 nM CDDO-ME. Considering the data from both Figure 5.2.12A and B, 
50n M CDDO-ME was chosen to be used in the following experiments.  
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5.2.14 KKO H1299 cells have comparability greater protein expression of 
NRF2-target genes than GOF H1299 cells. 
 
To validate data from the bioinformatics analyses (Figure 5.2.2), the levels 
of protein encoded by several NRF2-target genes in both KKO and GOF H1299 
cell lines that had been treated with DMSO l or CDDO-ME for 3 or 24 hr were 
assessed. As shown in Figure 5.2.13A, KKO cells have higher basal protein 
levels of NRF2, NQO1, HMOX1, and GCLM, than the GOF H1299 cells. At the 
24-hr time point, shown in Figure 5.2.13B, CDDO-ME treatment increases the 
abundance of NRF2, NQO1, HMOX1 and GCLM proteins in the EV H1299 cell 
line relative to the control. By contrast, in the KKO H1299 cell line, CDDO-ME 
B 
Figure 5.2.12: Treatment of “wild-type” EV H1299 cells with inducers increases the 
abundance of NRF2 protein and NQO1 
(A) EV H1299 cells, which contain wild-type KEAP1 and NRF2, were treated with inducers 
for 3 hr before NRF2 and NQO1 protein levels were measured by western blot. The band on 
the image corresponding to NRF2 protein is indicated with a * symbol. This image represents 
three independent biological replicates. (B) EV H1299 cells, were treated with inducers for 
24 hr before NRF2 and NQO1 protein levels were measured. All treatments were carried out 
in DMEM supplemented with 10% FCS. This image is one representative image of three 
independent biological replicates. 
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treatment surprisingly only increased the protein levels of HMOX1 relative to the 
control. Potentially NRF2, NQO1 and GCLM proteins may be at their highest 
detectable levels in the KKO H1299 cells already and therefore further increases 
are not possible. Furthermore, NQO1 protein levels appear to be unaffected by 
CDDO-ME treatment in GOF cells, whereas HMOX1 protein is increased by 
CDDO-ME in these cells. Even after treatment with CDDO-ME, NQO1, HMOX1 
and GCLM protein levels were not higher in the GOF cells than in untreated KKO 
cells. These findings suggest that removal of KEAP1 has a more pronounced 
effect on NRF2-target gene expression that disruption of the KEAP1-binding 
ETGE motif in NRF2. 
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Figure 5.2.13: KKO H1299 cells contain higher levels of proteins encoded by NRF2-
target genes than do GOF H1299 cells. 
(A) Protein analysis of several NRF2-target genes across the panel of four CRISPR/Cas9 cell 
lines: EV, KKO, NKO and GOF, treated either with DMSO or 50 nM CDDO-ME for 3 hr. Cell 
lines and treatments are indicated across the top of the image. The names of the proteins 
being analysed are given down the left-hand side and their corresponding molecular weights 
down the right-hand side of the image. This image is one representative image of three 
independent biological replicates. (B) Protein analysis of several NRF2-target genes across 
the panel of four CRISPR/Cas9 cell lines: EV, KKO, NKO and GOF treated either with DMSO 
or 50 nM CDDO-ME for 24 hr. Cell lines and treatments are indicated across the top of the 
image. The names of the proteins being analysed are given down the left-hand side and their 
corresponding molecular weights down the right-hand side of the image. All treatments were 
carried out in DMEM supplemented with 10% FCS. This image is one representative image 
of three independent biological replicates. 
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5.2.15 Expression of mRNA for NRF2-target genes is higher in KKO H1299 
cells than GOF H1299 cells 
To establish whether the increase in abundance of proteins encoded by 
NRF2-target genes in KKO H1299 cells (Figure 5.2.13) is reflected at a mRNA 
level, analysis of several NRF2-target genes was carried out across the 
CRISPR/Cas9 panel of cells that had been treated with either 50 nM CDDO-ME 
or DMSO for 24 hr.  
As shown in Figure 5.2.14 A-F, the levels of mRNA for NQO1, SLC7A11, 
GCLC, GLCM and HMOX1 were increased by treatment of the EV, KKO and 
GOF cell lines with 50 nM CDDO-ME for 24 hr, whereas treatment with CDDO-
ME did not significantly alter the expression of NFE2L2 across the panel of 
CRISPR/Cas9 cell lines.  Even in the presence of CDDO-ME the GOF H1299 
cells still showed lower mRNA expression of several NRF2-target genes when 
compared to untreated KKO H1299 cells. This further supports the idea that 
knockout of KEAP1 has a great effect on NRF2-signalling that a disruption of 
KEAP1-mediated degradation. 
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Figure 5.2.14: KKO H1299 cells constitutively overexpress NRF2-target genes to a 
greater extent than EV H1299 or GOF H1299 cells, and the NRF2-target genes in KKO 
H1299 cells can be induced by CDDO-ME.  
 
(A-F) The expression of NRF2-target genes was measured across the panel of H1299 
CRISPR cell lines using TaqMan qRT-PCR. Cells were either treated with DMSO or 50 nM 
CDDO-ME for 24 hr in DMEM supplemented with 10% FCS. The data displayed are fold 
change gene expression normalized to the expression of the house keeper protein, actin. The 
value on each graph represents the mean value obtained from three independent biological 
replicates and the associated SEM. T-tests were calculated using GraphPad Prism software. 
Significant alterations relative to the EV H1299 DMSO-treated control are indicated on the 
graphs. Also, significant alterations between the DMSO treated and CDDO-ME treated bars 
for that cell line is indicated above the black line. All significant increases are denoted with the 
* symbol; * represents P< 0.05, ** P<0.01 and ** P< 0.001. P values > 0.05 were deemed not 
significant and are denoted by “ns”. Significant decreases are denoted with a $ symbol, and 
the same cut offs applied.  
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5.2.16 The enhanced expression of NRF2-target genes observed in KEAP1-
knockout cells relative to NRF2-gain-of-function cells is not due to 
alterations in AKT signalling.  
Active AKT signalling has been shown to phosphorylate GSK-3 at Ser-9 
and Ser-21 leading to its inactivation (Cross et al., 1995). When GSK-3 is 
inactivated it can no longer phosphorylate NRF2, thus halting SCFb-TrCP-mediated 
degradation and increasing NRF2-target gene expression. Thus, changes in AKT 
signalling could potentially account for the greater NRF2-target gene expression 
seen in the KKO cells compared to that in GOF cells (Figure 5.2.15A). To 
determine whether KKO cells have higher AKT signalling than the GOF cells, 
western blotting was carried out. As shown in Figure 5.2.15B and C, neither 
treatment with CDDO-ME for 3 or 24 hr altered the protein expression of p-Ser 
473 AKT across any of the four CRISPR/Cas9 cell lines. Also, the basal 
expression of p-Ser 473 AKT was not altered between the KKO and GOF cells. 
This suggests that the alterations in NRF2-target gene expression seen between 
the KKO and the GOF cell line is not due to differences in AKT signalling. 
However, to be certain, the protein expression of p-Thr 308 and total AKT should 
be determined, and the phosphorylation at both sites should be calculated relative 
to the total AKT level. 
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Figure 5.2.15: Changes in NRF2-target gene expression between the H1299 CRISPR cell 
lines is not due to differences in AKT signalling 
(A) Diagram showing how the phosphorylation of AKT affects NRF2 activity and NRF2-target 
gene expression. (B) Protein analysis of AKT activity across the H1299 panel treated with 
either DMSO or 50 nM CDDO-ME for 3 hr in 10% FCS supplemented DMEM. The cell line 
name and treatments are indicated above the image. Protein expression of p-Ser 473 was 
used as a read out of AKT activity. This image is one representative image of three 
independent biological replicates. (C) Protein analysis of AKT activity across the H1299 panel 
treated with either DMSO or 50 nM CDDO-ME for 24 hr in10% FCS supplemented DMEM.  
The cell line name and treatments are indicated above the image. Protein expression of p-Ser 
473 was used as a read out of AKT activity. This image is one representative image of three 
independent biological replicates.   
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5.2.17 Inhibition of AKT does not affect the levels of protein encoded by 
NRF2-target genes in any of the four CRISPR cell lines 
To determine whether inhibition of AKT would lead to a reduction in NRF2-
target gene expression, western blotting was carried out using lysates treated 
with the AKT inhibitor, MK2206. The data shown in Figure 5.2.16 demonstrates 
that neither treatment with 1 µM MK2206 or 5 µM MK2206 for 24 hr alters: NRF2, 
NQO1 or HMOX1 protein levels. This could be due to MK2206 not fully 
inactivating AKT, so the abundance of p-Ser 473 AKT was examined. 
Reassuringly the protein expression of p-Ser 473 AKT is decreased in every cell 
line treated with MK2206 at both concentrations.  
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5.2.18 The expression of other KEAP1 binding proteins is not altered 
between the KKO and GOF cell lines. 
Work by Ben Major and colleagues has identified several KEAP1-
interacting proteins that can function as indirect regulators of NRF2 through their 
abilities to compete for KEAP1 binding (Hast et al., 2013). To determine if the 
expression of KEAP1 interacting proteins is different in the GOF and KKO cells, 
the protein levels of: TSC22D4, NRF1, p62/SQSTM1 and PGAM5 were 
measured by western blotting. As shown in Figure 5.2.17, the protein levels of 
none of these four KEAP1-interacting proteins were altered in any of the four 
CRISPR/Cas9 cell lines. It should be noted the protein expression of p62 is 
slightly reduced in the NKO H1299 cell line, this is to be expected as p62 is a 
NRF2-target gene. 
 
 
 
 
 
 
 
Figure 5.2.16: Treatment with the AKT inhibitor MK2206 does not affect NRF2-target 
gene expression across the four CRISPR/Cas9 cell lines 
EV, KKO, NKO and GOF H1299 cells were treated with either 1 µM or 5 µM MK2206 for 24 hr 
in 10% FCS supplemented DMEM. Western blotting was then carried out to assess the protein 
expression of NRF2, NRF2-target genes and p-Ser 473 AKT. This image is one representative 
image of three independent biological replicates.   
Figure 5.2.17: The abundance of the KEAP1-binding proteins TSC22D4, NRF1, PGAM 
and p62 is not substantially altered by knockout of KEAP1. 
The protein expression levels of four KEAP1-interacting proteins that may out compete NRF2 
for binding to KEAP1 was compared across the four CRISPR/Cas9 H1299 cell lines by western 
blotting. This image is one representative image of three independent biological replicates. 
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5.2.19 Glutathione-associated NRF2-target genes are overexpressed to a 
greater extent in KEAP1 mutant cells than in NFE2L2 mutant cells. 
In the bioinformatics analyses described in Section 5.2.2 the expression 
of NRF2-target genes associated with the synthesis and metabolism of 
glutathione, in both KEAP1-mut and NFE2L2-mut lung cancer cell lines, was 
investigated. Using the Sanger, AstraZeneca, and CCLE datasets and the 
software TIBCO Spotfire®, lung cancer cell lines (239 in total) were filtered for 
the presence of somatic mutations in either KEAP1 or NFE2L2. Next, the 
expression of GCLC, GCLM, SLC7A11 and GPX2 between the KEAP1-mut (28 
cell lines) and KEAP1-wt (211 cell lines) cell populations (as shown in Figure 
5.2.18A) and the NFE2L2-mut (8 cell lines) and NFE2L2-wt (231 cell lines) cell 
line populations (Figure 5.2.18B) was examined. This revealed the KEAP1-mut 
cell lines have a significantly higher expression of all four GSH-associated NRF2-
target genes when compared with KEAP1-wt cell lines. Also, the NFE2L2-mut 
cell lines have significantly higher expression of GPX2 when compared to the 
NFE2L2-wt cell lines. The expression of GCLC, GCLM and SLC7A11 is not 
significantly altered between cell lines harbouring a mutation in NFE2L2 or 
wildtype for the gene. Overall these data suggest that KEAP1-mut cell lines 
express NRF2-target genes associated with glutathione production and 
expenditure, to a greater extent than cell lines harbouring mutations in NFE2L2.  
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Figure 5.2.18: GSH-associated NRF2-target genes are more highly expressed in 
KEAP1 mutant cell lines than in NFE2L2 mutant cell lines.  
 
The black bars on each graph represent the mutant cell line population and the white bars 
represent the wildtype population. The names of all four genes analysed is given on the x-
axis. The fold change in gene expression of the mutant cell lines relative to the wildtype 
counterparts is displayed underneath the graph. Statistically significant change in gene 
expression in the mut cell lines relative to the wt cell lines are indicated on each graph. (A) 
Analysis of the expression of four NRF2-target genes associated with GSH in lung cancer 
cell lines that are either KEAP1-mut (28 cell lines) or KEAP1-wt (211 cell lines). (B) 
Analysis of the expression of four Nrf2-target genes associated with GSH in lung cancer 
cell lines that are either NFE2L2-mut (8 cell lines) or NFE2L2-wt (231 cell lines).  Data 
presented on both graphs represents the mean value obtained, and the error plotted is the 
associated SEM. All statistical analysis was carried out using GraphPad Prism 5 software. 
All significant increases are denoted as follows:  *, P< 0.05; **, P<0.01; *** P< 0.001. P 
values > 0.05 were deemed not significant and are denoted by “ns”. Significant decreases 
are denoted with a $ sign.  
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5.2.20 KKO H1299 cells contain higher levels of glutathione than GOF H1299 
cells.  
The relative overexpression of GCLC, GCLM and SLC7A11 in KEAP1-mut 
cells suggests they ought to contain higher glutathione levels. To investigate this 
possibility, total glutathione was measured across the four CRISPR H1299 cell 
lines using the mCB probe. mCB is a cell-permeable nonfluorescent compound 
that fluoresces upon contact with thiols such as glutathione. As shown in Figure 
5.2.219A, KKO H1299 cells contain significantly higher concentrations of total 
glutathione than either EV H1299 or GOF H1299 cells. NKO H1299 cells contain 
significantly lower glutathione levels when compared to the control cell line. 
Surprisingly GOF H1299 cells do not show a significant alteration in glutathione 
levels in comparison to the EV H1299 cells. However, it should be noted that 
there is a large associated error bar with the GOF H1299 data which may account 
for this.  
BSO is a potent inhibitor of glutamate-cysteine ligase that decreases 
intracellular glutathione concentrations. As shown in Figure 5.2.19B, treatment 
with BSO reduces the total glutathione level in KKO H1299 cells and GOF H1299 
cells relative to the DMSO control for each cell line. With the changes being 
significant in the KKO H1299 cells but only tending towards significance in the 
GOF H1299 cells. 
NAC is an antioxidant that stimulates glutathione production in the cell.  
Treatment with NAC could only increase total glutathione levels in the EV H1299 
cell line and not in either the KKO, NKO or GOF cell lines (Figure 5.2.19C). In the 
case of the KKO H1299 cells this may be due to them already having a very high 
level of glutathione that cannot be further increased. NKO H1299 cells have no 
NRF2, and since NRF2 controls the expression of genes involved in the 
production of glutathione, it makes sense that this pathway cannot be induced in 
these cells through NAC treatment. However, it is unclear at this moment to why 
the levels of glutathione in the GOF H1299 cells are not affected by NAC 
administration.   
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5.2.21 The increase in total glutathione levels seen in the KKO H1299 cells 
may be due to increased reduced glutathione. 
Glutathione exists in one of two states in the cell; either as GSH or GSSG. 
The GSH: GSSG ratio is used as an indicator of cell health. To determine the 
levels of GSH and GSSG in the cell, a assay adapted from Rahman et al. (2007) 
was performed. As shown is Figure 5.2.20, KKO H1299 cells contain higher total 
glutathione, GSH, and GSSG levels when compared to either the EV or GOF 
H1299 cell lines. Most noticeably, the levels of GSH appear to be very robustly 
elevated in the KKO cell line when compared to the GOF H1299 cells. 
 
 
 
 
 
Figure 5.2.19: KKO H1299 cells contain higher levels of total glutathione than 
GOF H1299 cells  
 
EV H1299 cells are represented by the white bar, KKO H1299 cells are represented by 
the black bar, NKO H1299 cells by the light grey bar and GOF H1299 by the dark grey 
bar, on each of the three graphs. The data obtained after treatment with either BSO or 
NAC is shown in the striped bars. (A) Total glutathione levels were measured using the 
mCB fluorescent probe. Cells were seeded in 10% FCS supplemented DMEM and once 
a confluency of 90% was reached, plates were washed thoroughly and incubated in the 
dark in the presence of 20 µM mCB- HBSS for 30 min before reading fluorescence. (B) 
Total glutathione levels were measured as above after 100 µM BSO treatment for 24 
hr. (C)Total glutathione levels were measured as above after 5 mM NAC treatment for 
3 hr. The bars displayed each graph represents the mean value obtained from three 
independent biological replicates minus the control well and normalized total protein 
concentration, and the associated SEM. Statistically significant alterations relative to 
the EV H1299 or EV H1299 DMSO treated data are denoted on the graphs. All statistical 
analysis was carried out using GraphPad Prism 5 software. All significant increases are 
denoted as follows:  *, P< 0.05; **, P<0.01; *** P< 0.001. P values > 0.05 were deemed 
not significant and are denoted by “ns”. Significant decreases are denoted with a $ sign.  
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Figure 5.2.20: KKO H1299 cells contain higher levels of glutathione than GOF H1299 
cells   
 
EV H1299 cells are represented by the white bar, KKO H1299 cells are represented by the 
black bar, NKO H1299 cells by the light grey bar and GOF H1299 by the dark grey bar, on 
each of the three graphs. (A) Analysis of total glutathione levels across the panel of H1299 
CRISPR/Cas9 cell lines. (B) Analysis of GSH levels across the panel of H1299 CRISPR/Cas9 
cell lines. (C) Analysis of GSSG levels across the panel of H1299 CRISPR/Cas9 cell lines. 
The bars displayed each graph represents the mean value obtained from three independent 
biological replicates minus the control well and normalized total protein concentration, and the 
associated SEM. Statistically significant alterations relative to the EV H1299 cell lines are 
denoted on the graph. All statistical analysis was carried out using GraphPad Prism 5 
software. All significant increases are denoted as follows:  *, P< 0.05; **, P<0.01; *** P< 0.001. 
P values > 0.05 were deemed not significant and are denoted by “ns”. Significant decreases 
are denoted with a $ sign.  
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5.2.22 The GSH:GSSG ratio can be altered in both KKO and GOF H1299 cells 
through treatment with BSO. 
To determine whether the levels of GSH and GSSG can be altered by 
treatment with BSO the same assay as described above in section 5.2.21 was 
carried out in the presence of BSO. The data in Figure 5.2.21, show that 
treatment with BSO leads to a significant decrease in GSH, GSSG and total 
glutathione levels in both the KKO and GOF cell lines, with the effect of BSO 
being more pronounced on GSSG levels than those of GSH. The largest 
decrease in total, reduced and oxidized glutathione levels was seen in KKO 
H1299 cells, suggesting that maintenance of their glutathione levels is more 
sensitive to inhibition of continuing biosynthesis than is the maintenance of 
glutathione levels in the other cell lines.  
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Figure 5.2.21: KKO H1299 cells contain greater levels of total glutathione than GOF 
H1299 cells due to augmented levels of GSH. 
EV H1299 cells are represented by the white bar, KKO H1299 cells are represented by the 
black bar, NKO H1299 cells by the light grey bar and GOF H1299 by the dark grey bar, on 
each of the three graphs. the data obtained after treatment with BSO is shown in the striped 
bars. (A) Total glutathione levels were measured across the four CRISPR/Cas9 cell lines, in 
the presence or absence of BSO. Cells were treated with 100 µM BSO for 24 hr prior to 
analysis. (B) GSH levels were measured across the four CRISPR/Cas9 cell lines, in the 
presence or absence of inhibitor BSO. Cells were treated with 100 µM BSO for 24 hr prior to 
analysis (C) GSSG levels were measured across the four CRISPR/Cas9 cell lines, in the 
presence or absence of BSO.  Cells were treated with 100 µM BSO for 24 hr prior to analysis. 
All treatments were carried out in DMEM supplemented with 10% FCS. The bars displayed 
each graph represents the mean value obtained from three independent biological replicates 
minus the control well and normalized total protein concentration, and the associated SEM. 
Statistically significant alterations relative to the DMSO treated EV H1299 cell line are denoted 
on the graph and significant alterations upon treatment between the different cell lines are 
denoted above the black line. All statistical analysis was carried out using GraphPad Prism 5 
software. All significant increases are denoted as follows:  *, P< 0.05; **, P<0.01; *** P< 0.001. 
P values > 0.05 were deemed not significant and are denoted by “ns”. Significant decreases 
are denoted with a $ sign. 
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5.2.23 KKO H1299 cells are more markedly re-sensitized to cisplatin 
chemotherapy by co-administration of BSO than GOF H1299 or EV H1299 
cells.  
In cancer cells, increased GSH synthesis has been associated with 
development of drug resistance through an increased capacity of GSH to form 
GSH-conjugates with antineoplastic drugs, which can lead to the more rapid 
export and elimination of anticancer drugs from cells. To determine whether 
treatment with BSO might result in a decrease in GSH levels that leads to 
increased sensitivity to cisplatin, cell viability was accessed using the MTT assay. 
To this end, EV, KKO, NKO and GOF H1299 cells were treated with a serial 
dilution of cisplatin, alone or in combination with 100 µM BSO, for 72 hr. Data in 
Figure 5.2.22 and Table 5.2.6 show that the most significant change in sensitivity 
to cisplatin treatment in the presence of BSO was in KKO H1299 cells. Although 
it should be taken into consideration that the IC50 values displayed will be 
estimated values extrapolated from the graphs given below. It should also be 
noted that surprisingly in this assay the GOF H1299 cells did not show an 
increased IC50 towards cisplatin alone when compared with that in EV H1299 
cells. It would be assumed that the increased NRF2-signaling in the GOF cells 
would have made them more resistant to cisplatin as seen in the KKO cells. At 
present, it is difficult to draw conclusions about why GOF cells do not display 
increased resistance to cisplatin.  
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Figure 5.2.22:  KKO H1299 cells can be re-sensitized to cisplatin by co-administration 
of BSO. 
(A-C) The cell viability of the four CRISPR/Cas9 cell lines in the presence of either a range of 
cisplatin concentrations or cisplatin combined with 100 µM BSO, was accessed via MTT 
assay. The data displayed is one representative graph from three independent biological 
replicates with the associated percentage error. The bars displayed each graph represents 
the mean value obtained from three replicates minus the control well and the associated 
percentage error. 
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Table 5.2.6: Variation in cisplatin IC50, with and without co-administration of BSO, 
across the four CRISPR/Cas9 cell lines. 
Average value for three independent biological replicates is displayed in the table, along with 
the associated standard deviation (StDev). All statistical analysis was carried out using 
GraphPad Prism 5 software. All significant increases are denoted as follows:  *, P< 0.05; **, 
P<0.01; *** P< 0.001. P values > 0.05 were deemed not significant and are denoted by “ns”. 
Significant decreases are denoted with a $ sign. 
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5.3 Discussion  
 
In this chapter, cell lines with KEAP1 mutations have been shown to exhibit 
a more pronounced “NRF2-gene expression signature” than cell lines with 
NFE2L2 mutations. The enhanced NRF2-signalling seen in KEAP1 mutant cell 
lines seems to result in them being more dependent on certain NRF2-regulated 
pathways, which can consequently be targeted therapeutically. Here it has been 
highlighted that cell lines that harbour a mutation in KEAP1 are more dependent 
on glutathione biosynthesis and therefore more sensitive to glutathione inhibition. 
5.3.1 The advantages of the CRISPR/Cas9 cell line approach to generate 
mutant lung cancer cell lines  
 
To validate our bioinformatics findings, we initially used a panel of six 
commercially available lung cancer cell lines: amongst theses, two harboured 
KEAP1 mutations, two harboured NFE2L2 mutations and two expressed both 
wildtype KEAP1 and NFE2L2. Characterisation of these cell lines showed similar 
elevations in mRNA and protein levels of NRF2-target genes in the KEAP1 
mutant cell lines when compared with the NFE2L2 mutant cell lines. However, 
because of different genetic backgrounds and somatic mutations in these 
commercially-available cell lines, it was not possible to attribute such changes 
solely to the presence of mutant KEAP1 or mutant NFE2L2. 
In an attempt to analyse the effect of mutations in just KEAP1 or NFE2L2 
on gene expression and phenotype, the isogenic H1299 CRISPR/Cas9 panel 
was generated. Nevertheless, this CRISPR/Cas9-generated panel is not without 
its limitations. In particular, part of the CRISPR/Cas9 methodology involves clonal 
selection, which introduces clone-specific variation. In this chapter, only one 
clone per CRISPR/Cas9 cell line has been studied. Thus, to robustly validate the 
findings several key experiments ought to be repeated with at least two other 
clones per cell line. Another possible weakness in the experimental design is that 
the cell lines generated either have a knockout of KEAP1 or a partial deletion of 
the Neh2 domain of NRF2, and these do not accurately mimic the types of 
mutations found in lung cancer; for example, KEAP1 protein is never fully deleted 
in lung cancer cells, but rather is subject to single amino acid substitution 
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mutations. To generate a more human representative model, cell lines could be 
generated by CRISPR/Cas9 with single amino acid substitutions to mimic the 
exact mutations observed in human tumours. Also, mutations in KEAP1 and 
NFE2L2 do not occur alone in cancer. It is thought that mutations that dysregulate 
NRF2 occur to support the promotion phase of carcinogenesis but are not 
fundamental for cancer initiation, nor are the sufficient to initiate cancer. They 
therefore coexist with mutations in common oncogenic genes such as KRAS and 
TP53. In this context, it should be noted that the presence of KEAP1 mutations 
alone have been reported to produce no adverse phenotype in ADC mouse 
models (Best et al., 2018). Also, we have generated preliminary data in the lab 
suggesting that alteration in KRAS signalling will affect NRF2 activation and 
NRF2-target gene expression (see, Appendix 8.9). Therefore, to get a better 
understanding of the role that KEAP1 mutations and NFE2L2 mutations have on 
NRF2-signalling during tumourigenesis it would be useful to make combinational 
CRISPR/Cas9 cell lines with alterations in several genes, mirroring what is 
observed in human tumours.  
5.3.2 Why would KEAP1 mutants have more pronounced signalling?  
 
From the data presented in this chapter using both the commercial panel 
of six cell lines and the isogenic H1299 CRISPR/Cas9 panel, it is clear that 
mutations in KEAP1 and NFE2L2 are different in terms of their effects on NRF2-
signalling.  
We have briefly eluded to a potential reason for this in Figure 5.2.18, were 
the protein expression of four KEAP1-binding proteins was analysed in the KKO 
and GOF H1299 cells. Ben Major and colleagues, carried out a comprehensive 
mass spectrometry-based analysis to identify proteins that possess an ETGE or 
ESGE and can interact with KEAP1 (Hast et al., 2013). It is thought that these 
KEAP1-interacting proteins can function as indirect regulators of NRF2 through 
outcompeting it for binding to KEAP1, which would lead to an increase in NRF2 
activity. They identified 42 KEAP1-binding proteins, out of which 17 contained 
either an ETGE motif, an ESGE motif or both motifs. In this chapter we looked at 
the expression of only four of these 17 KEAP1-interacting proteins, namely: 
TSC22D4 (which contains an ETGE motif), NRF1 (which contains both an DLG 
and ETGE motif), p62/SQSTM1 (which contains a phosphorylatable STGE motif 
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and inhibits the interaction of the DLG domain of NRF2 with KEAP1 (Komatsu et 
al., 2010)) and PGAM5 (which has an ESGE motif). Surprisingly, the abundance 
of these four proteins was not significantly altered across our CRISPR/Cas9 
panel of H1299 cell lines, particularly in the KKO cells, and therefore seem 
unlikely to account for their altered NRF2-target gene expression. This suggests 
that potentially the expression of KEAP1-interacting proteins is not altered in this 
panel. However, it is more likely that just the four proteins we chose to analyse 
were not altered. Moving forward, it would be interesting to look at the expression 
of other KEAP1-interacting proteins such as dipeptidyl peptidase 3 (DPP3) which 
has been shown to be elevated in cancer and interact with NRF2 (Lu et al., 2016).   
5.3.3 Mutations in the ETGE region of NRF2 do not always lead to an 
elevation in NRF2-signaling  
 
Mutations in NFE2L2 in lung cancer have been shown to occur in the 
region of the gene encoding the Neh2 domain, with all mutations clustering to 
amino acids 24-34 and 75-82, in the Neh2 region (Hayes and McMahon, 2009; 
Fukutomi et al., 2014). This strict focal clustering of mutations is a common 
feature of oncogenic genes. Mutations in the two regions of NFE2L2 that are 
closely associated with the DLG and ETGE motifs have been shown in impair 
KEAP1-mediated degradation of NRF2 and result in increased transactivation by 
the transcription factor. This is due to the Neh2 domain not requiring to undergo 
a post-translational modification event before KEAP1 is able to direct NRF2 for 
proteasomal degradation, and so suggests the structural integrity of the DLG and 
ETGE motifs is critical for the interaction between NRF2 and KEAP1 (Shibata et 
al., 2008).  
In an initial attempt to validate the bioinformatics we used a commercial 
panel of six cell lines, of which H2228 and H1568 harboured mutations in 
NFE2L2. These cell lines were chosen as they expressed mutations in either the 
DLG or ETGE motifs of NRF2, which would suggest that they have high NRF2-
signalling. However, when the expression of NRF2-target genes in these two cell 
lines was analysed (shown in Figure 5.2.5 and 5.2.6) H2228 cells appeared to 
have the expected elevation in NRF2-target gene expression but H1568 cells 
showed the opposite. This was surprising for two reasons: (1) mutations in the 
DLG and ETGE motifs have often shown to be similar in terms of their effect in 
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NRF2 signalling; (2) H1568 cells have a mutation in the high affinity ETGE motif 
and H2228 cells possess a mutation in the low affinity DLG motif. Work by 
(Shibata et al., 2008) demonstrated that lung cancer cell lines with mutations in 
the DLG motif can still be partially bound by KEAP1, probably due to the presence 
of an intact ETGE high affinity site. Therefore, out of our two chosen NFE2L2 
mutant cell lines, the H1568 cells with a mutated ETGE and intact DLG motif 
would be expected to show higher NRF2-target gene expression than the H2228 
cells, with a mutated DLG and an interact ETGE motif, but we see the opposite. 
Potentially, this could be due to these two cell lines harbouring mutations in other 
genes that are affecting NRF2-target gene expression. Both of these cell lines 
also harbour homozygous mutations in TP53, which are thought to be oncogenic. 
No other mutations in KEAP1, KRAS, CUL3, PIK3CA, PTEN, STK11 or EGFR 
were found in H2228 or H1568 cell lines. Potentially one of these cell lines could 
possess a mutation in gene that is dramatically influencing NRF2-signalling in a 
manner that we have not explored.  
At this point we are unable to account for the surprising differences in 
NRF2-target gene expression between these two NFE2L2-mutant cell lines, this 
would require a more in-depth analysis of the KEAP1 binding ability in a 
considerably larger panel of NFE2L2 mutant cell lines.   
5.3.4 Mutations in KEAP1 and NFE2L2 alone are not sufficient to induce the 
expression of NRF2-target genes involved in the pentose phosphate 
pathway (PPP). 
 
Masayuki Yamamoto and Hozumi Motohashi and their colleagues 
published an in-depth analysis into the role that NRF2-signalling plays in 
metabolism. In particular, they demonstrated that NRF2 has the ability to activate 
several metabolism genes, including but not limited to, glucose-6-phosphate 
dehydrogenase (G6PD) and phosphogluconate dehydrogenase (PGD) (Mitsuishi 
et al., 2012). In Figure 5.2.14 we accessed the protein expression of both of these 
metabolism-associated genes across our panel of H1299 CRISPR/Cas9 cell lines 
and found surprisingly that the protein expression of both G6PD and PGD was 
unaltered in the four cell lines and unaffected by CDDO-ME treatment. There are 
several factors that may account for this unusual result. Firstly; we could have 
been “unlucky” in our choice of metabolism markers, in that G6PD and PGD may 
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not be altered but other metabolism genes could be. To get a better 
understanding we could look at the expression of TKT, TALDO1 and PPAT, which 
were also shown to be upregulated by NRF2. Secondly, in the fore mentioned 
publication by the Yamamoto group they analysed the expression of metabolism 
genes in cell lines harbouring mutations in KEAP1, not the expression of these 
genes in cell lines with NFE2L2 mutations. This would not account for why we 
failed to see a change in the protein levels of G6PD or PGD in the KKO H1299 
cells but potentially could explain why we did not see expression changes in the 
GOF H1299 cells. The third, and most likely, explanation for this data is that our 
CRISPR/Cas9 panel do not harbour any mutations that would lead to a disruption 
of PTEN-PI3K–AKT signalling. As highlighted by Kate Sutherland and 
colleagues, only when PTEN signalling was abolished to create aberrant AKT 
signalling in the absence of KEAP1, was an increased metabolic signature seen. 
Importantly this metabolic activation was not seen in the presence of mutations 
in KEAP1 alone (Best et al., 2018). Since we do not have elevated AKT signalling 
in the H1299 cell lines, we may not see changes in the expression of metabolism 
associated proteins. It would be interesting to siRNA knock out PTEN in the KKO 
H1299 cells and see if this leads to increased expression of NRF2-target genes 
associated with the PPP. However, care should be taken when combining 
mutations in PTEN and KEAP1 to study metabolism, as these two mutations are 
mutually exclusive, at least in lung cancer (this concept is discussed in more 
detail in Chapter 4).  
5.3.5 Are differences in the zygosity of KEAP1 and NFE2L2 mutant H1299 
cell lines responsible for their distinct phenotypes? 
 
It became evident from the bioinformatics analyses (discussed in full in 
Chapter 4) that the majority of KEAP1 mutations are homozygous whereas 
NFE2L2 mutations are heterozygous. To determine whether the enhanced 
NRF2-gene expression signature that we see in KEAP1-mutant H1299 cells is 
not because we are comparing a homozygous mutation with a homozygous 
mutant NFE2L2 mutant cell line, we sent our cell lines to undergo shotgun 
cloning followed by sequencing. The sequencing results (Appendix 8.10) show 
that the KKO H1299 cell line that we have been using in this chapter is a 
KEAP1 homozygous KO, whereas the GOF H1299 cell line is heterozygous for 
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a deletion of amino acids 28-35 in the Neh2 domain of NRF2. This means that 
the two cell lines that we have generated do veraciously mimic human lung 
cancer cell lines. Although it would be extremely interesting to generate a 
homozygous NFE2L2 mutant cell line to see whether it would have a similar 
elevated NRF2-gene expression signature as a homozygous KEAP1 mutant 
cell line, such mutations would appear to be rare in cancer cells. It might 
therefore be more appropriate to select a KEAP1 heterozygous KO H1299 
clone from amongst our KKO pool of cells and compare them with GOF H1299 
cells. 
It is also worth noting that sequencing revealed that disruption of the 
Neh2 domain within the NFE2L2 gene means that isoform 6 of NRF2 is still 
expressed in these cell lines. Isoform 6 is minor isoform composed of 505 
amino acids which contains a CNC-bZIP domain. This may in part account for 
the partial detection of NRF2 protein expression in the NKO H1299 cell line, but 
this would require further investigation. 
5.3.6 Concluding remarks  
 
Mutations in KEAP1 and NFE2L2 have always been grouped together and 
treated as being equally effective in terms of their ability to upregulate NRF2-
directed ARE-driven gene expression. Also, the majority of papers that are 
concerned with NRF2 signalling tend to utilise KEAP1-mutant cells and cells 
harbouring NFE2L2 mutants are rarely used. In this chapter, we have attempted 
to demonstrate through the use of bioinformatics, commercial cell lines and 
isogenic CRISPR/Cas9 cell lines, that KEAP1 and NFE2L2 mutations are in fact 
different. We have demonstrated that KEAP1 mutant cells have higher NRF2-
signaling in comparison to NFE2L2 mutant cell lines. In particular, KEAP1-mutant 
cells have enhanced glutathione biosynthesis and seem to be dependent on this 
pathway for survival because they are more susceptible to inhibition by BSO. This 
presents the idea that through targeting specific NRF2-regulated pathways in 
tumours we can enhanced the effect of currently available chemotherapeutic 
agents. However, to fully validate this model we would have to expand our panel 
of commercial cell lines and generate CRISPR/Cas9 cell lines that mimic human 
cancer better. The data presented in this chapter is just the start of what could be 
a very exciting discovery.  
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6.0 Final discussion and future perspectives 
 
Cells are constantly battling against the damaging effects ROS and are 
therefore relent on the activity of the redox-regulated transcription factor, NRF2 
to orchestrate protection against such a threat. Since the discovery of the role of 
NRF2 as the master regulator of the cell oxidative stress responses, the field of 
NRF2 research has expanded exponentially. This is in part due to the 
identification of over 200 ARE-containing genes that are trans-activated by NRF2, 
in response to a variety of stressors. NRF2 is now accepted to be critical for 
several cell pathways such as: metabolism, detoxification, antioxidant production, 
purine synthesis, drug efflux, iron-binding, NADPH generation, proteasome 
subunit assembly, apoptosis and autophagy; the majority of which can be 
regarded as cytoprotective (Hayes and Dinkova-Kostova, 2014; Tebay et al., 
2015).   
Aberrant expression of NRF2 is commonly associated with lung cancer 
and was initially implicated in causing the  increased expression of cytoprotective 
enzymes that were found in resistant NSCLC cells (Homma et al., 2009). 
However, more recently it has been shown that NRF2 can play a role in 
development of each of the hallmarks of cancer including, metabolic 
reprograming leading to increase glycolysis, continuous proliferative signalling, 
decreased apoptotic cell death, increased replicative capacity, enhanced 
angiogenesis, prototoxic stress, high levels of genomic instability, increased 
tissues invasiveness and metastatic potential, ability to avoid immune defences, 
resistance to antigrowth signals and increased tumorigenic inflammatory 
signalling (Rojo de la Vega et al., 2018; Hanahan and Weinberg, 2000; Hanahan 
and Weinberg, 2011).  
Pervious work has shown that mutations in NFE2L2, KEAP1 and CUL3 
occur in lung cancer and result in increased NRF2 activity through inhibition of 
KEAP1-directed degradation of the transcription factor. In this thesis, we have 
investigated mutations in KEAP1, NFE2L2 and CUL3 separately to access their 
individual impact on NRF2 activity using NRF2-target gene expression as a read 
out and studied the influence that a priming kinase plays in KEAP1-independent 
degradation of NRF2. Through this, we hoped to gain a greater insight into the 
complex role that NRF2 plays in oncogenesis and the potential of stimulating 
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alternative NRF2 degradation pathways to decrease the expression of the 
transcription factor in lung cancer tumours harbouring the aforementioned 
mutations.  
6.1 NRF2 inhibitors – history and limitations  
 
Hyper-activation of NRF2 signalling is seen in several forms of cancer and 
correlates with poor prognosis and enhanced resistance to platinum-based 
antineoplastic drugs and nitrogen mustards. Therefore, in the field there has been 
a momentous drive to produce specific and effective NRF2 inhibitors, to no avail. 
One of the most promising candidates was the natural derived quassinoid 
compound, brusatol. The antitumor effects of brusatol were documented in the 
1970s (Hall et al., 1979; Elgebaly et al., 1979) and again in the early 2000s (Mata-
Greenwood et al., 2002) but it was not until 2011 that work published by Donna 
Zhang’s group identified this compound as a reversible inhibitor of NRF2. 
Brusatol has been shown in both in vitro and in vivo models to ameliorate 
chemoresistance to cisplatin through inhibiting NRF2 protein expression (Ren et 
al., 2011). Subsequent research carried out by other groups has now 
demonstrated that nanomolar concentrations of brusatol leads to the depletion of 
NRF2 protein expression independently of  KEAP1, the UPS and any currently 
documented form of NRF2 regulation, suggesting it is through a currently 
uncharacterised mechanism (Olayanju et al., 2015). However, even though this 
compound is specific for NRF2, as it has been shown to not affect the protein 
levels of several other proteins with both short and long half-lives (Olayanju et al., 
2015), but it is not specific for cancer cells and has the potential to sensitize non-
cancer cells to the damaging effects of antineoplastic drugs. Although it should 
be noted that other groups have published contrasting data showing that brusatol 
inhibits RNA, DNA and global protein synthesis in the cell (Hall et al., 1979).    
Global inhibition of NRF2 in all cell types through the administration of brusatol 
would not be advantageous as NRF2 is responsible for cell defences that are 
fundamental for normal cell survival. However, due to cancer cells having 
enhanced levels of ROS they maybe more sensitive to NRF2 inhibition than 
normal cells, and this could be potentially exploited by using the correct 
concentration of brusatol. Due to the lack of a characterized mechanism of action 
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and the potential non-target effects, a lot of work will still need to be carried out 
before brusatol reaches clinical administration. 
ML385 is a thiazole-indoline compound and another potentially promising 
NRF2 inhibitor (Singh et al., 2016). ML385 directly interacts with the Neh1 domain 
of NRF2, prevents dimerization and at micromolar concentrations has been 
shown in in vivo NSCLC models to re-sensitize cells to carboplatin leading to 
reduced tumour proliferation. One limitation of ML385 is that it may potentially 
target other transcription factors, aside from NRF2 (Singh et al., 2016). 
6.2 KEAP1-independent repression of NRF2 is influenced by a priming 
kinase  
 
An alternative non-pharmacological mechanism by which the activity of 
NRF2 can be decreased, is to stimulate the SCFβ-TrCP mediated degradation 
pathway. This is a particularly attractive concept as it would potentially ameliorate 
the effects of NRF2 upregulation in tumours harbouring mutations in KEAP1, 
NFE2L2 and CUL3. Research into KEAP1-independent mechanisms of NRF2 
degradation has peaked in recent years, with it now being widely accepted that 
GSK-3 mediates phosphorylation of the Neh6 domain. This is fundamental for the 
formation of the phosphodegron to which the substrate adaptor protein β-TrCP 
binds leading to the ubiquitination of NRF2 and subsequent 26S proteasomal 
degradation of the transcription factor. In Chapter 3 of this thesis, we have 
continued to investigate this form of NRF2 regulation, focusing on the notion that 
a priming kinase may work in concert with GSK-3. We have demonstrated, 
through using the DYRK family of kinases as an example, that phosphorylation 
of Ser-347 functions as a priming event leading to subsequently enhanced 
phosphorylation by GSK-3 at Ser-342 and Ser-338, accentuating SCFβ-TrCP 
mediated degradation. We have also shown that regulation of this priming event 
would affect cell proliferation and chemosensitvity to platinum-based therapies, 
through altering GSK-3 signalling without directly targeting GSK-3 itself.  
However, development of specific small molecule activators of the priming kinase 
or peptides that would mimic the priming phosphate and bind to GSK-3 locking it 
in a “primed state”, is required. 
We have also indicated that we believe that another kinase mediates the 
phosphorylation of Ser-335. Since β-TrCP binding to a substrate is enhanced by 
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the presence of two phosphorylated neighbouring residues, targeting the kinase 
that phosphorylates Ser-335 would provide another mechanism by which to 
regulate NRF2 degradation independently from KEAP1 and another novel 
potential therapeutic target. Currently we do not know the identity of the kinase 
that may target Ser-335 but as mentioned in the discussion of Chapter 3, we 
believe that due to previous literature linking CK1, DYRK and GSK-3 together, 
unpublished data from our lab identifying FXXXF docking motifs in NRF2 and 
also the extensive homology of the amino acids sequence surrounding the 335 
site with that of a CK1 consensus sequence, that potentially CK1 mediates the 
phosphorylation at this site.  
6.3 Bioinformatics analysis of the prevalence, co-occurrence and impact of 
mutations in KEAP1 and NFE2L2 in lung cancer cell lines and tumours. 
 
Mouse models are a valuable tool for analysing the organism-wide effect 
of alterations in the expression of a particular gene. NRF2 KO mice are viable 
with normal embryonic development and no outwardly adverse phenotype (Chan 
et al., 1996) . However, through carrying out ageing studies with these animals 
and exposing them to various stimuli, it has been revealed that NRF2 KO mice 
have impaired liver regeneration (Beyer et al., 2008), are at more risk of 
developing cancer (Khor et al., 2008; auf dem Keller et al., 2006), are more 
susceptible to toxins (Enomoto et al., 2001), develop retinopathies (Zhao et al., 
2011), have impaired immune systems (Jiang et al., 2004; Innamorato et al., 
2008) and  defective cardiac function (Erkens et al., 2015). 
Hyper-activation NRF2 has also been studied in mice, through the 
disruption of KEAP1 but rarely through a gain-of-function mutation in the NFE2L2 
gene. One group has studied the effect of NRF2 hyper-activation in human 
patients that have extensive multisystem disorder due to de novo mutations in 
NFE2L2. The four patients studied have mutations in the Neh2 domain that have 
previously been described in cancer cells and present with various symptoms, 
such as: immunodeficiency’s, neurological symptoms, and 
hypohomocysteinaemia (Huppke et al., 2017). Murine models with altered NRF2 
levels have been a particularly valuable tool in identifying novel NRF2-target 
genes that play a role in carcinogenesis. However, often a disruption in KEAP1 
is paired with several disruptions in other oncogenic genes. This is 
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understandable as it will lead to cancer, permitting the study role of NRF2 in the 
progression/severity of the disease, and often a combination of alterations in 
several genes must happen to allow quicker initiation of the disease due to time 
constraints. Although caution should be taken to make sure that the cancer model 
in mice is a true reflection of the human disease and does not have genes altered 
that are not seen altered alongside KEAP1 mutations in human disease. In this 
thesis, we have shown that KEAP1 and NFE2L2 mutations should be treated 
separately. Thus, whilst KEAP1 and NFE2L2 mutations do not co-exist in either 
lung cancer tumours or cell lines, each co-exists alongside different mutations 
and they also have different effects on NRF2-target gene expression. One of the 
key findings of Chapter 4  was that KEAP1 mutations co-exists with mutations in 
KRAS and are mutually exclusive to mutations in NFE2L2 and TP53. Whereas, 
mutations in NFE2L2 co-occur with mutations in TP53 and are mutually exclusive 
from mutations in KEAP1 and KRAS. Often in mouse lung tumourigenesis models 
that relate to NRF2, KEAP1 mutations are combined with PTEN and KRAS 
mutations, a combination that we believe does not naturally occur in human lung 
cancer.  
Another key finding of Chapter 4 was that mutations in KEAP1 and 
NFE2L2 show different zygosities, with mutations in KEAP1 being predominantly 
homozygous and mutations in NFE2L2 being predominantly heterozygous. This 
potentially accounts for the data we obtained using commercially available cell 
lines and our generated H1299 CRISPR-Cas9 panel, showing that an alteration 
in KEAP1 has a more pronounced elevation in NRF2-target genes expression, in 
contrast to a NFE2L2 alteration. As heterozygous NFE2L2 mutant cell lines will 
still poses one allele encoding wildtype NRF2, a portion of the transcription factor 
in the cell is still subject to degradation by KEAP1. By contrast, a homozygous 
disruption in KEAP1 will mean that these cell lines will be completely devoid of 
KEAP1-mediated NRF2 degradation. The reason behind the variation in 
zygosities between KEAP1 and NFE2L2 mutants in lung cancer is currently 
unknown. Generally, homozygous mutations are often associated with tumour 
suppressor genes and mutations that lead to a loss of function. It is thought that 
mutations  in tumour suppressor genes are “molecularly recessive” (Futreal et al., 
2004) and therefore require both copies of the gene to be mutated to exert an 
effect. This in combination with the notion that mutations in tumour suppressor 
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genes tend to be spread throughout the protein showing no clear focal point, 
suggests that KEAP1 may be a tumour suppressor gene (Baeissa et al., 2016). 
It has been extensively debated to whether NFE2L2 can be classed as an 
oncogene with the field deciding that such a narrow classification would not be 
appropriate. However, the data generated in Chapter 4 of this thesis indicates 
that NFE2L2 has a mutational pattern that is comparable to that of an oncogene 
with heterozygous mutations that all tend to occur in a particular region of the 
protein. Mutations in oncogenes are thought to be “molecularly dominate” and 
only one altered copy of the gene is required to cause an oncogenic phenotype, 
as seen in BRAF mutations (Baeissa et al., 2016). If we apply Vogelstein’s 20:20 
rule, which states that if 20% of mutations observed in a gene are missense 
mutations that occur at a single position in the sequence, NFE2L2 would be 
classified as a oncogene (Vogelstein et al., 2013).  
To gather a greater understanding of the impact of mutations in KEAP1 
and NFE2L2, we would suggest that the next logical step would be to generate 
NFE2L2 homozygous gain-of-function H1299 cells using CRISPR-Cas9 gene 
editing, which could be compared directly to our already existing homozygous 
KEAP1 KO H1299 cells. Once we have carried out the required cell experiments, 
the next stage would be to combine this zygosity data with our data showing the 
co-occurrence of KEAP1 and NFE2L2 with other oncogenic mutations to 
generate a more robust and translationally relevant mouse model of lung 
carcinogenesis to study the role of NRF2 signalling.  
6.4 KEAP1 mutant cell lines increase glutathione biosynthesis more than 
NFE2L2 mutant cell lines and are therefore more sensitive to inhibition of 
this pathway. 
 
A great controversy centres around the role NRF2 plays in cancer. Several 
papers have documented the beneficial role that NRF2 plays in halting the 
progression of cancer in the early stages, but a wealth of papers have also 
highlighted that cancer cells increase NRF2 signalling to permit their survival. For 
example, the expression of the AKR family of proteins are robustly elevated upon 
increased NRF2 activity. The AKRs are well known for their detoxification 
potential but also metabolize carcinogens found in cigarette smoke and 
potentially enhance mutagenesis driving cancer progression (Penning, 2017). 
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This raises the argument of whether it would be safe to inhibit NRF2 
therapeutically for the treatment of cancer. We have discussed at length in this 
thesis, the oncogenic effects of high levels of NRF2 in cancer due to somatic 
mutations in KEAP1, NFE2L2 or CUL3 and the associated resistance to 
antineoplastic drugs that is seen in cell lines and tumours with aberrant NRF2 
signalling. However, it is important to highlight the beneficial role that NRF2 plays 
in cancer prevention and the issue this raises in developing drugs to target the 
transcription factor. 
Firstly, NRF2 KO mice are more susceptible to carcinogenesis than their 
wildtype counterparts (Khor et al., 2008). Also, several pharmacological 
activators of NRF2 have been shown to delay cancer progression, such as 
Sulforaphane and CDDO-ME (Beaver et al., 2018; Kim et al., 2012). SFN  is a 
naturally occurring potent isothiocyanate compound found in cruciferous 
vegetables that activates NRF2 through impairing KEAP1 function, and has been 
shown in both in vitro and in vivo experiments to halt cancer progression (Zhang 
et al., 1994). KEAP1 contains several cysteine residues that function as thiol 
based cellular switches to regulate the activity of KEAP1, and subsequently 
NRF2, upon exposure to oxidative of electrophilic stress (Sporn and Liby, 2012). 
There are 27 cysteine residues in human KEAP1 that when modified alone, or in 
combination, lead to a conformational change in KEAP1 resulting in impaired 
KEAP1-mediated degradation of NRF2. SFN targets Cys-151 and at least three 
other Cys residues forming reversible thiol adducts, impairing the interaction 
between KEAP1 and CUL3 and leading to reduced ubiquitination of NRF2 (Hu et 
al., 2011a). SFN has been shown to inhibit the progression of carcinogenesis in 
the early stages of skin, lung, breast, colon and stomach cancer. However, the 
range of proteins effected by SFN administration is dose dependent. At low 
nanomolar concentrations of SFN, KEAP1 is inhibited but at higher 
concentrations SFN inhibits other proteins such as NF-κB and MAPK  (Sporn and 
Liby, 2012; Kensler et al., 2013; Clarke et al., 2008). 
CDDO methyl ester (CDDO-ME; also known as bardoloxone methyl or 
RTA 402) is a synthetic triterpenoid derived from Oleanolic acid. CDDO- ME, like 
SFN, forms a thiol adduct on Cys-151 of KEAP1, which increases NRF2 activity 
through inhibiting CUL3 binding to KEAP1 (Cleasby et al., 2014). Also like SFN, 
the number of CDDO-ME target proteins increases in a dose dependant manner, 
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and at low concentrations inhibits KEAP1 but at high millimolar doses also inhibits 
IKKβ and NF-κB (Ahmad et al., 2006). The antineoplastic effects of CDDO-ME 
have been extensively studied in both in vitro and in vivo models and has shown 
promising results in phase I clinical trials for advanced solid tumours and 
lymphoma (Hong et al., 2012). CDDO-ME can also function as a radioprotector, 
through neutralising the damaging effects of ROS due to radiotherapy in non-
cancerous lung and breast cells (El-Ashmawy et al., 2014).  
As NRF2 appears to play both a beneficial and detrimental role in cancer 
depending on the stage of the cancer and the smoking status of the patient, and 
the lack of both specific NRF2 activators or inhibitors, maybe targeting NRF2 itself 
is not the best therapeutic strategy. In Chapter 5 of this thesis we have 
demonstrated that inhibition of GSH biosynthesis has a more pronounced effect 
in KEAP1 mutant than NFE2L2 mutant cell lines and can re-sensitise KEAP1 
mutant cells to cisplatin. Therefore, potentially targeting the subgroup of NRF2-
target genes that are upregulated is a better way of decreasing the cancer 
protective effects of NRF2 signalling in established later stage cancer. 
Glutathione biosynthesis is only one of the key NRF2 regulated pathways that is 
involved in carcinogenesis and potentially targeting other subgroups of NRF2-
target genes e.g. drug detoxification genes will also show promising results.  
6.5 Thesis summary and concluding remarks  
 
The involvement of the transcription factor NRF2 in cancer has been 
studied extensively over the past decade. The field has made many rapid 
advancements in understanding the role of NRF2 in both cancer initiation and 
progression. However, a NRF2 biomarker has not been established. Biomarkers 
are cellular alterations that can be measured in patients tissues, cells or fluids, 
that can be used to study disease progression, diagnose disease, screen 
populations and measure the effect of treatments (Mayeux, 2004). EGFR and 
KRAS are two of the most commonly mutated genes in NSCLC and are 
associated with a negative disease outcome. The mutational status of KRAS and 
EGFR is often screened in lung cancer patients and is used as a predicative 
biomarker of whether patients will respond to EGFR inhibitors (Martin et al., 2013; 
Vincent et al., 2012). Since the expression of NRF2 itself is not a good read out 
for NRF2 activity, several NRF2 target genes have been suggested as 
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biomarkers of NRF2 activity such as AKR1B and 1C family members and NQO1. 
AKR1B10 expression is dramatically elevated in lung cancer tissues in 
comparison  to neighbouring non-cancerous tissues, where it is undetectable (Zu 
et al., 2009). Also NQO1 expression has been shown to function as prognostic 
biomarker in pancreatic (Awadallah et al., 2008) and  ovarian cancer (Cui et al., 
2015). The establishment of a NRF2 biomarker would provide a greater insight 
into the fluctuations in NRF2 activity during disease and would dramatically aid in 
the development of specific NRF2 targeting compounds.  
Overall in this thesis we have demonstrated the importance of a novel 
priming phosphorylation site within the Neh6 domain of NRF2 for SCFβ-TrCP 
mediated degradation of the transcription factor and highlighted the differences 
between KEAP1 and NFE2L2 mutations in lung cancer.  
ROS are often referred to as the “achilleas heel” of cancer cells due to the 
cancers high dependency on ROS for survival (Cui, 2012). However, oxidative 
stress is a hallmark of several diseases and degenerative disorders, not just 
cancer, highlighting the large therapeutic potential of targeting NRF2 signalling 
and the importance in studying the pathways/ events that lead to the 
dysregulation of NRF2 degradation.  
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8.0 Appendix  
 
8.1 Appendix I  
 
 
Mutation Primer Sequence (5’-3’) 
S335A GAA TTC AAT GAC TCT GAC GCT GGC ATT TCA CTG AAC ACG 
S338A GAC TCT GAC TCT GGC ATT GCG CTG AAC ACG AGT CCC AGT CCC 
S342A GGC ATT TCA CTG AAC ACG GCT CCC AGC CGA GCG TCC CCA 
S347A ACG AGT CCC AGC CGA GCG GCC CCA GAG CAC TCC GTG GAG 
V345R CTA AAC ACA AGT CCC AGT CGG GCA TCA CCA GAA CAC TCA 
 
Table 8.1.1: Oligonucleotide primers sequences for the generation of site mutant 
plasmids 
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8.2 Appendix II  
 
 
 
Cell line name Guide sequence (5’-3’) 
NRF2 GOF H1299 / NRF2 GOF H1299 TGG AGG CAA GAT ATA GAT CT 
KEAP1 KO H1299 CAC CGC ACC TTC AGC TAC ACC CTG G 
 
Table 8.2.1: Guide sequences for the generation of CRISPR/Cas9 cell lines 
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8.3 Appendix III 
 
 
 
Table 8.3.1: Source and dilution of all primary antibodies  
 
 
 
 
 
 
 
 
 
 
 
Antibody Company and catalogue number Dilution 
Rabbit anti-NRF2 Abcam (ab62352) 1:1000 
Rabbit anti-KRAS Abcam (ab180772) 1:750 
Rabbit anti-NQO1 In house 1:2000 
Rabbit anti-Phospho GSK-
3a/b (Ser9/21) 
Cell signalling Technology (93318) 1:1000 
Rabbit anti-Phospho AKT 
(Thr 308) 
Cell signalling Technology (4056S) 1:1000 
Rabbit anti-GSK-3a/b Cell signalling Technology (5676S) 1:1000 
Rabbit anti-Phospho AKT 
(Ser473) 
Cell signalling Technology (4060S) 1:1000 
Rabbit anti-G6PD Cell signalling Technology (12263S) 1:1000 
Rabbit anti-PGD Cell signalling Technology (13389S) 1:1000 
Rabbit anti-GAPDH Cell signalling Technology (2118S) 1:2000 
Rabbit anti-AKT (Pan) Cell signalling Technology (4691S) 1:1000 
Rabbit anti-AKR1B10 Home made 1:2000 
Rabbit anti-AKR1C1 Home made 1:2000 
Rabbit anti-GCLM ThermoFisher Scientific (PA5-26111) 1:1000 
Rabbit anti-HMOX-1 BioVison (3391-100) 1:1000 
Rabbit anti-ME1 Invitrogen (PA5-21550) 1:1000 
Rabbit anti- GPX2 Abcam(ab137431) 1:1000 
Rabbit anti-SLC7A11 Abcam (ab37185) 1:1000 
Rabbit anti- GCLC Invitrogen (PA5-16581) 1:1000 
Rat anti- KEAP1 Clone 144 Merck (MABS514) 1:1000 
Mouse anti-Lamin A/C Sigma-Aldrich (SAB4200236) 1:1000 
Mouse anti-Lamin B2 Santa Cruz Biotechnology (sc-377379) 1:1000 
Mouse anti-P62 Merck (MABC32) 1:1000 
Rabbit anti-PGAM5 Merck (ABC517) 1:1000 
Rabbit anti-TSC22D4 ThermoFisher Scientific (PA5-40333) 1:1000 
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8.4 Appendix IV  
 
Gene Catalogue number 
AKR1C2 Hs04194036_gH 
NQO1 Hs02512143_s1 
KEAP1 Hs00202227_m1 
NFE2L2 Hs00975961_g1 
GCLC Hs00155249_m1 
GCLM Hs00157694_m1 
GPX2 Hs01591589_m1 
SLC7A11 Hs00921938_m1 
G6PD Hs00166169_m1 
PGD Hs00427230_m1 
ME1 Hs00159110_m1 
IDH1 Hs00271858_m1 
HMOX1 Hs01110250_m1 
GAPDH Hs02758991_g1 
AKR1B10 Hs00252524_m1 
AKR1C1 Hs04230636_Sh 
AKR1C3 Hs00366267_m1 
TALDO1 Hs00997203_m1 
KRAS Hs00364284_g1 
18S rRNA  Hs99999901_s1 
 
Table 8.4.1: List and catalogue number of TaqMan probes sets purchased from Applied 
Biosystems 
 
 
 
 
 
Gene TaqMan primer probe sequences (5’-3’) 
ACTIN FW primer 
ACTIN RV primer 
ACTIN probe 
GCGCGGCTACAGCTTCA 
TCTCCTTAATGTCACGCA 
CACCACGGCCGAGCGGG 
HMOX1 FW primer 
HMOX1 RV primer 
HMOX1 probe 
AGTGCCACCAAGTTCAAGC 
TATCACCCTCTGCCTGACTG 
ACCGCTCCCGCATGAACTCC 
 
Table 8.4.2: List of sequences of customised TaqMan primers and probes 
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8.5 Appendix V  
 
Amino acid Abbreviation Letter 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamic acid Glu E 
Glutamine Gln Q 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Try W 
Tyrosine Tyr Y 
Valine Val V 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8.5.1: List of amino acid names, abbreviation and letter codes 
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8.6 Appendix VI 
 
 
 
 
 
 
1:500 (3rd bleed)  P-S342 Nrf2
Non- phospho 338 peptide 
Phospho 338 peptide 
1   0.1   0.01   0.001   (µg)
1:1000 (3rd bleed)  P-S342 Nrf2
Non- phospho 338 peptide 
Phospho 338 peptide 
1   0.1   0.01   0.001   (µg)
1:500 (3rd bleed)  P-S347 Nrf2
Non- phospho 338 peptide 
Phospho 338 peptide 
1   0.1   0.01   0.001   (µg)
1:1000 (3rd bleed)  P-S347 Nrf2
Non- phospho 338 peptide 
Phospho 338 peptide 
1   0.1   0.01   0.001   (µg)
1:500 (3rd bleed)  P-S342 Nrf2
Non- phospho 347peptide 
Phospho 347 peptide 
1   0.1   0.01   0.001   (µg)
1:1000 (3rd bleed)  P-S342 Nrf2
Non- phospho 347peptide 
Phospho 347 peptide 
1   0.1   0.01   0.001   (µg)
1:500 (3rd bleed)  P-S347 Nrf2
Non- phospho 347peptide 
Phospho 347 peptide 
1   0.1   0.01   0.001   (µg)
1:1000 (3rd bleed)  P-S347 Nrf2
Non- phospho 347peptide 
Phospho 347 peptide 
1   0.1   0.01   0.001   (µg)
1:500 (3rd bleed)  P-S342 Nrf2
Non- phospho 342 peptide 
Phospho 342 peptide 
1   0.1   0.01   0.001   (µg)
1:1000 (3rd bleed)  P-S342 Nrf2
Non- phospho 342 peptide 
Phospho 342 peptide 
1   0.1   0.01   0.001   (µg)
1:500 (3rd bleed)  P-S347 Nrf2
Non- phospho 342 peptide 
Phospho 342 peptide 
1   0.1   0.01   0.001   (µg)
1:1000 (3rd bleed)  P-S347 Nrf2
Non- phospho 342 peptide 
Phospho 342 peptide 
1   0.1   0.01   0.001   (µg)
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Figure 8.6.1: Dot blot optimization for the in house phospho-specific antibodies  
Dilutions of the peptides are indicated above the images; the name of the peptide is given 
down the left-hand side of the image and the antibodies (dilution) used to probe the 
membrane is indicated below the image. Dilutions of phospho peptides and non-phospho 
peptides were dotted on to nitrocellulose membranes. Membranes were blocked in 5% 
BSA for 1 hr and then incubated in primary antibody for 2 hr. Membranes were then 
incubated in 1:1000 sheep HRP-conjugated secondary antibody followed by visualization 
with ECL. These images are representative of three biological replicates. 
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8.7 Appendix VII  
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Figure 8.7.1: β-TrCP mediated degradation of NRF2 is similar to that of β-Catenin, 
which also requires priming of GSK-3 
Schematic highlighting the similarities in the β-TrCP mediated degradation of NRF2 and 
that of β-catenin. Priming by DYRK leads to enhanced phosphorylation of NRF2 by GSK-3 
leading to the formation of the phosphodegron to which the substrate adaptor protein β-
TrCP binds. Once β-TrCP is bound to NRF2 is recruits the CUL1 ubiquitin machinery 
complex that labels NRF2 with ubiquitin for subsequent degradation through the 26S 
proteasome route. This pathway of degradation for NRF2 is extremely similar to the well 
characterised β-catenin degradation pathway. Priming by CK1 leads to enhanced 
phosphorylation of β-catenin by GSK-3 leading to the formation of the phosphodegron to 
which β-TrCP binds. Once bound β-TrCP recruits the CUL1 ubiquitin machinery complex 
leading to degradation of β-catenin through the 26S proteasome. Adapted from Robertson 
et al. (2018). 
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8.8 Appendix VIII 
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Figure 8.8.1: KKO H1299 cells express lower protein levels of KEAP1 
Protein analysis of KEAP1 and NQO1 across the H1299 CRISPR panel of cell lines. This 
image is taken from one experiment and representative of three independent biological 
replicates. 
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8.9 Appendix IX 
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Figure 8.9.1: AKT signalling is increase in cell lines harbouring a KRAS mutation 
and knock down of KRAS leads to decreased NRF2-target gene expression.  
(A) Protein analysis of the AKT signalling pathway in: A549, H460, H2228, H1568, H1299 
and H1395 cells. Cell lines are indicated across the top of the image, the names of the 
proteins being analysed are given down the left-hand side of the image and their 
corresponding molecular weights on the right-hand side. This image is one representative 
image of three independent biological replicates. (B) Protein analysis of NRF2-target 
genes and AKT signalling in DLD1 cells upon siRNA knock down of KRAS. The results for 
the siRNA control are given in the left lane of the western blot and the siRNA KRAS 
knockdown results are given in the right line of the image. The names of the proteins 
being analysed are given down the left-hand side of the image and their corresponding 
molecular weights on the right-hand side. This image is a representative of three 
independent biological replicates. (C) mRNA analysis of NRF2-target genes after siRNA 
knockdown of KRAS in DLD1 cells. The white bar corresponds to the siRNA control cells 
and the black bar represents the siRNA KRAS knockdown cells. The values displayed on 
the graphs are the mean value from three replicate experiments and the associated SEM. 
All statistical analysis was carried out using GraphPad Prism 5 software. All significant 
increases are denoted as follows:  *, P< 0.05; **, P<0.01; *** P< 0.001. P values > 0.05 
were deemed not significant and are denoted by “ns”. Significant decreases are denoted 
with a $ sign. 
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8.10 Appendix X 
 
 
Cell line name Name of the gene disrupted Sequencing results 
Predicated 
affect 
Clone 8 KKO KEAP1 Homozygous in-frame deletion 87bp (M1) 
KEAP1 protein 
not produced  
Clone 40 NKO NFE2L2 
Heterozygous NRF2 KO 
deletion 20bp (L23) and 7bp 
(D29) 
NRF2 protein 
not produced  
Clone 31 GOF NFE2L2 
Heterozygous in-frame 
deletion 3bp (D29) and 24bp 
(R25-V32) 
KEAP1 binding 
to NRF2 
impaired and 
NRF2 levels 
increased  
 
 
 
 
 
 
 
 
 
 
 
Table 8.10.1: Sequencing results for the CRISPR/Cas9 H1299 cells 
Sequencing was kindly carried out by Mr Thomas McCartney. The name of the cell lines are 
given in the first left-hand side of the column, followed by the name of the gene which has 
been altered, the sequencing results and the predicated effect of the disruption; in the 
adjacent columns.  
 
